



ANNEX V

To Study Report

P3-C3-005

DARWIN EU[®] - Incidence rates of venous thromboembolic events in patients with selected cancers

31/10/2025

Version 4.0

Authors: Anton Barchuk, Melissa Leung, Cesar Barboza, Ioanna Nika, Talita Duarte-Salles

Public

CONTENTS

Table 1. Incidence rates [95% confidence interval] of thromboembolic events in bone cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).	8
Table 2. Incidence rates [95% confidence interval] of thromboembolic events in brain cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).	8
Table 3. Incidence rates [95% confidence interval] of thromboembolic events in breast cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).	9
Table 4. Incidence rates [95% confidence interval] of thromboembolic events in colorectal cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).	10
Table 5. Incidence rates [95% confidence interval] of thromboembolic events in corpus uteri cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).	11
Table 6. Incidence rates [95% confidence interval] of thromboembolic events in oesophageal cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).	12
Table 7. Incidence rates [95% confidence interval] of thromboembolic events in kidney cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).	13
Table 8. Incidence rates [95% confidence interval] of thromboembolic events in liver cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).	14
Table 9. Incidence rates [95% confidence interval] of thromboembolic events in lung cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).	15
Table 10. Incidence rates [95% confidence interval] of thromboembolic events in leukaemia and lymphoma after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).	16
Table 11. Incidence rates [95% confidence interval] of thromboembolic events in melanoma after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).	16
Table 12. Incidence rates [95% confidence interval] of thromboembolic events in ovarian cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).	17
Table 13. Incidence rates [95% confidence interval] of thromboembolic events in pancreatic cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).	18
Table 14. Incidence rates [95% confidence interval] of thromboembolic events in prostate cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).	20
Table 15. Incidence rates [95% confidence interval] of thromboembolic events in stomach cancer after 2 years of follow-up, by database, per 100,000 person-years (2016–2022).	21
Table 16. Incidence rates of Deep vein thrombosis (DVT) per 100,000 person-years (95% CI) from meta-analysis by cancer type.	22
Table 17. Incidence rates of Disseminated intravascular coagulation (DIC) per 100,000 person-years (95% CI) from meta-analysis by cancer type.	24
Table 18. Incidence rates of PE and DVT combined (VTE) per 100,000 person-years (95% CI) from meta-analysis by cancer type.	26
Table 19. Incidence rates of Pelvic vein thrombosis (PVT) per 100,000 person-years (95% CI) from meta-analysis by cancer type.	28

Table 20. Incidence rates of Pulmonary embolism (PE) per 100,000 person-years (95% CI) from meta-analysis by cancer type.....	30
Table 21. Incidence rates of Retinal vein thrombosis broad (RVT) per 100,000 person-years (95% CI) from meta-analysis by cancer type.	32
Table 22. Incidence rates of Splanchnic extrahepatic vein thrombosis (SVT) per 100,000 person-years (95% CI) from meta-analysis by cancer type.	34
Table 23. Demographic characteristics (sex and age) of bone cancer, by database (2016–2022).	36
Table 24. Demographic characteristics (sex and age) of brain cancer, by database (2016–2022).	37
Table 25. Demographic characteristics (sex and age) of breast cancer, by database (2016–2022).	38
Table 26. Demographic characteristics (sex and age) of colorectal cancer, by database (2016–2022).	39
Table 27. Demographic characteristics (sex and age) of corpus uteri cancer, by database (2016–2022).	39
Table 28. Demographic characteristics (sex and age) of oesophageal cancer, by database (2016–2022).	40
Table 30. Demographic characteristics (sex and age) of liver cancer, by database (2016–2022).	42
Table 31. Demographic characteristics (sex and age) of lung cancer, by database (2016–2022).	43
Table 32. Demographic characteristics (sex and age) of leukaemia and lymphoma, by database (2016–2022).....	44
Table 33. Demographic characteristics (sex and age) of melanoma, by database (2016–2022).....	45
Table 34. Demographic characteristics (sex and age) of ovarian cancer, by database (2016–2022).	46
Table 35. Demographic characteristics (sex and age) of pancreatic cancer, by database (2016–2022).	47
Table 36. Demographic characteristics (sex and age) of prostate cancer, by database (2016–2022).....	48
Table 37. Demographic characteristics (sex and age) of stomach cancer, by database (2016–2022).....	48
Table 38. Medical conditions recorded anytime up to 181 days before the diagnosis of bone cancer, by database (2016–2022).....	49
Table 39. Medical conditions recorded anytime up to 181 days before the diagnosis of brain cancer, by database (2016–2022).....	51
Table 40. Medical conditions recorded anytime up to 181 days before the diagnosis of breast cancer, by database (2016–2022).....	54
Table 41. Medical conditions recorded anytime up to 181 days before the diagnosis of colorectal cancer, by database (2016–2022).....	56
Table 42. Medical conditions recorded anytime up to 181 days before the diagnosis of corpus uteri cancer, by database (2016–2022).....	58
Table 43. Medical conditions recorded anytime up to 181 days before the diagnosis of oesophageal cancer, by database (2016–2022).....	60
Table 44. Medical conditions recorded anytime up to 181 days before the diagnosis of kidney cancer, by database (2016–2022).....	63
Table 45. Medical conditions recorded anytime up to 181 days before the diagnosis of liver cancer, by database (2016–2022).....	64

Table 46. Medical conditions recorded anytime up to 181 days before the diagnosis of lung cancer, by database (2016–2022).	67
Table 47. Medical conditions recorded anytime up to 181 days before the diagnosis of leukaemia and lymphoma, by database (2016–2022).	69
Table 48. Medical conditions recorded anytime up to 181 days before the diagnosis of melanoma, by database (2016–2022).	71
Table 49. Medical conditions recorded anytime up to 181 days before the diagnosis of ovarian cancer, by database (2016–2022).	73
Table 50. Medical conditions recorded anytime up to 181 days before the diagnosis of pancreatic cancer, by database (2016–2022).	76
Table 51. Medical conditions recorded anytime up to 181 days before the diagnosis of prostate cancer, by database (2016–2022).	77
Table 52. Medical conditions recorded anytime up to 181 days before the diagnosis of stomach cancer, by database (2016–2022).	80
Table 53. Medical conditions recorded 180 to 1 days before the diagnosis of bone cancer, by database (2016–2022).	81
Table 54. Medical conditions recorded 180 to 1 days before the diagnosis of brain cancer, by database (2016–2022).	84
Table 55. Medical conditions recorded 180 to 1 days before the diagnosis of breast cancer, by database (2016–2022).	85
Table 56. Medical conditions recorded 180 to 1 days before the diagnosis of colorectal cancer, by database (2016–2022).	88
Table 57. Medical conditions recorded 180 to 1 days before the diagnosis of corpus uteri cancer, by database (2016–2022).	89
Table 58. Medical conditions recorded 180 to 1 days before the diagnosis of oesophageal cancer, by database (2016–2022).	92
Table 59. Medical conditions recorded 180 to 1 days before the diagnosis of kidney cancer, by database (2016–2022).	93
Table 60. Medical conditions recorded 180 to 1 days before the diagnosis of liver cancer, by database (2016–2022).	96
Table 61. Medical conditions recorded 180 to 1 days before the diagnosis of lung cancer, by database (2016–2022).	97
Table 62. Medical conditions recorded 180 to 1 days before the diagnosis of leukaemia and lymphoma, by database (2016–2022).	100
Table 63. Medical conditions recorded 180 to 1 days before the diagnosis of melanoma, by database (2016–2022).	101
Table 64. Medical conditions recorded 180 to 1 days before the diagnosis of ovarian cancer, by database (2016–2022).	104
Table 65. Medical conditions recorded 180 to 1 days before the diagnosis of pancreatic cancer, by database (2016–2022).	105

Table 66. Medical conditions recorded 180 to 1 days before the diagnosis of prostate cancer, by database (2016–2022).	108
Table 67. Medical conditions recorded 180 to 1 days before the diagnosis of stomach cancer, by database (2016–2022).	109
Table 68. Medical conditions recorded at the time of the diagnosis of bone cancer, by database (2016–2022).....	112
Table 69. Medical conditions recorded at the time of the diagnosis of brain cancer, by database (2016–2022).....	113
Table 70. Medical conditions recorded at the time of the diagnosis of breast cancer, by database (2016–2022).....	116
Table 71. Medical conditions recorded at the time of the diagnosis of colorectal cancer, by database (2016–2022).....	117
Table 72. Medical conditions recorded at the time of the diagnosis of corpus uteri cancer, by database (2016–2022).	120
Table 73. Medical conditions recorded at the time of the diagnosis of oesophageal cancer, by database (2016–2022).	121
Table 74. Medical conditions recorded at the time of the diagnosis of kidney cancer, by database (2016–2022).....	124
Table 75. Medical conditions recorded at the time of the diagnosis of liver cancer, by database (2016–2022).....	125
Table 76. Medical conditions recorded at the time of the diagnosis of lung cancer, by database (2016–2022).....	128
Table 77. Medical conditions recorded at the time of the diagnosis of leukaemia and lymphoma, by database (2016–2022).....	129
Table 78. Medical conditions recorded at the time of the diagnosis of melanoma, by database (2016–2022).	132
Table 79. Medical conditions recorded at the time of the diagnosis of ovarian cancer, by database (2016–2022).....	133
Table 80. Medical conditions recorded at the time of the diagnosis of pancreatic cancer, by database (2016–2022).	136
Table 81. Medical conditions recorded at the time of the diagnosis of prostate cancer, by database (2016–2022).....	137
Table 82. Medical conditions recorded at the time of the diagnosis of stomach cancer, by database (2016–2022).....	140
Table 83. Medications recorded at the time of the diagnosis of bone cancer, by database (2016–2022). .	141
Table 84. Medications recorded at the time of the diagnosis of brain cancer, by database (2016–2022). .	143
Table 85. Medications recorded at the time of the diagnosis of breast cancer, by database (2016–2022). .	144
Table 86. Medications recorded at the time of the diagnosis of colorectal cancer, by database (2016–2022).	145

Table 87. Medications recorded at the time of the diagnosis of corpus uteri cancer, by database (2016–2022).....	146
Table 88. Medications recorded at the time of the diagnosis of oesophageal cancer, by database (2016–2022).....	147
Table 89. Medications recorded at the time of the diagnosis of kidney cancer, by database (2016–2022).	149
Table 90. Medications recorded at the time of the diagnosis of liver cancer, by database (2016–2022)....	150
Table 91. Medications recorded at the time of the diagnosis of lung cancer, by database (2016–2022)....	151
Table 92. Medications recorded at the time of the diagnosis of leukaemia and lymphoma, by database (2016–2022).	152
Table 93. Medications recorded at the time of the diagnosis of melanoma, by database (2016–2022).	153
Table 94. Medications recorded at the time of the diagnosis of ovarian cancer, by database (2016–2022).	155
Table 95. Medications recorded at the time of the diagnosis of pancreatic cancer, by database (2016–2022).	156
Table 96. Medications recorded at the time of the diagnosis of prostate cancer, by database (2016–2022).	157
Table 97. Medications recorded at the time of the diagnosis of stomach cancer, by database (2016–2022).	159
Table 98. Medications recorded 0 to 90 days after the diagnosis of bone cancer, by database (2016–2022).	160
Table 99. Medications recorded 0 to 90 days after the diagnosis of brain cancer, by database (2016–2022).	162
Table 100. Medications recorded 0 to 90 days after the diagnosis of breast cancer, by database (2016–2022).....	163
Table 101. Medications recorded 0 to 90 days after the diagnosis of colorectal cancer, by database (2016–2022).....	164
Table 102. Medications recorded 0 to 90 days after the diagnosis of corpus uteri cancer, by database (2016–2022).	165
Table 103. Medications recorded 0 to 90 days after the diagnosis of oesophageal cancer, by database (2016–2022).	167
Table 104. Medications recorded 0 to 90 days after the diagnosis of kidney cancer, by database (2016–2022).....	168
Table 105. Medications recorded 0 to 90 days after the diagnosis of liver cancer, by database (2016–2022).	169
Table 106. Medications recorded 0 to 90 days after the diagnosis of lung cancer, by database (2016–2022).	171
Table 107. Medications recorded 0 to 90 days after the diagnosis of leukaemia and lymphoma, by database (2016–2022).	172
Table 108. Medications recorded 0 to 90 days after the diagnosis of melanoma, by database (2016–2022).	173

Table 109. Medications recorded 0 to 90 days after the diagnosis of ovarian cancer, by database (2016–2022).....	175
Table 110. Medications recorded 0 to 90 days after the diagnosis of pancreatic cancer, by database (2016–2022).....	176
Table 111. Medications recorded 0 to 90 days after the diagnosis of prostate cancer, by database (2016–2022).....	177
Table 112. Medications recorded 0 to 90 days after the diagnosis of stomach cancer, by database (2016–2022).....	179
Table 113. Procedures recorded 0 to 90 days after the diagnosis of bone cancer, by database (2016–2022).	180
Table 114. Procedures recorded 0 to 90 days after the diagnosis of brain cancer, by database (2016–2022).	181
Table 115. Procedures recorded 0 to 90 days after the diagnosis of breast cancer, by database (2016–2022).	181
Table 116. Procedures recorded 0 to 90 days after the diagnosis of colorectal cancer, by database (2016–2022).....	182
Table 117. Procedures recorded 0 to 90 days after the diagnosis of corpus uteri cancer, by database (2016–2022).....	182
Table 118. Procedures recorded 0 to 90 days after the diagnosis of oesophageal cancer, by database (2016–2022).....	183
Table 119. Procedures recorded 0 to 90 days after the diagnosis of kidney cancer, by database (2016–2022).	183
Table 120. Procedures recorded 0 to 90 days after the diagnosis of liver cancer, by database (2016–2022).	184
Table 121. Procedures recorded 0 to 90 days after the diagnosis of lung cancer, by database (2016–2022).	184
Table 122. Procedures recorded 0 to 90 days after the diagnosis of leukaemia and lymphoma, by database (2016–2022).	185
Table 123. Procedures recorded 0 to 90 days after the diagnosis of melanoma, by database (2016–2022).	185
Table 124. Procedures recorded 0 to 90 days after the diagnosis of ovarian cancer, by database (2016–2022).....	186
Table 125. Procedures recorded 0 to 90 days after the diagnosis of pancreatic cancer, by database (2016–2022).....	186
Table 126. Procedures recorded 0 to 90 days after the diagnosis of prostate cancer, by database (2016–2022).....	187
Table 127. Procedures recorded 0 to 90 days after the diagnosis of stomach cancer, by database (2016–2022).....	187

Table 1. Incidence rates [95% confidence interval] of thromboembolic events in bone cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Deep vein thrombosis (DVT)	0	NC	0	NC		1,516 [981, 2,238]	0	1,907 [767, 3,930]	1,267 [655, 2,213]
Disseminated intravascular coagulation (DIC)	0	0	0	0		NC	0	0	0
PE and DVT combined (VTE)	0	1,356 [545, 2,793]	0	887 [458, 1,550]		2,014 [1,386, 2,828]	0	3,087 [1,541, 5,524]	3,730 [2,583, 5,212]
Pelvic vein thrombosis (PVT)	0	0	0	0		NC	0	0	NC
Pulmonary embolism (PE)	0	965 [313, 2,252]	0	654 [299, 1,242]		898 [503, 1,482]	0	1,358 [441, 3,169]	3,014 [2,003, 4,357]
Retinal vein thrombosis (RVT)	0	0	0	0		NC	0	0	0
Splanchnic extrahepatic vein thrombosis (SVT)	0	0	0	0		NC	0	0	0

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 2. Incidence rates [95% confidence interval] of thromboembolic events in brain cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Deep vein thrombosis (DVT)	0	975 [693, 1,333]	NC	870 [602, 1,215]	2,197 [883, 4,527]	3,221 [2,706, 3,805]	2,469 [1,276, 4,313]	3,418 [2,253, 4,973]	2,439 [1,968, 2,988]
Disseminated intravascular coagulation (DIC)	0	NC	0	0	0	NC	0	0	NC

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
PE and DVT combined (VTE)	NC	3,971 [3,368, 4,650]	5,082 [2,194, 10,014]	1,716 [1,327, 2,183]	6,858 [4,245, 10,483]	5,581 [4,888, 6,343]	7,971 [5,612, 10,986]	7,945 [6,078, 10,206]	6,498 [5,700, 7,376]
Pelvic vein thrombosis (PVT)	0	0	0	0	0	159 [64, 328]	0	NC	257 [123, 473]
Pulmonary embolism (PE)	NC	3,265 [2,724, 3,882]	4,385 [1,763, 9,034]	947 [667, 1,305]	4,474 [2,446, 7,507]	3,403 [2,873, 4,002]	6,586 [4,475, 9,348]	4,681 [3,296, 6,453]	4,388 [3,744, 5,111]
Retinal vein thrombosis (RVT)	0	NC	0	NC	0	NC	NC	NC	NC
Splanchnic extrahepatic vein thrombosis (SVT)	0	0	0	NC	0	NC	0	0	0

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 3. Incidence rates [95% confidence interval] of thromboembolic events in breast cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Deep vein thrombosis (DVT)	0	196 [163, 235]	353 [142, 727]	345 [307, 387]	419 [310, 554]	562 [502, 628]	250 [162, 369]	673 [585, 771]	335 [294, 380]
Disseminated intravascular coagulation (DIC)	NC	NC	0	NC	0	12 [5, 26]	0	0	NC
PE and DVT combined (VTE)	341 [170, 610]	665 [601, 733]	865 [504, 1,386]	769 [711, 831]	891 [727, 1,081]	978 [897, 1,064]	761 [598, 954]	1,333 [1,207, 1,470]	1,002 [929, 1,078]
Pelvic vein thrombosis (PVT)	0	NC	NC	0	0	50	0	22	61

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
						[33, 72]		[9, 46]	[44, 82]
Pulmonary embolism (PE)	341 [170, 610]	503 [448, 563]	549 [274, 982]	502 [456, 552]	496 [377, 641]	529 [470, 593]	551 [415, 718]	713 [622, 813]	709 [648, 773]
Retinal vein thrombosis (RVT)	0	67 [48, 92]	NC	21 [12, 33]	0	28 [16, 46]	49 [16, 115]	64 [39, 98]	66 [49, 88]
Splanchnic extrahepatic vein thrombosis (SVT)	NC	18 [9, 32]	NC	8 [3, 17]	0	34 [20, 53]	0	NC	15 [8, 27]

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 4. Incidence rates [95% confidence interval] of thromboembolic events in colorectal cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Deep vein thrombosis (DVT)	0	569 [503, 640]	1,035 [535, 1,809]	668 [583, 761]	607 [454, 797]	1,241 [1,140, 1,347]	1,161 [915, 1,453]	1,585 [1,400, 1,788]	783 [696, 877]
Disseminated intravascular coagulation (DIC)	0	NC	0	0	0	84 [60, 115]	NC	NC	NC
PE and DVT combined (VTE)	1,209 [486, 2,490]	2,149 [2,018, 2,286]	2,762 [1,877, 3,920]	1,673 [1,536, 1,818]	1,840 [1,561, 2,155]	2,414 [2,272, 2,562]	3,306 [2,874, 3,785]	3,793 [3,499, 4,105]	3,067 [2,889, 3,253]
Pelvic vein thrombosis (PVT)	0	NC	443 [144, 1,034]	0	0	58 [39, 85]	NC	35 [13, 76]	157 [120, 202]
Pulmonary embolism (PE)	1,209	1,680	1,830	1,128	1,248	1,507	2,478	2,375	2,460

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
	[486, 2,490]	[1,566, 1,801]	[1,133, 2,797]	[1,017, 1,247]	[1,022, 1,510]	[1,396, 1,624]	[2,109, 2,893]	[2,147, 2,622]	[2,302, 2,625]
Retinal vein thrombosis (RVT)	NC	76 [54, 105]	NC	32 [16, 57]	0	41 [25, 64]	120 [52, 237]	88 [49, 144]	132 [98, 174]
Splanchnic extrahepatic vein thrombosis (SVT)	0	107 [80, 140]	NC	64 [40, 97]	0	263 [219, 314]	120 [52, 236]	157 [103, 228]	120 [88, 160]

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 5. Incidence rates [95% confidence interval] of thromboembolic events in corpus uteri cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Deep vein thrombosis (DVT)	0	575 [428, 756]	1,222 [397, 2,853]	701 [526, 914]	570 [209, 1,240]	1,509 [1,250, 1,806]	418 [168, 861]	1,022 [730, 1,392]	736 [584, 916]
Disseminated intravascular coagulation (DIC)	0	0	0	0	0	NC	0	0	NC
PE and DVT combined (VTE)	NC	1,818 [1,545, 2,126]	1,721 [692, 3,545]	1,267 [1,026, 1,547]	1,640 [955, 2,626]	2,530 [2,189, 2,909]	2,216 [1,552, 3,067]	2,200 [1,755, 2,723]	2,045 [1,782, 2,337]
Pelvic vein thrombosis (PVT)	0	NC	NC	0	0	62 [20, 145]	0	NC	136 [76, 225]
Pulmonary embolism (PE)	NC	1,259 [1,035, 1,517]	NC	714 [538, 929]	1,048 [523, 1,875]	1,515 [1,256, 1,812]	2,022 [1,392, 2,839]	1,351 [1,012, 1,767]	1,467 [1,247, 1,716]
Retinal vein thrombosis (RVT)	0	NC	NC	NC	0	NC	0	NC	100 [50, 180]

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Splanchnic extrahepatic vein thrombosis (SVT)	0	NC	0	NC	0	NC	0	NC	45 [15, 106]

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 6. Incidence rates [95% confidence interval] of thromboembolic events in oesophageal cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Deep vein thrombosis (DVT)	0	521 [303, 834]	NC	641 [406, 961]	733 [295, 1,510]	2,872 [2,163, 3,738]	1,647 [941, 2,674]	3,061 [2,458, 3,767]	924 [586, 1,386]
Disseminated intravascular coagulation (DIC)	0	0	0	0	0	NC	0	0	NC
PE and DVT combined (VTE)	0	3,742 [3,097, 4,481]	16,153 [5,245, 37,696]	2,048 [1,602, 2,579]	3,129 [2,096, 4,494]	4,995 [4,037, 6,113]	6,743 [5,170, 8,644]	7,865 [6,856, 8,982]	5,167 [4,298, 6,161]
Pelvic vein thrombosis (PVT)	0	0	0	0	0	0	0	NC	NC
Pulmonary embolism (PE)	0	3,292 [2,693, 3,986]	NC	1,460 [1,090, 1,915]	2,450 [1,553, 3,676]	3,015 [2,289, 3,898]	5,311 [3,942, 7,001]	4,835 [4,065, 5,709]	4,239 [3,460, 5,141]
Retinal vein thrombosis (RVT)	0	NC	0	0	0	0	NC	NC	NC
Splanchnic extrahepatic vein thrombosis (SVT)	0	NC	0	0	0	714 [390, 1,197]	NC	NC	NC

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 7. Incidence rates [95% confidence interval] of thromboembolic events in kidney cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Deep vein thrombosis (DVT)	0	610 [472, 776]	1,339 [491, 2,914]	471 [363, 601]	353 [130, 769]	2,269 [2,001, 2,563]	2,359 [1,661, 3,251]	1,065 [620, 1,705]	536 [405, 696]
Disseminated intravascular coagulation (DIC)	0	0	0	NC	0	59 [24, 122]	0	0	NC
PE and DVT combined (VTE)	0	1,758 [1,514, 2,031]	2,494 [1,245, 4,463]	1,318 [1,130, 1,528]	1,271 [787, 1,943]	3,097 [2,781, 3,440]	3,984 [3,047, 5,117]	3,342 [2,488, 4,394]	2,116 [1,841, 2,420]
Pelvic vein thrombosis (PVT)	0	NC	NC	0	0	94 [47, 168]	0	NC	142 [80, 235]
Pulmonary embolism (PE)	0	1,245 [1,043, 1,476]	1,555 [625, 3,203]	927 [772, 1,105]	1,077 [638, 1,701]	1,462 [1,250, 1,700]	2,137 [1,480, 2,986]	2,283 [1,599, 3,161]	1,738 [1,491, 2,014]
Retinal vein thrombosis (RVT)	0	73 [32, 145]	NC	NC	0	77 [35, 145]	NC	303 [99, 708]	86 [39, 163]
Splanchnic extrahepatic vein thrombosis (SVT)	0	NC	0	NC	0	230 [151, 334]	NC	0	NC

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 8. Incidence rates [95% confidence interval] of thromboembolic events in liver cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Deep vein thrombosis (DVT)	0	1,241 [870, 1,719]	NC	726 [465, 1,080]	2,303 [1,190, 4,023]	1,736 [1,418, 2,104]	2,278 [1,137, 4,075]	1,038 [537, 1,814]	1,127 [802, 1,541]
Disseminated intravascular coagulation (DIC)	0	NC	0	NC	0	245 [137, 404]	0	0	0
PE and DVT combined (VTE)	0	3,541 [2,878, 4,311]	8,127 [2,639, 18,967]	1,974 [1,520, 2,521]	4,774 [3,059, 7,103]	3,155 [2,719, 3,641]	6,221 [4,167, 8,935]	3,643 [2,614, 4,942]	4,634 [3,935, 5,420]
Pelvic vein thrombosis (PVT)	0	0	0	0	0	NC	0	0	142 [46, 332]
Pulmonary embolism (PE)	0	2,457 [1,915, 3,104]	NC	1,361 [992, 1,821]	2,720 [1,487, 4,563]	1,969 [1,631, 2,356]	5,247 [3,396, 7,746]	2,521 [1,688, 3,620]	3,869 [3,239, 4,585]
Retinal vein thrombosis (RVT)	0	NC	0	0	0	NC	0	NC	256 [117, 487]
Splanchnic extrahepatic vein thrombosis (SVT)	0	3,563 [2,905, 4,325]	12,161 [5,250, 23,963]	2,118 [1,651, 2,675]	0	12,650 [11,737, 13,614]	5,194 [3,361, 7,667]	2,679 [1,820, 3,802]	2,444 [1,952, 3,022]

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 9. Incidence rates [95% confidence interval] of thromboembolic events in lung cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Deep vein thrombosis (DVT)	0	687 [596, 787]	1,510 [554, 3,287]	694 [590, 812]	824 [609, 1,089]	3,027 [2,794, 3,274]	1,528 [1,123, 2,032]	1,606 [1,372, 1,868]	1,194 [1,031, 1,376]
Disseminated intravascular coagulation (DIC)	0	20 [7, 43]	0	0	0	66 [36, 110]	0	NC	NC
PE and DVT combined (VTE)	1,303 [563, 2,568]	4,334 [4,097, 4,582]	5,767 [3,614, 8,731]	2,381 [2,181, 2,595]	3,033 [2,600, 3,517]	7,638 [7,258, 8,031]	6,847 [5,931, 7,864]	5,889 [5,423, 6,384]	6,307 [5,913, 6,719]
Pelvic vein thrombosis (PVT)	0	0	0	0	0	52 [26, 93]	0	NC	142 [90, 213]
Pulmonary embolism (PE)	1,303 [563, 2,568]	3,757 [3,537, 3,987]	4,396 [2,561, 7,039]	1,865 [1,690, 2,053]	2,257 [1,890, 2,675]	5,644 [5,322, 5,980]	5,862 [5,025, 6,797]	4,378 [3,983, 4,803]	5,377 [5,018, 5,756]
Retinal vein thrombosis (RVT)	0	80 [51, 119]	0	52 [27, 91]	0	57 [29, 99]	NC	85 [39, 160]	192 [131, 273]
Splanchnic extrahepatic vein thrombosis (SVT)	0	26 [11, 52]	0	22 [7, 50]	0	160 [110, 223]	NC	NC	80 [42, 136]

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 10. Incidence rates [95% confidence interval] of thromboembolic events in leukaemia and lymphoma after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Deep vein thrombosis (DVT)	0	387 [331, 450]	952 [507, 1,627]	454 [396, 517]	788 [555, 1,086]	1,020 [928, 1,119]	680 [474, 946]	883 [744, 1,042]	384 [322, 454]
Disseminated intravascular coagulation (DIC)	NC	32 [17, 53]	NC	NC	0	161 [126, 202]	132 [53, 273]	NC	22 [10, 43]
PE and DVT combined (VTE)	525 [211, 1,082]	1,233 [1,130, 1,344]	1,412 [850, 2,205]	911 [828, 1,000]	1,717 [1,359, 2,140]	1,639 [1,522, 1,764]	1,773 [1,424, 2,182]	1,682 [1,485, 1,899]	1,214 [1,101, 1,335]
Pelvic vein thrombosis (PVT)	0	NC	NC	0	0	82 [58, 113]	0	30 [10, 71]	75 [49, 109]
Pulmonary embolism (PE)	525 [211, 1,082]	906 [818, 1,000]	722 [346, 1,328]	552 [489, 622]	937 [681, 1,258]	845 [762, 934]	1,287 [995, 1,637]	880 [741, 1,037]	896 [800, 1,000]
Retinal vein thrombosis (RVT)	NC	109 [81, 145]	0	68 [47, 94]	0	35 [20, 57]	NC	98 [56, 158]	183 [142, 233]
Splanchnic extrahepatic vein thrombosis (SVT)	0	45 [28, 70]	NC	52 [34, 76]	0	148 [114, 187]	114 [42, 247]	42 [17, 87]	50 [29, 79]

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 11. Incidence rates [95% confidence interval] of thromboembolic events in melanoma after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Deep vein thrombosis (DVT)	0	171 [129, 222]	NC	202 [160, 250]	160 [73, 304]	385 [287, 505]	144 [47, 337]	225 [137, 347]	140 [89, 211]
Disseminated intravascular coagulation (DIC)	0	NC	0	0	0	NC	0	0	NC
PE and DVT combined (VTE)	0	510 [435, 594]	NC	366 [310, 430]	467 [305, 684]	617 [492, 765]	494 [288, 792]	568 [422, 749]	594 [481, 725]

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Pelvic vein thrombosis (PVT)	0	NC	NC	0	0	37 [12, 86]	0	0	42 [17, 87]
Pulmonary embolism (PE)	0	362 [300, 433]	NC	206 [165, 255]	302 [176, 483]	332 [242, 444]	376 [200, 642]	347 [236, 493]	484 [384, 604]
Retinal vein thrombosis (RVT)	0	49 [28, 79]	NC	32 [17, 54]	0	51 [21, 106]	0	89 [38, 176]	79 [42, 135]
Splanchnic extrahepatic vein thrombosis (SVT)	0	15 [5, 35]	0	NC	0	NC	0	NC	NC

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 12. Incidence rates [95% confidence interval] of thromboembolic events in ovarian cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Deep vein thrombosis (DVT)	0	1,007 [732, 1,352]	1,461 [475, 3,411]	826 [615, 1,086]	1,144 [494, 2,253]	1,994 [1,617, 2,432]	2,299 [1,441, 3,480]	2,182 [1,624, 2,868]	988 [728, 1,310]
Disseminated intravascular coagulation (DIC)	0	0	0	0	0	0	0	0	0
PE and DVT combined (VTE)	0	4,379 [3,765, 5,066]	3,294 [1,644, 5,894]	2,469 [2,087, 2,900]	3,695 [2,391, 5,455]	4,428 [3,848, 5,070]	6,419 [4,874, 8,298]	6,241 [5,239, 7,377]	4,352 [3,770, 4,999]
Pelvic vein thrombosis (PVT)	0	0	NC	0	0	NC	0	0	366 [217, 578]
Pulmonary embolism (PE)	0	3,674	2,675	1,833	2,461	3,024	4,766	4,284	3,551

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
		[3,117, 4,302]	[1,223, 5,079]	[1,509, 2,206]	[1,434, 3,941]	[2,553, 3,556]	[3,463, 6,398]	[3,478, 5,221]	[3,031, 4,134]
Retinal vein thrombosis (RVT)	0	NC	0	0	0	NC	0	NC	NC
Splanchnic extrahepatic vein thrombosis (SVT)	0	NC	0	NC	0	200 [96, 368]	NC	NC	NC

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 13. Incidence rates [95% confidence interval] of thromboembolic events in pancreatic cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Deep vein thrombosis (DVT)	0	2,002 [1,631, 2,433]	3,529 [1,295, 7,682]	1,014 [779, 1,297]	2,524 [1,649, 3,699]	4,181 [3,676, 4,737]	5,085 [3,580, 7,009]	5,915 [4,711, 7,332]	2,485 [2,107, 2,912]
Disseminated intravascular coagulation (DIC)	0	NC	0	0	0	181 [90, 324]	NC	0	0
PE and DVT combined (VTE)	NC	9,135 [8,300, 10,030]	8,962 [5,016, 14,782]	3,217 [2,780, 3,703]	6,191 [4,746, 7,936]	8,785 [8,037, 9,584]	18,371 [15,292, 21,888]	13,454 [11,565, 15,563]	10,312 [9,506, 11,168]
Pelvic vein thrombosis (PVT)	0	NC	0	0	0	99 [36, 216]	0	0	431 [284, 628]
Pulmonary embolism (PE)	NC	7,299 [6,561, 8,096]	6,845 [3,537, 11,956]	2,465 [2,089, 2,890]	3,878 [2,771, 5,281]	6,247 [5,625, 6,919]	14,421 [11,733, 17,540]	8,001 [6,588, 9,628]	8,508 [7,784, 9,282]
Retinal vein thrombosis (RVT)	0	NC	0	NC	0	99	0	NC	80

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
						[36, 216]			[26, 187]
Splanchnic extrahepatic vein thrombosis (SVT)	0	1,137 [864, 1,470]	5,196 [2,376, 9,865]	518 [357, 728]	0	4,990 [4,438, 5,593]	4,512 [3,106, 6,337]	1,441 [892, 2,202]	1,297 [1,030, 1,613]

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 14. Incidence rates [95% confidence interval] of thromboembolic events in prostate cancer after 2 year of follow-up, by database, per 100,000 person-years (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Deep vein thrombosis (DVT)	0	292 [248, 340]	648 [323, 1,159]	291 [255, 330]	502 [359, 683]	532 [461, 610]	207 [138, 300]	400 [327, 485]	265 [228, 307]
Disseminated intravascular coagulation (DIC)	0	NC	0	NC	0	39 [22, 64]	0	NC	NC
PE and DVT combined (VTE)	385 [141, 838]	788 [715, 867]	1,017 [593, 1,628]	667 [612, 725]	1,018 [807, 1,267]	852 [762, 950]	601 [476, 748]	862 [753, 983]	671 [610, 735]
Pelvic vein thrombosis (PVT)	0	NC	472 [204, 930]	0	0	31 [16, 54]	0	19 [6, 44]	80 [60, 104]
Pulmonary embolism (PE)	385 [141, 838]	554 [494, 620]	468 [202, 922]	438 [394, 486]	552 [401, 741]	464 [399, 538]	415 [314, 539]	489 [408, 581]	472 [422, 526]
Retinal vein thrombosis (RVT)	NC	88 [65, 117]	0	34 [22, 49]	0	65 [42, 96]	NC	139 [98, 192]	156 [128, 188]
Splanchnic extrahepatic vein thrombosis (SVT)	0	14 [6, 28]	0	10 [4, 19]	0	34 [18, 57]	NC	NC	NC

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 15. Incidence rates [95% confidence interval] of thromboembolic events in stomach cancer after 2 years of follow-up, by database, per 100,000 person-years (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Deep vein thrombosis (DVT)	0	649 [444, 916]	NC	649 [457, 894]	1,048 [453, 2,065]	2,666 [2,259, 3,125]	1,837 [917, 3,287]	2,726 [1,796, 3,966]	1,019 [717, 1,404]
Disseminated intravascular coagulation (DIC)	0	NC	0	0	0	204 [106, 357]	0	0	NC
PE and DVT combined (VTE)	NC	4,103 [3,547, 4,721]	6,696 [3,827, 10,874]	1,748 [1,417, 2,132]	3,082 [1,954, 4,625]	5,487 [4,890, 6,138]	8,277 [6,103, 10,975]	6,366 [4,870, 8,177]	5,267 [4,533, 6,085]
Pelvic vein thrombosis (PVT)	0	0	NC	0	0	171 [82, 314]	0	0	191 [77, 393]
Pulmonary embolism (PE)	NC	3,536 [3,024, 4,109]	5,648 [3,088, 9,477]	1,260 [984, 1,589]	2,093 [1,196, 3,399]	3,665 [3,185, 4,197]	6,995 [5,020, 9,489]	3,751 [2,641, 5,170]	4,411 [3,746, 5,160]
Retinal vein thrombosis (RVT)	0	NC	0	NC	0	85 [28, 199]	NC	NC	137 [44, 319]
Splanchnic extrahepatic vein thrombosis (SVT)	0	NC	0	NC	0	1,077 [827, 1,378]	NC	NC	136 [44, 317]

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 16. Incidence rates of Deep vein thrombosis (DVT) per 100,000 person-years (95% CI) from meta-analysis by cancer type.

Cancer type	Time at risk	Incidence per 100,000 py (95% CI)
Bone cancer	0 to 365	1,967 (181–3,753)
	0 to 730	1,461 (897–2,026)
Brain cancer	0 to 365	2,738 (1,499–3,978)
	0 to 730	2,146 (1,190–3,103)
Breast cancer	0 to 365	563 (356–769)
	0 to 730	392 (257–527)
Colorectal cancer	0 to 365	1,254 (772–1,735)
	0 to 730	946 (638–1,253)
Corpus uteri cancer	0 to 365	1,213 (630–1,795)
	0 to 730	811 (504–1,117)
Esophageal cancer	0 to 365	1,828 (555–3,101)
	0 to 730	1,449 (458–2,439)
Kidney cancer	0 to 365	1,892 (260–3,524)
	0 to 730	1,082 (411–1,754)
Liver cancer	0 to 365	1,762 (1,002–2,522)
	0 to 730	1,304 (826–1,781)
Lung cancer	0 to 365	1,790 (755–2,826)
	0 to 730	1,373 (717–2,029)

Cancer type	Time at risk	Incidence per 100,000 py (95% CI)
Lymphoma and leukemia	0 to 365	934 (602–1,265)
	0 to 730	670 (451–888)
Melanoma	0 to 365	230 (147–314)
	0 to 730	200 (126–274)
Ovarian cancer	0 to 365	2,024 (1,109–2,939)
	0 to 730	1,427 (930–1,924)
Pancreatic cancer	0 to 365	4,159 (2,034–6,283)
	0 to 730	3,238 (1,842–4,634)
Prostate cancer	0 to 365	441 (328–555)
	0 to 730	361 (249–472)
Stomach cancer	0 to 365	1,932 (818–3,046)
	0 to 730	1,451 (620–2,282)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 17. Incidence rates of Disseminated intravascular coagulation (DIC) per 100,000 person-years (95% CI) from meta-analysis by cancer type.

Cancer type	Time at risk	Incidence per 100,000 py (95% CI)
Bone cancer	0 to 365	NA
	0 to 730	NA
Brain cancer	0 to 365	NA
	0 to 730	NA
Breast cancer	0 to 365	20 (4–35)
	0 to 730	12 (3–22)
Colorectal cancer	0 to 365	138 (93–183)
	0 to 730	84 (58–110)
Corpus uteri cancer	0 to 365	NA
	0 to 730	NA
Esophageal cancer	0 to 365	NA
	0 to 730	NA
Kidney cancer	0 to 365	91 (18–163)
	0 to 730	59 (15–103)
Liver cancer	0 to 365	312 (136–489)
	0 to 730	245 (121–369)
Lung cancer	0 to 365	53 (0–433)
	0 to 730	40 (0–330)

Cancer type	Time at risk	Incidence per 100,000 py (95% CI)
Lymphoma and leukemia	0 to 365	127 (0–311)
	0 to 730	81 (0–194)
Melanoma	0 to 365	NA
	0 to 730	NA
Ovarian cancer	0 to 365	NA
	0 to 730	NA
Pancreatic cancer	0 to 365	244 (93–396)
	0 to 730	181 (74–288)
Prostate cancer	0 to 365	61 (28–94)
	0 to 730	39 (19–58)
Stomach cancer	0 to 365	299 (122–475)
	0 to 730	204 (89–320)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 18. Incidence rates of PE and DVT combined (VTE) per 100,000 person-years (95% CI) from meta-analysis by cancer type.

Cancer type	Time at risk	Incidence per 100,000 py (95% CI)
Bone cancer	0 to 365	3,076 (855–5,296)
	0 to 730	2,076 (623–3,530)
Brain cancer	0 to 365	7,295 (4,952–9,639)
	0 to 730	5,530 (3,699–7,361)
Breast cancer	0 to 365	1,208 (907–1,509)
	0 to 730	849 (641–1,057)
Colorectal cancer	0 to 365	3,606 (2,625–4,588)
	0 to 730	2,485 (1,848–3,122)
Corpus uteri cancer	0 to 365	2,649 (2,164–3,135)
	0 to 730	1,939 (1,583–2,294)
Esophageal cancer	0 to 365	6,287 (3,760–8,815)
	0 to 730	4,884 (2,908–6,860)
Kidney cancer	0 to 365	3,593 (2,144–5,042)
	0 to 730	2,354 (1,533–3,174)
Liver cancer	0 to 365	5,277 (3,673–6,882)
	0 to 730	3,818 (2,676–4,960)
Lung cancer	0 to 365	6,498 (4,203–8,793)
	0 to 730	4,811 (3,123–6,499)

Cancer type	Time at risk	Incidence per 100,000 py (95% CI)
Lymphoma and leukemia	0 to 365	1,912 (1,425–2,399)
	0 to 730	1,341 (1,022–1,660)
Melanoma	0 to 365	602 (478–726)
	0 to 730	512 (427–598)
Ovarian cancer	0 to 365	6,575 (4,660–8,489)
	0 to 730	4,371 (3,257–5,486)
Pancreatic cancer	0 to 365	12,697 (7,443–17,951)
	0 to 730	9,681 (5,901–13,462)
Prostate cancer	0 to 365	982 (876–1,087)
	0 to 730	752 (621–882)
Stomach cancer	0 to 365	6,548 (4,307–8,789)
	0 to 730	4,910 (3,187–6,632)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 19. Incidence rates of Pelvic vein thrombosis (PVT) per 100,000 person-years (95% CI) from meta-analysis by cancer type.

Cancer type	Time at risk	Incidence per 100,000 py (95% CI)
Bone cancer	0 to 365	NA
	0 to 730	NA
Brain cancer	0 to 365	270 (0–1,266)
	0 to 730	194 (0–787)
Breast cancer	0 to 365	58 (7–109)
	0 to 730	44 (0–94)
Colorectal cancer	0 to 365	112 (0–315)
	0 to 730	107 (0–295)
Corpus uteri cancer	0 to 365	192 (79–306)
	0 to 730	96 (0–565)
Esophageal cancer	0 to 365	NA
	0 to 730	NA
Kidney cancer	0 to 365	150 (0–820)
	0 to 730	112 (0–410)
Liver cancer	0 to 365	NA
	0 to 730	142 (18–267)
Lung cancer	0 to 365	108 (0–900)
	0 to 730	93 (0–662)

Cancer type	Time at risk	Incidence per 100,000 py (95% CI)
Lymphoma and leukemia	0 to 365	94 (13–176)
	0 to 730	62 (0–132)
Melanoma	0 to 365	NA
	0 to 730	40 (4–75)
Ovarian cancer	0 to 365	606 (309–903)
	0 to 730	366 (197–535)
Pancreatic cancer	0 to 365	559 (335–783)
	0 to 730	257 (0–2,366)
Prostate cancer	0 to 365	175 (0–837)
	0 to 730	98 (0–364)
Stomach cancer	0 to 365	273 (104–442)
	0 to 730	178 (58–298)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 20. Incidence rates of Pulmonary embolism (PE) per 100,000 person-years (95% CI) from meta-analysis by cancer type.

Cancer type	Time at risk	Incidence per 100,000 py (95% CI)
Bone cancer	0 to 365	1,941 (0–4,552)
	0 to 730	1,278 (159–2,396)
Brain cancer	0 to 365	5,043 (3,231–6,855)
	0 to 730	3,788 (2,430–5,146)
Breast cancer	0 to 365	779 (652–907)
	0 to 730	555 (470–640)
Colorectal cancer	0 to 365	2,699 (2,005–3,393)
	0 to 730	1,784 (1,356–2,211)
Corpus uteri cancer	0 to 365	1,812 (1,361–2,264)
	0 to 730	1,299 (947–1,652)
Esophageal cancer	0 to 365	4,645 (2,919–6,372)
	0 to 730	3,450 (2,199–4,701)
Kidney cancer	0 to 365	2,188 (1,559–2,817)
	0 to 730	1,474 (1,087–1,860)
Liver cancer	0 to 365	3,781 (2,152–5,410)
	0 to 730	2,683 (1,606–3,760)
Lung cancer	0 to 365	5,283 (3,447–7,118)
	0 to 730	3,858 (2,541–5,175)

Cancer type	Time at risk	Incidence per 100,000 py (95% CI)
Lymphoma and leukemia	0 to 365	1,212 (975–1,449)
	0 to 730	839 (680–999)
Melanoma	0 to 365	393 (267–519)
	0 to 730	338 (256–420)
Ovarian cancer	0 to 365	4,975 (3,662–6,289)
	0 to 730	3,248 (2,447–4,049)
Pancreatic cancer	0 to 365	9,502 (5,369–13,636)
	0 to 730	7,079 (4,150–10,008)
Prostate cancer	0 to 365	634 (593–674)
	0 to 730	477 (440–514)
Stomach cancer	0 to 365	4,950 (3,047–6,854)
	0 to 730	3,680 (2,232–5,128)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 21. Incidence rates of Retinal vein thrombosis broad (RVT) per 100,000 person-years (95% CI) from meta-analysis by cancer type.

Cancer type	Time at risk	Incidence per 100,000 py (95% CI)
Bone cancer	0 to 365	NA
	0 to 730	NA
Brain cancer	0 to 365	NA
	0 to 730	NA
Breast cancer	0 to 365	47 (17–77)
	0 to 730	48 (25–70)
Colorectal cancer	0 to 365	78 (24–132)
	0 to 730	76 (33–118)
Corpus uteri cancer	0 to 365	105 (21–189)
	0 to 730	100 (41–160)
Esophageal cancer	0 to 365	NA
	0 to 730	NA
Kidney cancer	0 to 365	87 (11–163)
	0 to 730	85 (15–154)
Liver cancer	0 to 365	NA
	0 to 730	256 (89–424)
Lung cancer	0 to 365	74 (26–121)
	0 to 730	87 (21–152)

Cancer type	Time at risk	Incidence per 100,000 py (95% CI)
Lymphoma and leukemia	0 to 365	119 (41–196)
	0 to 730	96 (28–165)
Melanoma	0 to 365	42 (0–149)
	0 to 730	50 (24–76)
Ovarian cancer	0 to 365	NA
	0 to 730	NA
Pancreatic cancer	0 to 365	123 (15–230)
	0 to 730	89 (0–207)
Prostate cancer	0 to 365	105 (36–174)
	0 to 730	94 (31–158)
Stomach cancer	0 to 365	NA
	0 to 730	100 (0–393)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 22. Incidence rates of Splanchnic extrahepatic vein thrombosis (SVT) per 100,000 person-years (95% CI) from meta-analysis by cancer type.

Cancer type	Time at risk	Incidence per 100,000 py (95% CI)
Bone cancer	0 to 365	NA
	0 to 730	NA
Brain cancer	0 to 365	NA
	0 to 730	NA
Breast cancer	0 to 365	21 (0–52)
	0 to 730	17 (1–33)
Colorectal cancer	0 to 365	199 (99–300)
	0 to 730	137 (65–210)
Corpus uteri cancer	0 to 365	NA
	0 to 730	45 (6–85)
Esophageal cancer	0 to 365	765 (291–1,238)
	0 to 730	714 (340–1,087)
Kidney cancer	0 to 365	363 (218–509)
	0 to 730	230 (143–316)
Liver cancer	0 to 365	7,448 (1,858–13,039)
	0 to 730	5,315 (1,285–9,344)
Lung cancer	0 to 365	164 (0–653)
	0 to 730	68 (0–168)

Cancer type	Time at risk	Incidence per 100,000 py (95% CI)
Lymphoma and leukemia	0 to 365	95 (18–172)
	0 to 730	70 (24–115)
Melanoma	0 to 365	NA
	0 to 730	15 (2–28)
Ovarian cancer	0 to 365	352 (134–571)
	0 to 730	200 (76–324)
Pancreatic cancer	0 to 365	3,274 (755–5,794)
	0 to 730	2,509 (657–4,360)
Prostate cancer	0 to 365	25 (0–203)
	0 to 730	17 (0–45)
Stomach cancer	0 to 365	876 (0–9,349)
	0 to 730	599 (0–6,576)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 23. Demographic characteristics (sex and age) of bone cancer, by database (2016–2022).

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
Number of patients		18	322	31	594	965	0	1,071	37	290
Sex	Female (%)	50.0	46.3	58.1	46.3	53.1	0	45.8	40.5	40.0
	Male (%)	50.0	53.7	41.9	53.7	46.9	0	54.2	59.5	60.0
Age	Median	62.5	60.0	59.0	64.0	59.0	0	59.0	69.0	66.0
	Mean	59.7	56.2	55.9	60.1	57.7	0	58.2	69.1	63.7
	18-34 (%)	<5	17.1	<5	10.8	12.6	0	12.8	0	6.2
	35-44 (%)	<5	10.9	16.1	9.8	9.4	0	12.0	0	7.9
	45-54 (%)	<5	16.1	<5	15.3	18.5	0	16.2	<5	14.1
	55-64 (%)	<5	15.5	22.6	14.5	22.1	0	19.0	18.9	18.3
	65-74 (%)	<5	21.4	25.8	27.4	17.3	0	17.1	48.6	23.1
	75-84 (%)	<5	14.3	<5	18.0	15.3	0	14.0	27.0	20.0
	85 and older (%)	<5	4.3	<5	4.2	4.7	0	8.8	0	10.3

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 24. Demographic characteristics (sex and age) of brain cancer, by database (2016–2022).

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
Number of patients		128	3,510	132	3,318	3,240	297	3,955	507	932
Sex	Female (%)	47.7	42.7	57.6	45.3	51.5	42.4	45.7	46.4	44.6
	Male (%)	52.3	57.3	42.4	54.7	48.5	57.6	54.3	53.6	55.4
Age	Median	60.5	64.0	56.0	65.0	60.0	65.0	64.0	70.0	65.0
	Mean	59.4	62.0	56.1	61.8	58.4	62.1	62.7	68.5	62.5
	18-34 (%)	7.8	7.1	6.8	8.4	11.0	5.4	5.6	0	6.0
	35-44 (%)	15.6	7.5	13.6	8.6	9.6	5.1	9.0	0	7.4
	45-54 (%)	14.8	13.4	24.2	11.9	16.5	19.2	16.0	5.1	13.4
	55-64 (%)	19.5	22.2	27.3	20.0	24.5	20.2	20.4	23.7	22.5
	65-74 (%)	22.7	27.4	18.9	28.5	19.3	30.3	22.4	47.1	28.1
	75-84 (%)	13.3	17.8	6.1	16.9	15.3	16.2	17.5	24.1	17.3
	85 and older (%)	6.2	4.5	<5	5.5	3.9	3.7	9.0	0	5.3

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 25. Demographic characteristics (sex and age) of breast cancer, by database (2016–2022).

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
Number of patients		1,853	31,873	1,243	38,047	56,337	6,553	31,931	5,180	18,134
Sex	Female (%)	91.3	99.2	99.6	99.5	98.3	98.1	99.0	99.2	99.4
	Male (%)	8.7	0.8	0.4	0.5	1.7	1.9	1.0	0.8	0.6
Age	Median	64.0	64.0	58.0	66.0	64.0	61.0	61.0	68.0	63.0
	Mean	63.1	63.2	58.1	65.6	63.8	61.1	61.5	66.6	62.9
	18-34 (%)	3.2	2.2	2.3	1.2	2.2	2.2	1.6	0	1.5
	35-44 (%)	6.7	7.3	11.4	4.9	6.2	8.9	11.1	0	7.0
	45-54 (%)	17.4	19.3	29.1	14.8	18.3	24.1	24.0	9.3	21.6
	55-64 (%)	23.5	23.2	25.1	24.7	24.2	23.8	22.7	28.6	24.6
	65-74 (%)	27.1	24.6	21.4	28.7	23.1	24.6	19.4	43.5	23.7
	75-84 (%)	15.3	17.7	8.9	18.2	20.6	11.1	13.3	18.7	14.8
85 and older (%)	6.7	5.6	1.8	7.6	5.5	5.3	7.9	0	6.8	

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 26. Demographic characteristics (sex and age) of colorectal cancer, by database (2016–2022).

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
Number of patients		382	29,279	762	23,146	24,061	5,400	29,755	3,848	11,798
Sex	Female (%)	50.3	46.8	62.5	47.5	48.0	44.3	42.2	47.3	45.1
	Male (%)	49.7	53.2	37.5	52.4	51.9	55.7	57.8	52.7	54.9
Age	Median	70.0	71.0	68.0	72.0	71.0	70.0	71.0	72.0	71.0
	Mean	69.0	69.8	66.8	71.0	69.5	68.9	70.5	70.1	69.9
	18-34 (%)	1.6	1.2	1.8	0.8	1.2	0.6	0.6	0	0.7
	35-44 (%)	3.9	2.1	3.0	1.9	2.6	2.1	2.2	0	2.9
	45-54 (%)	11.0	7.8	10.5	6.3	8.7	8.1	8.9	2.9	8.1
	55-64 (%)	20.7	18.3	23.8	17.7	20.6	23.2	20.5	19.8	19.3
	65-74 (%)	22.8	33.7	31.8	32.8	26.0	32.2	26.5	46.5	30.2
	75-84 (%)	25.1	26.8	22.8	28.3	31.1	25.5	26.6	30.8	26.5
85 and older (%)	14.9	10.0	6.3	12.2	9.9	8.2	14.7	0	12.1	

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 27. Demographic characteristics (sex and age) of corpus uteri cancer, by database (2016–2022).

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
Number of patients		60	4,910	260	6,121	5,113	622	4,858	899	2,453
Sex	Female (%)	93.3	100.0	100.0	99.9	99.6	100.0	99.9	100.0	100.0

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
	Male (%)	<5	0	0	0.1	0.4	0	<5	0	<5
Age	Median	73.5	68.0	61.0	70.0	66.0	69.0	66.0	69.0	68.0
	Mean	68.9	67.6	61.5	69.4	64.9	68.0	65.7	67.8	67.1
	18-34 (%)	<5	0.4	0	0.5	2.8	<5	1.2	0	0.3
	35-44 (%)	<5	2.3	7.3	2.1	5.2	1.4	4.6	0	2.7
	45-54 (%)	<5	10.9	19.6	7.3	13.9	9.6	13.7	5.1	9.9
	55-64 (%)	13.3	25.0	33.1	22.0	25.3	23.6	27.1	26.9	28.0
	65-74 (%)	26.7	32.1	27.7	33.9	24.1	36.0	26.6	47.9	32.0
	75-84 (%)	35.0	23.3	11.2	25.2	22.5	23.6	18.3	20.0	21.5
	85 and older (%)	10.0	6.2	<5	9.0	6.2	5.0	8.5	0	5.5

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 28. Demographic characteristics (sex and age) of oesophageal cancer, by database (2016–2022).

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
Number of patients		53	3,168	35	2,487	3,121	837	1,860	763	3,223
Sex	Female (%)	30.2	26.1	31.4	28.3	25.9	27.4	17.8	29.4	29.8
	Male (%)	69.8	73.9	68.6	71.6	74.0	72.6	82.2	70.6	70.2
Age	Median	65.0	70.0	66.0	69.0	68.0	70.0	66.0	72.0	72.0
	Mean	65.9	69.4	64.1	69.1	67.9	69.6	66.5	70.5	71.0

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
	18-34 (%)	<5	0.2	0	0.4	0.6	<5	0.5	0	<5
	35-44 (%)	<5	0.7	<5	1.3	1.6	1.0	2.5	0	1.2
	45-54 (%)	9.4	6.2	<5	7.0	8.1	6.1	13.8	1.6	6.4
	55-64 (%)	32.1	24.2	31.4	23.1	27.8	22.7	28.7	17.4	20.0
	65-74 (%)	26.4	37.8	42.9	38.1	31.1	39.2	27.4	50.7	32.6
	75-84 (%)	20.8	24.4	<5	22.4	24.8	22.9	19.2	30.3	29.3
	85 and older (%)	<5	6.6	0	7.7	5.9	8.0	8.0	0	10.4

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 29. Demographic characteristics (sex and age) of kidney cancer, by database (2016–2022).

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
Number of patients		33	6,498	289	6,394	9,149	1,068	7,404	950	1,096
Sex	Female (%)	39.4	32.5	53.3	40.0	38.6	36.0	36.6	36.6	37.1
	Male (%)	60.6	67.5	46.7	60.0	61.4	64.0	63.4	63.4	62.9
Age	Median	69.0	68.0	65.0	69.0	70.0	68.0	67.0	71.0	69.0
	Mean	68.9	66.1	65.3	68.3	68.7	67.2	66.5	69.6	67.2
	18-34 (%)	0	1.2	<5	1.1	1.0	0.7	1.1	0	0.9
	35-44 (%)	<5	3.9	2.1	3.1	2.8	3.5	5.0	0	3.6
	45-54 (%)	<5	12.4	15.2	8.9	9.3	11.6	14.8	3.2	12.5

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
	55-64 (%)	15.2	23.2	27.7	21.1	21.8	22.7	22.5	20.3	22.8
	65-74 (%)	27.3	33.7	31.8	34.3	28.0	32.8	26.5	48.2	29.3
	75-84 (%)	24.2	21.3	18.7	23.6	29.8	22.8	19.6	28.3	23.6
	85 and older (%)	15.2	4.1	3.5	8.0	7.3	6.1	10.6	0	7.3

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 30. Demographic characteristics (sex and age) of liver cancer, by database (2016–2022).

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
Number of patients		35	3,338	75	4,177	3,214	557	5,618	456	1,297
Sex	Female (%)	17.1	30.5	54.7	34.5	35.0	40.6	31.6	34.9	28.3
	Male (%)	82.9	69.5	45.3	65.5	64.8	59.4	68.4	65.1	71.7
Age	Median	70.0	71.0	69.0	72.0	71.0	71.0	70.0	73.0	71.0
	Mean	67.8	69.9	66.6	71.5	70.2	69.9	69.4	71.3	70.3
	18-34 (%)	<5	0.6	0	0.6	0.9	0.9	0.8	0	0.5
	35-44 (%)	0	1.8	6.7	1.7	2.0	2.0	2.5	0	0.9
	45-54 (%)	<5	5.5	10.7	5.0	6.3	6.3	9.4	1.8	6.9
	55-64 (%)	22.9	19.5	20.0	16.5	19.7	20.3	22.8	14.7	19.6
	65-74 (%)	28.6	37.1	33.3	36.0	30.5	33.9	26.3	48.7	35.5
75-84 (%)	28.6	28.4	26.7	28.6	31.5	28.0	25.3	34.9	27.4	

	IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
85 and older (%)	<5	7.0	<5	11.7	9.0	8.6	12.9	0	9.3

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 31. Demographic characteristics (sex and age) of lung cancer, by database (2016–2022).

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
Number of patients		486	27,757	332	16,828	20,343	5,288	20,068	2,581	11,844
Sex	Female (%)	40.5	51.1	44.0	39.4	42.8	45.3	27.6	51.9	50.7
	Male (%)	59.5	48.9	56.0	60.6	57.1	54.7	72.4	48.1	49.3
Age	Median	66.0	71.0	67.0	72.0	69.0	70.0	69.0	73.0	73.0
	Mean	63.1	70.5	66.9	71.3	68.5	69.3	68.7	71.5	72.1
	18-34 (%)	8.4	0.2	<5	0.2	0.8	0.6	0.2	0	0.1
	35-44 (%)	4.3	0.7	<5	0.8	1.6	1.2	1.7	0	0.7
	45-54 (%)	11.3	5.0	10.8	3.6	7.4	7.2	9.0	1.7	4.4
	55-64 (%)	22.8	19.5	30.1	17.4	25.0	21.8	25.6	12.3	16.3
	65-74 (%)	28.8	38.8	32.2	41.2	33.1	36.5	32.2	50.2	36.1
	75-84 (%)	18.7	29.2	21.7	27.8	26.3	25.4	22.3	35.8	31.6
85 and older (%)	5.6	6.6	3.3	8.9	5.7	7.1	9.0	0	10.9	

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 32. Demographic characteristics (sex and age) of leukaemia and lymphoma, by database (2016–2022).

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
Number of patients		815	25,172	884	20,690	33,640	3,009	28,831	3,029	10,429
Sex	Female (%)	50.3	44.2	60.0	48.4	48.6	42.8	52.4	46.9	45.7
	Male (%)	49.7	55.8	40.0	51.6	51.4	57.2	47.6	53.1	54.3
Age	Median	66.0	70.0	58.0	68.0	66.0	68.0	67.0	71.0	68.0
	Mean	63.3	67.4	57.0	65.2	63.6	64.7	64.7	70.0	65.6
	18-34 (%)	8.3	3.9	12.1	6.7	7.2	6.7	6.9	0	5.6
	35-44 (%)	8.5	3.8	13.2	6.0	6.7	4.9	8.5	0	5.6
	45-54 (%)	10.6	8.7	17.9	9.2	12.4	10.8	12.7	4.3	11.0
	55-64 (%)	19.4	17.5	19.5	17.9	20.7	19.3	16.5	16.8	18.6
	65-74 (%)	22.9	31.1	21.4	28.7	22.4	27.8	20.2	47.7	26.6
	75-84 (%)	20.7	27.1	12.3	22.6	23.7	22.9	21.2	31.2	23.0
85 and older (%)	9.6	7.9	3.6	8.8	6.9	7.4	13.8	0	9.5	

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 33. Demographic characteristics (sex and age) of melanoma, by database (2016–2022).

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
Number of patients		130	17,145	526	8,820	28,972	3,096	7,928	1,797	5,235
Sex	Female (%)	56.9	52.5	69.6	48.7	54.9	51.9	53.2	52.0	52.5
	Male (%)	43.1	47.5	30.4	51.3	45.0	48.1	46.8	48.0	47.5
Age	Median	62.0	62.0	52.0	67.0	61.0	62.0	63.0	70.0	64.0
	Mean	60.7	60.7	53.3	64.5	60.1	61.1	62.2	68.6	62.7
	18-34 (%)	6.9	6.3	15.6	5.5	8.5	4.3	5.2	0	6.0
	35-44 (%)	12.3	10.5	16.9	7.1	10.6	8.1	12.1	0	8.5
	45-54 (%)	17.7	19.1	20.2	11.9	16.7	20.2	16.9	6.4	16.0
	55-64 (%)	18.5	19.1	19.8	20.4	20.8	23.4	18.5	22.0	19.6
	65-74 (%)	20.8	23.3	18.3	26.5	19.6	24.5	21.0	45.7	24.4
	75-84 (%)	16.9	16.7	6.8	19.7	18.9	15.4	16.5	25.8	17.7
	85 and older (%)	6.9	4.9	2.5	8.9	4.9	3.9	9.7	<5	7.7

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 34. Demographic characteristics (sex and age) of ovarian cancer, by database (2016–2022).

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
Number of patients		54	2,842	217	3,085	4,603	473	3,244	572	1,704
Sex	Female (%)	83.3	99.9	100.0	99.9	99.0	100.0	100.0	100.0	99.9
	Male (%)	16.7	<5	0	0	0.9	0	<5	0	<5
Age	Median	65.0	68.0	58.0	67.0	64.0	66.0	61.0	69.0	66.0
	Mean	63.1	65.9	56.1	65.4	62.9	65.3	61.5	67.8	64.6
	18-34 (%)	<5	3.1	10.1	4.4	5.0	1.1	4.7	0	3.1
	35-44 (%)	11.1	4.3	12.0	4.6	6.2	5.5	8.8	0	5.3
	45-54 (%)	13.0	12.5	20.7	12.4	15.9	13.3	21.7	7.3	14.8
	55-64 (%)	18.5	21.3	26.7	20.7	24.8	26.0	22.4	25.5	24.0
	65-74 (%)	22.2	28.7	19.4	29.8	22.7	29.2	19.8	44.4	25.9
	75-84 (%)	14.8	23.3	8.3	20.6	20.6	18.4	14.3	22.7	20.5
85 and older (%)	14.8	6.8	2.8	7.7	4.8	6.3	8.3	0	6.4	

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 35. Demographic characteristics (sex and age) of pancreatic cancer, by database (2016–2022).

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
Number of patients		123	6,587	193	8,139	6,387	1,252	6,705	907	2,354
Sex	Female (%)	63.4	47.7	60.6	50.7	49.2	49.9	50.1	47.9	49.4
	Male (%)	36.6	52.3	39.4	49.3	50.7	50.1	49.9	52.1	50.6
Age	Median	71.0	72.0	69.0	72.0	72.0	71.0	72.0	73.0	73.0
	Mean	70.4	70.5	67.5	72.0	70.9	69.8	71.4	71.2	71.8
	18-34 (%)	0	0.6	<5	0.3	0.6	0.9	0.4	0	<5
	35-44 (%)	<5	1.3	3.6	0.9	1.5	1.7	2.3	0	1.1
	45-54 (%)	7.3	7.0	8.8	4.8	7.0	8.1	8.4	2.2	5.6
	55-64 (%)	18.7	17.9	25.9	17.0	19.4	20.0	18.0	15.1	17.9
	65-74 (%)	35.0	34.5	25.4	35.4	27.9	31.4	27.0	46.1	32.2
	75-84 (%)	29.3	29.7	27.5	29.1	33.2	29.2	26.5	36.6	30.8
85 and older (%)	8.9	9.0	7.3	12.5	10.4	8.8	17.3	0	12.1	

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 36. Demographic characteristics (sex and age) of prostate cancer, by database (2016–2022).

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
Number of patients		920	29,476	1,067	36,620	51,871	4,527	22,704	7,069	15,485
Sex	Female (%)	2.3	4.1	<5	0.1	0.7	0	<5	<5	0.0
	Male (%)	97.7	95.9	99.7	99.9	99.3	100.0	100.0	100.0	100.0
Age	Median	74.0	70.0	66.0	72.0	72.0	70.0	71.0	71.0	71.0
	Mean	73.4	69.1	66.4	71.5	71.2	70.2	71.6	70.2	71.1
	18-34 (%)	<5	1.9	<5	0.0	0.2	<5	<5	0	<5
	35-44 (%)	1.2	2.3	0.6	0.1	0.5	0.3	0.1	0	0.1
	45-54 (%)	2.2	3.3	9.9	3.0	4.9	3.5	3.8	1.5	3.0
	55-64 (%)	15.1	19.4	31.2	18.3	20.1	21.1	20.4	16.7	20.1
	65-74 (%)	33.2	42.7	37.3	41.8	33.2	44.4	37.8	53.9	41.5
	75-84 (%)	33.4	25.0	18.6	28.5	33.7	25.0	27.2	27.9	27.8
85 and older (%)	14.6	5.5	2.2	8.2	7.4	5.6	10.7	0	7.4	

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 37. Demographic characteristics (sex and age) of stomach cancer, by database (2016–2022).

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
Number of patients		42	4,137	191	3,300	4,737	678	5,059	488	1,055
Sex	Female (%)	28.6	31.6	60.2	41.7	44.5	37.2	42.0	35.7	36.9

		IQVIA LPD	DK-DHR	EBB	FinOMOP-THL	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD
	Male (%)	71.4	68.4	39.8	58.3	55.3	62.8	58.0	64.3	63.1
Age	Median	71.5	70.0	66.0	72.0	72.0	70.0	72.0	72.0	75.0
	Mean	69.3	68.6	64.6	70.9	69.9	68.0	70.8	70.5	72.6
	18-34 (%)	<5	1.1	<5	1.2	1.3	2.5	0.9	0	0.6
	35-44 (%)	0	2.7	5.2	2.1	2.6	3.4	3.2	0	2.7
	45-54 (%)	<5	8.7	17.3	5.4	8.5	9.9	8.5	3.9	7.2
	55-64 (%)	21.4	21.0	19.9	18.6	20.0	19.0	16.9	16.2	14.0
	65-74 (%)	26.2	32.6	29.3	32.2	24.8	28.6	26.8	45.3	25.3
	75-84 (%)	33.3	25.7	22.0	27.4	31.7	27.1	27.2	34.6	32.6
85 and older (%)	<5	8.2	4.2	13.2	11.1	9.3	16.4	0	17.5	

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 38. Medical conditions recorded anytime up to 181 days before the diagnosis of bone cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	18	322	31	965	0	1,071	37	290	594
Anxiety	<5	33 (10%)	<5	93 (10%)	0	238 (22%)	7 (19%)	46 (16%)	32 (5%)
Asthma	<5	54 (17%)	6 (19%)	55 (6%)	0	49 (5%)	5 (14%)	16 (6%)	51 (9%)
Attention deficit hyperactivity disorder	0 (0%)	<5	0 (0%)	<5	0	<5	0 (0%)	<5	<5
Chronic kidney disease	0 (0%)	5 (2%)	<5	24 (2%)	0	80 (7%)	<5	26 (9%)	8 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Chronic liver disease	0 (0%)	<5	<5	9 (1%)	0	12 (1%)	0 (0%)	0 (0%)	<5
Chronic obstructive lung disease	<5	28 (9%)	5 (16%)	59 (6%)	0	62 (6%)	<5	20 (7%)	23 (4%)
Covid 19	0 (0%)	0 (0%)	0 (0%)	9 (1%)	0	33 (3%)	0 (0%)	0 (0%)	<5
Crohns disease	0 (0%)	<5	<5	<5	0	<5	0 (0%)	<5	<5
Deep vein thrombosis	0 (0%)	0 (0%)	0 (0%)	15 (2%)	0	5 (0%)	<5	<5	<5
Dementia	0 (0%)	<5	<5	12 (1%)	0	15 (1%)	<5	7 (2%)	19 (3%)
Depressive disorder	0 (0%)	60 (19%)	<5	81 (8%)	0	135 (13%)	<5	37 (13%)	41 (7%)
Diabetes mellitus	<5	30 (9%)	<5	120 (12%)	0	135 (13%)	<5	36 (12%)	74 (12%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	6 (33%)	56 (17%)	11 (35%)	265 (27%)	0	333 (31%)	12 (32%)	65 (22%)	164 (28%)
Gastroesophageal reflux disease	6 (33%)	<5	9 (29%)	33 (3%)	0	68 (6%)	<5	5 (2%)	10 (2%)
Gastrointestinal hemorrhage	0 (0%)	11 (3%)	<5	16 (2%)	0	51 (5%)	<5	19 (7%)	10 (2%)
Human immunodeficiency virus infection	0 (0%)	0 (0%)	0 (0%)	<5	0	<5	0 (0%)	0 (0%)	0 (0%)
Hyperlipidemia	5 (28%)	88 (27%)	7 (23%)	165 (17%)	0	232 (22%)	10 (27%)	16 (6%)	71 (12%)
Myocardial infarction	0 (0%)	15 (5%)	0 (0%)	13 (1%)	0	23 (2%)	<5	7 (2%)	16 (3%)
Obesity	0 (0%)	22 (7%)	<5	94 (10%)	0	213 (20%)	<5	<5	27 (5%)
Osteoarthritis	6 (33%)	52 (16%)	17 (55%)	347 (36%)	0	251 (23%)	12 (32%)	41 (14%)	101 (17%)
Parkinsons disease	0 (0%)	0 (0%)	0 (0%)	8 (1%)	0	10 (1%)	0 (0%)	<5	<5
PE and DVT combined	0 (0%)	<5	0 (0%)	25 (3%)	0	7 (1%)	<5	6 (2%)	12 (2%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Pelvic vein thrombosis	0 (0%)	0 (0%)	<5	0 (0%)	0	<5	0 (0%)	0 (0%)	<5
Pneumonia	<5	80 (25%)	6 (19%)	28 (3%)	0	73 (7%)	<5	7 (2%)	51 (9%)
Psoriasis	<5	23 (7%)	5 (16%)	19 (2%)	0	26 (2%)	<5	11 (4%)	12 (2%)
Pulmonary embolism	0 (0%)	<5	0 (0%)	12 (1%)	0	<5	<5	<5	8 (1%)
Renal impairment	0 (0%)	6 (2%)	<5	40 (4%)	0	90 (8%)	<5	31 (11%)	14 (2%)
Retinal vein thrombosis broad	0 (0%)	0 (0%)	0 (0%)	<5	0	<5	0 (0%)	0 (0%)	5 (1%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	<5	0 (0%)	<5	0	<5	0 (0%)	<5	<5
Splanchnic extrahepatic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	<5	0 (0%)	0 (0%)	0 (0%)
Thromboembolic disorder	0 (0%)	0 (0%)	0 (0%)	16 (2%)	0	11 (1%)	<5	0 (0%)	<5
Ulcerative colitis	0 (0%)	8 (2%)	0 (0%)	<5	0	<5	<5	<5	5 (1%)
Viral hepatitis	0 (0%)	<5	<5	6 (1%)	0	19 (2%)	0 (0%)	0 (0%)	<5
Visual system disorder	<5	188 (58%)	26 (84%)	125 (13%)	0	480 (45%)	9 (24%)	96 (33%)	196 (33%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 39. Medical conditions recorded anytime up to 181 days before the diagnosis of brain cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	128	3,510	132	3,240	297	3,955	507	932	3,318
Anxiety	18 (14%)	320 (9%)	36 (27%)	403 (12%)	30 (10%)	832 (21%)	45 (9%)	145 (16%)	226 (7%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Asthma	16 (12%)	512 (15%)	23 (17%)	259 (8%)	13 (4%)	170 (4%)	43 (8%)	66 (7%)	227 (7%)
Attention deficit hyperactivity disorder	0 (0%)	23 (1%)	0 (0%)	21 (1%)	<5	12 (0%)	0 (0%)	0 (0%)	9 (0%)
Chronic kidney disease	<5	40 (1%)	<5	100 (3%)	<5	357 (9%)	18 (4%)	75 (8%)	45 (1%)
Chronic liver disease	0 (0%)	28 (1%)	<5	11 (0%)	<5	62 (2%)	<5	<5	12 (0%)
Chronic obstructive lung disease	16 (12%)	253 (7%)	7 (5%)	198 (6%)	5 (2%)	267 (7%)	21 (4%)	50 (5%)	108 (3%)
Covid 19	0 (0%)	0 (0%)	8 (6%)	14 (0%)	5 (2%)	108 (3%)	<5	<5	16 (0%)
Crohns disease	0 (0%)	16 (0%)	<5	10 (0%)	<5	<5	<5	5 (1%)	17 (1%)
Deep vein thrombosis	0 (0%)	29 (1%)	<5	34 (1%)	<5	38 (1%)	9 (2%)	20 (2%)	23 (1%)
Dementia	<5	44 (1%)	<5	65 (2%)	0 (0%)	72 (2%)	<5	6 (1%)	76 (2%)
Depressive disorder	<5	638 (18%)	39 (30%)	382 (12%)	11 (4%)	491 (12%)	53 (10%)	117 (13%)	208 (6%)
Diabetes mellitus	12 (9%)	370 (11%)	13 (10%)	463 (14%)	27 (9%)	590 (15%)	41 (8%)	71 (8%)	489 (15%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	48 (38%)	616 (18%)	51 (39%)	1,091 (34%)	57 (19%)	1,363 (34%)	161 (32%)	171 (18%)	1,061 (32%)
Gastroesophageal reflux disease	22 (17%)	46 (1%)	31 (23%)	103 (3%)	5 (2%)	274 (7%)	46 (9%)	39 (4%)	65 (2%)
Gastrointestinal hemorrhage	0 (0%)	137 (4%)	<5	52 (2%)	9 (3%)	165 (4%)	42 (8%)	54 (6%)	53 (2%)
Human immunodeficiency virus infection	0 (0%)	<5	0 (0%)	7 (0%)	<5	16 (0%)	<5	0 (0%)	<5
Hyperlipidemia	28 (22%)	1,065 (30%)	37 (28%)	669 (21%)	21 (7%)	1,006 (25%)	88 (17%)	85 (9%)	438 (13%)
Myocardial infarction	<5	142 (4%)	5 (4%)	77 (2%)	8 (3%)	103 (3%)	25 (5%)	19 (2%)	92 (3%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Obesity	<5	251 (7%)	17 (13%)	323 (10%)	<5	835 (21%)	41 (8%)	20 (2%)	104 (3%)
Osteoarthritis	22 (17%)	584 (17%)	51 (39%)	696 (21%)	22 (7%)	977 (25%)	114 (22%)	149 (16%)	560 (17%)
Parkinsons disease	<5	18 (1%)	<5	24 (1%)	0 (0%)	34 (1%)	<5	<5	21 (1%)
PE and DVT combined	5 (4%)	61 (2%)	<5	54 (2%)	<5	61 (2%)	15 (3%)	28 (3%)	44 (1%)
Pelvic vein thrombosis	0 (0%)	10 (0%)	<5	0 (0%)	0 (0%)	18 (0%)	<5	<5	10 (0%)
Pneumonia	<5	903 (26%)	17 (13%)	124 (4%)	18 (6%)	251 (6%)	25 (5%)	12 (1%)	228 (7%)
Psoriasis	<5	228 (6%)	11 (8%)	72 (2%)	<5	113 (3%)	15 (3%)	20 (2%)	43 (1%)
Pulmonary embolism	5 (4%)	37 (1%)	0 (0%)	24 (1%)	<5	32 (1%)	8 (2%)	11 (1%)	24 (1%)
Renal impairment	<5	65 (2%)	5 (4%)	150 (5%)	14 (5%)	402 (10%)	26 (5%)	76 (8%)	87 (3%)
Retinal vein thrombosis broad	<5	22 (1%)	<5	<5	0 (0%)	16 (0%)	<5	<5	21 (1%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	<5	0 (0%)
Schizophrenia	0 (0%)	27 (1%)	0 (0%)	13 (0%)	0 (0%)	15 (0%)	<5	<5	29 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	<5
Thromboembolic disorder	0 (0%)	<5	0 (0%)	41 (1%)	0 (0%)	37 (1%)	<5	<5	11 (0%)
Ulcerative colitis	0 (0%)	36 (1%)	0 (0%)	17 (1%)	<5	17 (0%)	6 (1%)	<5	30 (1%)
Viral hepatitis	0 (0%)	19 (1%)	5 (4%)	28 (1%)	<5	79 (2%)	<5	<5	6 (0%)
Visual system disorder	14 (11%)	2,114 (60%)	100 (76%)	486 (15%)	91 (31%)	1,786 (45%)	148 (29%)	284 (30%)	1,101 (33%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 40. Medical conditions recorded anytime up to 181 days before the diagnosis of breast cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	1,853	31,873	1,243	56,337	6,553	31,931	5,180	18,134	38,047
Anxiety	271 (15%)	3,761 (12%)	366 (29%)	5,225 (9%)	906 (14%)	8,980 (28%)	588 (11%)	3,395 (19%)	2,862 (8%)
Asthma	196 (11%)	5,868 (18%)	185 (15%)	3,245 (6%)	436 (7%)	1,757 (6%)	557 (11%)	1,453 (8%)	3,443 (9%)
Attention deficit hyperactivity disorder	<5	151 (0%)	0 (0%)	156 (0%)	25 (0%)	28 (0%)	<5	8 (0%)	36 (0%)
Chronic kidney disease	19 (1%)	276 (1%)	15 (1%)	1,151 (2%)	50 (1%)	2,160 (7%)	210 (4%)	1,478 (8%)	312 (1%)
Chronic liver disease	6 (0%)	212 (1%)	22 (2%)	249 (0%)	19 (0%)	310 (1%)	17 (0%)	63 (0%)	178 (0%)
Chronic obstructive lung disease	178 (10%)	2,383 (7%)	68 (5%)	2,504 (4%)	224 (3%)	1,035 (3%)	144 (3%)	708 (4%)	820 (2%)
Covid 19	<5	<5	56 (5%)	216 (0%)	178 (3%)	886 (3%)	<5	71 (0%)	113 (0%)
Crohns disease	5 (0%)	197 (1%)	6 (0%)	202 (0%)	33 (1%)	62 (0%)	32 (1%)	51 (0%)	144 (0%)
Deep vein thrombosis	0 (0%)	191 (1%)	22 (2%)	359 (1%)	50 (1%)	193 (1%)	51 (1%)	210 (1%)	245 (1%)
Dementia	19 (1%)	410 (1%)	7 (1%)	925 (2%)	56 (1%)	743 (2%)	22 (0%)	242 (1%)	1,391 (4%)
Depressive disorder	88 (5%)	6,981 (22%)	465 (37%)	4,212 (7%)	390 (6%)	5,254 (16%)	689 (13%)	3,193 (18%)	2,867 (8%)
Diabetes mellitus	194 (10%)	2,836 (9%)	121 (10%)	5,959 (11%)	534 (8%)	3,611 (11%)	320 (6%)	1,504 (8%)	5,107 (13%)
Disseminated intravascular coagulation	0 (0%)	5 (0%)	0 (0%)	<5	0 (0%)	5 (0%)	0 (0%)	<5	<5
Essential hypertension	639 (34%)	5,902 (19%)	498 (40%)	15,313 (27%)	1,422 (22%)	9,175 (29%)	1,296 (25%)	3,039 (17%)	12,423 (33%)
Gastroesophageal reflux disease	255 (14%)	598 (2%)	379 (30%)	1,395 (2%)	98 (1%)	2,275 (7%)	473 (9%)	731 (4%)	1,127 (3%)
Gastrointestinal hemorrhage	<5	1,038 (3%)	25 (2%)	755 (1%)	178 (3%)	1,159 (4%)	399 (8%)	1,018 (6%)	626 (2%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Human immunodeficiency virus infection	0 (0%)	13 (0%)	<5	17 (0%)	0 (0%)	26 (0%)	0 (0%)	0 (0%)	5 (0%)
Hyperlipidemia	391 (21%)	8,836 (28%)	341 (27%)	7,339 (13%)	493 (8%)	6,844 (21%)	641 (12%)	1,280 (7%)	5,190 (14%)
Myocardial infarction	7 (0%)	657 (2%)	19 (2%)	633 (1%)	95 (1%)	293 (1%)	83 (2%)	205 (1%)	676 (2%)
Obesity	22 (1%)	3,353 (11%)	218 (18%)	5,278 (9%)	181 (3%)	6,540 (20%)	329 (6%)	613 (3%)	1,402 (4%)
Osteoarthritis	253 (14%)	5,717 (18%)	596 (48%)	10,348 (18%)	825 (13%)	8,387 (26%)	1,157 (22%)	3,275 (18%)	8,743 (23%)
Parkinsons disease	<5	281 (1%)	12 (1%)	304 (1%)	8 (0%)	215 (1%)	14 (0%)	54 (0%)	223 (1%)
PE and DVT combined	8 (0%)	470 (1%)	30 (2%)	723 (1%)	89 (1%)	294 (1%)	96 (2%)	328 (2%)	551 (1%)
Pelvic vein thrombosis	0 (0%)	73 (0%)	31 (2%)	0 (0%)	0 (0%)	171 (1%)	33 (1%)	77 (0%)	130 (0%)
Pneumonia	46 (2%)	8,892 (28%)	211 (17%)	1,200 (2%)	369 (6%)	1,709 (5%)	141 (3%)	269 (1%)	2,310 (6%)
Psoriasis	43 (2%)	2,228 (7%)	81 (7%)	1,035 (2%)	131 (2%)	674 (2%)	118 (2%)	584 (3%)	494 (1%)
Pulmonary embolism	8 (0%)	287 (1%)	11 (1%)	408 (1%)	41 (1%)	134 (0%)	52 (1%)	136 (1%)	352 (1%)
Renal impairment	20 (1%)	425 (1%)	24 (2%)	1,770 (3%)	288 (4%)	2,360 (7%)	261 (5%)	1,577 (9%)	613 (2%)
Retinal vein thrombosis broad	<5	147 (0%)	<5	47 (0%)	0 (0%)	71 (0%)	15 (0%)	69 (0%)	183 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	8 (0%)	48 (0%)	0 (0%)
Schizophrenia	6 (0%)	304 (1%)	10 (1%)	160 (0%)	11 (0%)	137 (0%)	8 (0%)	40 (0%)	400 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	5 (0%)	<5	<5	0 (0%)	11 (0%)	<5	0 (0%)	7 (0%)
Thromboembolic disorder	<5	11 (0%)	0 (0%)	610 (1%)	0 (0%)	201 (1%)	<5	13 (0%)	81 (0%)
Ulcerative colitis	6 (0%)	385 (1%)	10 (1%)	220 (0%)	35 (1%)	111 (0%)	52 (1%)	78 (0%)	310 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Viral hepatitis	<5	118 (0%)	21 (2%)	314 (1%)	13 (0%)	392 (1%)	19 (0%)	21 (0%)	52 (0%)
Visual system disorder	207 (11%)	19,843 (62%)	997 (80%)	5,704 (10%)	2,012 (31%)	14,012 (44%)	1,546 (30%)	5,648 (31%)	13,631 (36%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 41. Medical conditions recorded anytime up to 181 days before the diagnosis of colorectal cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	382	29,279	762	24,061	5,400	29,755	3,848	11,798	23,146
Anxiety	39 (10%)	2,342 (8%)	191 (25%)	1,923 (8%)	471 (9%)	5,089 (17%)	331 (9%)	1,523 (13%)	938 (4%)
Asthma	32 (8%)	4,819 (16%)	107 (14%)	1,482 (6%)	306 (6%)	1,286 (4%)	369 (10%)	862 (7%)	2,121 (9%)
Attention deficit hyperactivity disorder	0 (0%)	91 (0%)	<5	81 (0%)	16 (0%)	19 (0%)	0 (0%)	<5	14 (0%)
Chronic kidney disease	10 (3%)	504 (2%)	31 (4%)	1,170 (5%)	69 (1%)	3,859 (13%)	188 (5%)	1,427 (12%)	426 (2%)
Chronic liver disease	<5	261 (1%)	28 (4%)	217 (1%)	14 (0%)	511 (2%)	27 (1%)	61 (1%)	156 (1%)
Chronic obstructive lung disease	40 (10%)	3,220 (11%)	75 (10%)	2,043 (8%)	328 (6%)	3,006 (10%)	184 (5%)	825 (7%)	996 (4%)
Covid 19	6 (2%)	<5	28 (4%)	100 (0%)	125 (2%)	615 (2%)	8 (0%)	40 (0%)	79 (0%)
Crohns disease	6 (2%)	166 (1%)	<5	137 (1%)	23 (0%)	49 (0%)	23 (1%)	39 (0%)	103 (0%)
Deep vein thrombosis	0 (0%)	235 (1%)	13 (2%)	281 (1%)	57 (1%)	308 (1%)	44 (1%)	188 (2%)	186 (1%)
Dementia	5 (1%)	453 (2%)	20 (3%)	757 (3%)	56 (1%)	940 (3%)	15 (0%)	182 (2%)	1,091 (5%)
Depressive disorder	21 (5%)	5,021 (17%)	257 (34%)	1,765 (7%)	222 (4%)	3,770 (13%)	415 (11%)	1,365 (12%)	1,088 (5%)
Diabetes mellitus	66 (17%)	4,226 (14%)	149 (20%)	5,078 (21%)	780 (14%)	6,358 (21%)	393 (10%)	1,629 (14%)	4,951 (21%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Disseminated intravascular coagulation	0 (0%)	<5	0 (0%)	<5	0 (0%)	8 (0%)	<5	0 (0%)	<5
Essential hypertension	158 (41%)	7,277 (25%)	429 (56%)	10,438 (43%)	1,457 (27%)	13,325 (45%)	1,229 (32%)	2,697 (23%)	9,701 (42%)
Gastroesophageal reflux disease	49 (13%)	462 (2%)	240 (31%)	972 (4%)	76 (1%)	2,057 (7%)	324 (8%)	437 (4%)	491 (2%)
Gastrointestinal hemorrhage	0 (0%)	1,126 (4%)	35 (5%)	737 (3%)	176 (3%)	1,936 (7%)	306 (8%)	949 (8%)	637 (3%)
Human immunodeficiency virus infection	<5	51 (0%)	0 (0%)	37 (0%)	8 (0%)	124 (0%)	<5	<5	12 (0%)
Hyperlipidemia	98 (26%)	11,585 (40%)	277 (36%)	5,895 (25%)	466 (9%)	9,047 (30%)	696 (18%)	1,167 (10%)	4,237 (18%)
Myocardial infarction	8 (2%)	1,589 (5%)	56 (7%)	865 (4%)	196 (4%)	1,085 (4%)	175 (5%)	404 (3%)	972 (4%)
Obesity	<5	2,088 (7%)	149 (20%)	2,773 (12%)	112 (2%)	7,359 (25%)	228 (6%)	378 (3%)	823 (4%)
Osteoarthritis	58 (15%)	5,351 (18%)	409 (54%)	5,350 (22%)	657 (12%)	8,630 (29%)	897 (23%)	2,328 (20%)	4,814 (21%)
Parkinsons disease	<5	306 (1%)	13 (2%)	222 (1%)	15 (0%)	344 (1%)	18 (0%)	51 (0%)	206 (1%)
PE and DVT combined	<5	633 (2%)	26 (3%)	465 (2%)	98 (2%)	466 (2%)	78 (2%)	306 (3%)	444 (2%)
Pelvic vein thrombosis	0 (0%)	52 (0%)	26 (3%)	0 (0%)	0 (0%)	123 (0%)	24 (1%)	55 (0%)	57 (0%)
Pneumonia	12 (3%)	8,661 (30%)	161 (21%)	940 (4%)	371 (7%)	2,264 (8%)	176 (5%)	296 (3%)	1,987 (9%)
Psoriasis	11 (3%)	2,083 (7%)	64 (8%)	618 (3%)	128 (2%)	797 (3%)	84 (2%)	361 (3%)	314 (1%)
Pulmonary embolism	<5	433 (1%)	14 (2%)	235 (1%)	49 (1%)	233 (1%)	42 (1%)	145 (1%)	284 (1%)
Renal impairment	10 (3%)	734 (3%)	41 (5%)	1,752 (7%)	375 (7%)	4,338 (15%)	262 (7%)	1,530 (13%)	745 (3%)
Retinal vein thrombosis broad	0 (0%)	251 (1%)	10 (1%)	39 (0%)	0 (0%)	126 (0%)	15 (0%)	89 (1%)	218 (1%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	17 (0%)	7 (0%)	73 (1%)	0 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Schizophrenia	<5	199 (1%)	8 (1%)	74 (0%)	9 (0%)	122 (0%)	22 (1%)	30 (0%)	182 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	14 (0%)	0 (0%)	6 (0%)	0 (0%)	23 (0%)	<5	8 (0%)	7 (0%)
Thromboembolic disorder	0 (0%)	8 (0%)	<5	350 (1%)	0 (0%)	324 (1%)	9 (0%)	14 (0%)	68 (0%)
Ulcerative colitis	<5	325 (1%)	12 (2%)	206 (1%)	23 (0%)	85 (0%)	61 (2%)	82 (1%)	227 (1%)
Viral hepatitis	<5	122 (0%)	13 (2%)	199 (1%)	11 (0%)	492 (2%)	25 (1%)	8 (0%)	47 (0%)
Visual system disorder	37 (10%)	17,893 (61%)	636 (83%)	3,930 (16%)	1,763 (33%)	15,381 (52%)	1,289 (33%)	4,136 (35%)	8,727 (38%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 42. Medical conditions recorded anytime up to 181 days before the diagnosis of corpus uteri cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	60	4,910	260	5,113	622	4,858	899	2,453	6,121
Anxiety	12 (20%)	545 (11%)	74 (28%)	571 (11%)	67 (11%)	1,289 (27%)	94 (10%)	448 (18%)	360 (6%)
Asthma	7 (12%)	861 (18%)	36 (14%)	324 (6%)	38 (6%)	289 (6%)	84 (9%)	184 (8%)	528 (9%)
Attention deficit hyperactivity disorder	0 (0%)	15 (0%)	0 (0%)	21 (0%)	<5	<5	0 (0%)	<5	7 (0%)
Chronic kidney disease	<5	63 (1%)	6 (2%)	187 (4%)	9 (1%)	489 (10%)	47 (5%)	294 (12%)	78 (1%)
Chronic liver disease	<5	25 (1%)	<5	26 (1%)	0 (0%)	53 (1%)	<5	15 (1%)	37 (1%)
Chronic obstructive lung disease	7 (12%)	300 (6%)	23 (9%)	287 (6%)	16 (3%)	135 (3%)	16 (2%)	62 (3%)	93 (2%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Covid 19	0 (0%)	0 (0%)	6 (2%)	22 (0%)	13 (2%)	144 (3%)	0 (0%)	9 (0%)	19 (0%)
Crohns disease	0 (0%)	18 (0%)	<5	16 (0%)	<5	7 (0%)	<5	6 (0%)	15 (0%)
Deep vein thrombosis	0 (0%)	33 (1%)	7 (3%)	46 (1%)	5 (1%)	51 (1%)	6 (1%)	43 (2%)	48 (1%)
Dementia	<5	51 (1%)	<5	131 (3%)	<5	114 (2%)	<5	22 (1%)	267 (4%)
Depressive disorder	<5	1,049 (21%)	97 (37%)	494 (10%)	21 (3%)	886 (18%)	122 (14%)	386 (16%)	429 (7%)
Diabetes mellitus	11 (18%)	852 (17%)	52 (20%)	949 (19%)	85 (14%)	919 (19%)	86 (10%)	399 (16%)	1,395 (23%)
Disseminated intravascular coagulation	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	29 (48%)	1,239 (25%)	152 (58%)	1,925 (38%)	200 (32%)	1,889 (39%)	274 (30%)	588 (24%)	2,687 (44%)
Gastroesophageal reflux disease	9 (15%)	84 (2%)	86 (33%)	142 (3%)	10 (2%)	402 (8%)	69 (8%)	100 (4%)	194 (3%)
Gastrointestinal hemorrhage	0 (0%)	156 (3%)	9 (3%)	107 (2%)	25 (4%)	205 (4%)	51 (6%)	123 (5%)	136 (2%)
Human immunodeficiency virus infection	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Hyperlipidemia	17 (28%)	1,801 (37%)	85 (33%)	862 (17%)	46 (7%)	1,319 (27%)	121 (13%)	199 (8%)	1,064 (17%)
Myocardial infarction	<5	118 (2%)	6 (2%)	88 (2%)	10 (2%)	61 (1%)	10 (1%)	39 (2%)	137 (2%)
Obesity	<5	854 (17%)	96 (37%)	1,024 (20%)	29 (5%)	1,704 (35%)	117 (13%)	199 (8%)	527 (9%)
Osteoarthritis	10 (17%)	1,001 (20%)	140 (54%)	1,078 (21%)	87 (14%)	1,662 (34%)	223 (25%)	562 (23%)	1,598 (26%)
Parkinsons disease	<5	45 (1%)	0 (0%)	23 (0%)	0 (0%)	23 (0%)	<5	5 (0%)	34 (1%)
PE and DVT combined	<5	100 (2%)	7 (3%)	83 (2%)	6 (1%)	72 (1%)	17 (2%)	68 (3%)	116 (2%)
Pelvic vein thrombosis	0 (0%)	10 (0%)	<5	0 (0%)	0 (0%)	18 (0%)	<5	9 (0%)	12 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Pneumonia	<5	1,368 (28%)	50 (19%)	147 (3%)	31 (5%)	259 (5%)	27 (3%)	40 (2%)	410 (7%)
Psoriasis	0 (0%)	377 (8%)	15 (6%)	109 (2%)	13 (2%)	98 (2%)	25 (3%)	92 (4%)	81 (1%)
Pulmonary embolism	<5	73 (1%)	<5	44 (1%)	<5	38 (1%)	13 (1%)	28 (1%)	74 (1%)
Renal impairment	<5	88 (2%)	10 (4%)	280 (5%)	42 (7%)	547 (11%)	55 (6%)	307 (13%)	140 (2%)
Retinal vein thrombosis broad	0 (0%)	36 (1%)	0 (0%)	<5	0 (0%)	12 (0%)	5 (1%)	12 (0%)	41 (1%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	<5	11 (0%)	0 (0%)
Schizophrenia	0 (0%)	47 (1%)	<5	25 (0%)	<5	36 (1%)	<5	12 (0%)	102 (2%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Thromboembolic disorder	0 (0%)	<5	0 (0%)	83 (2%)	0 (0%)	45 (1%)	0 (0%)	<5	17 (0%)
Ulcerative colitis	0 (0%)	51 (1%)	<5	17 (0%)	<5	17 (0%)	6 (1%)	8 (0%)	35 (1%)
Viral hepatitis	0 (0%)	15 (0%)	<5	41 (1%)	<5	56 (1%)	<5	<5	8 (0%)
Visual system disorder	8 (13%)	3,075 (63%)	201 (77%)	665 (13%)	227 (36%)	2,348 (48%)	295 (33%)	899 (37%)	2,429 (40%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 43. Medical conditions recorded anytime up to 181 days before the diagnosis of oesophageal cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	53	3,168	35	3,121	837	1,860	763	3,223	2,487
Anxiety	6 (11%)	328 (10%)	6 (17%)	235 (8%)	65 (8%)	311 (17%)	81 (11%)	352 (11%)	90 (4%)
Asthma	5 (9%)	580 (18%)	<5	225 (7%)	46 (5%)	68 (4%)	93 (12%)	274 (9%)	209 (8%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Attention deficit hyperactivity disorder	0 (0%)	9 (0%)	0 (0%)	11 (0%)	0 (0%)	<5	0 (0%)	<5	<5
Chronic kidney disease	<5	68 (2%)	0 (0%)	126 (4%)	7 (1%)	206 (11%)	48 (6%)	439 (14%)	54 (2%)
Chronic liver disease	0 (0%)	71 (2%)	<5	62 (2%)	<5	99 (5%)	11 (1%)	25 (1%)	36 (1%)
Chronic obstructive lung disease	9 (17%)	547 (17%)	<5	388 (12%)	79 (9%)	311 (17%)	72 (9%)	311 (10%)	195 (8%)
Covid 19	0 (0%)	0 (0%)	0 (0%)	12 (0%)	25 (3%)	49 (3%)	<5	11 (0%)	8 (0%)
Crohns disease	0 (0%)	18 (1%)	0 (0%)	18 (1%)	6 (1%)	<5	6 (1%)	9 (0%)	8 (0%)
Deep vein thrombosis	0 (0%)	35 (1%)	<5	26 (1%)	6 (1%)	26 (1%)	13 (2%)	62 (2%)	20 (1%)
Dementia	0 (0%)	71 (2%)	0 (0%)	106 (3%)	9 (1%)	44 (2%)	9 (1%)	35 (1%)	99 (4%)
Depressive disorder	<5	648 (20%)	15 (43%)	252 (8%)	29 (3%)	193 (10%)	95 (12%)	363 (11%)	131 (5%)
Diabetes mellitus	8 (15%)	463 (15%)	5 (14%)	635 (20%)	123 (15%)	388 (21%)	108 (14%)	491 (15%)	535 (22%)
Disseminated intravascular coagulation	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	22 (42%)	850 (27%)	22 (63%)	1,318 (42%)	230 (27%)	790 (42%)	317 (42%)	751 (23%)	1,046 (42%)
Gastroesophageal reflux disease	13 (25%)	82 (3%)	11 (31%)	232 (7%)	9 (1%)	132 (7%)	98 (13%)	135 (4%)	57 (2%)
Gastrointestinal hemorrhage	0 (0%)	203 (6%)	<5	98 (3%)	36 (4%)	114 (6%)	78 (10%)	210 (7%)	60 (2%)
Human immunodeficiency virus infection	0 (0%)	5 (0%)	0 (0%)	5 (0%)	0 (0%)	11 (1%)	0 (0%)	<5	<5
Hyperlipidemia	17 (32%)	1,376 (43%)	10 (29%)	734 (24%)	67 (8%)	512 (28%)	172 (23%)	322 (10%)	430 (17%)
Myocardial infarction	<5	231 (7%)	<5	135 (4%)	43 (5%)	79 (4%)	62 (8%)	129 (4%)	126 (5%)
Obesity	<5	180 (6%)	<5	311 (10%)	16 (2%)	445 (24%)	63 (8%)	99 (3%)	98 (4%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Osteoarthritis	10 (19%)	562 (18%)	21 (60%)	711 (23%)	84 (10%)	416 (22%)	189 (25%)	691 (21%)	504 (20%)
Parkinsons disease	<5	35 (1%)	0 (0%)	26 (1%)	<5	12 (1%)	5 (1%)	17 (1%)	17 (1%)
PE and DVT combined	<5	73 (2%)	<5	51 (2%)	12 (1%)	33 (2%)	25 (3%)	106 (3%)	47 (2%)
Pelvic vein thrombosis	0 (0%)	7 (0%)	<5	0 (0%)	0 (0%)	12 (1%)	<5	16 (0%)	6 (0%)
Pneumonia	<5	1,112 (35%)	10 (29%)	155 (5%)	81 (10%)	162 (9%)	65 (9%)	92 (3%)	248 (10%)
Psoriasis	<5	275 (9%)	<5	92 (3%)	24 (3%)	52 (3%)	26 (3%)	122 (4%)	49 (2%)
Pulmonary embolism	<5	45 (1%)	<5	31 (1%)	6 (1%)	14 (1%)	14 (2%)	54 (2%)	29 (1%)
Renal impairment	<5	103 (3%)	<5	203 (7%)	57 (7%)	242 (13%)	68 (9%)	469 (15%)	96 (4%)
Retinal vein thrombosis broad	0 (0%)	31 (1%)	0 (0%)	8 (0%)	0 (0%)	<5	<5	25 (1%)	28 (1%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	<5	18 (1%)	0 (0%)
Schizophrenia	0 (0%)	47 (1%)	0 (0%)	16 (1%)	<5	9 (0%)	6 (1%)	15 (0%)	41 (2%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	<5
Thromboembolic disorder	0 (0%)	<5	0 (0%)	45 (1%)	0 (0%)	45 (2%)	6 (1%)	<5	6 (0%)
Ulcerative colitis	0 (0%)	45 (1%)	0 (0%)	22 (1%)	6 (1%)	6 (0%)	7 (1%)	13 (0%)	26 (1%)
Viral hepatitis	0 (0%)	9 (0%)	0 (0%)	37 (1%)	<5	49 (3%)	7 (1%)	7 (0%)	5 (0%)
Visual system disorder	<5	1,881 (59%)	24 (69%)	438 (14%)	269 (32%)	885 (48%)	272 (36%)	1,225 (38%)	886 (36%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 44. Medical conditions recorded anytime up to 181 days before the diagnosis of kidney cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	33	6,498	289	9,149	1,068	7,404	950	1,096	6,394
Anxiety	<5	600 (9%)	55 (19%)	642 (7%)	109 (10%)	1,552 (21%)	93 (10%)	169 (15%)	318 (5%)
Asthma	<5	1,146 (18%)	45 (16%)	452 (5%)	66 (6%)	325 (4%)	116 (12%)	86 (8%)	652 (10%)
Attention deficit hyperactivity disorder	0 (0%)	44 (1%)	0 (0%)	32 (0%)	<5	9 (0%)	0 (0%)	<5	6 (0%)
Chronic kidney disease	<5	201 (3%)	25 (9%)	600 (7%)	13 (1%)	1,252 (17%)	88 (9%)	170 (16%)	251 (4%)
Chronic liver disease	0 (0%)	77 (1%)	11 (4%)	79 (1%)	5 (0%)	147 (2%)	6 (1%)	7 (1%)	51 (1%)
Chronic obstructive lung disease	<5	696 (11%)	27 (9%)	713 (8%)	78 (7%)	639 (9%)	49 (5%)	74 (7%)	302 (5%)
Covid 19	0 (0%)	0 (0%)	10 (3%)	35 (0%)	31 (3%)	180 (2%)	<5	<5	29 (0%)
Crohns disease	0 (0%)	52 (1%)	<5	47 (1%)	9 (1%)	30 (0%)	10 (1%)	8 (1%)	42 (1%)
Deep vein thrombosis	0 (0%)	45 (1%)	5 (2%)	87 (1%)	10 (1%)	73 (1%)	16 (2%)	19 (2%)	44 (1%)
Dementia	0 (0%)	66 (1%)	<5	160 (2%)	17 (2%)	175 (2%)	7 (1%)	13 (1%)	213 (3%)
Depressive disorder	<5	1,231 (19%)	84 (29%)	579 (6%)	51 (5%)	1,017 (14%)	107 (11%)	174 (16%)	369 (6%)
Diabetes mellitus	5 (15%)	1,195 (18%)	71 (25%)	1,935 (21%)	204 (19%)	1,531 (21%)	134 (14%)	165 (15%)	1,612 (25%)
Disseminated intravascular coagulation	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	16 (48%)	1,979 (30%)	189 (65%)	4,000 (44%)	342 (32%)	3,496 (47%)	422 (44%)	284 (26%)	3,179 (50%)
Gastroesophageal reflux disease	6 (18%)	143 (2%)	92 (32%)	278 (3%)	18 (2%)	584 (8%)	101 (11%)	42 (4%)	191 (3%)
Gastrointestinal hemorrhage	<5	325 (5%)	12 (4%)	158 (2%)	34 (3%)	409 (6%)	105 (11%)	86 (8%)	172 (3%)
Human immunodeficiency virus infection	0 (0%)	6 (0%)	0 (0%)	<5	<5	18 (0%)	<5	0 (0%)	8 (0%)
Hyperlipidemia	8 (24%)	2,845 (44%)	105 (36%)	1,977 (22%)	93 (9%)	2,253 (30%)	207 (22%)	121 (11%)	1,213 (19%)
Myocardial infarction	<5	399 (6%)	21 (7%)	312 (3%)	51 (5%)	301 (4%)	59 (6%)	41 (4%)	301 (5%)
Obesity	<5	665 (10%)	82 (28%)	1,201 (13%)	26 (2%)	1,969 (27%)	63 (7%)	35 (3%)	359 (6%)
Osteoarthritis	<5	1,265 (19%)	167 (58%)	1,886 (21%)	152 (14%)	2,041 (28%)	234 (25%)	220 (20%)	1,513 (24%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	<5	80 (1%)	8 (3%)	91 (1%)	<5	74 (1%)	5 (1%)	10 (1%)	56 (1%)
PE and DVT combined	0 (0%)	121 (2%)	8 (3%)	180 (2%)	21 (2%)	109 (1%)	22 (2%)	36 (3%)	124 (2%)
Pelvic vein thrombosis	0 (0%)	24 (0%)	5 (2%)	0 (0%)	0 (0%)	48 (1%)	7 (1%)	7 (1%)	22 (0%)
Pneumonia	<5	2,139 (33%)	59 (20%)	312 (3%)	89 (8%)	575 (8%)	64 (7%)	26 (2%)	581 (9%)
Psoriasis	0 (0%)	516 (8%)	15 (5%)	198 (2%)	24 (2%)	219 (3%)	27 (3%)	41 (4%)	117 (2%)
Pulmonary embolism	0 (0%)	83 (1%)	5 (2%)	99 (1%)	12 (1%)	51 (1%)	7 (1%)	20 (2%)	85 (1%)
Renal impairment	<5	248 (4%)	25 (9%)	854 (9%)	120 (11%)	1,353 (18%)	115 (12%)	180 (16%)	360 (6%)
Retinal vein thrombosis broad	0 (0%)	63 (1%)	<5	14 (0%)	0 (0%)	25 (0%)	6 (1%)	<5	46 (1%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	5 (0%)	<5	<5	0 (0%)
Schizophrenia	0 (0%)	60 (1%)	0 (0%)	30 (0%)	<5	37 (0%)	<5	<5	59 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	<5	0 (0%)	0 (0%)
Thromboembolic disorder	0 (0%)	<5	0 (0%)	126 (1%)	0 (0%)	61 (1%)	<5	5 (0%)	28 (0%)
Ulcerative colitis	0 (0%)	94 (1%)	<5	45 (0%)	14 (1%)	30 (0%)	18 (2%)	<5	71 (1%)
Viral hepatitis	0 (0%)	47 (1%)	<5	59 (1%)	5 (0%)	144 (2%)	6 (1%)	<5	23 (0%)
Visual system disorder	<5	4,043 (62%)	243 (84%)	1,174 (13%)	362 (34%)	3,690 (50%)	324 (34%)	380 (35%)	2,430 (38%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 45. Medical conditions recorded anytime up to 181 days before the diagnosis of liver cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	35	3,338	75	3,214	557	5,618	456	1,297	4,177
Anxiety	<5	368 (11%)	18 (24%)	275 (9%)	45 (8%)	981 (17%)	51 (11%)	182 (14%)	176 (4%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Asthma	<5	588 (18%)	11 (15%)	252 (8%)	45 (8%)	231 (4%)	60 (13%)	93 (7%)	436 (10%)
Attention deficit hyperactivity disorder	0 (0%)	10 (0%)	0 (0%)	14 (0%)	<5	5 (0%)	0 (0%)	<5	<5
Chronic kidney disease	0 (0%)	108 (3%)	<5	237 (7%)	7 (1%)	740 (13%)	42 (9%)	188 (14%)	114 (3%)
Chronic liver disease	<5	768 (23%)	25 (33%)	542 (17%)	38 (7%)	1,847 (33%)	92 (20%)	267 (21%)	720 (17%)
Chronic obstructive lung disease	6 (17%)	542 (16%)	13 (17%)	423 (13%)	68 (12%)	795 (14%)	41 (9%)	124 (10%)	323 (8%)
Covid 19	0 (0%)	0 (0%)	6 (8%)	11 (0%)	13 (2%)	132 (2%)	<5	<5	8 (0%)
Crohns disease	0 (0%)	28 (1%)	<5	21 (1%)	<5	11 (0%)	<5	8 (1%)	32 (1%)
Deep vein thrombosis	0 (0%)	32 (1%)	5 (7%)	47 (1%)	6 (1%)	80 (1%)	5 (1%)	20 (2%)	43 (1%)
Dementia	<5	72 (2%)	<5	129 (4%)	<5	171 (3%)	<5	22 (2%)	250 (6%)
Depressive disorder	<5	742 (22%)	26 (35%)	265 (8%)	33 (6%)	744 (13%)	71 (16%)	195 (15%)	279 (7%)
Diabetes mellitus	11 (31%)	1,091 (33%)	22 (29%)	1,227 (38%)	136 (24%)	1,814 (32%)	142 (31%)	438 (34%)	1,820 (44%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5
Essential hypertension	17 (49%)	1,198 (36%)	50 (67%)	1,769 (55%)	153 (27%)	2,766 (49%)	231 (51%)	342 (26%)	2,238 (54%)
Gastroesophageal reflux disease	5 (14%)	89 (3%)	29 (39%)	148 (5%)	9 (2%)	435 (8%)	61 (13%)	55 (4%)	113 (3%)
Gastrointestinal hemorrhage	0 (0%)	384 (12%)	<5	111 (3%)	28 (5%)	565 (10%)	49 (11%)	131 (10%)	265 (6%)
Human immunodeficiency virus infection	0 (0%)	11 (0%)	0 (0%)	8 (0%)	<5	72 (1%)	<5	<5	7 (0%)
Hyperlipidemia	7 (20%)	1,466 (44%)	28 (37%)	920 (29%)	40 (7%)	1,409 (25%)	99 (22%)	88 (7%)	778 (19%)
Myocardial infarction	<5	233 (7%)	8 (11%)	151 (5%)	26 (5%)	214 (4%)	37 (8%)	68 (5%)	243 (6%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Obesity	0 (0%)	371 (11%)	21 (28%)	523 (16%)	19 (3%)	1,553 (28%)	58 (13%)	67 (5%)	306 (7%)
Osteoarthritis	5 (14%)	727 (22%)	48 (64%)	873 (27%)	82 (15%)	1,643 (29%)	139 (30%)	310 (24%)	957 (23%)
Parkinsons disease	<5	45 (1%)	<5	41 (1%)	<5	52 (1%)	<5	<5	36 (1%)
PE and DVT combined	<5	82 (2%)	6 (8%)	70 (2%)	15 (3%)	102 (2%)	14 (3%)	32 (2%)	84 (2%)
Pelvic vein thrombosis	0 (0%)	11 (0%)	<5	0 (0%)	0 (0%)	18 (0%)	<5	<5	13 (0%)
Pneumonia	0 (0%)	1,303 (39%)	20 (27%)	177 (6%)	70 (13%)	576 (10%)	43 (9%)	49 (4%)	528 (13%)
Psoriasis	<5	352 (11%)	8 (11%)	122 (4%)	25 (4%)	224 (4%)	17 (4%)	68 (5%)	142 (3%)
Pulmonary embolism	<5	50 (1%)	<5	29 (1%)	12 (2%)	39 (1%)	9 (2%)	15 (1%)	44 (1%)
Renal impairment	0 (0%)	161 (5%)	<5	329 (10%)	58 (10%)	936 (17%)	66 (14%)	216 (17%)	231 (6%)
Retinal vein thrombosis broad	0 (0%)	27 (1%)	0 (0%)	8 (0%)	0 (0%)	20 (0%)	<5	12 (1%)	36 (1%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	<5	9 (1%)	0 (0%)
Schizophrenia	0 (0%)	52 (2%)	0 (0%)	13 (0%)	<5	44 (1%)	<5	<5	55 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	20 (1%)	<5	14 (0%)	0 (0%)	86 (2%)	<5	<5	12 (0%)
Thromboembolic disorder	0 (0%)	7 (0%)	<5	49 (2%)	0 (0%)	73 (1%)	<5	<5	18 (0%)
Ulcerative colitis	<5	69 (2%)	<5	24 (1%)	6 (1%)	21 (0%)	7 (2%)	10 (1%)	77 (2%)
Viral hepatitis	0 (0%)	274 (8%)	15 (20%)	254 (8%)	14 (3%)	1,248 (22%)	25 (5%)	43 (3%)	152 (4%)
Visual system disorder	5 (14%)	2,157 (65%)	66 (88%)	673 (21%)	228 (41%)	3,105 (55%)	181 (40%)	613 (47%)	1,875 (45%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 46. Medical conditions recorded anytime up to 181 days before the diagnosis of lung cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	486	27,757	332	20,343	5,288	20,068	2,581	11,844	16,828
Anxiety	78 (16%)	3,324 (12%)	67 (20%)	1,960 (10%)	506 (10%)	3,892 (19%)	329 (13%)	1,863 (16%)	838 (5%)
Asthma	73 (15%)	7,066 (25%)	74 (22%)	2,146 (11%)	424 (8%)	801 (4%)	356 (14%)	992 (8%)	2,344 (14%)
Attention deficit hyperactivity disorder	0 (0%)	77 (0%)	0 (0%)	71 (0%)	19 (0%)	20 (0%)	<5	<5	11 (0%)
Chronic kidney disease	7 (1%)	586 (2%)	13 (4%)	997 (5%)	97 (2%)	2,483 (12%)	203 (8%)	1,762 (15%)	399 (2%)
Chronic liver disease	<5	416 (1%)	6 (2%)	255 (1%)	22 (0%)	509 (3%)	34 (1%)	110 (1%)	163 (1%)
Chronic obstructive lung disease	143 (29%)	8,152 (29%)	79 (24%)	5,491 (27%)	1,159 (22%)	5,344 (27%)	598 (23%)	3,184 (27%)	3,599 (21%)
Covid 19	<5	<5	7 (2%)	72 (0%)	112 (2%)	351 (2%)	8 (0%)	34 (0%)	46 (0%)
Crohns disease	<5	228 (1%)	<5	100 (0%)	36 (1%)	46 (0%)	24 (1%)	37 (0%)	75 (0%)
Deep vein thrombosis	0 (0%)	200 (1%)	<5	240 (1%)	64 (1%)	183 (1%)	48 (2%)	192 (2%)	151 (1%)
Dementia	<5	444 (2%)	8 (2%)	630 (3%)	64 (1%)	443 (2%)	33 (1%)	248 (2%)	770 (5%)
Depressive disorder	13 (3%)	6,832 (25%)	114 (34%)	1,965 (10%)	323 (6%)	2,774 (14%)	395 (15%)	1,995 (17%)	1,151 (7%)
Diabetes mellitus	54 (11%)	4,137 (15%)	48 (14%)	4,257 (21%)	778 (15%)	4,346 (22%)	355 (14%)	1,721 (15%)	3,765 (22%)
Disseminated intravascular coagulation	0 (0%)	9 (0%)	0 (0%)	0 (0%)	0 (0%)	9 (0%)	0 (0%)	0 (0%)	<5
Essential hypertension	194 (40%)	7,565 (27%)	182 (55%)	8,921 (44%)	1,406 (27%)	8,980 (45%)	1,135 (44%)	2,846 (24%)	7,337 (44%)
Gastroesophageal reflux disease	73 (15%)	599 (2%)	111 (33%)	872 (4%)	83 (2%)	1,383 (7%)	322 (12%)	466 (4%)	382 (2%)
Gastrointestinal hemorrhage	<5	1,554 (6%)	16 (5%)	423 (2%)	212 (4%)	1,186 (6%)	254 (10%)	802 (7%)	491 (3%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Human immunodeficiency virus infection	<5	38 (0%)	0 (0%)	27 (0%)	<5	110 (1%)	<5	<5	14 (0%)
Hyperlipidemia	161 (33%)	13,267 (48%)	120 (36%)	5,331 (26%)	485 (9%)	6,753 (34%)	675 (26%)	1,284 (11%)	3,234 (19%)
Myocardial infarction	15 (3%)	2,246 (8%)	40 (12%)	1,134 (6%)	320 (6%)	1,089 (5%)	250 (10%)	679 (6%)	1,126 (7%)
Obesity	7 (1%)	1,819 (7%)	59 (18%)	2,125 (10%)	86 (2%)	4,306 (21%)	201 (8%)	341 (3%)	497 (3%)
Osteoarthritis	76 (16%)	5,600 (20%)	188 (57%)	4,864 (24%)	688 (13%)	5,119 (26%)	747 (29%)	2,704 (23%)	3,470 (21%)
Parkinsons disease	<5	307 (1%)	<5	183 (1%)	10 (0%)	157 (1%)	11 (0%)	35 (0%)	102 (1%)
PE and DVT combined	<5	582 (2%)	7 (2%)	479 (2%)	107 (2%)	288 (1%)	74 (3%)	307 (3%)	353 (2%)
Pelvic vein thrombosis	0 (0%)	64 (0%)	5 (2%)	0 (0%)	0 (0%)	82 (0%)	16 (1%)	36 (0%)	42 (0%)
Pneumonia	43 (9%)	12,213 (44%)	99 (30%)	1,560 (8%)	636 (12%)	2,456 (12%)	257 (10%)	616 (5%)	2,731 (16%)
Psoriasis	11 (2%)	2,425 (9%)	32 (10%)	634 (3%)	153 (3%)	610 (3%)	94 (4%)	506 (4%)	394 (2%)
Pulmonary embolism	<5	411 (1%)	<5	272 (1%)	50 (1%)	150 (1%)	36 (1%)	138 (1%)	222 (1%)
Renal impairment	8 (2%)	859 (3%)	20 (6%)	1,505 (7%)	477 (9%)	2,896 (14%)	276 (11%)	1,887 (16%)	675 (4%)
Retinal vein thrombosis broad	<5	277 (1%)	5 (2%)	36 (0%)	0 (0%)	103 (1%)	13 (1%)	105 (1%)	159 (1%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	8 (0%)	6 (0%)	67 (1%)	0 (0%)
Schizophrenia	7 (1%)	361 (1%)	<5	96 (0%)	21 (0%)	192 (1%)	14 (1%)	42 (0%)	347 (2%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	10 (0%)	0 (0%)	5 (0%)	0 (0%)	10 (0%)	<5	6 (0%)	8 (0%)
Thromboembolic disorder	0 (0%)	28 (0%)	0 (0%)	339 (2%)	0 (0%)	334 (2%)	12 (0%)	25 (0%)	50 (0%)
Ulcerative colitis	<5	347 (1%)	<5	112 (1%)	32 (1%)	90 (0%)	31 (1%)	49 (0%)	136 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Viral hepatitis	0 (0%)	167 (1%)	6 (2%)	219 (1%)	18 (0%)	507 (3%)	27 (1%)	21 (0%)	43 (0%)
Visual system disorder	71 (15%)	17,578 (63%)	264 (80%)	3,251 (16%)	1,864 (35%)	10,110 (50%)	1,014 (39%)	4,468 (38%)	6,581 (39%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 47. Medical conditions recorded anytime up to 181 days before the diagnosis of leukaemia and lymphoma, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	815	25,172	884	33,640	3,009	28,831	3,029	10,429	20,690
Anxiety	104 (13%)	2,294 (9%)	219 (25%)	3,370 (10%)	271 (9%)	6,274 (22%)	313 (10%)	1,475 (14%)	1,234 (6%)
Asthma	125 (15%)	4,499 (18%)	137 (15%)	2,500 (7%)	186 (6%)	1,563 (5%)	368 (12%)	828 (8%)	1,881 (9%)
Attention deficit hyperactivity disorder	<5	118 (0%)	0 (0%)	179 (1%)	20 (1%)	50 (0%)	0 (0%)	17 (0%)	65 (0%)
Chronic kidney disease	7 (1%)	545 (2%)	29 (3%)	1,509 (4%)	23 (1%)	3,649 (13%)	206 (7%)	1,222 (12%)	353 (2%)
Chronic liver disease	<5	248 (1%)	26 (3%)	352 (1%)	10 (0%)	502 (2%)	21 (1%)	60 (1%)	157 (1%)
Chronic obstructive lung disease	122 (15%)	2,777 (11%)	75 (8%)	3,111 (9%)	150 (5%)	2,412 (8%)	161 (5%)	697 (7%)	791 (4%)
Covid 19	<5	<5	29 (3%)	191 (1%)	91 (3%)	842 (3%)	6 (0%)	44 (0%)	91 (0%)
Crohns disease	7 (1%)	211 (1%)	6 (1%)	195 (1%)	28 (1%)	89 (0%)	31 (1%)	44 (0%)	105 (1%)
Deep vein thrombosis	0 (0%)	248 (1%)	20 (2%)	451 (1%)	27 (1%)	358 (1%)	60 (2%)	223 (2%)	211 (1%)
Dementia	5 (1%)	280 (1%)	10 (1%)	780 (2%)	34 (1%)	910 (3%)	20 (1%)	135 (1%)	719 (3%)
Depressive disorder	25 (3%)	4,805 (19%)	285 (32%)	2,786 (8%)	142 (5%)	4,185 (15%)	371 (12%)	1,309 (13%)	1,335 (6%)
Diabetes mellitus	86 (11%)	3,148 (13%)	134 (15%)	6,092 (18%)	363 (12%)	5,051 (18%)	340 (11%)	1,159 (11%)	3,697 (18%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Disseminated intravascular coagulation	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	10 (0%)	0 (0%)	0 (0%)	<5
Essential hypertension	309 (38%)	6,283 (25%)	407 (46%)	12,763 (38%)	662 (22%)	11,046 (38%)	1,157 (38%)	2,045 (20%)	7,486 (36%)
Gastroesophageal reflux disease	120 (15%)	502 (2%)	280 (32%)	1,283 (4%)	37 (1%)	2,184 (8%)	307 (10%)	395 (4%)	614 (3%)
Gastrointestinal hemorrhage	13 (2%)	1,258 (5%)	27 (3%)	774 (2%)	111 (4%)	1,625 (6%)	288 (10%)	682 (7%)	519 (3%)
Human immunodeficiency virus infection	<5	48 (0%)	<5	59 (0%)	<5	118 (0%)	0 (0%)	8 (0%)	14 (0%)
Hyperlipidemia	216 (27%)	9,353 (37%)	242 (27%)	7,873 (23%)	245 (8%)	7,603 (26%)	622 (21%)	859 (8%)	3,180 (15%)
Myocardial infarction	10 (1%)	1,448 (6%)	43 (5%)	1,121 (3%)	106 (4%)	907 (3%)	165 (5%)	355 (3%)	846 (4%)
Obesity	9 (1%)	1,804 (7%)	168 (19%)	3,938 (12%)	51 (2%)	6,444 (22%)	235 (8%)	346 (3%)	747 (4%)
Osteoarthritis	151 (19%)	4,988 (20%)	415 (47%)	7,535 (22%)	343 (11%)	8,084 (28%)	781 (26%)	1,952 (19%)	4,308 (21%)
Parkinsons disease	7 (1%)	276 (1%)	5 (1%)	272 (1%)	8 (0%)	326 (1%)	16 (1%)	41 (0%)	156 (1%)
PE and DVT combined	13 (2%)	605 (2%)	29 (3%)	776 (2%)	48 (2%)	528 (2%)	87 (3%)	317 (3%)	457 (2%)
Pelvic vein thrombosis	0 (0%)	58 (0%)	22 (2%)	0 (0%)	0 (0%)	150 (1%)	17 (1%)	53 (1%)	61 (0%)
Pneumonia	37 (5%)	8,488 (34%)	191 (22%)	1,563 (5%)	260 (9%)	2,502 (9%)	192 (6%)	280 (3%)	1,877 (9%)
Psoriasis	18 (2%)	1,958 (8%)	72 (8%)	1,121 (3%)	85 (3%)	738 (3%)	94 (3%)	369 (4%)	346 (2%)
Pulmonary embolism	13 (2%)	403 (2%)	13 (1%)	408 (1%)	22 (1%)	240 (1%)	39 (1%)	123 (1%)	272 (1%)
Renal impairment	9 (1%)	762 (3%)	44 (5%)	2,387 (7%)	209 (7%)	4,106 (14%)	276 (9%)	1,319 (13%)	630 (3%)
Retinal vein thrombosis broad	<5	184 (1%)	12 (1%)	66 (0%)	0 (0%)	124 (0%)	19 (1%)	75 (1%)	149 (1%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	21 (0%)	9 (0%)	59 (1%)	0 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Schizophrenia	<5	199 (1%)	<5	139 (0%)	<5	118 (0%)	8 (0%)	22 (0%)	205 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	27 (0%)	0 (0%)	20 (0%)	0 (0%)	39 (0%)	<5	6 (0%)	19 (0%)
Thromboembolic disorder	<5	18 (0%)	<5	531 (2%)	0 (0%)	354 (1%)	11 (0%)	10 (0%)	86 (0%)
Ulcerative colitis	<5	366 (1%)	14 (2%)	196 (1%)	20 (1%)	144 (0%)	39 (1%)	53 (1%)	188 (1%)
Viral hepatitis	<5	129 (1%)	11 (1%)	410 (1%)	5 (0%)	528 (2%)	14 (0%)	19 (0%)	57 (0%)
Visual system disorder	129 (16%)	15,947 (63%)	714 (81%)	5,632 (17%)	1,041 (35%)	14,741 (51%)	1,017 (34%)	3,593 (34%)	7,672 (37%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 48. Medical conditions recorded anytime up to 181 days before the diagnosis of melanoma, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	130	17,145	526	28,972	3,096	7,928	1,797	5,235	8,820
Anxiety	17 (13%)	1,295 (8%)	131 (25%)	1,616 (6%)	339 (11%)	1,837 (23%)	151 (8%)	741 (14%)	491 (6%)
Asthma	10 (8%)	2,403 (14%)	58 (11%)	1,289 (4%)	178 (6%)	362 (5%)	164 (9%)	352 (7%)	593 (7%)
Attention deficit hyperactivity disorder	0 (0%)	90 (1%)	0 (0%)	93 (0%)	17 (1%)	9 (0%)	0 (0%)	7 (0%)	13 (0%)
Chronic kidney disease	<5	204 (1%)	12 (2%)	494 (2%)	21 (1%)	718 (9%)	89 (5%)	468 (9%)	145 (2%)
Chronic liver disease	0 (0%)	56 (0%)	6 (1%)	112 (0%)	6 (0%)	61 (1%)	<5	14 (0%)	37 (0%)
Chronic obstructive lung disease	8 (6%)	764 (4%)	23 (4%)	942 (3%)	107 (3%)	392 (5%)	61 (3%)	158 (3%)	137 (2%)
Covid 19	0 (0%)	0 (0%)	16 (3%)	78 (0%)	100 (3%)	290 (4%)	0 (0%)	23 (0%)	42 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Crohns disease	<5	98 (1%)	<5	101 (0%)	24 (1%)	25 (0%)	13 (1%)	20 (0%)	47 (1%)
Deep vein thrombosis	0 (0%)	106 (1%)	10 (2%)	152 (1%)	25 (1%)	62 (1%)	13 (1%)	71 (1%)	67 (1%)
Dementia	0 (0%)	170 (1%)	6 (1%)	300 (1%)	13 (0%)	179 (2%)	9 (1%)	73 (1%)	337 (4%)
Depressive disorder	<5	2,639 (15%)	157 (30%)	1,316 (5%)	136 (4%)	1,003 (13%)	173 (10%)	678 (13%)	487 (6%)
Diabetes mellitus	11 (8%)	1,394 (8%)	55 (10%)	2,432 (8%)	243 (8%)	1,011 (13%)	122 (7%)	454 (9%)	1,366 (15%)
Disseminated intravascular coagulation	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	45 (35%)	2,973 (17%)	191 (36%)	5,829 (20%)	649 (21%)	2,773 (35%)	541 (30%)	957 (18%)	2,977 (34%)
Gastroesophageal reflux disease	15 (12%)	280 (2%)	139 (26%)	530 (2%)	37 (1%)	523 (7%)	144 (8%)	180 (3%)	220 (2%)
Gastrointestinal hemorrhage	<5	536 (3%)	18 (3%)	287 (1%)	98 (3%)	332 (4%)	130 (7%)	346 (7%)	147 (2%)
Human immunodeficiency virus infection	0 (0%)	16 (0%)	0 (0%)	16 (0%)	<5	21 (0%)	0 (0%)	<5	<5
Hyperlipidemia	39 (30%)	4,689 (27%)	130 (25%)	3,293 (11%)	232 (7%)	1,989 (25%)	282 (16%)	414 (8%)	1,374 (16%)
Myocardial infarction	<5	608 (4%)	10 (2%)	390 (1%)	55 (2%)	208 (3%)	73 (4%)	121 (2%)	303 (3%)
Obesity	0 (0%)	1,272 (7%)	69 (13%)	1,496 (5%)	60 (2%)	1,603 (20%)	117 (7%)	141 (3%)	258 (3%)
Osteoarthritis	20 (15%)	2,796 (16%)	220 (42%)	3,158 (11%)	305 (10%)	1,999 (25%)	434 (24%)	882 (17%)	1,700 (19%)
Parkinsons disease	0 (0%)	154 (1%)	6 (1%)	150 (1%)	10 (0%)	81 (1%)	9 (1%)	24 (0%)	87 (1%)
PE and DVT combined	<5	266 (2%)	11 (2%)	272 (1%)	43 (1%)	88 (1%)	23 (1%)	116 (2%)	146 (2%)
Pelvic vein thrombosis	0 (0%)	42 (0%)	12 (2%)	0 (0%)	0 (0%)	53 (1%)	16 (1%)	25 (0%)	25 (0%)
Pneumonia	<5	4,184 (24%)	84 (16%)	547 (2%)	182 (6%)	534 (7%)	62 (3%)	74 (1%)	573 (6%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Psoriasis	<5	1,039 (6%)	32 (6%)	1,300 (4%)	54 (2%)	183 (2%)	36 (2%)	160 (3%)	114 (1%)
Pulmonary embolism	<5	169 (1%)	<5	141 (0%)	20 (1%)	41 (1%)	14 (1%)	55 (1%)	86 (1%)
Renal impairment	<5	269 (2%)	13 (2%)	783 (3%)	127 (4%)	789 (10%)	106 (6%)	494 (9%)	240 (3%)
Retinal vein thrombosis broad	0 (0%)	106 (1%)	<5	22 (0%)	0 (0%)	26 (0%)	8 (0%)	36 (1%)	48 (1%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	5 (0%)	6 (0%)	27 (1%)	0 (0%)
Schizophrenia	0 (0%)	78 (0%)	<5	37 (0%)	<5	28 (0%)	<5	6 (0%)	42 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	8 (0%)	<5	0 (0%)	0 (0%)	7 (0%)	0 (0%)	0 (0%)	<5
Thromboembolic disorder	0 (0%)	<5	0 (0%)	227 (1%)	0 (0%)	63 (1%)	<5	<5	22 (0%)
Ulcerative colitis	<5	227 (1%)	<5	112 (0%)	25 (1%)	35 (0%)	22 (1%)	37 (1%)	72 (1%)
Viral hepatitis	<5	46 (0%)	<5	127 (0%)	10 (0%)	95 (1%)	8 (0%)	11 (0%)	12 (0%)
Visual system disorder	18 (14%)	10,378 (61%)	411 (78%)	3,364 (12%)	923 (30%)	3,795 (48%)	566 (31%)	1,685 (32%)	2,972 (34%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 49. Medical conditions recorded anytime up to 181 days before the diagnosis of ovarian cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	54	2,842	217	4,603	473	3,244	572	1,704	3,085
Anxiety	6 (11%)	329 (12%)	58 (27%)	534 (12%)	55 (12%)	889 (27%)	72 (13%)	318 (19%)	252 (8%)
Asthma	9 (17%)	511 (18%)	21 (10%)	308 (7%)	28 (6%)	184 (6%)	63 (11%)	127 (7%)	258 (8%)
Attention deficit hyperactivity disorder	0 (0%)	10 (0%)	0 (0%)	14 (0%)	<5	5 (0%)	0 (0%)	<5	7 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Chronic kidney disease	<5	28 (1%)	5 (2%)	141 (3%)	6 (1%)	227 (7%)	26 (5%)	157 (9%)	37 (1%)
Chronic liver disease	0 (0%)	22 (1%)	5 (2%)	30 (1%)	<5	35 (1%)	<5	7 (0%)	15 (0%)
Chronic obstructive lung disease	8 (15%)	230 (8%)	14 (6%)	264 (6%)	19 (4%)	76 (2%)	21 (4%)	75 (4%)	60 (2%)
Covid 19	0 (0%)	0 (0%)	13 (6%)	17 (0%)	10 (2%)	90 (3%)	0 (0%)	10 (1%)	7 (0%)
Crohns disease	0 (0%)	15 (1%)	0 (0%)	24 (1%)	<5	7 (0%)	5 (1%)	5 (0%)	7 (0%)
Deep vein thrombosis	0 (0%)	15 (1%)	<5	45 (1%)	5 (1%)	24 (1%)	<5	28 (2%)	23 (1%)
Dementia	<5	29 (1%)	<5	89 (2%)	5 (1%)	56 (2%)	<5	14 (1%)	116 (4%)
Depressive disorder	0 (0%)	626 (22%)	79 (36%)	421 (9%)	35 (7%)	490 (15%)	72 (13%)	282 (17%)	251 (8%)
Diabetes mellitus	18 (33%)	280 (10%)	24 (11%)	622 (14%)	50 (11%)	340 (10%)	29 (5%)	145 (9%)	430 (14%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	28 (52%)	575 (20%)	86 (40%)	1,447 (31%)	98 (21%)	925 (29%)	135 (24%)	300 (18%)	1,054 (34%)
Gastroesophageal reflux disease	8 (15%)	46 (2%)	47 (22%)	137 (3%)	<5	219 (7%)	52 (9%)	71 (4%)	76 (2%)
Gastrointestinal hemorrhage	<5	89 (3%)	5 (2%)	67 (1%)	13 (3%)	136 (4%)	43 (8%)	82 (5%)	38 (1%)
Human immunodeficiency virus infection	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	5 (0%)	0 (0%)	0 (0%)	<5
Hyperlipidemia	13 (24%)	888 (31%)	58 (27%)	774 (17%)	34 (7%)	720 (22%)	68 (12%)	148 (9%)	434 (14%)
Myocardial infarction	<5	68 (2%)	<5	71 (2%)	9 (2%)	30 (1%)	11 (2%)	15 (1%)	80 (3%)
Obesity	<5	275 (10%)	42 (19%)	520 (11%)	13 (3%)	726 (22%)	41 (7%)	69 (4%)	120 (4%)
Osteoarthritis	12 (22%)	516 (18%)	92 (42%)	903 (20%)	72 (15%)	814 (25%)	121 (21%)	329 (19%)	696 (23%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	0 (0%)	29 (1%)	<5	41 (1%)	0 (0%)	22 (1%)	<5	5 (0%)	23 (1%)
PE and DVT combined	0 (0%)	45 (2%)	<5	80 (2%)	5 (1%)	39 (1%)	5 (1%)	44 (3%)	47 (2%)
Pelvic vein thrombosis	0 (0%)	<5	<5	0 (0%)	0 (0%)	16 (0%)	<5	<5	6 (0%)
Pneumonia	<5	815 (29%)	34 (16%)	131 (3%)	26 (5%)	167 (5%)	15 (3%)	28 (2%)	188 (6%)
Psoriasis	<5	181 (6%)	23 (11%)	93 (2%)	13 (3%)	67 (2%)	12 (2%)	51 (3%)	41 (1%)
Pulmonary embolism	0 (0%)	32 (1%)	<5	43 (1%)	0 (0%)	21 (1%)	<5	17 (1%)	24 (1%)
Renal impairment	<5	42 (1%)	6 (3%)	213 (5%)	21 (4%)	247 (8%)	31 (5%)	166 (10%)	59 (2%)
Retinal vein thrombosis broad	0 (0%)	18 (1%)	<5	<5	0 (0%)	10 (0%)	5 (1%)	10 (1%)	14 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	<5	8 (0%)	0 (0%)
Schizophrenia	0 (0%)	21 (1%)	<5	14 (0%)	<5	8 (0%)	<5	<5	29 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	<5
Thromboembolic disorder	0 (0%)	<5	<5	67 (1%)	0 (0%)	14 (0%)	<5	<5	8 (0%)
Ulcerative colitis	0 (0%)	40 (1%)	<5	18 (0%)	<5	16 (0%)	9 (2%)	9 (1%)	26 (1%)
Viral hepatitis	0 (0%)	9 (0%)	6 (3%)	42 (1%)	<5	41 (1%)	<5	<5	7 (0%)
Visual system disorder	7 (13%)	1,730 (61%)	181 (83%)	575 (12%)	166 (35%)	1,444 (45%)	182 (32%)	507 (30%)	1,135 (37%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 50. Medical conditions recorded anytime up to 181 days before the diagnosis of pancreatic cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	123	6,587	193	6,387	1,252	6,705	907	2,354	8,139
Anxiety	17 (14%)	658 (10%)	55 (28%)	697 (11%)	122 (10%)	1,337 (20%)	95 (10%)	290 (12%)	348 (4%)
Asthma	14 (11%)	1,147 (17%)	27 (14%)	496 (8%)	74 (6%)	340 (5%)	103 (11%)	183 (8%)	781 (10%)
Attention deficit hyperactivity disorder	0 (0%)	23 (0%)	0 (0%)	32 (1%)	6 (0%)	<5	0 (0%)	0 (0%)	<5
Chronic kidney disease	<5	114 (2%)	7 (4%)	423 (7%)	25 (2%)	1,012 (15%)	65 (7%)	306 (13%)	148 (2%)
Chronic liver disease	<5	60 (1%)	6 (3%)	78 (1%)	<5	160 (2%)	10 (1%)	6 (0%)	54 (1%)
Chronic obstructive lung disease	18 (15%)	866 (13%)	16 (8%)	757 (12%)	92 (7%)	690 (10%)	48 (5%)	193 (8%)	464 (6%)
Covid 19	<5	0 (0%)	<5	25 (0%)	20 (2%)	177 (3%)	<5	<5	16 (0%)
Crohns disease	0 (0%)	36 (1%)	<5	43 (1%)	11 (1%)	12 (0%)	<5	10 (0%)	41 (1%)
Deep vein thrombosis	0 (0%)	55 (1%)	7 (4%)	99 (2%)	16 (1%)	63 (1%)	13 (1%)	51 (2%)	84 (1%)
Dementia	<5	113 (2%)	<5	279 (4%)	14 (1%)	247 (4%)	11 (1%)	44 (2%)	431 (5%)
Depressive disorder	7 (6%)	1,372 (21%)	80 (41%)	663 (10%)	62 (5%)	1,057 (16%)	117 (13%)	277 (12%)	458 (6%)
Diabetes mellitus	29 (24%)	1,421 (22%)	49 (25%)	2,034 (32%)	257 (21%)	1,962 (29%)	146 (16%)	519 (22%)	2,418 (30%)
Disseminated intravascular coagulation	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	59 (48%)	1,906 (29%)	124 (64%)	3,367 (53%)	383 (31%)	3,204 (48%)	346 (38%)	549 (23%)	3,745 (46%)
Gastroesophageal reflux disease	14 (11%)	137 (2%)	62 (32%)	355 (6%)	19 (2%)	552 (8%)	90 (10%)	104 (4%)	204 (3%)
Gastrointestinal hemorrhage	<5	343 (5%)	14 (7%)	182 (3%)	50 (4%)	395 (6%)	80 (9%)	183 (8%)	213 (3%)
Human immunodeficiency virus infection	<5	7 (0%)	<5	<5	<5	33 (0%)	<5	<5	<5
Hyperlipidemia	53 (43%)	2,961 (45%)	66 (34%)	2,019 (32%)	129 (10%)	2,168 (32%)	203 (22%)	242 (10%)	1,601 (20%)
Myocardial infarction	0 (0%)	397 (6%)	15 (8%)	292 (5%)	50 (4%)	268 (4%)	52 (6%)	104 (4%)	443 (5%)
Obesity	<5	542 (8%)	42 (22%)	804 (13%)	25 (2%)	1,654 (25%)	93 (10%)	77 (3%)	336 (4%)
Osteoarthritis	24 (20%)	1,445 (22%)	123 (64%)	1,897 (30%)	192 (15%)	2,295 (34%)	261 (29%)	541 (23%)	2,056 (25%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	<5	75 (1%)	<5	62 (1%)	5 (0%)	66 (1%)	5 (1%)	7 (0%)	68 (1%)
PE and DVT combined	<5	141 (2%)	9 (5%)	179 (3%)	25 (2%)	104 (2%)	26 (3%)	73 (3%)	173 (2%)
Pelvic vein thrombosis	0 (0%)	12 (0%)	<5	0 (0%)	0 (0%)	26 (0%)	5 (1%)	8 (0%)	31 (0%)
Pneumonia	<5	2,190 (33%)	48 (25%)	375 (6%)	104 (8%)	590 (9%)	46 (5%)	76 (3%)	718 (9%)
Psoriasis	<5	566 (9%)	18 (9%)	206 (3%)	34 (3%)	196 (3%)	17 (2%)	88 (4%)	149 (2%)
Pulmonary embolism	<5	95 (1%)	<5	98 (2%)	9 (1%)	56 (1%)	14 (2%)	24 (1%)	107 (1%)
Renal impairment	<5	162 (2%)	12 (6%)	608 (10%)	102 (8%)	1,128 (17%)	94 (10%)	331 (14%)	272 (3%)
Retinal vein thrombosis broad	0 (0%)	60 (1%)	0 (0%)	16 (0%)	0 (0%)	31 (0%)	5 (1%)	9 (0%)	83 (1%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	<5	6 (0%)	0 (0%)
Schizophrenia	0 (0%)	49 (1%)	<5	28 (0%)	<5	30 (0%)	<5	5 (0%)	74 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	<5	<5	5 (0%)	0 (0%)	11 (0%)	0 (0%)	<5	<5
Thromboembolic disorder	<5	<5	<5	138 (2%)	0 (0%)	82 (1%)	0 (0%)	<5	34 (0%)
Ulcerative colitis	0 (0%)	99 (2%)	0 (0%)	63 (1%)	11 (1%)	30 (0%)	6 (1%)	13 (1%)	84 (1%)
Viral hepatitis	0 (0%)	33 (1%)	<5	76 (1%)	<5	156 (2%)	6 (1%)	0 (0%)	17 (0%)
Visual system disorder	15 (12%)	4,158 (63%)	162 (84%)	1,384 (22%)	413 (33%)	3,696 (55%)	334 (37%)	945 (40%)	3,214 (39%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 51. Medical conditions recorded anytime up to 181 days before the diagnosis of prostate cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	920	29,476	1,067	51,871	4,527	22,704	7,069	15,485	36,620
Anxiety	84 (9%)	1,706 (6%)	140 (13%)	2,241 (4%)	273 (6%)	2,996 (13%)	470 (7%)	1,481 (10%)	859 (2%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Asthma	119 (13%)	4,129 (14%)	131 (12%)	1,984 (4%)	236 (5%)	735 (3%)	657 (9%)	1,046 (7%)	2,779 (8%)
Attention deficit hyperactivity disorder	0 (0%)	53 (0%)	0 (0%)	122 (0%)	8 (0%)	9 (0%)	0 (0%)	<5	15 (0%)
Chronic kidney disease	19 (2%)	472 (2%)	32 (3%)	2,009 (4%)	63 (1%)	2,867 (13%)	345 (5%)	1,730 (11%)	627 (2%)
Chronic liver disease	0 (0%)	150 (1%)	22 (2%)	240 (0%)	8 (0%)	279 (1%)	21 (0%)	58 (0%)	135 (0%)
Chronic obstructive lung disease	141 (15%)	2,375 (8%)	114 (11%)	2,857 (6%)	283 (6%)	2,646 (12%)	269 (4%)	942 (6%)	1,632 (4%)
Covid 19	<5	5 (0%)	26 (2%)	127 (0%)	112 (2%)	458 (2%)	8 (0%)	43 (0%)	95 (0%)
Crohns disease	<5	143 (0%)	7 (1%)	140 (0%)	20 (0%)	44 (0%)	33 (0%)	46 (0%)	135 (0%)
Deep vein thrombosis	0 (0%)	230 (1%)	23 (2%)	369 (1%)	32 (1%)	237 (1%)	92 (1%)	251 (2%)	305 (1%)
Dementia	16 (2%)	268 (1%)	8 (1%)	825 (2%)	41 (1%)	502 (2%)	36 (1%)	144 (1%)	1,253 (3%)
Depressive disorder	23 (2%)	3,907 (13%)	241 (23%)	1,895 (4%)	137 (3%)	1,916 (8%)	518 (7%)	1,359 (9%)	1,242 (3%)
Diabetes mellitus	144 (16%)	3,589 (12%)	161 (15%)	8,361 (16%)	498 (11%)	4,334 (19%)	639 (9%)	1,802 (12%)	7,233 (20%)
Disseminated intravascular coagulation	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	<5
Essential hypertension	476 (52%)	6,731 (23%)	608 (57%)	18,735 (36%)	1,230 (27%)	10,754 (47%)	2,514 (36%)	3,876 (25%)	14,977 (41%)
Gastroesophageal reflux disease	123 (13%)	504 (2%)	294 (28%)	1,285 (2%)	66 (1%)	1,550 (7%)	558 (8%)	598 (4%)	845 (2%)
Gastrointestinal hemorrhage	8 (1%)	1,195 (4%)	65 (6%)	930 (2%)	156 (3%)	1,316 (6%)	611 (9%)	1,094 (7%)	855 (2%)
Human immunodeficiency virus infection	<5	28 (0%)	<5	45 (0%)	<5	41 (0%)	<5	6 (0%)	22 (0%)
Hyperlipidemia	367 (40%)	11,741 (40%)	363 (34%)	9,780 (19%)	417 (9%)	7,002 (31%)	1,449 (20%)	1,681 (11%)	6,764 (18%)
Myocardial infarction	22 (2%)	2,013 (7%)	122 (11%)	1,861 (4%)	238 (5%)	1,001 (4%)	446 (6%)	691 (4%)	1,964 (5%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Obesity	10 (1%)	1,245 (4%)	140 (13%)	3,662 (7%)	58 (1%)	4,976 (22%)	373 (5%)	346 (2%)	891 (2%)
Osteoarthritis	158 (17%)	5,580 (19%)	560 (52%)	8,205 (16%)	487 (11%)	6,061 (27%)	1,578 (22%)	3,144 (20%)	7,159 (20%)
Parkinsons disease	16 (2%)	292 (1%)	14 (1%)	446 (1%)	13 (0%)	293 (1%)	44 (1%)	75 (0%)	401 (1%)
PE and DVT combined	8 (1%)	525 (2%)	33 (3%)	680 (1%)	65 (1%)	331 (1%)	154 (2%)	374 (2%)	638 (2%)
Pelvic vein thrombosis	0 (0%)	74 (0%)	30 (3%)	0 (0%)	0 (0%)	111 (0%)	74 (1%)	111 (1%)	129 (0%)
Pneumonia	34 (4%)	7,945 (27%)	225 (21%)	1,260 (2%)	302 (7%)	1,640 (7%)	299 (4%)	303 (2%)	2,972 (8%)
Psoriasis	27 (3%)	1,964 (7%)	99 (9%)	959 (2%)	109 (2%)	662 (3%)	140 (2%)	481 (3%)	530 (1%)
Pulmonary embolism	8 (1%)	347 (1%)	17 (2%)	379 (1%)	37 (1%)	172 (1%)	87 (1%)	153 (1%)	378 (1%)
Renal impairment	20 (2%)	653 (2%)	48 (4%)	3,148 (6%)	331 (7%)	3,265 (14%)	461 (7%)	1,847 (12%)	1,150 (3%)
Retinal vein thrombosis broad	<5	247 (1%)	8 (1%)	66 (0%)	0 (0%)	101 (0%)	38 (1%)	137 (1%)	310 (1%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	11 (0%)	21 (0%)	104 (1%)	0 (0%)
Schizophrenia	5 (1%)	98 (0%)	6 (1%)	75 (0%)	9 (0%)	58 (0%)	19 (0%)	22 (0%)	129 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	11 (0%)	<5	7 (0%)	0 (0%)	10 (0%)	<5	6 (0%)	16 (0%)
Thromboembolic disorder	<5	9 (0%)	8 (1%)	457 (1%)	0 (0%)	260 (1%)	5 (0%)	18 (0%)	123 (0%)
Ulcerative colitis	<5	360 (1%)	11 (1%)	206 (0%)	24 (1%)	91 (0%)	69 (1%)	92 (1%)	303 (1%)
Viral hepatitis	<5	106 (0%)	15 (1%)	272 (1%)	8 (0%)	357 (2%)	39 (1%)	26 (0%)	33 (0%)
Visual system disorder	135 (15%)	17,148 (58%)	851 (80%)	5,177 (10%)	1,518 (34%)	11,354 (50%)	2,147 (30%)	5,306 (34%)	12,758 (35%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 52. Medical conditions recorded anytime up to 181 days before the diagnosis of stomach cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	42	4,137	191	4,737	678	5,059	488	1,055	3,300
Anxiety	7 (17%)	388 (9%)	40 (21%)	414 (9%)	66 (10%)	914 (18%)	61 (12%)	137 (13%)	123 (4%)
Asthma	<5	763 (18%)	24 (13%)	300 (6%)	37 (5%)	223 (4%)	65 (13%)	73 (7%)	285 (9%)
Attention deficit hyperactivity disorder	0 (0%)	13 (0%)	0 (0%)	16 (0%)	5 (1%)	6 (0%)	0 (0%)	0 (0%)	6 (0%)
Chronic kidney disease	0 (0%)	81 (2%)	7 (4%)	262 (6%)	13 (2%)	707 (14%)	41 (8%)	164 (16%)	69 (2%)
Chronic liver disease	0 (0%)	41 (1%)	6 (3%)	40 (1%)	7 (1%)	100 (2%)	<5	5 (0%)	21 (1%)
Chronic obstructive lung disease	5 (12%)	535 (13%)	18 (9%)	467 (10%)	65 (10%)	544 (11%)	35 (7%)	108 (10%)	183 (6%)
Covid 19	0 (0%)	<5	13 (7%)	19 (0%)	21 (3%)	94 (2%)	<5	<5	7 (0%)
Crohns disease	0 (0%)	25 (1%)	0 (0%)	21 (0%)	<5	11 (0%)	<5	<5	14 (0%)
Deep vein thrombosis	0 (0%)	42 (1%)	5 (3%)	60 (1%)	7 (1%)	63 (1%)	9 (2%)	16 (2%)	28 (1%)
Dementia	<5	64 (2%)	7 (4%)	169 (4%)	6 (1%)	162 (3%)	6 (1%)	27 (3%)	163 (5%)
Depressive disorder	<5	785 (19%)	55 (29%)	442 (9%)	43 (6%)	724 (14%)	60 (12%)	133 (13%)	158 (5%)
Diabetes mellitus	14 (33%)	684 (17%)	30 (16%)	1,089 (23%)	118 (17%)	1,148 (23%)	80 (16%)	174 (16%)	781 (24%)
Disseminated intravascular coagulation	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)
Essential hypertension	22 (52%)	1,080 (26%)	104 (54%)	2,110 (45%)	187 (28%)	2,280 (45%)	207 (42%)	237 (22%)	1,422 (43%)
Gastroesophageal reflux disease	5 (12%)	89 (2%)	66 (35%)	205 (4%)	11 (2%)	389 (8%)	45 (9%)	53 (5%)	72 (2%)
Gastrointestinal hemorrhage	0 (0%)	243 (6%)	12 (6%)	146 (3%)	30 (4%)	321 (6%)	40 (8%)	69 (7%)	108 (3%)
Human immunodeficiency virus infection	0 (0%)	6 (0%)	0 (0%)	<5	<5	12 (0%)	0 (0%)	0 (0%)	0 (0%)
Hyperlipidemia	18 (43%)	1,726 (42%)	67 (35%)	1,237 (26%)	69 (10%)	1,560 (31%)	122 (25%)	104 (10%)	554 (17%)
Myocardial infarction	<5	267 (6%)	15 (8%)	202 (4%)	31 (5%)	210 (4%)	39 (8%)	46 (4%)	186 (6%)
Obesity	<5	343 (8%)	31 (16%)	570 (12%)	24 (4%)	1,261 (25%)	46 (9%)	43 (4%)	113 (3%)
Osteoarthritis	12 (29%)	799 (19%)	104 (54%)	1,155 (24%)	93 (14%)	1,546 (31%)	134 (27%)	259 (25%)	675 (20%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	0 (0%)	49 (1%)	<5	58 (1%)	<5	43 (1%)	6 (1%)	10 (1%)	34 (1%)
PE and DVT combined	0 (0%)	93 (2%)	6 (3%)	107 (2%)	10 (1%)	91 (2%)	12 (2%)	23 (2%)	60 (2%)
Pelvic vein thrombosis	0 (0%)	8 (0%)	6 (3%)	0 (0%)	0 (0%)	19 (0%)	<5	<5	9 (0%)
Pneumonia	<5	1,392 (34%)	48 (25%)	218 (5%)	57 (8%)	396 (8%)	36 (7%)	26 (2%)	294 (9%)
Psoriasis	0 (0%)	314 (8%)	19 (10%)	125 (3%)	15 (2%)	148 (3%)	18 (4%)	48 (5%)	50 (2%)
Pulmonary embolism	0 (0%)	64 (2%)	<5	61 (1%)	<5	48 (1%)	<5	7 (1%)	35 (1%)
Renal impairment	0 (0%)	110 (3%)	10 (5%)	390 (8%)	66 (10%)	807 (16%)	54 (11%)	172 (16%)	106 (3%)
Retinal vein thrombosis broad	0 (0%)	36 (1%)	<5	8 (0%)	0 (0%)	25 (0%)	5 (1%)	9 (1%)	28 (1%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	<5	<5	0 (0%)
Schizophrenia	<5	42 (1%)	<5	17 (0%)	<5	22 (0%)	<5	<5	30 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	<5
Thromboembolic disorder	0 (0%)	<5	0 (0%)	62 (1%)	0 (0%)	65 (1%)	<5	0 (0%)	10 (0%)
Ulcerative colitis	0 (0%)	67 (2%)	<5	20 (0%)	5 (1%)	18 (0%)	8 (2%)	<5	34 (1%)
Viral hepatitis	0 (0%)	23 (1%)	<5	39 (1%)	<5	108 (2%)	<5	<5	8 (0%)
Visual system disorder	7 (17%)	2,535 (61%)	160 (84%)	800 (17%)	226 (33%)	2,762 (55%)	185 (38%)	403 (38%)	1,191 (36%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 53. Medical conditions recorded 180 to 1 days before the diagnosis of bone cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	18	322	31	965	0	1,071	37	290	594
Anxiety	<5	8 (2%)	<5	15 (2%)	0	49 (5%)	<5	<5	8 (1%)
Asthma	<5	16 (5%)	<5	18 (2%)	0	<5	<5	<5	17 (3%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Attention deficit hyperactivity disorder	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	<5	0 (0%)	0 (0%)	<5
Chronic kidney disease	0 (0%)	<5	0 (0%)	7 (1%)	0	16 (1%)	<5	<5	<5
Chronic liver disease	0 (0%)	<5	<5	6 (1%)	0	<5	0 (0%)	0 (0%)	<5
Chronic obstructive lung disease	0 (0%)	12 (4%)	<5	15 (2%)	0	14 (1%)	0 (0%)	<5	9 (2%)
Covid 19	0 (0%)	0 (0%)	0 (0%)	<5	0	34 (3%)	0 (0%)	<5	<5
Crohns disease	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	0 (0%)	0 (0%)	0 (0%)	<5
Deep vein thrombosis	0 (0%)	0 (0%)	0 (0%)	<5	0	<5	<5	<5	<5
Dementia	0 (0%)	<5	<5	7 (1%)	0	6 (1%)	0 (0%)	0 (0%)	10 (2%)
Depressive disorder	0 (0%)	18 (6%)	<5	15 (2%)	0	21 (2%)	<5	0 (0%)	12 (2%)
Diabetes mellitus	<5	22 (7%)	<5	48 (5%)	0	34 (3%)	<5	<5	33 (6%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	<5	17 (5%)	<5	94 (10%)	0	75 (7%)	<5	<5	72 (12%)
Gastroesophageal reflux disease	<5	0 (0%)	0 (0%)	7 (1%)	0	7 (1%)	0 (0%)	<5	<5
Gastrointestinal hemorrhage	0 (0%)	0 (0%)	0 (0%)	<5	0	8 (1%)	<5	<5	0 (0%)
Human immunodeficiency virus infection	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Hyperlipidemia	<5	56 (17%)	<5	37 (4%)	0	53 (5%)	<5	<5	25 (4%)
Myocardial infarction	0 (0%)	<5	0 (0%)	8 (1%)	0	8 (1%)	0 (0%)	0 (0%)	5 (1%)
Obesity	0 (0%)	5 (2%)	<5	15 (2%)	0	27 (3%)	0 (0%)	<5	<5
Osteoarthritis	<5	12 (4%)	<5	112 (12%)	0	40 (4%)	<5	<5	35 (6%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	0 (0%)	<5	0 (0%)	7 (1%)	0	<5	0 (0%)	0 (0%)	<5
PE and DVT combined	0 (0%)	<5	0 (0%)	<5	0	<5	<5	<5	9 (2%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	<5	0 (0%)	0 (0%)	<5
Pneumonia	0 (0%)	17 (5%)	<5	<5	0	14 (1%)	0 (0%)	<5	12 (2%)
Psoriasis	0 (0%)	6 (2%)	<5	0 (0%)	0	<5	0 (0%)	0 (0%)	<5
Pulmonary embolism	0 (0%)	<5	0 (0%)	<5	0	<5	0 (0%)	<5	7 (1%)
Renal impairment	0 (0%)	<5	0 (0%)	11 (1%)	0	19 (2%)	<5	<5	5 (1%)
Retinal vein thrombosis broad	0 (0%)	0 (0%)	0 (0%)	<5	0	0 (0%)	0 (0%)	0 (0%)	<5
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	<5	0 (0%)	0 (0%)	<5
Splanchnic extrahepatic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Thromboembolic disorder	0 (0%)	0 (0%)	0 (0%)	<5	0	5 (0%)	0 (0%)	0 (0%)	<5
Ulcerative colitis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	0 (0%)	0 (0%)	0 (0%)	<5
Viral hepatitis	0 (0%)	<5	<5	<5	0	<5	0 (0%)	0 (0%)	<5
Visual system disorder	0 (0%)	30 (9%)	7 (23%)	16 (2%)	0	112 (10%)	<5	13 (4%)	46 (8%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 54. Medical conditions recorded 180 to 1 days before the diagnosis of brain cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	128	3,510	132	3,240	297	3,955	507	932	3,318
Anxiety	9 (7%)	100 (3%)	15 (11%)	114 (4%)	12 (4%)	213 (5%)	14 (3%)	35 (4%)	89 (3%)
Asthma	6 (5%)	149 (4%)	9 (7%)	42 (1%)	<5	28 (1%)	19 (4%)	0 (0%)	85 (3%)
Attention deficit hyperactivity disorder	0 (0%)	7 (0%)	0 (0%)	<5	<5	<5	0 (0%)	0 (0%)	6 (0%)
Chronic kidney disease	0 (0%)	25 (1%)	<5	19 (1%)	<5	85 (2%)	12 (2%)	<5	22 (1%)
Chronic liver disease	0 (0%)	7 (0%)	0 (0%)	<5	0 (0%)	17 (0%)	0 (0%)	0 (0%)	9 (0%)
Chronic obstructive lung disease	12 (9%)	128 (4%)	<5	37 (1%)	<5	69 (2%)	9 (2%)	8 (1%)	48 (1%)
Covid 19	0 (0%)	<5	<5	18 (1%)	5 (2%)	138 (3%)	6 (1%)	<5	25 (1%)
Crohns disease	0 (0%)	8 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	10 (0%)
Deep vein thrombosis	0 (0%)	8 (0%)	<5	10 (0%)	0 (0%)	10 (0%)	0 (0%)	<5	5 (0%)
Dementia	<5	41 (1%)	<5	54 (2%)	<5	59 (1%)	5 (1%)	<5	68 (2%)
Depressive disorder	<5	303 (9%)	19 (14%)	107 (3%)	<5	162 (4%)	22 (4%)	12 (1%)	85 (3%)
Diabetes mellitus	11 (9%)	313 (9%)	7 (5%)	182 (6%)	14 (5%)	180 (5%)	24 (5%)	11 (1%)	275 (8%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	35 (27%)	197 (6%)	25 (19%)	428 (13%)	18 (6%)	375 (9%)	102 (20%)	10 (1%)	555 (17%)
Gastroesophageal reflux disease	13 (10%)	8 (0%)	5 (4%)	25 (1%)	0 (0%)	51 (1%)	13 (3%)	<5	15 (0%)
Gastrointestinal hemorrhage	0 (0%)	13 (0%)	<5	9 (0%)	<5	31 (1%)	<5	<5	14 (0%)
Human immunodeficiency virus infection	0 (0%)	<5	0 (0%)	0 (0%)	<5	11 (0%)	0 (0%)	0 (0%)	<5
Hyperlipidemia	15 (12%)	702 (20%)	11 (8%)	151 (5%)	<5	273 (7%)	47 (9%)	<5	199 (6%)
Myocardial infarction	<5	10 (0%)	<5	14 (0%)	<5	29 (1%)	20 (4%)	<5	23 (1%)
Obesity	<5	15 (0%)	<5	31 (1%)	0 (0%)	141 (4%)	14 (3%)	<5	27 (1%)
Osteoarthritis	9 (7%)	44 (1%)	10 (8%)	137 (4%)	7 (2%)	137 (3%)	18 (4%)	6 (1%)	138 (4%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	<5	10 (0%)	0 (0%)	19 (1%)	0 (0%)	14 (0%)	<5	0 (0%)	18 (1%)
PE and DVT combined	<5	16 (0%)	<5	21 (1%)	0 (0%)	21 (1%)	<5	7 (1%)	29 (1%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5
Pneumonia	0 (0%)	107 (3%)	0 (0%)	11 (0%)	6 (2%)	37 (1%)	<5	<5	71 (2%)
Psoriasis	<5	37 (1%)	<5	11 (0%)	<5	15 (0%)	6 (1%)	<5	12 (0%)
Pulmonary embolism	<5	9 (0%)	0 (0%)	12 (0%)	0 (0%)	15 (0%)	<5	<5	24 (1%)
Renal impairment	0 (0%)	31 (1%)	<5	31 (1%)	12 (4%)	98 (2%)	16 (3%)	9 (1%)	38 (1%)
Retinal vein thrombosis broad	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	5 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	7 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	21 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Thromboembolic disorder	0 (0%)	0 (0%)	0 (0%)	8 (0%)	0 (0%)	10 (0%)	0 (0%)	0 (0%)	<5
Ulcerative colitis	0 (0%)	13 (0%)	0 (0%)	<5	<5	<5	<5	0 (0%)	14 (0%)
Viral hepatitis	0 (0%)	<5	0 (0%)	<5	0 (0%)	19 (0%)	0 (0%)	0 (0%)	<5
Visual system disorder	7 (5%)	385 (11%)	24 (18%)	98 (3%)	23 (8%)	468 (12%)	33 (7%)	42 (5%)	350 (11%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 55. Medical conditions recorded 180 to 1 days before the diagnosis of breast cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	1,853	31,873	1,243	56,337	6,553	31,931	5,180	18,134	38,047
Anxiety	114 (6%)	818 (3%)	88 (7%)	1,165 (2%)	244 (4%)	1,122 (4%)	31 (1%)	294 (2%)	948 (2%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Asthma	68 (4%)	1,840 (6%)	68 (5%)	583 (1%)	126 (2%)	214 (1%)	68 (1%)	101 (1%)	874 (2%)
Attention deficit hyperactivity disorder	<5	55 (0%)	0 (0%)	18 (0%)	7 (0%)	<5	0 (0%)	<5	18 (0%)
Chronic kidney disease	14 (1%)	138 (0%)	8 (1%)	243 (0%)	24 (0%)	348 (1%)	28 (1%)	83 (0%)	135 (0%)
Chronic liver disease	<5	91 (0%)	5 (0%)	49 (0%)	8 (0%)	50 (0%)	<5	14 (0%)	85 (0%)
Chronic obstructive lung disease	79 (4%)	1,270 (4%)	9 (1%)	562 (1%)	96 (1%)	142 (0%)	27 (1%)	124 (1%)	225 (1%)
Covid 19	<5	<5	44 (4%)	213 (0%)	223 (3%)	1,018 (3%)	<5	55 (0%)	192 (1%)
Crohns disease	5 (0%)	64 (0%)	<5	22 (0%)	5 (0%)	10 (0%)	<5	<5	69 (0%)
Deep vein thrombosis	0 (0%)	30 (0%)	<5	49 (0%)	7 (0%)	49 (0%)	<5	22 (0%)	42 (0%)
Dementia	9 (0%)	279 (1%)	<5	271 (0%)	26 (0%)	172 (1%)	10 (0%)	39 (0%)	672 (2%)
Depressive disorder	43 (2%)	2,534 (8%)	109 (9%)	842 (1%)	112 (2%)	585 (2%)	42 (1%)	99 (1%)	680 (2%)
Diabetes mellitus	131 (7%)	2,083 (7%)	64 (5%)	1,531 (3%)	356 (5%)	494 (2%)	61 (1%)	95 (1%)	2,145 (6%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	419 (23%)	1,003 (3%)	235 (19%)	4,287 (8%)	542 (8%)	996 (3%)	196 (4%)	106 (1%)	3,393 (9%)
Gastroesophageal reflux disease	99 (5%)	50 (0%)	76 (6%)	274 (0%)	19 (0%)	206 (1%)	47 (1%)	39 (0%)	140 (0%)
Gastrointestinal hemorrhage	<5	77 (0%)	<5	106 (0%)	52 (1%)	190 (1%)	13 (0%)	48 (0%)	94 (0%)
Human immunodeficiency virus infection	0 (0%)	10 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	5 (0%)
Hyperlipidemia	230 (12%)	5,495 (17%)	86 (7%)	1,460 (3%)	113 (2%)	774 (2%)	49 (1%)	37 (0%)	909 (2%)
Myocardial infarction	6 (0%)	59 (0%)	9 (1%)	115 (0%)	42 (1%)	55 (0%)	22 (0%)	14 (0%)	124 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Obesity	10 (1%)	301 (1%)	32 (3%)	476 (1%)	38 (1%)	802 (3%)	39 (1%)	18 (0%)	283 (1%)
Osteoarthritis	80 (4%)	520 (2%)	126 (10%)	1,575 (3%)	210 (3%)	888 (3%)	63 (1%)	205 (1%)	1,560 (4%)
Parkinsons disease	5 (0%)	144 (0%)	7 (1%)	103 (0%)	5 (0%)	28 (0%)	6 (0%)	7 (0%)	138 (0%)
PE and DVT combined	7 (0%)	94 (0%)	<5	118 (0%)	15 (0%)	88 (0%)	7 (0%)	47 (0%)	167 (0%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	21 (0%)	0 (0%)	0 (0%)	13 (0%)
Pneumonia	22 (1%)	919 (3%)	7 (1%)	143 (0%)	113 (2%)	217 (1%)	11 (0%)	39 (0%)	378 (1%)
Psoriasis	15 (1%)	375 (1%)	16 (1%)	139 (0%)	22 (0%)	66 (0%)	<5	46 (0%)	127 (0%)
Pulmonary embolism	7 (0%)	66 (0%)	<5	75 (0%)	8 (0%)	48 (0%)	6 (0%)	25 (0%)	133 (0%)
Renal impairment	14 (1%)	181 (1%)	10 (1%)	402 (1%)	112 (2%)	399 (1%)	37 (1%)	124 (1%)	232 (1%)
Retinal vein thrombosis broad	<5	44 (0%)	<5	7 (0%)	0 (0%)	7 (0%)	0 (0%)	7 (0%)	53 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	7 (0%)	0 (0%)
Schizophrenia	<5	116 (0%)	7 (1%)	34 (0%)	<5	16 (0%)	<5	<5	178 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	5 (0%)
Thromboembolic disorder	0 (0%)	<5	0 (0%)	84 (0%)	0 (0%)	38 (0%)	0 (0%)	<5	19 (0%)
Ulcerative colitis	<5	105 (0%)	<5	29 (0%)	8 (0%)	11 (0%)	8 (0%)	<5	94 (0%)
Viral hepatitis	<5	30 (0%)	<5	24 (0%)	<5	48 (0%)	0 (0%)	0 (0%)	13 (0%)
Visual system disorder	81 (4%)	3,200 (10%)	229 (18%)	631 (1%)	601 (9%)	2,923 (9%)	90 (2%)	381 (2%)	2,774 (7%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 56. Medical conditions recorded 180 to 1 days before the diagnosis of colorectal cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	382	29,279	762	24,061	5,400	29,755	3,848	11,798	23,146
Anxiety	17 (4%)	493 (2%)	40 (5%)	408 (2%)	159 (3%)	725 (2%)	38 (1%)	102 (1%)	204 (1%)
Asthma	11 (3%)	1,656 (6%)	47 (6%)	305 (1%)	88 (2%)	207 (1%)	108 (3%)	53 (0%)	660 (3%)
Attention deficit hyperactivity disorder	0 (0%)	28 (0%)	0 (0%)	10 (0%)	<5	<5	0 (0%)	0 (0%)	6 (0%)
Chronic kidney disease	5 (1%)	300 (1%)	14 (2%)	305 (1%)	39 (1%)	1,015 (3%)	66 (2%)	109 (1%)	238 (1%)
Chronic liver disease	<5	131 (0%)	7 (1%)	35 (0%)	6 (0%)	139 (0%)	13 (0%)	20 (0%)	101 (0%)
Chronic obstructive lung disease	21 (5%)	1,930 (7%)	20 (3%)	547 (2%)	134 (2%)	713 (2%)	90 (2%)	105 (1%)	414 (2%)
Covid 19	5 (1%)	<5	11 (1%)	100 (0%)	109 (2%)	731 (2%)	9 (0%)	37 (0%)	121 (1%)
Crohns disease	<5	118 (0%)	<5	43 (0%)	17 (0%)	18 (0%)	9 (0%)	10 (0%)	88 (0%)
Deep vein thrombosis	0 (0%)	64 (0%)	<5	62 (0%)	14 (0%)	88 (0%)	<5	45 (0%)	56 (0%)
Dementia	<5	355 (1%)	7 (1%)	279 (1%)	32 (1%)	316 (1%)	17 (0%)	38 (0%)	613 (3%)
Depressive disorder	9 (2%)	1,902 (6%)	59 (8%)	413 (2%)	59 (1%)	602 (2%)	56 (1%)	58 (0%)	215 (1%)
Diabetes mellitus	50 (13%)	3,467 (12%)	108 (14%)	1,777 (7%)	530 (10%)	1,306 (4%)	162 (4%)	127 (1%)	2,405 (10%)
Disseminated intravascular coagulation	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	106 (28%)	2,247 (8%)	179 (23%)	3,647 (15%)	572 (11%)	2,184 (7%)	462 (12%)	80 (1%)	3,397 (15%)
Gastroesophageal reflux disease	28 (7%)	76 (0%)	72 (9%)	238 (1%)	21 (0%)	289 (1%)	52 (1%)	32 (0%)	114 (0%)
Gastrointestinal hemorrhage	<5	1,117 (4%)	24 (3%)	802 (3%)	283 (5%)	3,413 (11%)	139 (4%)	965 (8%)	2,017 (9%)
Human immunodeficiency virus infection	<5	51 (0%)	0 (0%)	6 (0%)	6 (0%)	25 (0%)	0 (0%)	0 (0%)	11 (0%)
Hyperlipidemia	66 (17%)	7,225 (25%)	73 (10%)	1,428 (6%)	101 (2%)	1,760 (6%)	126 (3%)	21 (0%)	940 (4%)
Myocardial infarction	6 (2%)	205 (1%)	32 (4%)	196 (1%)	107 (2%)	328 (1%)	70 (2%)	54 (0%)	299 (1%)
Obesity	<5	294 (1%)	26 (3%)	333 (1%)	16 (0%)	1,237 (4%)	56 (1%)	10 (0%)	168 (1%)
Osteoarthritis	27 (7%)	387 (1%)	94 (12%)	895 (4%)	124 (2%)	996 (3%)	79 (2%)	125 (1%)	681 (3%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	<5	200 (1%)	8 (1%)	76 (0%)	<5	108 (0%)	15 (0%)	<5	154 (1%)
PE and DVT combined	<5	282 (1%)	10 (1%)	127 (1%)	30 (1%)	154 (1%)	11 (0%)	104 (1%)	218 (1%)
Pelvic vein thrombosis	0 (0%)	5 (0%)	11 (1%)	0 (0%)	0 (0%)	53 (0%)	0 (0%)	<5	23 (0%)
Pneumonia	6 (2%)	1,414 (5%)	17 (2%)	138 (1%)	115 (2%)	401 (1%)	35 (1%)	43 (0%)	570 (2%)
Psoriasis	<5	362 (1%)	15 (2%)	86 (0%)	23 (0%)	99 (0%)	7 (0%)	22 (0%)	73 (0%)
Pulmonary embolism	<5	225 (1%)	8 (1%)	78 (0%)	16 (0%)	81 (0%)	7 (0%)	63 (1%)	175 (1%)
Renal impairment	5 (1%)	409 (1%)	21 (3%)	483 (2%)	131 (2%)	1,225 (4%)	87 (2%)	174 (1%)	385 (2%)
Retinal vein thrombosis broad	0 (0%)	65 (0%)	<5	7 (0%)	0 (0%)	26 (0%)	<5	5 (0%)	66 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)
Schizophrenia	<5	78 (0%)	<5	17 (0%)	<5	24 (0%)	8 (0%)	<5	77 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	6 (0%)	0 (0%)	<5	0 (0%)	9 (0%)	0 (0%)	<5	<5
Thromboembolic disorder	0 (0%)	<5	0 (0%)	73 (0%)	0 (0%)	82 (0%)	<5	0 (0%)	23 (0%)
Ulcerative colitis	<5	151 (1%)	5 (1%)	80 (0%)	17 (0%)	24 (0%)	19 (0%)	13 (0%)	205 (1%)
Viral hepatitis	<5	25 (0%)	<5	20 (0%)	<5	111 (0%)	<5	0 (0%)	13 (0%)
Visual system disorder	18 (5%)	3,260 (11%)	172 (23%)	504 (2%)	488 (9%)	3,528 (12%)	123 (3%)	314 (3%)	1,801 (8%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 57. Medical conditions recorded 180 to 1 days before the diagnosis of corpus uteri cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	60	4,910	260	5,113	622	4,858	899	2,453	6,121
Anxiety	9 (15%)	145 (3%)	15 (6%)	128 (3%)	13 (2%)	197 (4%)	8 (1%)	36 (1%)	91 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Asthma	0 (0%)	253 (5%)	17 (7%)	70 (1%)	9 (1%)	27 (1%)	16 (2%)	18 (1%)	161 (3%)
Attention deficit hyperactivity disorder	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5
Chronic kidney disease	<5	32 (1%)	<5	45 (1%)	8 (1%)	88 (2%)	14 (2%)	19 (1%)	38 (1%)
Chronic liver disease	<5	13 (0%)	0 (0%)	6 (0%)	0 (0%)	14 (0%)	0 (0%)	<5	17 (0%)
Chronic obstructive lung disease	<5	160 (3%)	<5	70 (1%)	<5	17 (0%)	5 (1%)	5 (0%)	30 (0%)
Covid 19	0 (0%)	<5	7 (3%)	27 (1%)	15 (2%)	150 (3%)	<5	0 (0%)	27 (0%)
Crohns disease	0 (0%)	6 (0%)	<5	7 (0%)	<5	<5	<5	0 (0%)	7 (0%)
Deep vein thrombosis	0 (0%)	10 (0%)	<5	20 (0%)	5 (1%)	22 (0%)	<5	14 (1%)	22 (0%)
Dementia	0 (0%)	40 (1%)	<5	42 (1%)	<5	19 (0%)	<5	<5	137 (2%)
Depressive disorder	<5	377 (8%)	24 (9%)	106 (2%)	7 (1%)	107 (2%)	9 (1%)	6 (0%)	102 (2%)
Diabetes mellitus	9 (15%)	696 (14%)	32 (12%)	309 (6%)	59 (9%)	153 (3%)	24 (3%)	29 (1%)	702 (11%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	19 (32%)	603 (12%)	82 (32%)	631 (12%)	83 (13%)	308 (6%)	62 (7%)	32 (1%)	940 (15%)
Gastroesophageal reflux disease	6 (10%)	6 (0%)	12 (5%)	31 (1%)	<5	37 (1%)	10 (1%)	5 (0%)	31 (1%)
Gastrointestinal hemorrhage	0 (0%)	15 (0%)	<5	24 (0%)	11 (2%)	51 (1%)	<5	10 (0%)	31 (1%)
Human immunodeficiency virus infection	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Hyperlipidemia	9 (15%)	1,134 (23%)	28 (11%)	201 (4%)	10 (2%)	209 (4%)	15 (2%)	<5	244 (4%)
Myocardial infarction	<5	12 (0%)	<5	14 (0%)	<5	13 (0%)	<5	<5	31 (1%)
Obesity	<5	545 (11%)	23 (9%)	128 (3%)	6 (1%)	285 (6%)	21 (2%)	12 (0%)	242 (4%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Osteoarthritis	0 (0%)	73 (1%)	41 (16%)	179 (4%)	14 (2%)	186 (4%)	17 (2%)	26 (1%)	277 (5%)
Parkinsons disease	<5	27 (1%)	0 (0%)	12 (0%)	0 (0%)	<5	<5	<5	25 (0%)
PE and DVT combined	0 (0%)	39 (1%)	<5	38 (1%)	8 (1%)	36 (1%)	<5	30 (1%)	74 (1%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	6 (0%)	0 (0%)	0 (0%)	<5
Pneumonia	<5	119 (2%)	<5	17 (0%)	11 (2%)	30 (1%)	6 (1%)	5 (0%)	93 (2%)
Psoriasis	0 (0%)	65 (1%)	<5	14 (0%)	<5	8 (0%)	<5	<5	16 (0%)
Pulmonary embolism	0 (0%)	32 (1%)	0 (0%)	21 (0%)	<5	17 (0%)	<5	17 (1%)	56 (1%)
Renal impairment	<5	47 (1%)	<5	75 (1%)	16 (3%)	100 (2%)	16 (2%)	32 (1%)	72 (1%)
Retinal vein thrombosis broad	0 (0%)	8 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	14 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)
Schizophrenia	0 (0%)	18 (0%)	<5	6 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	53 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Thromboembolic disorder	0 (0%)	<5	0 (0%)	20 (0%)	0 (0%)	7 (0%)	0 (0%)	<5	<5
Ulcerative colitis	0 (0%)	16 (0%)	0 (0%)	<5	<5	<5	<5	0 (0%)	14 (0%)
Viral hepatitis	0 (0%)	<5	<5	6 (0%)	0 (0%)	13 (0%)	0 (0%)	0 (0%)	<5
Visual system disorder	<5	513 (10%)	51 (20%)	82 (2%)	67 (11%)	528 (11%)	20 (2%)	62 (3%)	469 (8%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 58. Medical conditions recorded 180 to 1 days before the diagnosis of oesophageal cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	53	3,168	35	3,121	837	1,860	763	3,223	2,487
Anxiety	<5	59 (2%)	<5	50 (2%)	17 (2%)	37 (2%)	<5	31 (1%)	18 (1%)
Asthma	0 (0%)	205 (6%)	<5	54 (2%)	12 (1%)	13 (1%)	25 (3%)	13 (0%)	53 (2%)
Attention deficit hyperactivity disorder	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5
Chronic kidney disease	0 (0%)	41 (1%)	0 (0%)	37 (1%)	<5	47 (3%)	16 (2%)	16 (0%)	26 (1%)
Chronic liver disease	0 (0%)	38 (1%)	0 (0%)	16 (1%)	<5	23 (1%)	6 (1%)	7 (0%)	19 (1%)
Chronic obstructive lung disease	<5	362 (11%)	<5	119 (4%)	41 (5%)	63 (3%)	20 (3%)	36 (1%)	86 (3%)
Covid 19	0 (0%)	0 (0%)	<5	7 (0%)	18 (2%)	48 (3%)	0 (0%)	6 (0%)	11 (0%)
Crohns disease	0 (0%)	8 (0%)	0 (0%)	5 (0%)	<5	0 (0%)	<5	<5	6 (0%)
Deep vein thrombosis	0 (0%)	8 (0%)	0 (0%)	<5	<5	7 (0%)	<5	9 (0%)	7 (0%)
Dementia	0 (0%)	41 (1%)	0 (0%)	32 (1%)	<5	14 (1%)	<5	8 (0%)	76 (3%)
Depressive disorder	<5	274 (9%)	<5	63 (2%)	6 (1%)	31 (2%)	12 (2%)	15 (0%)	17 (1%)
Diabetes mellitus	<5	371 (12%)	<5	207 (7%)	81 (10%)	65 (3%)	38 (5%)	25 (1%)	257 (10%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	13 (25%)	230 (7%)	9 (26%)	463 (15%)	85 (10%)	123 (7%)	104 (14%)	19 (1%)	348 (14%)
Gastroesophageal reflux disease	11 (21%)	31 (1%)	10 (29%)	90 (3%)	7 (1%)	54 (3%)	17 (2%)	53 (2%)	75 (3%)
Gastrointestinal hemorrhage	0 (0%)	65 (2%)	0 (0%)	39 (1%)	14 (2%)	39 (2%)	13 (2%)	42 (1%)	64 (3%)
Human immunodeficiency virus infection	0 (0%)	5 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5
Hyperlipidemia	6 (11%)	867 (27%)	<5	169 (5%)	18 (2%)	105 (6%)	22 (3%)	8 (0%)	99 (4%)
Myocardial infarction	<5	19 (1%)	<5	33 (1%)	19 (2%)	20 (1%)	20 (3%)	12 (0%)	35 (1%)
Obesity	<5	22 (1%)	<5	41 (1%)	<5	88 (5%)	16 (2%)	<5	20 (1%)
Osteoarthritis	<5	39 (1%)	<5	116 (4%)	17 (2%)	50 (3%)	15 (2%)	28 (1%)	68 (3%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	<5	19 (1%)	0 (0%)	12 (0%)	0 (0%)	<5	<5	<5	13 (1%)
PE and DVT combined	<5	30 (1%)	<5	9 (0%)	7 (1%)	10 (1%)	<5	25 (1%)	20 (1%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5
Pneumonia	<5	230 (7%)	<5	24 (1%)	17 (2%)	23 (1%)	<5	17 (1%)	94 (4%)
Psoriasis	0 (0%)	47 (1%)	0 (0%)	11 (0%)	7 (1%)	5 (0%)	<5	<5	10 (0%)
Pulmonary embolism	<5	24 (1%)	<5	5 (0%)	<5	<5	<5	16 (0%)	17 (1%)
Renal impairment	0 (0%)	59 (2%)	<5	64 (2%)	13 (2%)	56 (3%)	20 (3%)	24 (1%)	42 (2%)
Retinal vein thrombosis broad	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	<5	<5
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)
Schizophrenia	0 (0%)	18 (1%)	0 (0%)	<5	<5	0 (0%)	0 (0%)	0 (0%)	26 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	<5
Thromboembolic disorder	0 (0%)	<5	0 (0%)	<5	0 (0%)	7 (0%)	0 (0%)	<5	<5
Ulcerative colitis	0 (0%)	11 (0%)	0 (0%)	<5	<5	<5	0 (0%)	0 (0%)	13 (1%)
Viral hepatitis	0 (0%)	<5	0 (0%)	<5	0 (0%)	8 (0%)	<5	<5	<5
Visual system disorder	<5	296 (9%)	7 (20%)	57 (2%)	58 (7%)	176 (9%)	26 (3%)	108 (3%)	171 (7%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 59. Medical conditions recorded 180 to 1 days before the diagnosis of kidney cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	33	6,498	289	9,149	1,068	7,404	950	1,096	6,394
Anxiety	<5	139 (2%)	19 (7%)	181 (2%)	32 (3%)	239 (3%)	10 (1%)	18 (2%)	116 (2%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Asthma	<5	439 (7%)	19 (7%)	93 (1%)	22 (2%)	55 (1%)	37 (4%)	9 (1%)	287 (4%)
Attention deficit hyperactivity disorder	0 (0%)	17 (0%)	0 (0%)	5 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	<5
Chronic kidney disease	<5	204 (3%)	14 (5%)	182 (2%)	9 (1%)	443 (6%)	35 (4%)	17 (2%)	220 (3%)
Chronic liver disease	0 (0%)	48 (1%)	<5	19 (0%)	<5	43 (1%)	<5	<5	42 (1%)
Chronic obstructive lung disease	<5	457 (7%)	9 (3%)	196 (2%)	42 (4%)	178 (2%)	30 (3%)	13 (1%)	197 (3%)
Covid 19	0 (0%)	0 (0%)	9 (3%)	30 (0%)	28 (3%)	220 (3%)	5 (1%)	<5	44 (1%)
Crohns disease	0 (0%)	29 (0%)	0 (0%)	8 (0%)	0 (0%)	5 (0%)	<5	0 (0%)	35 (1%)
Deep vein thrombosis	0 (0%)	29 (0%)	<5	27 (0%)	5 (0%)	26 (0%)	0 (0%)	7 (1%)	19 (0%)
Dementia	0 (0%)	40 (1%)	<5	56 (1%)	8 (1%)	68 (1%)	5 (1%)	<5	139 (2%)
Depressive disorder	0 (0%)	434 (7%)	14 (5%)	128 (1%)	19 (2%)	167 (2%)	20 (2%)	10 (1%)	110 (2%)
Diabetes mellitus	6 (18%)	1,029 (16%)	49 (17%)	566 (6%)	143 (13%)	339 (5%)	63 (7%)	17 (2%)	897 (14%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	12 (36%)	626 (10%)	93 (32%)	1,263 (14%)	155 (15%)	715 (10%)	169 (18%)	14 (1%)	1,625 (25%)
Gastroesophageal reflux disease	5 (15%)	31 (0%)	22 (8%)	57 (1%)	6 (1%)	87 (1%)	32 (3%)	<5	44 (1%)
Gastrointestinal hemorrhage	0 (0%)	50 (1%)	<5	34 (0%)	16 (1%)	121 (2%)	12 (1%)	<5	57 (1%)
Human immunodeficiency virus infection	0 (0%)	5 (0%)	0 (0%)	0 (0%)	0 (0%)	5 (0%)	0 (0%)	0 (0%)	8 (0%)
Hyperlipidemia	8 (24%)	1,862 (29%)	26 (9%)	464 (5%)	11 (1%)	559 (8%)	39 (4%)	7 (1%)	489 (8%)
Myocardial infarction	<5	58 (1%)	10 (3%)	68 (1%)	27 (3%)	85 (1%)	19 (2%)	<5	84 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Obesity	0 (0%)	90 (1%)	18 (6%)	169 (2%)	7 (1%)	341 (5%)	27 (3%)	<5	99 (2%)
Osteoarthritis	<5	104 (2%)	35 (12%)	333 (4%)	33 (3%)	301 (4%)	18 (2%)	14 (1%)	273 (4%)
Parkinsons disease	<5	48 (1%)	<5	25 (0%)	<5	21 (0%)	6 (1%)	0 (0%)	51 (1%)
PE and DVT combined	0 (0%)	83 (1%)	<5	60 (1%)	14 (1%)	49 (1%)	7 (1%)	13 (1%)	112 (2%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	7 (0%)	<5	0 (0%)	5 (0%)
Pneumonia	<5	497 (8%)	5 (2%)	74 (1%)	42 (4%)	142 (2%)	17 (2%)	10 (1%)	255 (4%)
Psoriasis	0 (0%)	99 (2%)	<5	24 (0%)	5 (0%)	22 (0%)	<5	<5	42 (1%)
Pulmonary embolism	0 (0%)	57 (1%)	<5	37 (0%)	9 (1%)	30 (0%)	7 (1%)	6 (1%)	96 (2%)
Renal impairment	<5	259 (4%)	20 (7%)	278 (3%)	72 (7%)	534 (7%)	51 (5%)	36 (3%)	324 (5%)
Retinal vein thrombosis broad	0 (0%)	14 (0%)	<5	5 (0%)	0 (0%)	6 (0%)	0 (0%)	0 (0%)	15 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	19 (0%)	0 (0%)	7 (0%)	<5	15 (0%)	<5	<5	30 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5
Thromboembolic disorder	0 (0%)	<5	0 (0%)	29 (0%)	0 (0%)	20 (0%)	0 (0%)	0 (0%)	10 (0%)
Ulcerative colitis	0 (0%)	40 (1%)	<5	19 (0%)	<5	10 (0%)	<5	<5	45 (1%)
Viral hepatitis	0 (0%)	17 (0%)	<5	5 (0%)	0 (0%)	36 (0%)	0 (0%)	0 (0%)	17 (0%)
Visual system disorder	<5	664 (10%)	66 (23%)	132 (1%)	94 (9%)	890 (12%)	31 (3%)	29 (3%)	553 (9%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 60. Medical conditions recorded 180 to 1 days before the diagnosis of liver cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	35	3,338	75	3,214	557	5,618	456	1,297	4,177
Anxiety	<5	66 (2%)	<5	69 (2%)	9 (2%)	149 (3%)	7 (2%)	13 (1%)	40 (1%)
Asthma	<5	193 (6%)	6 (8%)	47 (1%)	12 (2%)	34 (1%)	21 (5%)	8 (1%)	149 (4%)
Attention deficit hyperactivity disorder	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	<5	<5
Chronic kidney disease	0 (0%)	71 (2%)	<5	68 (2%)	5 (1%)	220 (4%)	17 (4%)	17 (1%)	73 (2%)
Chronic liver disease	<5	770 (23%)	12 (16%)	259 (8%)	32 (6%)	642 (11%)	50 (11%)	125 (10%)	755 (18%)
Chronic obstructive lung disease	<5	332 (10%)	5 (7%)	107 (3%)	29 (5%)	200 (4%)	22 (5%)	18 (1%)	149 (4%)
Covid 19	<5	0 (0%)	<5	15 (0%)	17 (3%)	145 (3%)	0 (0%)	<5	18 (0%)
Crohns disease	0 (0%)	13 (0%)	<5	6 (0%)	0 (0%)	7 (0%)	0 (0%)	0 (0%)	17 (0%)
Deep vein thrombosis	0 (0%)	19 (1%)	0 (0%)	14 (0%)	<5	37 (1%)	<5	5 (0%)	22 (1%)
Dementia	0 (0%)	36 (1%)	<5	45 (1%)	<5	60 (1%)	<5	6 (0%)	137 (3%)
Depressive disorder	0 (0%)	285 (9%)	<5	71 (2%)	11 (2%)	144 (3%)	10 (2%)	9 (1%)	61 (1%)
Diabetes mellitus	8 (23%)	918 (28%)	17 (23%)	447 (14%)	85 (15%)	443 (8%)	72 (16%)	23 (2%)	971 (23%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5
Essential hypertension	9 (26%)	371 (11%)	22 (29%)	607 (19%)	49 (9%)	574 (10%)	98 (21%)	7 (1%)	991 (24%)
Gastroesophageal reflux disease	<5	15 (0%)	7 (9%)	49 (2%)	<5	70 (1%)	8 (2%)	5 (0%)	17 (0%)
Gastrointestinal hemorrhage	0 (0%)	116 (3%)	<5	32 (1%)	13 (2%)	169 (3%)	6 (1%)	20 (2%)	100 (2%)
Human immunodeficiency virus infection	0 (0%)	9 (0%)	0 (0%)	<5	<5	15 (0%)	0 (0%)	0 (0%)	7 (0%)
Hyperlipidemia	5 (14%)	888 (27%)	6 (8%)	216 (7%)	6 (1%)	319 (6%)	19 (4%)	6 (0%)	222 (5%)
Myocardial infarction	0 (0%)	15 (0%)	5 (7%)	34 (1%)	10 (2%)	58 (1%)	18 (4%)	<5	68 (2%)
Obesity	0 (0%)	54 (2%)	6 (8%)	48 (1%)	<5	297 (5%)	13 (3%)	6 (0%)	83 (2%)
Osteoarthritis	<5	40 (1%)	15 (20%)	166 (5%)	19 (3%)	210 (4%)	10 (2%)	18 (1%)	155 (4%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	0 (0%)	27 (1%)	<5	10 (0%)	0 (0%)	21 (0%)	<5	<5	30 (1%)
PE and DVT combined	0 (0%)	69 (2%)	<5	23 (1%)	6 (1%)	52 (1%)	<5	18 (1%)	71 (2%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5
Pneumonia	0 (0%)	270 (8%)	<5	33 (1%)	18 (3%)	90 (2%)	12 (3%)	11 (1%)	176 (4%)
Psoriasis	<5	69 (2%)	<5	23 (1%)	5 (1%)	42 (1%)	<5	<5	43 (1%)
Pulmonary embolism	0 (0%)	54 (2%)	<5	12 (0%)	<5	22 (0%)	<5	13 (1%)	52 (1%)
Renal impairment	0 (0%)	114 (3%)	<5	106 (3%)	26 (5%)	298 (5%)	30 (7%)	32 (2%)	139 (3%)
Retinal vein thrombosis broad	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	8 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	24 (1%)	0 (0%)	<5	<5	8 (0%)	<5	0 (0%)	34 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	61 (2%)	0 (0%)	11 (0%)	0 (0%)	100 (2%)	6 (1%)	13 (1%)	51 (1%)
Thromboembolic disorder	0 (0%)	<5	0 (0%)	13 (0%)	0 (0%)	26 (0%)	<5	<5	17 (0%)
Ulcerative colitis	0 (0%)	26 (1%)	0 (0%)	5 (0%)	<5	7 (0%)	<5	<5	47 (1%)
Viral hepatitis	0 (0%)	174 (5%)	7 (9%)	67 (2%)	12 (2%)	319 (6%)	5 (1%)	12 (1%)	103 (2%)
Visual system disorder	<5	371 (11%)	19 (25%)	113 (4%)	51 (9%)	719 (13%)	20 (4%)	57 (4%)	392 (9%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 61. Medical conditions recorded 180 to 1 days before the diagnosis of lung cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	486	27,757	332	20,343	5,288	20,068	2,581	11,844	16,828
Anxiety	41 (8%)	871 (3%)	22 (7%)	433 (2%)	150 (3%)	596 (3%)	48 (2%)	186 (2%)	183 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Asthma	29 (6%)	3,056 (11%)	44 (13%)	664 (3%)	139 (3%)	177 (1%)	78 (3%)	83 (1%)	1,190 (7%)
Attention deficit hyperactivity disorder	<5	25 (0%)	0 (0%)	8 (0%)	5 (0%)	<5	0 (0%)	0 (0%)	5 (0%)
Chronic kidney disease	6 (1%)	369 (1%)	7 (2%)	272 (1%)	50 (1%)	706 (4%)	79 (3%)	108 (1%)	231 (1%)
Chronic liver disease	<5	150 (1%)	0 (0%)	74 (0%)	<5	123 (1%)	11 (0%)	10 (0%)	91 (1%)
Chronic obstructive lung disease	110 (23%)	6,795 (24%)	70 (21%)	2,386 (12%)	712 (13%)	1,995 (10%)	331 (13%)	907 (8%)	2,917 (17%)
Covid 19	<5	5 (0%)	12 (4%)	105 (1%)	152 (3%)	533 (3%)	11 (0%)	39 (0%)	96 (1%)
Crohns disease	0 (0%)	87 (0%)	0 (0%)	24 (0%)	13 (0%)	12 (0%)	7 (0%)	<5	42 (0%)
Deep vein thrombosis	0 (0%)	89 (0%)	<5	70 (0%)	23 (0%)	117 (1%)	11 (0%)	66 (1%)	59 (0%)
Dementia	<5	274 (1%)	<5	219 (1%)	51 (1%)	161 (1%)	23 (1%)	62 (1%)	503 (3%)
Depressive disorder	6 (1%)	2,870 (10%)	24 (7%)	487 (2%)	98 (2%)	487 (2%)	67 (3%)	92 (1%)	229 (1%)
Diabetes mellitus	42 (9%)	3,431 (12%)	28 (8%)	1,462 (7%)	536 (10%)	1,057 (5%)	168 (7%)	137 (1%)	1,907 (11%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	<5	<5	0 (0%)
Essential hypertension	150 (31%)	1,869 (7%)	94 (28%)	3,260 (16%)	506 (10%)	1,941 (10%)	489 (19%)	71 (1%)	3,211 (19%)
Gastroesophageal reflux disease	41 (8%)	66 (0%)	38 (11%)	230 (1%)	16 (0%)	244 (1%)	71 (3%)	44 (0%)	99 (1%)
Gastrointestinal hemorrhage	<5	192 (1%)	<5	112 (1%)	63 (1%)	262 (1%)	15 (1%)	63 (1%)	121 (1%)
Human immunodeficiency virus infection	0 (0%)	36 (0%)	0 (0%)	<5	<5	29 (0%)	0 (0%)	0 (0%)	14 (0%)
Hyperlipidemia	103 (21%)	8,412 (30%)	35 (11%)	1,362 (7%)	97 (2%)	1,600 (8%)	142 (6%)	27 (0%)	928 (6%)
Myocardial infarction	11 (2%)	271 (1%)	23 (7%)	275 (1%)	144 (3%)	332 (2%)	97 (4%)	82 (1%)	354 (2%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Obesity	<5	185 (1%)	8 (2%)	243 (1%)	18 (0%)	776 (4%)	53 (2%)	9 (0%)	127 (1%)
Osteoarthritis	31 (6%)	428 (2%)	31 (9%)	923 (5%)	136 (3%)	746 (4%)	92 (4%)	186 (2%)	647 (4%)
Parkinsons disease	<5	126 (0%)	<5	65 (0%)	<5	44 (0%)	9 (0%)	5 (0%)	57 (0%)
PE and DVT combined	<5	527 (2%)	8 (2%)	204 (1%)	65 (1%)	199 (1%)	33 (1%)	193 (2%)	279 (2%)
Pelvic vein thrombosis	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	10 (0%)	<5	<5	8 (0%)
Pneumonia	25 (5%)	6,692 (24%)	63 (19%)	957 (5%)	413 (8%)	1,468 (7%)	172 (7%)	334 (3%)	2,384 (14%)
Psoriasis	<5	392 (1%)	5 (2%)	97 (0%)	35 (1%)	88 (0%)	11 (0%)	29 (0%)	116 (1%)
Pulmonary embolism	<5	461 (2%)	5 (2%)	151 (1%)	42 (1%)	114 (1%)	24 (1%)	133 (1%)	237 (1%)
Renal impairment	6 (1%)	510 (2%)	7 (2%)	424 (2%)	195 (4%)	848 (4%)	111 (4%)	194 (2%)	346 (2%)
Retinal vein thrombosis broad	<5	65 (0%)	0 (0%)	8 (0%)	0 (0%)	14 (0%)	<5	<5	57 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)
Schizophrenia	<5	178 (1%)	<5	25 (0%)	9 (0%)	38 (0%)	<5	<5	186 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	6 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	<5	<5	5 (0%)
Thromboembolic disorder	0 (0%)	<5	<5	83 (0%)	0 (0%)	90 (0%)	<5	6 (0%)	28 (0%)
Ulcerative colitis	<5	88 (0%)	0 (0%)	17 (0%)	12 (0%)	13 (0%)	5 (0%)	<5	61 (0%)
Viral hepatitis	0 (0%)	48 (0%)	0 (0%)	32 (0%)	<5	100 (0%)	5 (0%)	0 (0%)	17 (0%)
Visual system disorder	19 (4%)	3,230 (12%)	63 (19%)	435 (2%)	429 (8%)	2,288 (11%)	137 (5%)	393 (3%)	1,481 (9%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 62. Medical conditions recorded 180 to 1 days before the diagnosis of leukaemia and lymphoma, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	815	25,172	884	33,640	3,009	28,831	3,029	10,429	20,690
Anxiety	49 (6%)	529 (2%)	53 (6%)	729 (2%)	78 (3%)	1,035 (4%)	43 (1%)	148 (1%)	359 (2%)
Asthma	29 (4%)	1,582 (6%)	60 (7%)	511 (2%)	54 (2%)	255 (1%)	104 (3%)	58 (1%)	698 (3%)
Attention deficit hyperactivity disorder	0 (0%)	31 (0%)	0 (0%)	30 (0%)	<5	<5	0 (0%)	<5	28 (0%)
Chronic kidney disease	8 (1%)	439 (2%)	9 (1%)	423 (1%)	13 (0%)	991 (3%)	82 (3%)	111 (1%)	232 (1%)
Chronic liver disease	<5	130 (1%)	7 (1%)	88 (0%)	10 (0%)	159 (1%)	7 (0%)	11 (0%)	98 (0%)
Chronic obstructive lung disease	56 (7%)	1,665 (7%)	22 (2%)	930 (3%)	62 (2%)	631 (2%)	70 (2%)	125 (1%)	352 (2%)
Covid 19	5 (1%)	<5	18 (2%)	232 (1%)	102 (3%)	1,178 (4%)	14 (0%)	42 (0%)	133 (1%)
Crohns disease	<5	109 (0%)	<5	57 (0%)	14 (0%)	35 (0%)	11 (0%)	6 (0%)	78 (0%)
Deep vein thrombosis	0 (0%)	95 (0%)	7 (1%)	102 (0%)	16 (1%)	164 (1%)	8 (0%)	61 (1%)	77 (0%)
Dementia	<5	194 (1%)	<5	275 (1%)	18 (1%)	283 (1%)	11 (0%)	34 (0%)	420 (2%)
Depressive disorder	13 (2%)	1,836 (7%)	63 (7%)	692 (2%)	33 (1%)	736 (3%)	42 (1%)	73 (1%)	346 (2%)
Diabetes mellitus	55 (7%)	2,580 (10%)	83 (9%)	2,081 (6%)	257 (9%)	1,077 (4%)	138 (5%)	97 (1%)	1,858 (9%)
Disseminated intravascular coagulation	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	<5
Essential hypertension	210 (26%)	1,614 (6%)	176 (20%)	4,521 (13%)	257 (9%)	1,961 (7%)	414 (14%)	83 (1%)	2,996 (14%)
Gastroesophageal reflux disease	56 (7%)	74 (0%)	61 (7%)	278 (1%)	11 (0%)	303 (1%)	61 (2%)	30 (0%)	133 (1%)
Gastrointestinal hemorrhage	<5	221 (1%)	5 (1%)	177 (1%)	33 (1%)	377 (1%)	25 (1%)	75 (1%)	156 (1%)
Human immunodeficiency virus infection	0 (0%)	43 (0%)	<5	15 (0%)	<5	47 (0%)	0 (0%)	0 (0%)	14 (0%)
Hyperlipidemia	120 (15%)	5,863 (23%)	76 (9%)	1,850 (5%)	48 (2%)	1,589 (6%)	141 (5%)	14 (0%)	828 (4%)
Myocardial infarction	7 (1%)	221 (1%)	26 (3%)	250 (1%)	44 (1%)	273 (1%)	80 (3%)	48 (0%)	256 (1%)
Obesity	<5	202 (1%)	31 (4%)	544 (2%)	10 (0%)	1,086 (4%)	46 (2%)	15 (0%)	169 (1%)
Osteoarthritis	50 (6%)	433 (2%)	80 (9%)	1,446 (4%)	87 (3%)	1,075 (4%)	88 (3%)	139 (1%)	797 (4%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	<5	191 (1%)	<5	94 (0%)	5 (0%)	93 (0%)	12 (0%)	<5	113 (1%)
PE and DVT combined	9 (1%)	267 (1%)	13 (1%)	235 (1%)	23 (1%)	233 (1%)	25 (1%)	100 (1%)	225 (1%)
Pelvic vein thrombosis	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	24 (0%)	<5	<5	16 (0%)
Pneumonia	19 (2%)	1,988 (8%)	29 (3%)	334 (1%)	123 (4%)	734 (3%)	86 (3%)	87 (1%)	719 (3%)
Psoriasis	10 (1%)	379 (2%)	22 (2%)	185 (1%)	16 (1%)	115 (0%)	8 (0%)	36 (0%)	120 (1%)
Pulmonary embolism	9 (1%)	185 (1%)	6 (1%)	145 (0%)	9 (0%)	87 (0%)	20 (1%)	43 (0%)	160 (1%)
Renal impairment	9 (1%)	620 (2%)	15 (2%)	681 (2%)	99 (3%)	1,205 (4%)	139 (5%)	173 (2%)	391 (2%)
Retinal vein thrombosis broad	0 (0%)	51 (0%)	<5	18 (0%)	0 (0%)	17 (0%)	<5	10 (0%)	53 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	6 (0%)	0 (0%)
Schizophrenia	<5	87 (0%)	<5	23 (0%)	<5	29 (0%)	<5	<5	113 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	36 (0%)	<5	8 (0%)	0 (0%)	22 (0%)	<5	11 (0%)	29 (0%)
Thromboembolic disorder	0 (0%)	11 (0%)	0 (0%)	111 (0%)	0 (0%)	108 (0%)	<5	0 (0%)	40 (0%)
Ulcerative colitis	0 (0%)	106 (0%)	<5	42 (0%)	7 (0%)	33 (0%)	10 (0%)	9 (0%)	101 (0%)
Viral hepatitis	<5	40 (0%)	<5	53 (0%)	<5	138 (0%)	<5	<5	22 (0%)
Visual system disorder	47 (6%)	3,083 (12%)	172 (19%)	885 (3%)	292 (10%)	3,624 (13%)	133 (4%)	350 (3%)	1,874 (9%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 63. Medical conditions recorded 180 to 1 days before the diagnosis of melanoma, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	130	17,145	526	28,972	3,096	7,928	1,797	5,235	8,820
Anxiety	7 (5%)	258 (2%)	36 (7%)	328 (1%)	84 (3%)	234 (3%)	9 (1%)	47 (1%)	139 (2%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Asthma	<5	705 (4%)	20 (4%)	212 (1%)	37 (1%)	37 (0%)	15 (1%)	22 (0%)	177 (2%)
Attention deficit hyperactivity disorder	0 (0%)	36 (0%)	0 (0%)	22 (0%)	<5	0 (0%)	0 (0%)	<5	<5
Chronic kidney disease	<5	98 (1%)	6 (1%)	134 (0%)	17 (1%)	136 (2%)	12 (1%)	22 (0%)	44 (0%)
Chronic liver disease	0 (0%)	28 (0%)	0 (0%)	20 (0%)	<5	13 (0%)	0 (0%)	<5	14 (0%)
Chronic obstructive lung disease	6 (5%)	365 (2%)	7 (1%)	217 (1%)	37 (1%)	63 (1%)	16 (1%)	20 (0%)	44 (0%)
Covid 19	<5	<5	16 (3%)	113 (0%)	111 (4%)	322 (4%)	<5	16 (0%)	53 (1%)
Crohns disease	<5	34 (0%)	0 (0%)	22 (0%)	8 (0%)	<5	<5	<5	28 (0%)
Deep vein thrombosis	0 (0%)	15 (0%)	0 (0%)	30 (0%)	8 (0%)	11 (0%)	0 (0%)	7 (0%)	12 (0%)
Dementia	0 (0%)	118 (1%)	<5	103 (0%)	8 (0%)	44 (1%)	<5	19 (0%)	144 (2%)
Depressive disorder	0 (0%)	825 (5%)	40 (8%)	254 (1%)	39 (1%)	139 (2%)	12 (1%)	34 (1%)	116 (1%)
Diabetes mellitus	7 (5%)	1,089 (6%)	27 (5%)	766 (3%)	162 (5%)	148 (2%)	27 (2%)	34 (1%)	637 (7%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	31 (24%)	473 (3%)	87 (17%)	1,862 (6%)	218 (7%)	334 (4%)	108 (6%)	38 (1%)	901 (10%)
Gastroesophageal reflux disease	10 (8%)	19 (0%)	28 (5%)	101 (0%)	11 (0%)	47 (1%)	7 (0%)	8 (0%)	24 (0%)
Gastrointestinal hemorrhage	0 (0%)	32 (0%)	<5	34 (0%)	30 (1%)	53 (1%)	<5	10 (0%)	27 (0%)
Human immunodeficiency virus infection	0 (0%)	12 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	<5
Hyperlipidemia	25 (19%)	3,040 (18%)	38 (7%)	730 (3%)	56 (2%)	254 (3%)	22 (1%)	12 (0%)	295 (3%)
Myocardial infarction	<5	47 (0%)	5 (1%)	82 (0%)	23 (1%)	40 (1%)	8 (0%)	<5	52 (1%)
Obesity	<5	115 (1%)	12 (2%)	168 (1%)	9 (0%)	209 (3%)	12 (1%)	5 (0%)	61 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Osteoarthritis	8 (6%)	246 (1%)	42 (8%)	574 (2%)	74 (2%)	193 (2%)	18 (1%)	56 (1%)	311 (4%)
Parkinsons disease	0 (0%)	112 (1%)	<5	49 (0%)	7 (0%)	16 (0%)	<5	<5	63 (1%)
PE and DVT combined	<5	38 (0%)	<5	65 (0%)	12 (0%)	20 (0%)	0 (0%)	11 (0%)	32 (0%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	6 (0%)	0 (0%)	0 (0%)	<5
Pneumonia	0 (0%)	387 (2%)	<5	62 (0%)	42 (1%)	78 (1%)	8 (0%)	9 (0%)	79 (1%)
Psoriasis	<5	215 (1%)	9 (2%)	248 (1%)	11 (0%)	27 (0%)	<5	12 (0%)	58 (1%)
Pulmonary embolism	<5	24 (0%)	<5	38 (0%)	<5	12 (0%)	0 (0%)	<5	21 (0%)
Renal impairment	<5	116 (1%)	9 (2%)	214 (1%)	55 (2%)	146 (2%)	17 (1%)	30 (1%)	66 (1%)
Retinal vein thrombosis broad	0 (0%)	25 (0%)	<5	<5	0 (0%)	<5	0 (0%)	6 (0%)	20 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	5 (0%)	0 (0%)
Schizophrenia	0 (0%)	33 (0%)	<5	12 (0%)	<5	<5	0 (0%)	0 (0%)	19 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Thromboembolic disorder	0 (0%)	0 (0%)	0 (0%)	28 (0%)	0 (0%)	11 (0%)	0 (0%)	0 (0%)	<5
Ulcerative colitis	<5	76 (0%)	0 (0%)	10 (0%)	5 (0%)	6 (0%)	<5	5 (0%)	27 (0%)
Viral hepatitis	<5	10 (0%)	0 (0%)	20 (0%)	<5	11 (0%)	0 (0%)	0 (0%)	<5
Visual system disorder	<5	1,582 (9%)	94 (18%)	402 (1%)	268 (9%)	909 (11%)	57 (3%)	129 (2%)	794 (9%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 64. Medical conditions recorded 180 to 1 days before the diagnosis of ovarian cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	54	2,842	217	4,603	473	3,244	572	1,704	3,085
Anxiety	5 (9%)	92 (3%)	16 (7%)	124 (3%)	23 (5%)	135 (4%)	10 (2%)	29 (2%)	71 (2%)
Asthma	<5	172 (6%)	12 (6%)	49 (1%)	7 (1%)	34 (1%)	23 (4%)	12 (1%)	96 (3%)
Attention deficit hyperactivity disorder	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5
Chronic kidney disease	0 (0%)	19 (1%)	<5	43 (1%)	6 (1%)	55 (2%)	11 (2%)	13 (1%)	29 (1%)
Chronic liver disease	0 (0%)	18 (1%)	<5	18 (0%)	<5	12 (0%)	0 (0%)	<5	15 (0%)
Chronic obstructive lung disease	<5	134 (5%)	5 (2%)	68 (1%)	5 (1%)	16 (0%)	8 (1%)	15 (1%)	32 (1%)
Covid 19	0 (0%)	<5	8 (4%)	16 (0%)	10 (2%)	101 (3%)	<5	<5	12 (0%)
Crohns disease	0 (0%)	5 (0%)	0 (0%)	8 (0%)	<5	<5	<5	<5	7 (0%)
Deep vein thrombosis	0 (0%)	10 (0%)	0 (0%)	13 (0%)	0 (0%)	25 (1%)	<5	24 (1%)	19 (1%)
Dementia	0 (0%)	20 (1%)	0 (0%)	34 (1%)	5 (1%)	21 (1%)	<5	6 (0%)	72 (2%)
Depressive disorder	<5	236 (8%)	18 (8%)	84 (2%)	8 (2%)	70 (2%)	10 (2%)	9 (1%)	61 (2%)
Diabetes mellitus	14 (26%)	210 (7%)	21 (10%)	173 (4%)	37 (8%)	84 (3%)	16 (3%)	13 (1%)	224 (7%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	13 (24%)	374 (13%)	40 (18%)	481 (10%)	45 (10%)	217 (7%)	60 (10%)	18 (1%)	479 (16%)
Gastroesophageal reflux disease	0 (0%)	14 (0%)	15 (7%)	49 (1%)	<5	37 (1%)	24 (4%)	5 (0%)	23 (1%)
Gastrointestinal hemorrhage	0 (0%)	23 (1%)	<5	19 (0%)	<5	32 (1%)	6 (1%)	13 (1%)	20 (1%)
Human immunodeficiency virus infection	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5
Hyperlipidemia	7 (13%)	578 (20%)	23 (11%)	163 (4%)	5 (1%)	147 (5%)	13 (2%)	5 (0%)	133 (4%)
Myocardial infarction	0 (0%)	10 (0%)	<5	13 (0%)	6 (1%)	9 (0%)	6 (1%)	<5	25 (1%)
Obesity	<5	229 (8%)	11 (5%)	66 (1%)	<5	136 (4%)	14 (2%)	<5	50 (2%)
Osteoarthritis	5 (9%)	32 (1%)	17 (8%)	163 (4%)	10 (2%)	122 (4%)	12 (2%)	16 (1%)	124 (4%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	0 (0%)	9 (0%)	<5	9 (0%)	0 (0%)	6 (0%)	<5	0 (0%)	15 (0%)
PE and DVT combined	0 (0%)	62 (2%)	<5	28 (1%)	<5	42 (1%)	7 (1%)	57 (3%)	86 (3%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5
Pneumonia	0 (0%)	160 (6%)	<5	26 (1%)	13 (3%)	29 (1%)	7 (1%)	8 (0%)	80 (3%)
Psoriasis	0 (0%)	31 (1%)	<5	14 (0%)	<5	13 (0%)	<5	<5	8 (0%)
Pulmonary embolism	0 (0%)	53 (2%)	<5	16 (0%)	<5	18 (1%)	5 (1%)	38 (2%)	69 (2%)
Renal impairment	0 (0%)	40 (1%)	5 (2%)	67 (1%)	15 (3%)	78 (2%)	17 (3%)	28 (2%)	54 (2%)
Retinal vein thrombosis broad	0 (0%)	<5	<5	0 (0%)	0 (0%)	<5	<5	0 (0%)	<5
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	11 (0%)	<5	<5	<5	<5	<5	0 (0%)	18 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Thromboembolic disorder	0 (0%)	0 (0%)	0 (0%)	16 (0%)	0 (0%)	10 (0%)	0 (0%)	0 (0%)	5 (0%)
Ulcerative colitis	0 (0%)	13 (0%)	0 (0%)	<5	<5	<5	6 (1%)	0 (0%)	16 (1%)
Viral hepatitis	0 (0%)	<5	<5	<5	0 (0%)	7 (0%)	0 (0%)	0 (0%)	<5
Visual system disorder	<5	255 (9%)	40 (18%)	69 (1%)	39 (8%)	270 (8%)	17 (3%)	41 (2%)	210 (7%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 65. Medical conditions recorded 180 to 1 days before the diagnosis of pancreatic cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	123	6,587	193	6,387	1,252	6,705	907	2,354	8,139
Anxiety	8 (7%)	153 (2%)	13 (7%)	127 (2%)	30 (2%)	209 (3%)	12 (1%)	32 (1%)	61 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Asthma	7 (6%)	398 (6%)	10 (5%)	99 (2%)	25 (2%)	59 (1%)	39 (4%)	5 (0%)	251 (3%)
Attention deficit hyperactivity disorder	0 (0%)	14 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5
Chronic kidney disease	<5	72 (1%)	5 (3%)	105 (2%)	13 (1%)	268 (4%)	33 (4%)	16 (1%)	72 (1%)
Chronic liver disease	0 (0%)	53 (1%)	6 (3%)	41 (1%)	5 (0%)	54 (1%)	6 (1%)	<5	42 (1%)
Chronic obstructive lung disease	8 (7%)	517 (8%)	9 (5%)	196 (3%)	41 (3%)	171 (3%)	25 (3%)	32 (1%)	213 (3%)
Covid 19	0 (0%)	<5	5 (3%)	40 (1%)	27 (2%)	194 (3%)	<5	<5	39 (0%)
Crohns disease	0 (0%)	16 (0%)	0 (0%)	14 (0%)	6 (0%)	<5	<5	0 (0%)	21 (0%)
Deep vein thrombosis	0 (0%)	45 (1%)	<5	43 (1%)	18 (1%)	50 (1%)	<5	20 (1%)	51 (1%)
Dementia	0 (0%)	77 (1%)	<5	100 (2%)	11 (1%)	82 (1%)	12 (1%)	8 (0%)	259 (3%)
Depressive disorder	<5	559 (8%)	22 (11%)	165 (3%)	25 (2%)	220 (3%)	22 (2%)	16 (1%)	109 (1%)
Diabetes mellitus	23 (19%)	1,609 (24%)	38 (20%)	924 (14%)	213 (17%)	620 (9%)	97 (11%)	165 (7%)	1,727 (21%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	38 (31%)	734 (11%)	64 (33%)	1,294 (20%)	143 (11%)	733 (11%)	180 (20%)	14 (1%)	1,547 (19%)
Gastroesophageal reflux disease	9 (7%)	40 (1%)	26 (13%)	122 (2%)	9 (1%)	102 (2%)	31 (3%)	14 (1%)	98 (1%)
Gastrointestinal hemorrhage	<5	95 (1%)	<5	57 (1%)	16 (1%)	117 (2%)	10 (1%)	16 (1%)	92 (1%)
Human immunodeficiency virus infection	<5	7 (0%)	<5	<5	0 (0%)	10 (0%)	0 (0%)	0 (0%)	<5
Hyperlipidemia	27 (22%)	1,884 (29%)	24 (12%)	477 (7%)	20 (2%)	543 (8%)	53 (6%)	7 (0%)	466 (6%)
Myocardial infarction	<5	37 (1%)	6 (3%)	75 (1%)	16 (1%)	88 (1%)	29 (3%)	12 (1%)	120 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Obesity	0 (0%)	70 (1%)	7 (4%)	85 (1%)	<5	310 (5%)	20 (2%)	<5	63 (1%)
Osteoarthritis	8 (7%)	101 (2%)	29 (15%)	332 (5%)	31 (2%)	324 (5%)	26 (3%)	31 (1%)	315 (4%)
Parkinsons disease	0 (0%)	43 (1%)	<5	28 (0%)	<5	32 (0%)	<5	<5	51 (1%)
PE and DVT combined	0 (0%)	191 (3%)	<5	68 (1%)	25 (2%)	67 (1%)	14 (2%)	47 (2%)	166 (2%)
Pelvic vein thrombosis	0 (0%)	<5	<5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	7 (0%)
Pneumonia	<5	418 (6%)	<5	59 (1%)	28 (2%)	116 (2%)	14 (2%)	14 (1%)	243 (3%)
Psoriasis	0 (0%)	106 (2%)	5 (3%)	33 (1%)	9 (1%)	40 (1%)	<5	6 (0%)	31 (0%)
Pulmonary embolism	0 (0%)	153 (2%)	<5	29 (0%)	8 (1%)	25 (0%)	13 (1%)	32 (1%)	128 (2%)
Renal impairment	<5	107 (2%)	5 (3%)	174 (3%)	41 (3%)	304 (5%)	52 (6%)	33 (1%)	138 (2%)
Retinal vein thrombosis broad	0 (0%)	13 (0%)	<5	<5	0 (0%)	<5	0 (0%)	<5	25 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)
Schizophrenia	0 (0%)	20 (0%)	<5	8 (0%)	<5	11 (0%)	0 (0%)	0 (0%)	33 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	21 (0%)	<5	<5	0 (0%)	7 (0%)	<5	<5	12 (0%)
Thromboembolic disorder	0 (0%)	<5	<5	36 (1%)	0 (0%)	31 (0%)	0 (0%)	0 (0%)	32 (0%)
Ulcerative colitis	0 (0%)	39 (1%)	0 (0%)	14 (0%)	6 (0%)	8 (0%)	<5	<5	42 (1%)
Viral hepatitis	0 (0%)	12 (0%)	<5	26 (0%)	0 (0%)	41 (1%)	<5	0 (0%)	11 (0%)
Visual system disorder	5 (4%)	795 (12%)	36 (19%)	191 (3%)	93 (7%)	752 (11%)	40 (4%)	74 (3%)	697 (9%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 66. Medical conditions recorded 180 to 1 days before the diagnosis of prostate cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	920	29,476	1,067	51,871	4,527	22,704	7,069	15,485	36,620
Anxiety	31 (3%)	309 (1%)	28 (3%)	686 (1%)	66 (1%)	393 (2%)	35 (0%)	111 (1%)	193 (1%)
Asthma	37 (4%)	1,355 (5%)	67 (6%)	323 (1%)	60 (1%)	83 (0%)	77 (1%)	53 (0%)	915 (2%)
Attention deficit hyperactivity disorder	0 (0%)	22 (0%)	0 (0%)	20 (0%)	<5	0 (0%)	0 (0%)	<5	<5
Chronic kidney disease	8 (1%)	281 (1%)	22 (2%)	491 (1%)	28 (1%)	601 (3%)	70 (1%)	169 (1%)	362 (1%)
Chronic liver disease	0 (0%)	46 (0%)	<5	48 (0%)	<5	49 (0%)	<5	9 (0%)	60 (0%)
Chronic obstructive lung disease	60 (7%)	1,350 (5%)	43 (4%)	674 (1%)	103 (2%)	501 (2%)	83 (1%)	143 (1%)	688 (2%)
Covid 19	<5	<5	24 (2%)	151 (0%)	126 (3%)	563 (2%)	<5	35 (0%)	121 (0%)
Crohns disease	<5	41 (0%)	<5	20 (0%)	6 (0%)	9 (0%)	<5	<5	75 (0%)
Deep vein thrombosis	0 (0%)	87 (0%)	6 (1%)	84 (0%)	24 (1%)	65 (0%)	6 (0%)	53 (0%)	83 (0%)
Dementia	8 (1%)	164 (1%)	<5	319 (1%)	25 (1%)	145 (1%)	12 (0%)	30 (0%)	818 (2%)
Depressive disorder	12 (1%)	1,355 (5%)	60 (6%)	461 (1%)	30 (1%)	268 (1%)	35 (0%)	58 (0%)	260 (1%)
Diabetes mellitus	100 (11%)	3,053 (10%)	116 (11%)	2,298 (4%)	362 (8%)	749 (3%)	163 (2%)	202 (1%)	3,685 (10%)
Disseminated intravascular coagulation	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	337 (37%)	1,187 (4%)	306 (29%)	5,172 (10%)	498 (11%)	1,397 (6%)	537 (8%)	189 (1%)	5,412 (15%)
Gastroesophageal reflux disease	56 (6%)	38 (0%)	63 (6%)	217 (0%)	15 (0%)	193 (1%)	66 (1%)	42 (0%)	119 (0%)
Gastrointestinal hemorrhage	<5	125 (0%)	9 (1%)	154 (0%)	59 (1%)	290 (1%)	26 (0%)	95 (1%)	188 (1%)
Human immunodeficiency virus infection	<5	20 (0%)	<5	5 (0%)	<5	5 (0%)	0 (0%)	0 (0%)	19 (0%)
Hyperlipidemia	237 (26%)	7,801 (26%)	130 (12%)	2,250 (4%)	103 (2%)	1,039 (5%)	150 (2%)	62 (0%)	1,768 (5%)
Myocardial infarction	12 (1%)	133 (0%)	64 (6%)	327 (1%)	85 (2%)	201 (1%)	88 (1%)	32 (0%)	379 (1%)
Obesity	5 (1%)	131 (0%)	34 (3%)	410 (1%)	6 (0%)	710 (3%)	61 (1%)	12 (0%)	170 (0%)
Osteoarthritis	59 (6%)	482 (2%)	110 (10%)	1,356 (3%)	113 (2%)	672 (3%)	96 (1%)	248 (2%)	1,364 (4%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	8 (1%)	212 (1%)	8 (1%)	128 (0%)	10 (0%)	57 (0%)	12 (0%)	21 (0%)	302 (1%)
PE and DVT combined	<5	212 (1%)	13 (1%)	180 (0%)	37 (1%)	93 (0%)	18 (0%)	86 (1%)	243 (1%)
Pelvic vein thrombosis	0 (0%)	<5	<5	0 (0%)	0 (0%)	15 (0%)	<5	<5	12 (0%)
Pneumonia	18 (2%)	1,079 (4%)	19 (2%)	202 (0%)	92 (2%)	292 (1%)	24 (0%)	44 (0%)	618 (2%)
Psoriasis	5 (1%)	380 (1%)	20 (2%)	119 (0%)	19 (0%)	54 (0%)	7 (0%)	25 (0%)	133 (0%)
Pulmonary embolism	<5	137 (0%)	8 (1%)	107 (0%)	14 (0%)	34 (0%)	12 (0%)	38 (0%)	172 (0%)
Renal impairment	8 (1%)	464 (2%)	29 (3%)	859 (2%)	150 (3%)	787 (3%)	124 (2%)	289 (2%)	710 (2%)
Retinal vein thrombosis broad	0 (0%)	64 (0%)	5 (0%)	12 (0%)	0 (0%)	18 (0%)	<5	5 (0%)	108 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)
Schizophrenia	<5	24 (0%)	<5	15 (0%)	5 (0%)	7 (0%)	<5	<5	64 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	<5
Thromboembolic disorder	0 (0%)	5 (0%)	<5	82 (0%)	0 (0%)	51 (0%)	0 (0%)	<5	25 (0%)
Ulcerative colitis	<5	110 (0%)	<5	30 (0%)	7 (0%)	13 (0%)	21 (0%)	0 (0%)	139 (0%)
Viral hepatitis	<5	17 (0%)	<5	37 (0%)	<5	61 (0%)	0 (0%)	<5	<5
Visual system disorder	38 (4%)	2,915 (10%)	189 (18%)	684 (1%)	434 (10%)	2,618 (12%)	159 (2%)	436 (3%)	2,904 (8%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 67. Medical conditions recorded 180 to 1 days before the diagnosis of stomach cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	42	4,137	191	4,737	678	5,059	488	1,055	3,300
Anxiety	<5	86 (2%)	16 (8%)	91 (2%)	18 (3%)	160 (3%)	9 (2%)	10 (1%)	34 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Asthma	<5	284 (7%)	15 (8%)	71 (1%)	7 (1%)	39 (1%)	13 (3%)	<5	86 (3%)
Attention deficit hyperactivity disorder	0 (0%)	5 (0%)	0 (0%)	<5	<5	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Chronic kidney disease	0 (0%)	50 (1%)	<5	80 (2%)	8 (1%)	204 (4%)	16 (3%)	10 (1%)	34 (1%)
Chronic liver disease	0 (0%)	18 (0%)	<5	13 (0%)	<5	39 (1%)	<5	<5	15 (0%)
Chronic obstructive lung disease	<5	337 (8%)	7 (4%)	127 (3%)	24 (4%)	128 (3%)	14 (3%)	16 (2%)	69 (2%)
Covid 19	0 (0%)	0 (0%)	7 (4%)	23 (0%)	20 (3%)	121 (2%)	<5	<5	16 (0%)
Crohns disease	0 (0%)	16 (0%)	0 (0%)	7 (0%)	<5	<5	<5	0 (0%)	7 (0%)
Deep vein thrombosis	0 (0%)	12 (0%)	0 (0%)	10 (0%)	<5	23 (0%)	<5	5 (0%)	9 (0%)
Dementia	0 (0%)	36 (1%)	<5	71 (1%)	<5	68 (1%)	5 (1%)	<5	106 (3%)
Depressive disorder	0 (0%)	299 (7%)	11 (6%)	104 (2%)	14 (2%)	131 (3%)	8 (2%)	5 (0%)	40 (1%)
Diabetes mellitus	10 (24%)	570 (14%)	20 (10%)	361 (8%)	78 (12%)	304 (6%)	39 (8%)	10 (1%)	388 (12%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)
Essential hypertension	15 (36%)	328 (8%)	52 (27%)	734 (15%)	87 (13%)	497 (10%)	88 (18%)	<5	544 (16%)
Gastroesophageal reflux disease	7 (17%)	48 (1%)	26 (14%)	80 (2%)	7 (1%)	136 (3%)	15 (3%)	19 (2%)	74 (2%)
Gastrointestinal hemorrhage	<5	252 (6%)	12 (6%)	124 (3%)	21 (3%)	285 (6%)	19 (4%)	38 (4%)	289 (9%)
Human immunodeficiency virus infection	0 (0%)	6 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Hyperlipidemia	11 (26%)	1,153 (28%)	23 (12%)	292 (6%)	15 (2%)	392 (8%)	26 (5%)	0 (0%)	147 (4%)
Myocardial infarction	0 (0%)	43 (1%)	7 (4%)	55 (1%)	19 (3%)	61 (1%)	23 (5%)	8 (1%)	53 (2%)
Obesity	0 (0%)	74 (2%)	10 (5%)	56 (1%)	<5	288 (6%)	9 (2%)	0 (0%)	23 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Osteoarthritis	<5	69 (2%)	24 (13%)	196 (4%)	24 (4%)	211 (4%)	13 (3%)	17 (2%)	103 (3%)
Parkinsons disease	0 (0%)	27 (1%)	<5	16 (0%)	<5	21 (0%)	5 (1%)	<5	26 (1%)
PE and DVT combined	<5	48 (1%)	<5	32 (1%)	7 (1%)	45 (1%)	<5	12 (1%)	40 (1%)
Pelvic vein thrombosis	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Pneumonia	<5	225 (5%)	7 (4%)	40 (1%)	16 (2%)	63 (1%)	6 (1%)	10 (1%)	101 (3%)
Psoriasis	0 (0%)	45 (1%)	<5	14 (0%)	<5	26 (1%)	0 (0%)	<5	20 (1%)
Pulmonary embolism	<5	37 (1%)	<5	23 (0%)	<5	26 (1%)	<5	7 (1%)	33 (1%)
Renal impairment	0 (0%)	68 (2%)	<5	112 (2%)	27 (4%)	250 (5%)	25 (5%)	20 (2%)	50 (2%)
Retinal vein thrombosis broad	0 (0%)	7 (0%)	0 (0%)	<5	0 (0%)	5 (0%)	<5	0 (0%)	9 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	16 (0%)	0 (0%)	5 (0%)	<5	<5	<5	<5	18 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	<5	<5	0 (0%)	<5
Thromboembolic disorder	0 (0%)	<5	0 (0%)	10 (0%)	0 (0%)	21 (0%)	0 (0%)	0 (0%)	5 (0%)
Ulcerative colitis	0 (0%)	26 (1%)	0 (0%)	5 (0%)	<5	<5	<5	0 (0%)	20 (1%)
Viral hepatitis	0 (0%)	<5	<5	9 (0%)	<5	29 (1%)	0 (0%)	0 (0%)	<5
Visual system disorder	5 (12%)	470 (11%)	39 (20%)	109 (2%)	54 (8%)	643 (13%)	17 (3%)	30 (3%)	270 (8%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 68. Medical conditions recorded at the time of the diagnosis of bone cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	18	322	31	965	0	1,071	37	290	594
Anxiety	<5	<5	0 (0%)	19 (2%)	0	35 (3%)	0 (0%)	<5	<5
Asthma	<5	<5	<5	<5	0	10 (1%)	<5	0 (0%)	8 (1%)
Attention deficit hyperactivity disorder	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	<5	0 (0%)	0 (0%)	0 (0%)
Chronic kidney disease	0 (0%)	<5	0 (0%)	6 (1%)	0	22 (2%)	<5	0 (0%)	<5
Chronic liver disease	0 (0%)	0 (0%)	<5	0 (0%)	0	<5	0 (0%)	0 (0%)	<5
Chronic obstructive lung disease	0 (0%)	<5	0 (0%)	6 (1%)	0	24 (2%)	<5	0 (0%)	<5
Covid 19	0 (0%)	0 (0%)	0 (0%)	<5	0	14 (1%)	0 (0%)	0 (0%)	<5
Crohns disease	0 (0%)	0 (0%)	0 (0%)	<5	0	<5	0 (0%)	0 (0%)	0 (0%)
Deep vein thrombosis	0 (0%)	0 (0%)	0 (0%)	<5	0	5 (0%)	0 (0%)	<5	<5
Dementia	0 (0%)	<5	0 (0%)	<5	0	10 (1%)	<5	0 (0%)	9 (2%)
Depressive disorder	0 (0%)	0 (0%)	0 (0%)	14 (1%)	0	23 (2%)	<5	0 (0%)	5 (1%)
Diabetes mellitus	0 (0%)	5 (2%)	0 (0%)	22 (2%)	0	40 (4%)	<5	0 (0%)	5 (1%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	<5	6 (2%)	0 (0%)	41 (4%)	0	109 (10%)	14 (38%)	0 (0%)	42 (7%)
Gastroesophageal reflux disease	<5	0 (0%)	0 (0%)	<5	0	7 (1%)	<5	0 (0%)	0 (0%)
Gastrointestinal hemorrhage	0 (0%)	0 (0%)	<5	<5	0	6 (1%)	0 (0%)	0 (0%)	0 (0%)
Human immunodeficiency virus infection	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	<5	0 (0%)	0 (0%)	0 (0%)
Hyperlipidemia	0 (0%)	<5	0 (0%)	21 (2%)	0	87 (8%)	5 (14%)	0 (0%)	8 (1%)
Myocardial infarction	0 (0%)	0 (0%)	0 (0%)	<5	0	9 (1%)	0 (0%)	0 (0%)	<5
Obesity	0 (0%)	0 (0%)	0 (0%)	11 (1%)	0	33 (3%)	<5	0 (0%)	<5
Osteoarthritis	0 (0%)	<5	<5	85 (9%)	0	28 (3%)	<5	<5	5 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	0 (0%)	0 (0%)	0 (0%)	<5	0	<5	0 (0%)	0 (0%)	<5
PE and DVT combined	0 (0%)	0 (0%)	0 (0%)	5 (1%)	0	8 (1%)	0 (0%)	<5	10 (2%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Pneumonia	0 (0%)	<5	0 (0%)	<5	0	17 (2%)	0 (0%)	<5	<5
Psoriasis	0 (0%)	0 (0%)	0 (0%)	<5	0	0 (0%)	0 (0%)	0 (0%)	<5
Pulmonary embolism	0 (0%)	0 (0%)	0 (0%)	<5	0	6 (1%)	0 (0%)	<5	7 (1%)
Renal impairment	0 (0%)	<5	0 (0%)	8 (1%)	0	38 (4%)	<5	<5	<5
Retinal vein thrombosis broad	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	0 (0%)	0 (0%)	0 (0%)	<5
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	0 (0%)	0 (0%)	<5	0	<5	0 (0%)	0 (0%)	0 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Thromboembolic disorder	0 (0%)	0 (0%)	0 (0%)	<5	0	<5	0 (0%)	0 (0%)	0 (0%)
Ulcerative colitis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	0 (0%)	0 (0%)	0 (0%)	<5
Viral hepatitis	0 (0%)	0 (0%)	<5	0 (0%)	0	5 (0%)	0 (0%)	0 (0%)	<5
Visual system disorder	0 (0%)	<5	<5	8 (1%)	0	84 (8%)	<5	0 (0%)	5 (1%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 69. Medical conditions recorded at the time of the diagnosis of brain cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	128	3,510	132	3,240	297	3,955	507	932	3,318
Anxiety	<5	10 (0%)	<5	56 (2%)	5 (2%)	218 (6%)	25 (5%)	<5	7 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Asthma	6 (5%)	<5	<5	24 (1%)	<5	74 (2%)	27 (5%)	0 (0%)	45 (1%)
Attention deficit hyperactivity disorder	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	7 (0%)	0 (0%)	0 (0%)	5 (0%)
Chronic kidney disease	0 (0%)	7 (0%)	<5	6 (0%)	0 (0%)	150 (4%)	15 (3%)	0 (0%)	6 (0%)
Chronic liver disease	0 (0%)	<5	0 (0%)	<5	0 (0%)	39 (1%)	<5	0 (0%)	8 (0%)
Chronic obstructive lung disease	<5	15 (0%)	<5	17 (1%)	0 (0%)	148 (4%)	13 (3%)	0 (0%)	27 (1%)
Covid 19	0 (0%)	0 (0%)	<5	0 (0%)	<5	74 (2%)	8 (2%)	<5	<5
Crohns disease	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	<5	0 (0%)	<5
Deep vein thrombosis	0 (0%)	<5	<5	6 (0%)	0 (0%)	7 (0%)	<5	<5	<5
Dementia	0 (0%)	12 (0%)	<5	15 (0%)	<5	70 (2%)	8 (2%)	<5	36 (1%)
Depressive disorder	<5	14 (0%)	<5	58 (2%)	<5	174 (4%)	36 (7%)	0 (0%)	15 (0%)
Diabetes mellitus	6 (5%)	56 (2%)	<5	91 (3%)	<5	367 (9%)	45 (9%)	<5	112 (3%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	15 (12%)	116 (3%)	<5	175 (5%)	<5	951 (24%)	176 (35%)	0 (0%)	404 (12%)
Gastroesophageal reflux disease	<5	<5	0 (0%)	12 (0%)	<5	47 (1%)	22 (4%)	0 (0%)	<5
Gastrointestinal hemorrhage	0 (0%)	<5	0 (0%)	<5	<5	22 (1%)	<5	0 (0%)	<5
Human immunodeficiency virus infection	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	15 (0%)	<5	0 (0%)	<5
Hyperlipidemia	9 (7%)	39 (1%)	<5	56 (2%)	0 (0%)	735 (19%)	69 (14%)	0 (0%)	111 (3%)
Myocardial infarction	<5	<5	<5	6 (0%)	0 (0%)	58 (1%)	21 (4%)	0 (0%)	6 (0%)
Obesity	0 (0%)	9 (0%)	0 (0%)	36 (1%)	0 (0%)	194 (5%)	28 (6%)	0 (0%)	<5

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Osteoarthritis	5 (4%)	<5	<5	72 (2%)	<5	188 (5%)	23 (5%)	<5	17 (1%)
Parkinsons disease	<5	<5	<5	8 (0%)	0 (0%)	28 (1%)	<5	0 (0%)	10 (0%)
PE and DVT combined	<5	9 (0%)	<5	25 (1%)	0 (0%)	30 (1%)	8 (2%)	<5	22 (1%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5
Pneumonia	<5	14 (0%)	<5	<5	<5	37 (1%)	11 (2%)	<5	24 (1%)
Psoriasis	0 (0%)	<5	0 (0%)	6 (0%)	0 (0%)	50 (1%)	5 (1%)	0 (0%)	<5
Pulmonary embolism	<5	8 (0%)	<5	21 (1%)	0 (0%)	26 (1%)	6 (1%)	<5	21 (1%)
Renal impairment	0 (0%)	10 (0%)	<5	10 (0%)	<5	182 (5%)	25 (5%)	0 (0%)	14 (0%)
Retinal vein thrombosis broad	<5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	5 (0%)	0 (0%)	0 (0%)	<5
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	6 (0%)	0 (0%)	<5	0 (0%)	12 (0%)	<5	0 (0%)	15 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Thromboembolic disorder	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	7 (0%)	0 (0%)	0 (0%)	0 (0%)
Ulcerative colitis	0 (0%)	<5	0 (0%)	<5	0 (0%)	8 (0%)	<5	0 (0%)	<5
Viral hepatitis	0 (0%)	<5	<5	<5	0 (0%)	41 (1%)	<5	0 (0%)	<5
Visual system disorder	5 (4%)	32 (1%)	<5	49 (2%)	6 (2%)	387 (10%)	36 (7%)	<5	77 (2%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 70. Medical conditions recorded at the time of the diagnosis of breast cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	1,853	31,873	1,243	56,337	6,553	31,931	5,180	18,134	38,047
Anxiety	128 (7%)	76 (0%)	7 (1%)	1,824 (3%)	105 (2%)	991 (3%)	92 (2%)	14 (0%)	203 (1%)
Asthma	64 (3%)	219 (1%)	11 (1%)	503 (1%)	11 (0%)	324 (1%)	151 (3%)	<5	453 (1%)
Attention deficit hyperactivity disorder	<5	<5	0 (0%)	7 (0%)	<5	<5	0 (0%)	0 (0%)	6 (0%)
Chronic kidney disease	12 (1%)	41 (0%)	<5	325 (1%)	0 (0%)	394 (1%)	50 (1%)	<5	81 (0%)
Chronic liver disease	<5	10 (0%)	0 (0%)	60 (0%)	<5	97 (0%)	5 (0%)	<5	33 (0%)
Chronic obstructive lung disease	72 (4%)	219 (1%)	<5	534 (1%)	11 (0%)	186 (1%)	44 (1%)	<5	114 (0%)
Covid 19	<5	0 (0%)	<5	51 (0%)	89 (1%)	360 (1%)	0 (0%)	0 (0%)	22 (0%)
Crohns disease	<5	11 (0%)	0 (0%)	34 (0%)	<5	7 (0%)	5 (0%)	0 (0%)	22 (0%)
Deep vein thrombosis	0 (0%)	<5	0 (0%)	93 (0%)	<5	41 (0%)	<5	6 (0%)	11 (0%)
Dementia	18 (1%)	80 (0%)	0 (0%)	274 (0%)	<5	226 (1%)	17 (0%)	5 (0%)	503 (1%)
Depressive disorder	41 (2%)	158 (0%)	15 (1%)	829 (1%)	17 (0%)	758 (2%)	76 (1%)	<5	148 (0%)
Diabetes mellitus	141 (8%)	364 (1%)	11 (1%)	1,302 (2%)	29 (0%)	933 (3%)	112 (2%)	<5	702 (2%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	421 (23%)	1,181 (4%)	27 (2%)	3,508 (6%)	58 (1%)	2,559 (8%)	473 (9%)	11 (0%)	2,439 (6%)
Gastroesophageal reflux disease	114 (6%)	19 (0%)	<5	172 (0%)	9 (0%)	143 (0%)	112 (2%)	<5	31 (0%)
Gastrointestinal hemorrhage	<5	7 (0%)	0 (0%)	60 (0%)	30 (0%)	110 (0%)	<5	0 (0%)	22 (0%)
Human immunodeficiency virus infection	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	11 (0%)	0 (0%)	0 (0%)	<5
Hyperlipidemia	236 (13%)	397 (1%)	6 (0%)	1,076 (2%)	16 (0%)	1,816 (6%)	124 (2%)	<5	715 (2%)
Myocardial infarction	7 (0%)	18 (0%)	<5	187 (0%)	<5	79 (0%)	19 (0%)	<5	65 (0%)
Obesity	10 (1%)	255 (1%)	<5	776 (1%)	12 (0%)	864 (3%)	169 (3%)	0 (0%)	160 (0%)
Osteoarthritis	53 (3%)	27 (0%)	9 (1%)	2,044 (4%)	77 (1%)	749 (2%)	90 (2%)	<5	264 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	5 (0%)	22 (0%)	<5	92 (0%)	<5	63 (0%)	6 (0%)	<5	51 (0%)
PE and DVT combined	8 (0%)	16 (0%)	<5	276 (0%)	<5	101 (0%)	7 (0%)	14 (0%)	101 (0%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	9 (0%)	0 (0%)	0 (0%)	<5
Pneumonia	14 (1%)	50 (0%)	0 (0%)	102 (0%)	62 (1%)	160 (1%)	5 (0%)	5 (0%)	114 (0%)
Psoriasis	13 (1%)	24 (0%)	0 (0%)	163 (0%)	10 (0%)	83 (0%)	13 (0%)	<5	36 (0%)
Pulmonary embolism	8 (0%)	13 (0%)	<5	207 (0%)	<5	74 (0%)	6 (0%)	8 (0%)	91 (0%)
Renal impairment	12 (1%)	56 (0%)	<5	489 (1%)	11 (0%)	488 (2%)	54 (1%)	6 (0%)	151 (0%)
Retinal vein thrombosis broad	<5	<5	0 (0%)	<5	0 (0%)	8 (0%)	<5	<5	7 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	<5	28 (0%)	<5	28 (0%)	0 (0%)	59 (0%)	<5	0 (0%)	81 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5
Thromboembolic disorder	0 (0%)	0 (0%)	0 (0%)	122 (0%)	0 (0%)	33 (0%)	0 (0%)	0 (0%)	7 (0%)
Ulcerative colitis	5 (0%)	21 (0%)	<5	31 (0%)	<5	14 (0%)	13 (0%)	0 (0%)	28 (0%)
Viral hepatitis	<5	6 (0%)	0 (0%)	31 (0%)	<5	95 (0%)	<5	0 (0%)	8 (0%)
Visual system disorder	80 (4%)	110 (0%)	7 (1%)	498 (1%)	311 (5%)	1,909 (6%)	60 (1%)	8 (0%)	373 (1%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 71. Medical conditions recorded at the time of the diagnosis of colorectal cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	382	29,279	762	24,061	5,400	29,755	3,848	11,798	23,146
Anxiety	19 (5%)	59 (0%)	<5	287 (1%)	42 (1%)	774 (3%)	74 (2%)	5 (0%)	40 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Asthma	9 (2%)	207 (1%)	6 (1%)	161 (1%)	9 (0%)	341 (1%)	215 (6%)	<5	304 (1%)
Attention deficit hyperactivity disorder	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	<5
Chronic kidney disease	7 (2%)	106 (0%)	5 (1%)	272 (1%)	<5	1,414 (5%)	118 (3%)	<5	117 (1%)
Chronic liver disease	<5	57 (0%)	<5	64 (0%)	<5	247 (1%)	10 (0%)	6 (0%)	82 (0%)
Chronic obstructive lung disease	20 (5%)	590 (2%)	6 (1%)	292 (1%)	8 (0%)	1,180 (4%)	162 (4%)	8 (0%)	218 (1%)
Covid 19	<5	0 (0%)	<5	20 (0%)	49 (1%)	370 (1%)	13 (0%)	<5	36 (0%)
Crohns disease	<5	55 (0%)	<5	33 (0%)	6 (0%)	32 (0%)	17 (0%)	<5	50 (0%)
Deep vein thrombosis	0 (0%)	14 (0%)	<5	63 (0%)	<5	135 (0%)	6 (0%)	15 (0%)	36 (0%)
Dementia	5 (1%)	138 (0%)	<5	144 (1%)	<5	461 (2%)	33 (1%)	9 (0%)	401 (2%)
Depressive disorder	5 (1%)	106 (0%)	6 (1%)	209 (1%)	9 (0%)	828 (3%)	102 (3%)	0 (0%)	37 (0%)
Diabetes mellitus	31 (8%)	915 (3%)	23 (3%)	865 (4%)	46 (1%)	2,542 (9%)	330 (9%)	5 (0%)	710 (3%)
Disseminated intravascular coagulation	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	14 (0%)	0 (0%)	0 (0%)	<5
Essential hypertension	76 (20%)	2,440 (8%)	31 (4%)	1,628 (7%)	32 (1%)	5,391 (18%)	993 (26%)	5 (0%)	2,036 (9%)
Gastroesophageal reflux disease	12 (3%)	22 (0%)	8 (1%)	142 (1%)	9 (0%)	252 (1%)	96 (2%)	<5	24 (0%)
Gastrointestinal hemorrhage	0 (0%)	338 (1%)	7 (1%)	200 (1%)	505 (9%)	2,806 (9%)	127 (3%)	22 (0%)	343 (1%)
Human immunodeficiency virus infection	<5	7 (0%)	<5	<5	0 (0%)	59 (0%)	0 (0%)	0 (0%)	<5
Hyperlipidemia	48 (13%)	494 (2%)	8 (1%)	570 (2%)	5 (0%)	4,182 (14%)	216 (6%)	<5	559 (2%)
Myocardial infarction	6 (2%)	38 (0%)	10 (1%)	160 (1%)	11 (0%)	425 (1%)	113 (3%)	7 (0%)	118 (1%)
Obesity	<5	299 (1%)	10 (1%)	302 (1%)	<5	1,501 (5%)	100 (3%)	<5	76 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Osteoarthritis	20 (5%)	25 (0%)	9 (1%)	578 (2%)	36 (1%)	1,102 (4%)	87 (2%)	<5	94 (0%)
Parkinsons disease	<5	48 (0%)	<5	64 (0%)	<5	165 (1%)	24 (1%)	<5	65 (0%)
PE and DVT combined	5 (1%)	98 (0%)	7 (1%)	207 (1%)	5 (0%)	285 (1%)	25 (1%)	57 (0%)	208 (1%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	27 (0%)	0 (0%)	0 (0%)	14 (0%)
Pneumonia	6 (2%)	140 (0%)	<5	85 (0%)	45 (1%)	383 (1%)	46 (1%)	14 (0%)	183 (1%)
Psoriasis	<5	21 (0%)	<5	57 (0%)	<5	155 (1%)	8 (0%)	<5	18 (0%)
Pulmonary embolism	5 (1%)	85 (0%)	7 (1%)	158 (1%)	<5	206 (1%)	22 (1%)	45 (0%)	187 (1%)
Renal impairment	7 (2%)	157 (1%)	8 (1%)	409 (2%)	8 (0%)	1,930 (6%)	167 (4%)	24 (0%)	222 (1%)
Retinal vein thrombosis broad	<5	<5	0 (0%)	<5	0 (0%)	22 (0%)	<5	0 (0%)	5 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	21 (0%)	0 (0%)	6 (0%)	0 (0%)	65 (0%)	8 (0%)	0 (0%)	38 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	5 (0%)	0 (0%)	7 (0%)	0 (0%)	35 (0%)	<5	5 (0%)	5 (0%)
Thromboembolic disorder	0 (0%)	0 (0%)	0 (0%)	43 (0%)	0 (0%)	97 (0%)	<5	<5	15 (0%)
Ulcerative colitis	<5	66 (0%)	<5	41 (0%)	5 (0%)	38 (0%)	28 (1%)	<5	135 (1%)
Viral hepatitis	<5	<5	0 (0%)	15 (0%)	<5	168 (1%)	0 (0%)	0 (0%)	12 (0%)
Visual system disorder	11 (3%)	197 (1%)	8 (1%)	209 (1%)	200 (4%)	2,366 (8%)	133 (3%)	<5	269 (1%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 72. Medical conditions recorded at the time of the diagnosis of corpus uteri cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	60	4,910	260	5,113	622	4,858	899	2,453	6,121
Anxiety	<5	20 (0%)	0 (0%)	166 (3%)	9 (1%)	185 (4%)	36 (4%)	<5	13 (0%)
Asthma	<5	51 (1%)	<5	48 (1%)	0 (0%)	66 (1%)	33 (4%)	<5	109 (2%)
Attention deficit hyperactivity disorder	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5
Chronic kidney disease	<5	15 (0%)	0 (0%)	61 (1%)	0 (0%)	119 (2%)	25 (3%)	<5	31 (1%)
Chronic liver disease	<5	<5	0 (0%)	12 (0%)	0 (0%)	20 (0%)	0 (0%)	<5	10 (0%)
Chronic obstructive lung disease	<5	47 (1%)	<5	49 (1%)	0 (0%)	20 (0%)	7 (1%)	0 (0%)	20 (0%)
Covid 19	0 (0%)	0 (0%)	0 (0%)	<5	5 (1%)	49 (1%)	0 (0%)	0 (0%)	<5
Crohns disease	0 (0%)	<5	<5	<5	0 (0%)	<5	<5	0 (0%)	<5
Deep vein thrombosis	0 (0%)	5 (0%)	0 (0%)	23 (0%)	<5	32 (1%)	<5	<5	15 (0%)
Dementia	0 (0%)	18 (0%)	<5	30 (1%)	<5	31 (1%)	8 (1%)	0 (0%)	113 (2%)
Depressive disorder	<5	42 (1%)	0 (0%)	66 (1%)	<5	165 (3%)	26 (3%)	0 (0%)	32 (1%)
Diabetes mellitus	6 (10%)	261 (5%)	5 (2%)	175 (3%)	8 (1%)	335 (7%)	49 (5%)	<5	297 (5%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	14 (23%)	669 (14%)	16 (6%)	372 (7%)	6 (1%)	765 (16%)	166 (18%)	<5	804 (13%)
Gastroesophageal reflux disease	<5	<5	<5	27 (1%)	<5	27 (1%)	48 (5%)	0 (0%)	6 (0%)
Gastrointestinal hemorrhage	0 (0%)	<5	<5	11 (0%)	8 (1%)	33 (1%)	<5	0 (0%)	5 (0%)
Human immunodeficiency virus infection	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Hyperlipidemia	<5	125 (3%)	0 (0%)	127 (2%)	<5	484 (10%)	47 (5%)	<5	215 (4%)
Myocardial infarction	<5	<5	<5	24 (0%)	<5	20 (0%)	5 (1%)	0 (0%)	16 (0%)
Obesity	<5	707 (14%)	5 (2%)	156 (3%)	0 (0%)	441 (9%)	111 (12%)	<5	240 (4%)
Osteoarthritis	<5	9 (0%)	<5	196 (4%)	7 (1%)	171 (4%)	25 (3%)	<5	73 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	<5	6 (0%)	0 (0%)	7 (0%)	0 (0%)	12 (0%)	<5	0 (0%)	12 (0%)
PE and DVT combined	<5	19 (0%)	<5	42 (1%)	<5	48 (1%)	<5	8 (0%)	67 (1%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5
Pneumonia	<5	13 (0%)	<5	8 (0%)	5 (1%)	18 (0%)	<5	<5	29 (0%)
Psoriasis	0 (0%)	7 (0%)	<5	17 (0%)	<5	13 (0%)	9 (1%)	0 (0%)	11 (0%)
Pulmonary embolism	<5	16 (0%)	<5	26 (1%)	<5	25 (1%)	<5	7 (0%)	58 (1%)
Renal impairment	<5	25 (1%)	<5	83 (2%)	<5	162 (3%)	28 (3%)	<5	51 (1%)
Retinal vein thrombosis broad	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	<5
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	7 (0%)	0 (0%)	<5	0 (0%)	10 (0%)	<5	0 (0%)	20 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5
Thromboembolic disorder	0 (0%)	0 (0%)	0 (0%)	16 (0%)	0 (0%)	8 (0%)	0 (0%)	0 (0%)	<5
Ulcerative colitis	0 (0%)	6 (0%)	0 (0%)	0 (0%)	0 (0%)	5 (0%)	<5	0 (0%)	5 (0%)
Viral hepatitis	0 (0%)	<5	0 (0%)	5 (0%)	0 (0%)	20 (0%)	0 (0%)	0 (0%)	<5
Visual system disorder	<5	24 (0%)	<5	56 (1%)	41 (7%)	324 (7%)	17 (2%)	<5	103 (2%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 73. Medical conditions recorded at the time of the diagnosis of oesophageal cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	53	3,168	35	3,121	837	1,860	763	3,223	2,487
Anxiety	<5	5 (0%)	0 (0%)	32 (1%)	5 (1%)	39 (2%)	7 (1%)	<5	6 (0%)
Asthma	<5	17 (1%)	0 (0%)	15 (0%)	<5	14 (1%)	36 (5%)	0 (0%)	33 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Attention deficit hyperactivity disorder	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Chronic kidney disease	<5	5 (0%)	0 (0%)	16 (1%)	0 (0%)	70 (4%)	26 (3%)	<5	10 (0%)
Chronic liver disease	<5	18 (1%)	0 (0%)	10 (0%)	0 (0%)	43 (2%)	<5	<5	13 (1%)
Chronic obstructive lung disease	<5	82 (3%)	<5	58 (2%)	<5	113 (6%)	50 (7%)	<5	47 (2%)
Covid 19	0 (0%)	0 (0%)	0 (0%)	<5	<5	17 (1%)	<5	<5	<5
Crohns disease	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	<5	0 (0%)	<5
Deep vein thrombosis	0 (0%)	<5	0 (0%)	<5	0 (0%)	12 (1%)	<5	<5	<5
Dementia	0 (0%)	16 (1%)	0 (0%)	17 (1%)	0 (0%)	12 (1%)	7 (1%)	<5	39 (2%)
Depressive disorder	0 (0%)	11 (0%)	0 (0%)	30 (1%)	<5	35 (2%)	20 (3%)	0 (0%)	<5
Diabetes mellitus	<5	71 (2%)	0 (0%)	70 (2%)	9 (1%)	127 (7%)	74 (10%)	0 (0%)	89 (4%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5
Essential hypertension	7 (13%)	183 (6%)	<5	142 (5%)	6 (1%)	259 (14%)	238 (31%)	<5	231 (9%)
Gastroesophageal reflux disease	5 (9%)	7 (0%)	0 (0%)	34 (1%)	<5	25 (1%)	21 (3%)	<5	5 (0%)
Gastrointestinal hemorrhage	0 (0%)	27 (1%)	0 (0%)	17 (1%)	8 (1%)	69 (4%)	15 (2%)	8 (0%)	27 (1%)
Human immunodeficiency virus infection	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	12 (1%)	0 (0%)	0 (0%)	0 (0%)
Hyperlipidemia	<5	50 (2%)	0 (0%)	37 (1%)	<5	203 (11%)	32 (4%)	0 (0%)	61 (2%)
Myocardial infarction	0 (0%)	<5	0 (0%)	16 (1%)	<5	23 (1%)	27 (4%)	5 (0%)	18 (1%)
Obesity	<5	14 (0%)	0 (0%)	<5	<5	96 (5%)	16 (2%)	<5	<5
Osteoarthritis	<5	<5	0 (0%)	64 (2%)	5 (1%)	44 (2%)	12 (2%)	<5	9 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	<5	9 (0%)	0 (0%)	7 (0%)	0 (0%)	6 (0%)	5 (1%)	0 (0%)	8 (0%)
PE and DVT combined	<5	9 (0%)	0 (0%)	16 (1%)	<5	24 (1%)	6 (1%)	9 (0%)	19 (1%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5
Pneumonia	0 (0%)	33 (1%)	0 (0%)	12 (0%)	<5	46 (2%)	6 (1%)	7 (0%)	52 (2%)
Psoriasis	<5	<5	0 (0%)	5 (0%)	<5	9 (0%)	<5	0 (0%)	<5
Pulmonary embolism	<5	7 (0%)	0 (0%)	15 (0%)	<5	19 (1%)	<5	8 (0%)	16 (1%)
Renal impairment	<5	12 (0%)	0 (0%)	23 (1%)	0 (0%)	109 (6%)	31 (4%)	6 (0%)	21 (1%)
Retinal vein thrombosis broad	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	10 (0%)	0 (0%)	0 (0%)	0 (0%)	5 (0%)	<5	0 (0%)	15 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	<5	<5	<5	0 (0%)
Thromboembolic disorder	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	7 (0%)	0 (0%)	0 (0%)	<5
Ulcerative colitis	0 (0%)	<5	0 (0%)	<5	0 (0%)	5 (0%)	<5	0 (0%)	6 (0%)
Viral hepatitis	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	23 (1%)	<5	0 (0%)	<5
Visual system disorder	<5	14 (0%)	<5	12 (0%)	21 (3%)	99 (5%)	26 (3%)	<5	22 (1%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 74. Medical conditions recorded at the time of the diagnosis of kidney cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	33	6,498	289	9,149	1,068	7,404	950	1,096	6,394
Anxiety	<5	11 (0%)	0 (0%)	180 (2%)	10 (1%)	223 (3%)	22 (2%)	0 (0%)	21 (0%)
Asthma	<5	27 (0%)	<5	65 (1%)	<5	74 (1%)	72 (8%)	0 (0%)	113 (2%)
Attention deficit hyperactivity disorder	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Chronic kidney disease	0 (0%)	59 (1%)	9 (3%)	259 (3%)	0 (0%)	566 (8%)	64 (7%)	<5	137 (2%)
Chronic liver disease	<5	8 (0%)	0 (0%)	23 (0%)	0 (0%)	59 (1%)	<5	0 (0%)	14 (0%)
Chronic obstructive lung disease	<5	48 (1%)	<5	140 (2%)	6 (1%)	238 (3%)	42 (4%)	<5	100 (2%)
Covid 19	0 (0%)	0 (0%)	<5	6 (0%)	11 (1%)	102 (1%)	<5	0 (0%)	<5
Crohns disease	0 (0%)	5 (0%)	0 (0%)	8 (0%)	0 (0%)	7 (0%)	<5	0 (0%)	13 (0%)
Deep vein thrombosis	0 (0%)	14 (0%)	<5	28 (0%)	<5	97 (1%)	21 (2%)	<5	6 (0%)
Dementia	0 (0%)	8 (0%)	<5	51 (1%)	<5	84 (1%)	12 (1%)	0 (0%)	93 (1%)
Depressive disorder	0 (0%)	21 (0%)	<5	87 (1%)	<5	189 (3%)	34 (4%)	<5	23 (0%)
Diabetes mellitus	<5	99 (2%)	10 (3%)	406 (4%)	14 (1%)	600 (8%)	86 (9%)	0 (0%)	249 (4%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	5 (15%)	150 (2%)	22 (8%)	840 (9%)	13 (1%)	1,303 (18%)	327 (34%)	<5	774 (12%)
Gastroesophageal reflux disease	<5	0 (0%)	6 (2%)	39 (0%)	<5	70 (1%)	66 (7%)	0 (0%)	<5
Gastrointestinal hemorrhage	0 (0%)	11 (0%)	<5	18 (0%)	6 (1%)	93 (1%)	5 (1%)	<5	10 (0%)
Human immunodeficiency virus infection	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	13 (0%)	0 (0%)	0 (0%)	<5
Hyperlipidemia	5 (15%)	81 (1%)	12 (4%)	247 (3%)	0 (0%)	1,025 (14%)	84 (9%)	0 (0%)	246 (4%)
Myocardial infarction	0 (0%)	<5	5 (2%)	71 (1%)	<5	107 (1%)	34 (4%)	0 (0%)	34 (1%)
Obesity	0 (0%)	20 (0%)	5 (2%)	188 (2%)	0 (0%)	417 (6%)	68 (7%)	0 (0%)	40 (1%)
Osteoarthritis	<5	<5	<5	311 (3%)	9 (1%)	234 (3%)	37 (4%)	<5	53 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	<5	7 (0%)	<5	28 (0%)	0 (0%)	27 (0%)	5 (1%)	0 (0%)	18 (0%)
PE and DVT combined	0 (0%)	27 (0%)	<5	92 (1%)	<5	152 (2%)	30 (3%)	11 (1%)	60 (1%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5
Pneumonia	0 (0%)	31 (0%)	<5	35 (0%)	16 (1%)	106 (1%)	27 (3%)	<5	88 (1%)
Psoriasis	0 (0%)	<5	0 (0%)	28 (0%)	0 (0%)	38 (1%)	<5	0 (0%)	8 (0%)
Pulmonary embolism	0 (0%)	14 (0%)	<5	71 (1%)	<5	82 (1%)	10 (1%)	9 (1%)	57 (1%)
Renal impairment	0 (0%)	70 (1%)	12 (4%)	397 (4%)	15 (1%)	725 (10%)	121 (13%)	6 (1%)	187 (3%)
Retinal vein thrombosis broad	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	<5	<5	0 (0%)	<5
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	9 (0%)	0 (0%)	10 (0%)	<5	23 (0%)	<5	0 (0%)	14 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	11 (0%)	0 (0%)	0 (0%)	<5
Thromboembolic disorder	0 (0%)	0 (0%)	<5	23 (0%)	0 (0%)	34 (0%)	0 (0%)	0 (0%)	<5
Ulcerative colitis	0 (0%)	0 (0%)	<5	6 (0%)	<5	14 (0%)	5 (1%)	0 (0%)	14 (0%)
Viral hepatitis	0 (0%)	<5	0 (0%)	7 (0%)	0 (0%)	47 (1%)	<5	0 (0%)	<5
Visual system disorder	<5	22 (0%)	<5	88 (1%)	48 (4%)	547 (7%)	25 (3%)	<5	86 (1%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 75. Medical conditions recorded at the time of the diagnosis of liver cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	35	3,338	75	3,214	557	5,618	456	1,297	4,177
Anxiety	6 (17%)	10 (0%)	<5	25 (1%)	<5	145 (3%)	11 (2%)	0 (0%)	8 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Asthma	<5	20 (1%)	<5	14 (0%)	<5	79 (1%)	25 (5%)	0 (0%)	71 (2%)
Attention deficit hyperactivity disorder	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Chronic kidney disease	0 (0%)	23 (1%)	<5	40 (1%)	0 (0%)	362 (6%)	19 (4%)	<5	43 (1%)
Chronic liver disease	<5	458 (14%)	10 (13%)	291 (9%)	13 (2%)	1,545 (28%)	65 (14%)	56 (4%)	564 (14%)
Chronic obstructive lung disease	5 (14%)	71 (2%)	0 (0%)	48 (1%)	<5	380 (7%)	20 (4%)	<5	72 (2%)
Covid 19	0 (0%)	0 (0%)	0 (0%)	<5	<5	95 (2%)	<5	<5	6 (0%)
Crohns disease	0 (0%)	5 (0%)	<5	<5	0 (0%)	7 (0%)	<5	0 (0%)	8 (0%)
Deep vein thrombosis	0 (0%)	5 (0%)	0 (0%)	10 (0%)	0 (0%)	60 (1%)	<5	<5	8 (0%)
Dementia	0 (0%)	16 (0%)	<5	18 (1%)	0 (0%)	90 (2%)	5 (1%)	0 (0%)	91 (2%)
Depressive disorder	<5	17 (1%)	0 (0%)	26 (1%)	<5	171 (3%)	11 (2%)	0 (0%)	15 (0%)
Diabetes mellitus	9 (26%)	161 (5%)	<5	164 (5%)	11 (2%)	854 (15%)	89 (20%)	0 (0%)	328 (8%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	6 (0%)	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	11 (31%)	179 (5%)	<5	215 (7%)	5 (1%)	1,333 (24%)	135 (30%)	0 (0%)	556 (13%)
Gastroesophageal reflux disease	<5	<5	<5	13 (0%)	<5	57 (1%)	12 (3%)	0 (0%)	<5
Gastrointestinal hemorrhage	0 (0%)	28 (1%)	<5	13 (0%)	<5	180 (3%)	<5	0 (0%)	39 (1%)
Human immunodeficiency virus infection	0 (0%)	<5	0 (0%)	<5	0 (0%)	57 (1%)	0 (0%)	0 (0%)	<5
Hyperlipidemia	<5	40 (1%)	<5	47 (1%)	<5	774 (14%)	25 (5%)	0 (0%)	123 (3%)
Myocardial infarction	0 (0%)	<5	<5	10 (0%)	<5	87 (2%)	15 (3%)	0 (0%)	26 (1%)
Obesity	<5	15 (0%)	<5	30 (1%)	0 (0%)	361 (6%)	19 (4%)	<5	33 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Osteoarthritis	<5	<5	0 (0%)	40 (1%)	6 (1%)	204 (4%)	9 (2%)	<5	14 (0%)
Parkinsons disease	0 (0%)	8 (0%)	<5	9 (0%)	0 (0%)	28 (0%)	<5	0 (0%)	11 (0%)
PE and DVT combined	<5	29 (1%)	0 (0%)	27 (1%)	<5	97 (2%)	8 (2%)	12 (1%)	66 (2%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5
Pneumonia	<5	41 (1%)	0 (0%)	15 (0%)	9 (2%)	119 (2%)	15 (3%)	<5	72 (2%)
Psoriasis	0 (0%)	<5	<5	10 (0%)	<5	59 (1%)	<5	0 (0%)	13 (0%)
Pulmonary embolism	<5	26 (1%)	0 (0%)	21 (1%)	<5	59 (1%)	7 (2%)	11 (1%)	63 (2%)
Renal impairment	0 (0%)	45 (1%)	<5	65 (2%)	<5	665 (12%)	40 (9%)	<5	115 (3%)
Retinal vein thrombosis broad	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	8 (0%)	0 (0%)	0 (0%)	0 (0%)	26 (0%)	<5	0 (0%)	17 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	47 (1%)	<5	37 (1%)	0 (0%)	457 (8%)	15 (3%)	15 (1%)	52 (1%)
Thromboembolic disorder	0 (0%)	0 (0%)	0 (0%)	10 (0%)	0 (0%)	38 (1%)	<5	0 (0%)	10 (0%)
Ulcerative colitis	0 (0%)	12 (0%)	0 (0%)	<5	0 (0%)	11 (0%)	<5	0 (0%)	18 (0%)
Viral hepatitis	<5	81 (2%)	<5	49 (2%)	<5	850 (15%)	8 (2%)	<5	66 (2%)
Visual system disorder	<5	15 (0%)	<5	22 (1%)	12 (2%)	444 (8%)	20 (4%)	0 (0%)	73 (2%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 76. Medical conditions recorded at the time of the diagnosis of lung cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	486	27,757	332	20,343	5,288	20,068	2,581	11,844	16,828
Anxiety	26 (5%)	83 (0%)	<5	283 (1%)	29 (1%)	562 (3%)	71 (3%)	<5	40 (0%)
Asthma	22 (5%)	136 (0%)	21 (6%)	226 (1%)	22 (0%)	207 (1%)	105 (4%)	<5	580 (3%)
Attention deficit hyperactivity disorder	<5	<5	0 (0%)	<5	<5	<5	0 (0%)	0 (0%)	<5
Chronic kidney disease	<5	78 (0%)	<5	138 (1%)	0 (0%)	1,051 (5%)	105 (4%)	6 (0%)	91 (1%)
Chronic liver disease	0 (0%)	27 (0%)	0 (0%)	43 (0%)	0 (0%)	264 (1%)	17 (1%)	9 (0%)	66 (0%)
Chronic obstructive lung disease	72 (15%)	1,044 (4%)	35 (11%)	1,348 (7%)	112 (2%)	3,189 (16%)	585 (23%)	162 (1%)	1,989 (12%)
Covid 19	<5	0 (0%)	<5	18 (0%)	70 (1%)	367 (2%)	13 (1%)	7 (0%)	45 (0%)
Crohns disease	0 (0%)	8 (0%)	0 (0%)	10 (0%)	<5	15 (0%)	12 (0%)	0 (0%)	14 (0%)
Deep vein thrombosis	0 (0%)	17 (0%)	<5	47 (0%)	8 (0%)	205 (1%)	15 (1%)	18 (0%)	32 (0%)
Dementia	<5	80 (0%)	<5	81 (0%)	<5	236 (1%)	35 (1%)	7 (0%)	306 (2%)
Depressive disorder	<5	125 (0%)	<5	201 (1%)	14 (0%)	660 (3%)	102 (4%)	5 (0%)	49 (0%)
Diabetes mellitus	26 (5%)	345 (1%)	13 (4%)	587 (3%)	53 (1%)	1,859 (9%)	265 (10%)	7 (0%)	628 (4%)
Disseminated intravascular coagulation	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	<5	<5	0 (0%)	<5
Essential hypertension	64 (13%)	400 (1%)	24 (7%)	1,245 (6%)	30 (1%)	3,787 (19%)	730 (28%)	7 (0%)	1,855 (11%)
Gastroesophageal reflux disease	28 (6%)	5 (0%)	5 (2%)	78 (0%)	0 (0%)	196 (1%)	99 (4%)	<5	9 (0%)
Gastrointestinal hemorrhage	<5	20 (0%)	<5	28 (0%)	22 (0%)	197 (1%)	10 (0%)	<5	38 (0%)
Human immunodeficiency virus infection	<5	<5	0 (0%)	<5	0 (0%)	87 (0%)	0 (0%)	0 (0%)	8 (0%)
Hyperlipidemia	35 (7%)	238 (1%)	<5	369 (2%)	<5	3,404 (17%)	205 (8%)	<5	493 (3%)
Myocardial infarction	12 (2%)	28 (0%)	15 (5%)	156 (1%)	17 (0%)	439 (2%)	127 (5%)	12 (0%)	152 (1%)
Obesity	<5	25 (0%)	0 (0%)	165 (1%)	<5	866 (4%)	94 (4%)	<5	46 (0%)
Osteoarthritis	32 (7%)	16 (0%)	6 (2%)	397 (2%)	31 (1%)	709 (4%)	86 (3%)	12 (0%)	77 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	<5	14 (0%)	<5	24 (0%)	0 (0%)	78 (0%)	12 (0%)	0 (0%)	30 (0%)
PE and DVT combined	<5	123 (0%)	5 (2%)	193 (1%)	29 (1%)	502 (3%)	56 (2%)	114 (1%)	296 (2%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	7 (0%)	0 (0%)	0 (0%)	<5
Pneumonia	14 (3%)	884 (3%)	24 (7%)	391 (2%)	184 (3%)	1,703 (8%)	183 (7%)	82 (1%)	1,213 (7%)
Psoriasis	<5	13 (0%)	<5	44 (0%)	<5	134 (1%)	16 (1%)	0 (0%)	34 (0%)
Pulmonary embolism	<5	107 (0%)	<5	158 (1%)	21 (0%)	392 (2%)	44 (2%)	101 (1%)	270 (2%)
Renal impairment	<5	110 (0%)	6 (2%)	239 (1%)	16 (0%)	1,437 (7%)	154 (6%)	24 (0%)	186 (1%)
Retinal vein thrombosis broad	0 (0%)	<5	0 (0%)	<5	0 (0%)	9 (0%)	<5	0 (0%)	11 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	32 (0%)	0 (0%)	18 (0%)	0 (0%)	147 (1%)	8 (0%)	<5	115 (1%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	20 (0%)	0 (0%)	0 (0%)	<5
Thromboembolic disorder	0 (0%)	<5	<5	45 (0%)	0 (0%)	124 (1%)	0 (0%)	<5	28 (0%)
Ulcerative colitis	<5	8 (0%)	0 (0%)	12 (0%)	<5	26 (0%)	16 (1%)	0 (0%)	24 (0%)
Viral hepatitis	0 (0%)	6 (0%)	0 (0%)	23 (0%)	<5	207 (1%)	6 (0%)	0 (0%)	12 (0%)
Visual system disorder	18 (4%)	115 (0%)	<5	120 (1%)	125 (2%)	1,447 (7%)	89 (3%)	6 (0%)	226 (1%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 77. Medical conditions recorded at the time of the diagnosis of leukaemia and lymphoma, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	815	25,172	884	33,640	3,009	28,831	3,029	10,429	20,690
Anxiety	45 (6%)	43 (0%)	10 (1%)	372 (1%)	32 (1%)	894 (3%)	64 (2%)	11 (0%)	61 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Asthma	25 (3%)	96 (0%)	22 (2%)	267 (1%)	<5	375 (1%)	147 (5%)	<5	284 (1%)
Attention deficit hyperactivity disorder	<5	<5	0 (0%)	16 (0%)	<5	10 (0%)	0 (0%)	0 (0%)	7 (0%)
Chronic kidney disease	5 (1%)	93 (0%)	5 (1%)	400 (1%)	<5	1,666 (6%)	125 (4%)	21 (0%)	134 (1%)
Chronic liver disease	0 (0%)	32 (0%)	9 (1%)	73 (0%)	0 (0%)	263 (1%)	8 (0%)	11 (0%)	65 (0%)
Chronic obstructive lung disease	45 (6%)	205 (1%)	12 (1%)	502 (1%)	10 (0%)	966 (3%)	100 (3%)	16 (0%)	163 (1%)
Covid 19	<5	0 (0%)	6 (1%)	32 (0%)	38 (1%)	739 (3%)	26 (1%)	<5	41 (0%)
Crohns disease	<5	21 (0%)	0 (0%)	36 (0%)	0 (0%)	41 (0%)	13 (0%)	<5	23 (0%)
Deep vein thrombosis	0 (0%)	13 (0%)	<5	78 (0%)	6 (0%)	205 (1%)	11 (0%)	19 (0%)	20 (0%)
Dementia	<5	51 (0%)	<5	158 (0%)	<5	441 (2%)	26 (1%)	6 (0%)	278 (1%)
Depressive disorder	13 (2%)	90 (0%)	11 (1%)	325 (1%)	6 (0%)	811 (3%)	76 (3%)	5 (0%)	74 (0%)
Diabetes mellitus	52 (6%)	293 (1%)	26 (3%)	1,227 (4%)	29 (1%)	1,715 (6%)	213 (7%)	9 (0%)	608 (3%)
Disseminated intravascular coagulation	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	32 (0%)	<5	0 (0%)	<5
Essential hypertension	164 (20%)	521 (2%)	45 (5%)	2,098 (6%)	25 (1%)	3,539 (12%)	674 (22%)	21 (0%)	1,883 (9%)
Gastroesophageal reflux disease	56 (7%)	6 (0%)	5 (1%)	122 (0%)	<5	236 (1%)	77 (3%)	<5	23 (0%)
Gastrointestinal hemorrhage	<5	53 (0%)	<5	68 (0%)	22 (1%)	445 (2%)	19 (1%)	10 (0%)	34 (0%)
Human immunodeficiency virus infection	<5	15 (0%)	5 (1%)	19 (0%)	<5	119 (0%)	0 (0%)	<5	15 (0%)
Hyperlipidemia	90 (11%)	246 (1%)	28 (3%)	1,373 (4%)	5 (0%)	3,011 (10%)	179 (6%)	9 (0%)	659 (3%)
Myocardial infarction	6 (1%)	40 (0%)	14 (2%)	178 (1%)	8 (0%)	377 (1%)	97 (3%)	16 (0%)	127 (1%)
Obesity	<5	36 (0%)	33 (4%)	443 (1%)	0 (0%)	1,137 (4%)	61 (2%)	5 (0%)	98 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Osteoarthritis	31 (4%)	30 (0%)	14 (2%)	872 (3%)	22 (1%)	1,056 (4%)	87 (3%)	7 (0%)	103 (0%)
Parkinsons disease	7 (1%)	21 (0%)	0 (0%)	63 (0%)	<5	143 (0%)	18 (1%)	<5	49 (0%)
PE and DVT combined	12 (1%)	59 (0%)	7 (1%)	196 (1%)	8 (0%)	334 (1%)	29 (1%)	39 (0%)	98 (0%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	13 (0%)	0 (0%)	<5	<5
Pneumonia	20 (2%)	246 (1%)	14 (2%)	162 (0%)	54 (2%)	1,234 (4%)	93 (3%)	42 (0%)	326 (2%)
Psoriasis	9 (1%)	30 (0%)	<5	142 (0%)	5 (0%)	152 (1%)	19 (1%)	8 (0%)	48 (0%)
Pulmonary embolism	12 (1%)	46 (0%)	5 (1%)	135 (0%)	<5	183 (1%)	21 (1%)	21 (0%)	80 (0%)
Renal impairment	7 (1%)	169 (1%)	17 (2%)	713 (2%)	16 (1%)	2,333 (8%)	231 (8%)	49 (0%)	278 (1%)
Retinal vein thrombosis broad	0 (0%)	<5	0 (0%)	6 (0%)	0 (0%)	13 (0%)	<5	<5	<5
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)
Schizophrenia	<5	18 (0%)	<5	21 (0%)	0 (0%)	55 (0%)	5 (0%)	0 (0%)	48 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	10 (0%)	<5	13 (0%)	0 (0%)	44 (0%)	<5	5 (0%)	18 (0%)
Thromboembolic disorder	0 (0%)	<5	0 (0%)	77 (0%)	0 (0%)	107 (0%)	<5	<5	22 (0%)
Ulcerative colitis	<5	18 (0%)	0 (0%)	27 (0%)	0 (0%)	47 (0%)	11 (0%)	0 (0%)	36 (0%)
Viral hepatitis	0 (0%)	14 (0%)	5 (1%)	61 (0%)	0 (0%)	256 (1%)	<5	<5	15 (0%)
Visual system disorder	34 (4%)	186 (1%)	26 (3%)	326 (1%)	127 (4%)	2,472 (9%)	135 (4%)	25 (0%)	305 (1%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 78. Medical conditions recorded at the time of the diagnosis of melanoma, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	130	17,145	526	28,972	3,096	7,928	1,797	5,235	8,820
Anxiety	5 (4%)	19 (0%)	<5	360 (1%)	38 (1%)	159 (2%)	14 (1%)	<5	33 (0%)
Asthma	<5	72 (0%)	0 (0%)	136 (0%)	<5	41 (1%)	54 (3%)	0 (0%)	46 (1%)
Attention deficit hyperactivity disorder	0 (0%)	<5	0 (0%)	17 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	<5
Chronic kidney disease	<5	32 (0%)	<5	79 (0%)	<5	96 (1%)	29 (2%)	0 (0%)	20 (0%)
Chronic liver disease	<5	<5	0 (0%)	21 (0%)	0 (0%)	13 (0%)	0 (0%)	0 (0%)	5 (0%)
Chronic obstructive lung disease	<5	59 (0%)	0 (0%)	131 (0%)	5 (0%)	46 (1%)	21 (1%)	<5	13 (0%)
Covid 19	0 (0%)	0 (0%)	<5	23 (0%)	55 (2%)	113 (1%)	<5	0 (0%)	0 (0%)
Crohns disease	<5	7 (0%)	0 (0%)	13 (0%)	<5	<5	<5	<5	<5
Deep vein thrombosis	0 (0%)	<5	0 (0%)	23 (0%)	<5	8 (0%)	<5	<5	<5
Dementia	0 (0%)	26 (0%)	0 (0%)	35 (0%)	0 (0%)	28 (0%)	9 (1%)	0 (0%)	58 (1%)
Depressive disorder	0 (0%)	39 (0%)	9 (2%)	156 (1%)	11 (0%)	98 (1%)	22 (1%)	<5	27 (0%)
Diabetes mellitus	5 (4%)	183 (1%)	<5	383 (1%)	25 (1%)	140 (2%)	66 (4%)	<5	121 (1%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	20 (15%)	548 (3%)	7 (1%)	893 (3%)	31 (1%)	342 (4%)	254 (14%)	0 (0%)	325 (4%)
Gastroesophageal reflux disease	5 (4%)	6 (0%)	<5	51 (0%)	10 (0%)	34 (0%)	22 (1%)	0 (0%)	<5
Gastrointestinal hemorrhage	0 (0%)	<5	0 (0%)	13 (0%)	13 (0%)	35 (0%)	0 (0%)	<5	6 (0%)
Human immunodeficiency virus infection	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Hyperlipidemia	10 (8%)	227 (1%)	<5	392 (1%)	<5	288 (4%)	59 (3%)	0 (0%)	103 (1%)
Myocardial infarction	<5	7 (0%)	0 (0%)	58 (0%)	<5	27 (0%)	15 (1%)	0 (0%)	12 (0%)
Obesity	0 (0%)	34 (0%)	<5	215 (1%)	<5	171 (2%)	17 (1%)	0 (0%)	16 (0%)
Osteoarthritis	<5	17 (0%)	<5	418 (1%)	30 (1%)	133 (2%)	37 (2%)	0 (0%)	44 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	0 (0%)	26 (0%)	<5	33 (0%)	0 (0%)	18 (0%)	<5	0 (0%)	15 (0%)
PE and DVT combined	<5	8 (0%)	<5	50 (0%)	<5	13 (0%)	<5	<5	16 (0%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5
Pneumonia	<5	15 (0%)	0 (0%)	20 (0%)	22 (1%)	36 (0%)	<5	0 (0%)	15 (0%)
Psoriasis	<5	28 (0%)	<5	243 (1%)	6 (0%)	21 (0%)	6 (0%)	<5	23 (0%)
Pulmonary embolism	<5	5 (0%)	<5	33 (0%)	<5	8 (0%)	<5	<5	15 (0%)
Renal impairment	<5	38 (0%)	<5	124 (0%)	5 (0%)	109 (1%)	30 (2%)	0 (0%)	24 (0%)
Retinal vein thrombosis broad	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	<5
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	7 (0%)	<5	7 (0%)	0 (0%)	8 (0%)	0 (0%)	0 (0%)	6 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Thromboembolic disorder	0 (0%)	0 (0%)	0 (0%)	22 (0%)	0 (0%)	7 (0%)	0 (0%)	0 (0%)	<5
Ulcerative colitis	<5	7 (0%)	0 (0%)	8 (0%)	<5	<5	<5	0 (0%)	6 (0%)
Viral hepatitis	<5	<5	0 (0%)	22 (0%)	<5	13 (0%)	0 (0%)	0 (0%)	<5
Visual system disorder	<5	87 (1%)	10 (2%)	365 (1%)	141 (5%)	586 (7%)	34 (2%)	6 (0%)	149 (2%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 79. Medical conditions recorded at the time of the diagnosis of ovarian cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	54	2,842	217	4,603	473	3,244	572	1,704	3,085
Anxiety	<5	12 (0%)	<5	166 (4%)	6 (1%)	116 (4%)	21 (4%)	<5	11 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Asthma	<5	18 (1%)	<5	26 (1%)	<5	63 (2%)	34 (6%)	0 (0%)	54 (2%)
Attention deficit hyperactivity disorder	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Chronic kidney disease	0 (0%)	10 (0%)	<5	26 (1%)	0 (0%)	101 (3%)	13 (2%)	<5	20 (1%)
Chronic liver disease	0 (0%)	8 (0%)	<5	6 (0%)	<5	19 (1%)	0 (0%)	0 (0%)	13 (0%)
Chronic obstructive lung disease	<5	42 (1%)	<5	30 (1%)	0 (0%)	30 (1%)	18 (3%)	0 (0%)	18 (1%)
Covid 19	0 (0%)	0 (0%)	<5	<5	<5	38 (1%)	<5	0 (0%)	<5
Crohns disease	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	<5	0 (0%)	<5
Deep vein thrombosis	0 (0%)	<5	<5	17 (0%)	0 (0%)	35 (1%)	<5	5 (0%)	14 (0%)
Dementia	0 (0%)	7 (0%)	0 (0%)	23 (0%)	<5	32 (1%)	<5	<5	54 (2%)
Depressive disorder	0 (0%)	20 (1%)	<5	70 (2%)	<5	116 (4%)	20 (3%)	0 (0%)	<5
Diabetes mellitus	8 (15%)	77 (3%)	8 (4%)	94 (2%)	<5	166 (5%)	27 (5%)	0 (0%)	81 (3%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	8 (15%)	241 (8%)	14 (6%)	224 (5%)	<5	453 (14%)	111 (19%)	<5	336 (11%)
Gastroesophageal reflux disease	0 (0%)	<5	<5	13 (0%)	0 (0%)	26 (1%)	32 (6%)	0 (0%)	<5
Gastrointestinal hemorrhage	0 (0%)	<5	0 (0%)	6 (0%)	0 (0%)	20 (1%)	<5	<5	<5
Human immunodeficiency virus infection	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Hyperlipidemia	<5	52 (2%)	<5	68 (1%)	0 (0%)	318 (10%)	25 (4%)	<5	119 (4%)
Myocardial infarction	0 (0%)	0 (0%)	0 (0%)	15 (0%)	0 (0%)	15 (0%)	7 (1%)	0 (0%)	13 (0%)
Obesity	0 (0%)	175 (6%)	6 (3%)	59 (1%)	0 (0%)	176 (5%)	27 (5%)	<5	32 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Osteoarthritis	<5	0 (0%)	<5	101 (2%)	0 (0%)	124 (4%)	17 (3%)	<5	13 (0%)
Parkinsons disease	0 (0%)	<5	<5	5 (0%)	0 (0%)	13 (0%)	<5	0 (0%)	8 (0%)
PE and DVT combined	0 (0%)	25 (1%)	<5	71 (2%)	0 (0%)	86 (3%)	13 (2%)	17 (1%)	87 (3%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5
Pneumonia	0 (0%)	15 (1%)	<5	16 (0%)	6 (1%)	28 (1%)	12 (2%)	<5	25 (1%)
Psoriasis	<5	<5	<5	7 (0%)	0 (0%)	11 (0%)	<5	0 (0%)	6 (0%)
Pulmonary embolism	0 (0%)	24 (1%)	<5	58 (1%)	0 (0%)	61 (2%)	11 (2%)	14 (1%)	74 (2%)
Renal impairment	0 (0%)	15 (1%)	<5	43 (1%)	<5	144 (4%)	30 (5%)	5 (0%)	42 (1%)
Retinal vein thrombosis broad	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	7 (0%)	0 (0%)	<5	0 (0%)	8 (0%)	<5	0 (0%)	9 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Thromboembolic disorder	0 (0%)	0 (0%)	0 (0%)	15 (0%)	0 (0%)	14 (0%)	0 (0%)	<5	<5
Ulcerative colitis	0 (0%)	<5	0 (0%)	<5	0 (0%)	5 (0%)	<5	0 (0%)	7 (0%)
Viral hepatitis	0 (0%)	<5	<5	<5	0 (0%)	15 (0%)	0 (0%)	0 (0%)	<5
Visual system disorder	<5	8 (0%)	<5	32 (1%)	12 (3%)	199 (6%)	7 (1%)	0 (0%)	43 (1%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 80. Medical conditions recorded at the time of the diagnosis of pancreatic cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	123	6,587	193	6,387	1,252	6,705	907	2,354	8,139
Anxiety	14 (11%)	26 (0%)	<5	75 (1%)	5 (0%)	245 (4%)	16 (2%)	0 (0%)	11 (0%)
Asthma	<5	46 (1%)	<5	32 (1%)	0 (0%)	129 (2%)	63 (7%)	0 (0%)	163 (2%)
Attention deficit hyperactivity disorder	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5
Chronic kidney disease	<5	30 (0%)	<5	32 (1%)	0 (0%)	482 (7%)	36 (4%)	<5	41 (1%)
Chronic liver disease	0 (0%)	26 (0%)	5 (3%)	29 (0%)	0 (0%)	108 (2%)	5 (1%)	0 (0%)	38 (0%)
Chronic obstructive lung disease	6 (5%)	106 (2%)	5 (3%)	66 (1%)	<5	310 (5%)	41 (5%)	<5	130 (2%)
Covid 19	0 (0%)	0 (0%)	0 (0%)	<5	6 (0%)	107 (2%)	<5	0 (0%)	10 (0%)
Crohns disease	0 (0%)	5 (0%)	0 (0%)	<5	<5	10 (0%)	<5	0 (0%)	19 (0%)
Deep vein thrombosis	0 (0%)	8 (0%)	<5	17 (0%)	<5	85 (1%)	10 (1%)	6 (0%)	28 (0%)
Dementia	<5	33 (1%)	<5	34 (1%)	0 (0%)	137 (2%)	16 (2%)	0 (0%)	184 (2%)
Depressive disorder	0 (0%)	43 (1%)	<5	57 (1%)	<5	299 (4%)	34 (4%)	0 (0%)	25 (0%)
Diabetes mellitus	20 (16%)	486 (7%)	11 (6%)	363 (6%)	35 (3%)	1,147 (17%)	156 (17%)	10 (0%)	646 (8%)
Disseminated intravascular coagulation	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	23 (19%)	479 (7%)	10 (5%)	341 (5%)	9 (1%)	1,714 (26%)	253 (28%)	<5	1,135 (14%)
Gastroesophageal reflux disease	7 (6%)	7 (0%)	<5	32 (1%)	<5	92 (1%)	32 (4%)	0 (0%)	9 (0%)
Gastrointestinal hemorrhage	<5	25 (0%)	<5	27 (0%)	5 (0%)	137 (2%)	7 (1%)	<5	61 (1%)
Human immunodeficiency virus infection	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	30 (0%)	0 (0%)	0 (0%)	<5
Hyperlipidemia	15 (12%)	123 (2%)	8 (4%)	72 (1%)	<5	1,328 (20%)	80 (9%)	0 (0%)	322 (4%)
Myocardial infarction	<5	<5	<5	22 (0%)	<5	104 (2%)	32 (4%)	<5	55 (1%)
Obesity	0 (0%)	33 (1%)	<5	22 (0%)	<5	368 (5%)	23 (3%)	0 (0%)	27 (0%)
Osteoarthritis	6 (5%)	5 (0%)	<5	94 (1%)	5 (0%)	352 (5%)	32 (4%)	<5	42 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	0 (0%)	16 (0%)	0 (0%)	<5	0 (0%)	46 (1%)	6 (1%)	0 (0%)	33 (0%)
PE and DVT combined	<5	72 (1%)	<5	66 (1%)	8 (1%)	194 (3%)	44 (5%)	42 (2%)	203 (2%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	8 (0%)
Pneumonia	<5	64 (1%)	<5	24 (0%)	9 (1%)	93 (1%)	17 (2%)	<5	126 (2%)
Psoriasis	<5	9 (0%)	<5	6 (0%)	0 (0%)	53 (1%)	<5	0 (0%)	13 (0%)
Pulmonary embolism	<5	66 (1%)	<5	52 (1%)	<5	153 (2%)	39 (4%)	39 (2%)	189 (2%)
Renal impairment	<5	56 (1%)	5 (3%)	62 (1%)	<5	668 (10%)	65 (7%)	10 (0%)	90 (1%)
Retinal vein thrombosis broad	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	<5
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	6 (0%)	<5	<5	0 (0%)	22 (0%)	0 (0%)	0 (0%)	25 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	8 (0%)	<5	15 (0%)	0 (0%)	116 (2%)	8 (1%)	11 (0%)	16 (0%)
Thromboembolic disorder	0 (0%)	<5	0 (0%)	21 (0%)	0 (0%)	69 (1%)	<5	<5	23 (0%)
Ulcerative colitis	0 (0%)	10 (0%)	0 (0%)	6 (0%)	0 (0%)	15 (0%)	<5	<5	15 (0%)
Viral hepatitis	0 (0%)	<5	<5	6 (0%)	0 (0%)	76 (1%)	<5	0 (0%)	<5
Visual system disorder	7 (6%)	42 (1%)	<5	42 (1%)	19 (2%)	526 (8%)	36 (4%)	0 (0%)	137 (2%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 81. Medical conditions recorded at the time of the diagnosis of prostate cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	920	29,476	1,067	51,871	4,527	22,704	7,069	15,485	36,620
Anxiety	26 (3%)	15 (0%)	<5	947 (2%)	30 (1%)	327 (1%)	62 (1%)	<5	24 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Asthma	24 (3%)	73 (0%)	7 (1%)	245 (0%)	<5	130 (1%)	226 (3%)	<5	290 (1%)
Attention deficit hyperactivity disorder	0 (0%)	0 (0%)	0 (0%)	10 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5
Chronic kidney disease	8 (1%)	53 (0%)	<5	506 (1%)	<5	794 (3%)	145 (2%)	8 (0%)	160 (0%)
Chronic liver disease	<5	<5	<5	44 (0%)	<5	64 (0%)	5 (0%)	<5	21 (0%)
Chronic obstructive lung disease	32 (3%)	118 (0%)	5 (0%)	517 (1%)	12 (0%)	696 (3%)	138 (2%)	<5	222 (1%)
Covid 19	<5	0 (0%)	0 (0%)	25 (0%)	59 (1%)	242 (1%)	10 (0%)	<5	16 (0%)
Crohns disease	<5	<5	0 (0%)	11 (0%)	0 (0%)	8 (0%)	12 (0%)	0 (0%)	14 (0%)
Deep vein thrombosis	0 (0%)	<5	<5	83 (0%)	<5	61 (0%)	<5	11 (0%)	28 (0%)
Dementia	10 (1%)	29 (0%)	0 (0%)	258 (0%)	6 (0%)	259 (1%)	30 (0%)	5 (0%)	451 (1%)
Depressive disorder	8 (1%)	62 (0%)	<5	268 (1%)	8 (0%)	264 (1%)	93 (1%)	<5	48 (0%)
Diabetes mellitus	69 (8%)	262 (1%)	19 (2%)	1,703 (3%)	55 (1%)	1,082 (5%)	330 (5%)	<5	797 (2%)
Disseminated intravascular coagulation	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	7 (0%)	0 (0%)	0 (0%)	0 (0%)
Essential hypertension	226 (25%)	263 (1%)	42 (4%)	3,235 (6%)	90 (2%)	2,511 (11%)	1,281 (18%)	9 (0%)	2,312 (6%)
Gastroesophageal reflux disease	39 (4%)	<5	<5	149 (0%)	7 (0%)	137 (1%)	146 (2%)	0 (0%)	21 (0%)
Gastrointestinal hemorrhage	<5	18 (0%)	<5	77 (0%)	34 (1%)	206 (1%)	8 (0%)	<5	34 (0%)
Human immunodeficiency virus infection	<5	0 (0%)	0 (0%)	7 (0%)	0 (0%)	13 (0%)	0 (0%)	0 (0%)	6 (0%)
Hyperlipidemia	140 (15%)	270 (1%)	19 (2%)	1,310 (3%)	26 (1%)	1,997 (9%)	387 (5%)	<5	822 (2%)
Myocardial infarction	9 (1%)	<5	8 (1%)	317 (1%)	8 (0%)	243 (1%)	151 (2%)	5 (0%)	114 (0%)
Obesity	<5	26 (0%)	<5	456 (1%)	6 (0%)	622 (3%)	190 (3%)	<5	83 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Osteoarthritis	30 (3%)	10 (0%)	7 (1%)	1,262 (2%)	31 (1%)	511 (2%)	156 (2%)	9 (0%)	221 (1%)
Parkinsons disease	12 (1%)	32 (0%)	<5	171 (0%)	<5	108 (0%)	27 (0%)	<5	84 (0%)
PE and DVT combined	<5	20 (0%)	5 (0%)	230 (0%)	10 (0%)	108 (0%)	11 (0%)	20 (0%)	84 (0%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	5 (0%)
Pneumonia	15 (2%)	54 (0%)	<5	83 (0%)	41 (1%)	289 (1%)	21 (0%)	8 (0%)	141 (0%)
Psoriasis	5 (1%)	10 (0%)	5 (0%)	93 (0%)	<5	81 (0%)	26 (0%)	<5	43 (0%)
Pulmonary embolism	<5	17 (0%)	<5	165 (0%)	6 (0%)	62 (0%)	8 (0%)	11 (0%)	62 (0%)
Renal impairment	9 (1%)	87 (0%)	<5	898 (2%)	20 (0%)	1,068 (5%)	182 (3%)	34 (0%)	307 (1%)
Retinal vein thrombosis broad	0 (0%)	5 (0%)	0 (0%)	<5	0 (0%)	13 (0%)	<5	0 (0%)	13 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	<5	<5	0 (0%)	7 (0%)	0 (0%)	19 (0%)	<5	0 (0%)	29 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	<5	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Thromboembolic disorder	0 (0%)	<5	0 (0%)	53 (0%)	0 (0%)	52 (0%)	0 (0%)	0 (0%)	7 (0%)
Ulcerative colitis	<5	15 (0%)	0 (0%)	32 (0%)	<5	17 (0%)	19 (0%)	0 (0%)	38 (0%)
Viral hepatitis	<5	<5	0 (0%)	32 (0%)	<5	69 (0%)	<5	0 (0%)	5 (0%)
Visual system disorder	29 (3%)	101 (0%)	11 (1%)	394 (1%)	201 (4%)	1,654 (7%)	155 (2%)	9 (0%)	377 (1%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 82. Medical conditions recorded at the time of the diagnosis of stomach cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	42	4,137	191	4,737	678	5,059	488	1,055	3,300
Anxiety	<5	8 (0%)	<5	58 (1%)	<5	142 (3%)	9 (2%)	0 (0%)	<5
Asthma	0 (0%)	25 (1%)	<5	23 (0%)	0 (0%)	64 (1%)	29 (6%)	0 (0%)	47 (1%)
Attention deficit hyperactivity disorder	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	<5
Chronic kidney disease	0 (0%)	15 (0%)	<5	46 (1%)	0 (0%)	316 (6%)	25 (5%)	0 (0%)	21 (1%)
Chronic liver disease	0 (0%)	10 (0%)	0 (0%)	12 (0%)	0 (0%)	70 (1%)	<5	<5	7 (0%)
Chronic obstructive lung disease	<5	58 (1%)	<5	69 (1%)	<5	239 (5%)	22 (5%)	<5	40 (1%)
Covid 19	0 (0%)	0 (0%)	<5	<5	7 (1%)	63 (1%)	<5	0 (0%)	5 (0%)
Crohns disease	0 (0%)	<5	0 (0%)	<5	<5	6 (0%)	<5	0 (0%)	<5
Deep vein thrombosis	0 (0%)	<5	0 (0%)	10 (0%)	<5	41 (1%)	<5	0 (0%)	5 (0%)
Dementia	0 (0%)	12 (0%)	<5	27 (1%)	<5	84 (2%)	<5	<5	66 (2%)
Depressive disorder	0 (0%)	11 (0%)	<5	55 (1%)	<5	168 (3%)	15 (3%)	0 (0%)	8 (0%)
Diabetes mellitus	7 (17%)	88 (2%)	<5	144 (3%)	8 (1%)	520 (10%)	53 (11%)	0 (0%)	133 (4%)
Disseminated intravascular coagulation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	6 (0%)	<5	0 (0%)	0 (0%)
Essential hypertension	8 (19%)	181 (4%)	9 (5%)	265 (6%)	6 (1%)	1,053 (21%)	152 (31%)	0 (0%)	323 (10%)
Gastroesophageal reflux disease	<5	10 (0%)	5 (3%)	29 (1%)	5 (1%)	72 (1%)	20 (4%)	<5	5 (0%)
Gastrointestinal hemorrhage	<5	80 (2%)	7 (4%)	59 (1%)	14 (2%)	500 (10%)	27 (6%)	7 (1%)	77 (2%)
Human immunodeficiency virus infection	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	10 (0%)	0 (0%)	0 (0%)	0 (0%)
Hyperlipidemia	10 (24%)	79 (2%)	6 (3%)	94 (2%)	<5	791 (16%)	39 (8%)	0 (0%)	90 (3%)
Myocardial infarction	<5	7 (0%)	<5	25 (1%)	<5	89 (2%)	24 (5%)	<5	24 (1%)
Obesity	<5	39 (1%)	5 (3%)	30 (1%)	<5	289 (6%)	11 (2%)	0 (0%)	<5
Osteoarthritis	<5	<5	<5	102 (2%)	7 (1%)	230 (5%)	9 (2%)	0 (0%)	18 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Parkinsons disease	0 (0%)	6 (0%)	0 (0%)	12 (0%)	0 (0%)	30 (1%)	5 (1%)	<5	9 (0%)
PE and DVT combined	<5	16 (0%)	<5	40 (1%)	<5	95 (2%)	10 (2%)	<5	39 (1%)
Pelvic vein thrombosis	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Pneumonia	<5	23 (1%)	<5	14 (0%)	<5	72 (1%)	6 (1%)	<5	33 (1%)
Psoriasis	<5	<5	0 (0%)	15 (0%)	0 (0%)	40 (1%)	<5	0 (0%)	8 (0%)
Pulmonary embolism	<5	12 (0%)	<5	33 (1%)	0 (0%)	74 (1%)	7 (1%)	<5	35 (1%)
Renal impairment	0 (0%)	25 (1%)	<5	70 (1%)	<5	449 (9%)	40 (8%)	5 (0%)	38 (1%)
Retinal vein thrombosis broad	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)
Retinal vein thrombosis narrow	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Schizophrenia	0 (0%)	5 (0%)	0 (0%)	<5	0 (0%)	16 (0%)	<5	0 (0%)	9 (0%)
Splanchnic extrahepatic vein thrombosis	0 (0%)	<5	0 (0%)	<5	0 (0%)	33 (1%)	<5	0 (0%)	<5
Thromboembolic disorder	0 (0%)	0 (0%)	0 (0%)	13 (0%)	0 (0%)	25 (0%)	0 (0%)	0 (0%)	<5
Ulcerative colitis	0 (0%)	6 (0%)	0 (0%)	5 (0%)	0 (0%)	9 (0%)	<5	0 (0%)	9 (0%)
Viral hepatitis	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	53 (1%)	0 (0%)	0 (0%)	0 (0%)
Visual system disorder	<5	15 (0%)	<5	39 (1%)	21 (3%)	396 (8%)	13 (3%)	<5	39 (1%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 83. Medications recorded at the time of the diagnosis of bone cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	18	322	31	965	0	1,071	37	290	594
Agents acting on the renin angiotensin system	<5	71 (22%)	<5	119 (12%)	0	290 (27%)	0 (0%)	65 (22%)	25 (4%)
Antibacterials for systemic use	<5	21 (7%)	<5	18 (2%)	0	136 (13%)	0 (0%)	10 (3%)	63 (11%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Antidepressants	0 (0%)	23 (7%)	<5	41 (4%)	0	162 (15%)	0 (0%)	51 (18%)	33 (6%)
Antiepileptics	<5	12 (4%)	<5	<5	0	122 (11%)	0 (0%)	36 (12%)	50 (8%)
Antiinflammatory and antirheumatic products	<5	55 (17%)	<5	106 (11%)	0	244 (23%)	0 (0%)	31 (11%)	144 (24%)
Antineoplastic agents	<5	0 (0%)	<5	7 (1%)	0	14 (1%)	0 (0%)	<5	<5
Antipsoriatics	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	<5	0 (0%)	0 (0%)	0 (0%)
Antithrombotic agents	<5	42 (13%)	0 (0%)	79 (8%)	0	121 (11%)	0 (0%)	25 (9%)	64 (11%)
Beta blocking agents	<5	24 (7%)	<5	87 (9%)	0	129 (12%)	0 (0%)	32 (11%)	33 (6%)
Calcium channel blockers	<5	49 (15%)	0 (0%)	46 (5%)	0	99 (9%)	0 (0%)	44 (15%)	14 (2%)
Diuretics	<5	42 (13%)	<5	50 (5%)	0	129 (12%)	0 (0%)	32 (11%)	13 (2%)
Drugs for acid related disorders	<5	49 (15%)	<5	96 (10%)	0	377 (35%)	0 (0%)	74 (26%)	85 (14%)
Drugs for obstructive airway diseases	<5	28 (9%)	<5	26 (3%)	0	130 (12%)	0 (0%)	25 (9%)	23 (4%)
Drugs used in diabetes	<5	20 (6%)	0 (0%)	35 (4%)	0	117 (11%)	0 (0%)	22 (8%)	17 (3%)
Hormonal contraceptives for systemic use	0 (0%)	12 (4%)	0 (0%)	<5	0	9 (1%)	0 (0%)	<5	<5
Immunosuppressants	0 (0%)	<5	<5	6 (1%)	0	13 (1%)	0 (0%)	<5	<5
Lipid modifying agents	5 (28%)	65 (20%)	<5	68 (7%)	0	233 (22%)	0 (0%)	71 (24%)	22 (4%)
Opioids	<5	42 (13%)	0 (0%)	62 (6%)	0	238 (22%)	0 (0%)	83 (29%)	159 (27%)
Psycholeptics	<5	15 (5%)	<5	25 (3%)	0	277 (26%)	0 (0%)	18 (6%)	85 (14%)
Psychostimulants adhd	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	5 (0%)	0 (0%)	<5	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 84. Medications recorded at the time of the diagnosis of brain cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	128	3,510	132	3,240	297	3,955	507	932	3,318
Agents acting on the renin angiotensin system	14 (11%)	930 (26%)	17 (13%)	584 (18%)	65 (22%)	1,345 (34%)	0 (0%)	187 (20%)	327 (10%)
Antibacterials for systemic use	<5	121 (3%)	6 (5%)	67 (2%)	7 (2%)	258 (7%)	0 (0%)	24 (3%)	381 (11%)
Antidepressants	17 (13%)	354 (10%)	7 (5%)	217 (7%)	13 (4%)	813 (21%)	0 (0%)	156 (17%)	155 (5%)
Antiepileptics	33 (26%)	391 (11%)	22 (17%)	390 (12%)	15 (5%)	1,177 (30%)	0 (0%)	166 (18%)	696 (21%)
Antiinflammatory and antirheumatic products	8 (6%)	158 (5%)	5 (4%)	209 (6%)	11 (4%)	557 (14%)	0 (0%)	25 (3%)	403 (12%)
Antineoplastic agents	<5	17 (0%)	0 (0%)	20 (1%)	<5	31 (1%)	0 (0%)	<5	110 (3%)
Antipsoriatics	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	7 (0%)	0 (0%)	<5	0 (0%)
Antithrombotic agents	16 (12%)	662 (19%)	<5	340 (10%)	64 (22%)	411 (10%)	0 (0%)	87 (9%)	319 (10%)
Beta blocking agents	17 (13%)	238 (7%)	9 (7%)	369 (11%)	37 (12%)	504 (13%)	0 (0%)	123 (13%)	252 (8%)
Calcium channel blockers	<5	537 (15%)	10 (8%)	210 (6%)	18 (6%)	431 (11%)	0 (0%)	151 (16%)	170 (5%)
Diuretics	9 (7%)	413 (12%)	<5	193 (6%)	17 (6%)	517 (13%)	0 (0%)	77 (8%)	125 (4%)
Drugs for acid related disorders	30 (23%)	703 (20%)	21 (16%)	587 (18%)	75 (25%)	1,786 (45%)	0 (0%)	276 (30%)	994 (30%)
Drugs for obstructive airway diseases	12 (9%)	225 (6%)	<5	69 (2%)	9 (3%)	451 (11%)	0 (0%)	104 (11%)	158 (5%)
Drugs used in diabetes	11 (9%)	241 (7%)	<5	173 (5%)	31 (10%)	584 (15%)	0 (0%)	45 (5%)	225 (7%)
Hormonal contraceptives for systemic use	<5	67 (2%)	<5	13 (0%)	<5	11 (0%)	0 (0%)	14 (2%)	12 (0%)
Immunosuppressants	<5	18 (1%)	0 (0%)	11 (0%)	<5	50 (1%)	0 (0%)	6 (1%)	15 (0%)
Lipid modifying agents	17 (13%)	783 (22%)	5 (4%)	296 (9%)	63 (21%)	1,033 (26%)	0 (0%)	229 (25%)	210 (6%)
Opioids	18 (14%)	105 (3%)	<5	130 (4%)	6 (2%)	370 (9%)	0 (0%)	97 (10%)	277 (8%)
Psycholeptics	24 (19%)	307 (9%)	18 (14%)	199 (6%)	33 (11%)	1,262 (32%)	0 (0%)	79 (8%)	808 (24%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Psychostimulants adhd	<5	11 (0%)	<5	7 (0%)	<5	19 (0%)	0 (0%)	0 (0%)	<5

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 85. Medications recorded at the time of the diagnosis of breast cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	1,853	31,873	1,243	56,337	6,553	31,931	5,180	18,134	38,047
Agents acting on the renin angiotensin system	361 (19%)	7,322 (23%)	175 (14%)	6,172 (11%)	1,106 (17%)	8,231 (26%)	5 (0%)	3,402 (19%)	2,250 (6%)
Antibacterials for systemic use	95 (5%)	911 (3%)	79 (6%)	971 (2%)	150 (2%)	2,552 (8%)	0 (0%)	485 (3%)	2,952 (8%)
Antidepressants	325 (18%)	2,972 (9%)	61 (5%)	1,860 (3%)	487 (7%)	6,355 (20%)	<5	3,294 (18%)	1,616 (4%)
Antiepileptics	32 (2%)	783 (2%)	23 (2%)	202 (0%)	55 (1%)	2,012 (6%)	0 (0%)	873 (5%)	515 (1%)
Antiinflammatory and antirheumatic products	176 (9%)	1,392 (4%)	94 (8%)	2,016 (4%)	190 (3%)	4,337 (14%)	0 (0%)	599 (3%)	5,264 (14%)
Antineoplastic agents	11 (1%)	171 (1%)	8 (1%)	208 (0%)	54 (1%)	215 (1%)	<5	123 (1%)	234 (1%)
Antipsoriatics	0 (0%)	6 (0%)	0 (0%)	13 (0%)	<5	32 (0%)	0 (0%)	20 (0%)	15 (0%)
Antithrombotic agents	283 (15%)	4,221 (13%)	24 (2%)	2,799 (5%)	728 (11%)	2,621 (8%)	0 (0%)	1,079 (6%)	1,894 (5%)
Beta blocking agents	396 (21%)	2,147 (7%)	105 (8%)	4,572 (8%)	852 (13%)	3,191 (10%)	<5	1,942 (11%)	1,859 (5%)
Calcium channel blockers	122 (7%)	4,056 (13%)	65 (5%)	2,131 (4%)	551 (8%)	2,395 (8%)	5 (0%)	2,159 (12%)	1,047 (3%)
Diuretics	138 (7%)	4,257 (13%)	23 (2%)	2,427 (4%)	648 (10%)	3,970 (12%)	<5	2,073 (11%)	1,066 (3%)
Drugs for acid related disorders	367 (20%)	3,574 (11%)	78 (6%)	3,264 (6%)	1,146 (17%)	9,376 (29%)	<5	3,734 (21%)	2,338 (6%)
Drugs for obstructive airway diseases	102 (6%)	2,495 (8%)	54 (4%)	1,241 (2%)	424 (6%)	3,238 (10%)	<5	2,024 (11%)	1,840 (5%)
Drugs used in diabetes	154 (8%)	1,645 (5%)	32 (3%)	1,656 (3%)	391 (6%)	2,989 (9%)	<5	1,007 (6%)	982 (3%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Hormonal contraceptives for systemic use	31 (2%)	1,370 (4%)	15 (1%)	1,032 (2%)	284 (4%)	258 (1%)	0 (0%)	779 (4%)	352 (1%)
Immunosuppressants	6 (0%)	190 (1%)	5 (0%)	184 (0%)	50 (1%)	274 (1%)	<5	143 (1%)	132 (0%)
Lipid modifying agents	374 (20%)	5,677 (18%)	72 (6%)	2,704 (5%)	980 (15%)	6,092 (19%)	<5	3,578 (20%)	1,578 (4%)
Opioids	153 (8%)	1,004 (3%)	25 (2%)	1,217 (2%)	197 (3%)	2,806 (9%)	<5	1,630 (9%)	1,969 (5%)
Psycholeptics	361 (19%)	2,227 (7%)	113 (9%)	1,486 (3%)	517 (8%)	9,754 (31%)	0 (0%)	1,246 (7%)	4,768 (13%)
Psychostimulants adhd	12 (1%)	88 (0%)	0 (0%)	23 (0%)	14 (0%)	113 (0%)	0 (0%)	8 (0%)	11 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 86. Medications recorded at the time of the diagnosis of colorectal cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	382	29,279	762	24,061	5,400	29,755	3,848	11,798	23,146
Agents acting on the renin angiotensin system	62 (16%)	9,341 (32%)	163 (21%)	5,023 (21%)	1,374 (25%)	12,408 (42%)	<5	3,045 (26%)	1,595 (7%)
Antibacterials for systemic use	17 (4%)	1,061 (4%)	47 (6%)	466 (2%)	129 (2%)	2,537 (9%)	0 (0%)	358 (3%)	2,405 (10%)
Antidepressants	35 (9%)	2,194 (7%)	28 (4%)	852 (4%)	279 (5%)	4,765 (16%)	0 (0%)	1,497 (13%)	615 (3%)
Antiepileptics	7 (2%)	692 (2%)	17 (2%)	141 (1%)	50 (1%)	1,963 (7%)	0 (0%)	504 (4%)	262 (1%)
Antiinflammatory and antirheumatic products	21 (5%)	1,015 (3%)	41 (5%)	755 (3%)	126 (2%)	2,263 (8%)	0 (0%)	208 (2%)	1,682 (7%)
Antineoplastic agents	6 (2%)	190 (1%)	<5	78 (0%)	36 (1%)	162 (1%)	0 (0%)	60 (1%)	370 (2%)
Antipsoriatics	0 (0%)	13 (0%)	0 (0%)	8 (0%)	<5	55 (0%)	0 (0%)	12 (0%)	5 (0%)
Antithrombotic agents	74 (19%)	6,957 (24%)	46 (6%)	3,495 (15%)	1,188 (22%)	6,184 (21%)	0 (0%)	1,415 (12%)	2,512 (11%)
Beta blocking agents	61 (16%)	2,888 (10%)	111 (15%)	3,596 (15%)	1,037 (19%)	5,129 (17%)	0 (0%)	1,885 (16%)	1,477 (6%)
Calcium channel blockers	21 (5%)	5,570 (19%)	53 (7%)	1,790 (7%)	619 (11%)	4,154 (14%)	0 (0%)	2,055 (17%)	860 (4%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Diuretics	24 (6%)	5,040 (17%)	46 (6%)	2,458 (10%)	729 (14%)	5,428 (18%)	0 (0%)	1,687 (14%)	1,027 (4%)
Drugs for acid related disorders	57 (15%)	5,095 (17%)	94 (12%)	3,359 (14%)	1,242 (23%)	11,835 (40%)	0 (0%)	3,027 (26%)	2,504 (11%)
Drugs for obstructive airway diseases	19 (5%)	2,678 (9%)	23 (3%)	651 (3%)	407 (8%)	4,410 (15%)	0 (0%)	1,465 (12%)	967 (4%)
Drugs used in diabetes	40 (10%)	2,648 (9%)	56 (7%)	1,744 (7%)	616 (11%)	6,092 (20%)	0 (0%)	1,202 (10%)	959 (4%)
Hormonal contraceptives for systemic use	7 (2%)	230 (1%)	<5	53 (0%)	38 (1%)	108 (0%)	0 (0%)	71 (1%)	29 (0%)
Immunosuppressants	<5	221 (1%)	7 (1%)	118 (0%)	44 (1%)	304 (1%)	0 (0%)	89 (1%)	104 (0%)
Lipid modifying agents	69 (18%)	7,987 (27%)	81 (11%)	2,799 (12%)	1,462 (27%)	9,903 (33%)	0 (0%)	3,661 (31%)	1,280 (6%)
Opioids	65 (17%)	1,128 (4%)	39 (5%)	800 (3%)	156 (3%)	2,853 (10%)	0 (0%)	1,135 (10%)	1,993 (9%)
Psycholeptics	63 (16%)	1,747 (6%)	71 (9%)	769 (3%)	401 (7%)	8,031 (27%)	<5	684 (6%)	2,109 (9%)
Psychostimulants adhd	0 (0%)	54 (0%)	0 (0%)	14 (0%)	7 (0%)	103 (0%)	0 (0%)	<5	<5

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 87. Medications recorded at the time of the diagnosis of corpus uteri cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	60	4,910	260	5,113	622	4,858	899	2,453	6,121
Agents acting on the renin angiotensin system	12 (20%)	1,719 (35%)	56 (22%)	892 (17%)	144 (23%)	1,822 (38%)	0 (0%)	721 (29%)	391 (6%)
Antibacterials for systemic use	7 (12%)	217 (4%)	24 (9%)	110 (2%)	22 (4%)	430 (9%)	0 (0%)	89 (4%)	787 (13%)
Antidepressants	5 (8%)	455 (9%)	12 (5%)	214 (4%)	35 (6%)	1,089 (22%)	0 (0%)	438 (18%)	208 (3%)
Antiepileptics	<5	136 (3%)	7 (3%)	29 (1%)	<5	382 (8%)	0 (0%)	110 (4%)	63 (1%)
Antiinflammatory and antirheumatic products	5 (8%)	306 (6%)	19 (7%)	221 (4%)	19 (3%)	704 (14%)	0 (0%)	104 (4%)	1,168 (19%)
Antineoplastic agents	0 (0%)	26 (1%)	0 (0%)	14 (0%)	5 (1%)	32 (1%)	0 (0%)	21 (1%)	21 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Antipsoriatics	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	<5	0 (0%)
Antithrombotic agents	13 (22%)	913 (19%)	13 (5%)	525 (10%)	93 (15%)	971 (20%)	0 (0%)	221 (9%)	1,419 (23%)
Beta blocking agents	10 (17%)	522 (11%)	31 (12%)	653 (13%)	108 (17%)	711 (15%)	0 (0%)	403 (16%)	347 (6%)
Calcium channel blockers	<5	850 (17%)	18 (7%)	303 (6%)	67 (11%)	521 (11%)	0 (0%)	436 (18%)	201 (3%)
Diuretics	7 (12%)	1,014 (21%)	6 (2%)	403 (8%)	113 (18%)	854 (18%)	<5	492 (20%)	221 (4%)
Drugs for acid related disorders	9 (15%)	640 (13%)	18 (7%)	441 (9%)	128 (21%)	1,641 (34%)	0 (0%)	545 (22%)	325 (5%)
Drugs for obstructive airway diseases	5 (8%)	322 (7%)	8 (3%)	108 (2%)	35 (6%)	466 (10%)	0 (0%)	211 (9%)	228 (4%)
Drugs used in diabetes	10 (17%)	524 (11%)	18 (7%)	309 (6%)	83 (13%)	825 (17%)	0 (0%)	293 (12%)	229 (4%)
Hormonal contraceptives for systemic use	0 (0%)	53 (1%)	0 (0%)	74 (1%)	8 (1%)	66 (1%)	0 (0%)	21 (1%)	144 (2%)
Immunosuppressants	<5	35 (1%)	0 (0%)	16 (0%)	<5	55 (1%)	0 (0%)	24 (1%)	21 (0%)
Lipid modifying agents	13 (22%)	1,188 (24%)	17 (7%)	344 (7%)	138 (22%)	1,299 (27%)	0 (0%)	688 (28%)	284 (5%)
Opioids	11 (18%)	170 (3%)	9 (3%)	166 (3%)	19 (3%)	608 (13%)	0 (0%)	276 (11%)	458 (7%)
Psycholeptics	11 (18%)	330 (7%)	23 (9%)	144 (3%)	49 (8%)	1,486 (31%)	0 (0%)	166 (7%)	625 (10%)
Psychostimulants adhd	0 (0%)	<5	0 (0%)	<5	<5	17 (0%)	0 (0%)	<5	<5

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 88. Medications recorded at the time of the diagnosis of oesophageal cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	53	3,168	35	3,121	837	1,860	763	3,223	2,487
Agents acting on the renin angiotensin system	8 (15%)	1,073 (34%)	9 (26%)	651 (21%)	220 (26%)	681 (37%)	0 (0%)	934 (29%)	170 (7%)
Antibacterials for systemic use	<5	115 (4%)	<5	58 (2%)	14 (2%)	126 (7%)	<5	88 (3%)	241 (10%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Antidepressants	11 (21%)	289 (9%)	<5	147 (5%)	47 (6%)	250 (13%)	0 (0%)	439 (14%)	78 (3%)
Antiepileptics	<5	101 (3%)	<5	28 (1%)	9 (1%)	123 (7%)	0 (0%)	169 (5%)	43 (2%)
Antiinflammatory and antirheumatic products	<5	131 (4%)	<5	124 (4%)	19 (2%)	151 (8%)	0 (0%)	63 (2%)	170 (7%)
Antineoplastic agents	0 (0%)	16 (1%)	<5	12 (0%)	<5	6 (0%)	0 (0%)	22 (1%)	47 (2%)
Antipsoriatics	0 (0%)	<5	0 (0%)	<5	0 (0%)	5 (0%)	0 (0%)	<5	<5
Antithrombotic agents	15 (28%)	905 (29%)	5 (14%)	417 (13%)	219 (26%)	268 (14%)	0 (0%)	431 (13%)	225 (9%)
Beta blocking agents	10 (19%)	391 (12%)	8 (23%)	476 (15%)	167 (20%)	323 (17%)	0 (0%)	576 (18%)	178 (7%)
Calcium channel blockers	8 (15%)	663 (21%)	<5	230 (7%)	128 (15%)	241 (13%)	0 (0%)	630 (20%)	107 (4%)
Diuretics	9 (17%)	520 (16%)	<5	312 (10%)	116 (14%)	270 (15%)	0 (0%)	483 (15%)	110 (4%)
Drugs for acid related disorders	22 (42%)	1,446 (46%)	16 (46%)	918 (29%)	378 (45%)	1,047 (56%)	<5	1,801 (56%)	884 (36%)
Drugs for obstructive airway diseases	6 (11%)	400 (13%)	<5	128 (4%)	87 (10%)	367 (20%)	0 (0%)	495 (15%)	128 (5%)
Drugs used in diabetes	<5	285 (9%)	<5	211 (7%)	90 (11%)	358 (19%)	0 (0%)	362 (11%)	109 (4%)
Hormonal contraceptives for systemic use	0 (0%)	6 (0%)	0 (0%)	5 (0%)	<5	14 (1%)	0 (0%)	<5	<5
Immunosuppressants	0 (0%)	18 (1%)	0 (0%)	17 (1%)	7 (1%)	23 (1%)	0 (0%)	36 (1%)	14 (1%)
Lipid modifying agents	8 (15%)	981 (31%)	6 (17%)	374 (12%)	239 (29%)	573 (31%)	<5	1,103 (34%)	110 (4%)
Opioids	19 (36%)	233 (7%)	<5	163 (5%)	43 (5%)	208 (11%)	0 (0%)	462 (14%)	328 (13%)
Psycholeptics	9 (17%)	253 (8%)	<5	140 (4%)	79 (9%)	508 (27%)	0 (0%)	253 (8%)	287 (12%)
Psychostimulants adhd	0 (0%)	11 (0%)	<5	<5	<5	5 (0%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 89. Medications recorded at the time of the diagnosis of kidney cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	33	6,498	289	9,149	1,068	7,404	950	1,096	6,394
Agents acting on the renin angiotensin system	<5	2,692 (41%)	85 (29%)	1,865 (20%)	353 (33%)	3,467 (47%)	<5	359 (33%)	517 (8%)
Antibacterials for systemic use	<5	439 (7%)	45 (16%)	231 (3%)	62 (6%)	913 (12%)	0 (0%)	54 (5%)	899 (14%)
Antidepressants	<5	502 (8%)	9 (3%)	264 (3%)	70 (7%)	1,283 (17%)	0 (0%)	163 (15%)	201 (3%)
Antiepileptics	0 (0%)	225 (3%)	9 (3%)	47 (1%)	14 (1%)	558 (8%)	0 (0%)	50 (5%)	149 (2%)
Antiinflammatory and antirheumatic products	<5	589 (9%)	25 (9%)	283 (3%)	63 (6%)	727 (10%)	0 (0%)	47 (4%)	587 (9%)
Antineoplastic agents	0 (0%)	40 (1%)	<5	37 (0%)	11 (1%)	57 (1%)	0 (0%)	10 (1%)	163 (3%)
Antipsoriatics	0 (0%)	<5	0 (0%)	<5	<5	20 (0%)	0 (0%)	<5	<5
Antithrombotic agents	9 (27%)	1,732 (27%)	27 (9%)	1,096 (12%)	289 (27%)	1,200 (16%)	0 (0%)	157 (14%)	998 (16%)
Beta blocking agents	8 (24%)	851 (13%)	50 (17%)	1,218 (13%)	245 (23%)	1,435 (19%)	0 (0%)	212 (19%)	440 (7%)
Calcium channel blockers	<5	1,700 (26%)	28 (10%)	761 (8%)	168 (16%)	1,437 (19%)	<5	271 (25%)	334 (5%)
Diuretics	<5	1,306 (20%)	14 (5%)	816 (9%)	173 (16%)	1,415 (19%)	<5	184 (17%)	317 (5%)
Drugs for acid related disorders	10 (30%)	1,336 (21%)	38 (13%)	951 (10%)	313 (29%)	2,940 (40%)	<5	323 (29%)	550 (9%)
Drugs for obstructive airway diseases	<5	646 (10%)	11 (4%)	236 (3%)	108 (10%)	1,084 (15%)	0 (0%)	148 (14%)	330 (5%)
Drugs used in diabetes	<5	781 (12%)	29 (10%)	608 (7%)	146 (14%)	1,442 (19%)	0 (0%)	140 (13%)	331 (5%)
Hormonal contraceptives for systemic use	0 (0%)	25 (0%)	0 (0%)	13 (0%)	5 (0%)	40 (1%)	0 (0%)	<5	9 (0%)
Immunosuppressants	0 (0%)	43 (1%)	<5	37 (0%)	18 (2%)	167 (2%)	0 (0%)	17 (2%)	26 (0%)
Lipid modifying agents	9 (27%)	2,055 (32%)	35 (12%)	937 (10%)	339 (32%)	2,577 (35%)	<5	398 (36%)	353 (6%)
Opioids	9 (27%)	443 (7%)	23 (8%)	338 (4%)	70 (7%)	921 (12%)	0 (0%)	169 (15%)	1,006 (16%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Psycholeptics	<5	466 (7%)	32 (11%)	274 (3%)	98 (9%)	2,086 (28%)	<5	77 (7%)	619 (10%)
Psychostimulants adhd	0 (0%)	28 (0%)	0 (0%)	<5	5 (0%)	26 (0%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 90. Medications recorded at the time of the diagnosis of liver cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	35	3,338	75	3,214	557	5,618	456	1,297	4,177
Agents acting on the renin angiotensin system	8 (23%)	1,195 (36%)	20 (27%)	868 (27%)	139 (25%)	2,346 (42%)	0 (0%)	420 (32%)	367 (9%)
Antibacterials for systemic use	0 (0%)	197 (6%)	10 (13%)	121 (4%)	24 (4%)	610 (11%)	0 (0%)	72 (6%)	654 (16%)
Antidepressants	<5	289 (9%)	<5	133 (4%)	37 (7%)	904 (16%)	0 (0%)	209 (16%)	171 (4%)
Antiepileptics	0 (0%)	122 (4%)	<5	24 (1%)	8 (1%)	463 (8%)	0 (0%)	74 (6%)	114 (3%)
Antiinflammatory and antirheumatic products	<5	179 (5%)	9 (12%)	113 (4%)	31 (6%)	345 (6%)	0 (0%)	32 (2%)	424 (10%)
Antineoplastic agents	<5	24 (1%)	0 (0%)	16 (0%)	0 (0%)	28 (0%)	0 (0%)	<5	109 (3%)
Antipsoriatics	0 (0%)	<5	0 (0%)	<5	<5	17 (0%)	0 (0%)	<5	<5
Antithrombotic agents	9 (26%)	972 (29%)	7 (9%)	595 (19%)	162 (29%)	970 (17%)	0 (0%)	161 (12%)	579 (14%)
Beta blocking agents	5 (14%)	537 (16%)	15 (20%)	713 (22%)	147 (26%)	1,655 (29%)	0 (0%)	378 (29%)	386 (9%)
Calcium channel blockers	<5	715 (21%)	9 (12%)	326 (10%)	56 (10%)	913 (16%)	0 (0%)	241 (19%)	201 (5%)
Diuretics	6 (17%)	1,100 (33%)	7 (9%)	662 (21%)	107 (19%)	1,847 (33%)	0 (0%)	338 (26%)	511 (12%)
Drugs for acid related disorders	7 (20%)	1,032 (31%)	14 (19%)	737 (23%)	185 (33%)	2,808 (50%)	0 (0%)	529 (41%)	658 (16%)
Drugs for obstructive airway diseases	<5	345 (10%)	6 (8%)	105 (3%)	75 (13%)	1,007 (18%)	0 (0%)	200 (15%)	240 (6%)
Drugs used in diabetes	8 (23%)	702 (21%)	14 (19%)	493 (15%)	106 (19%)	1,732 (31%)	0 (0%)	340 (26%)	407 (10%)
Hormonal contraceptives for systemic use	<5	11 (0%)	<5	5 (0%)	<5	44 (1%)	0 (0%)	6 (0%)	<5

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Immunosuppressants	<5	24 (1%)	0 (0%)	24 (1%)	6 (1%)	93 (2%)	0 (0%)	18 (1%)	21 (1%)
Lipid modifying agents	6 (17%)	954 (29%)	7 (9%)	467 (15%)	155 (28%)	1,401 (25%)	0 (0%)	430 (33%)	252 (6%)
Opioids	8 (23%)	339 (10%)	<5	216 (7%)	48 (9%)	766 (14%)	0 (0%)	250 (19%)	996 (24%)
Psycholeptics	<5	371 (11%)	7 (9%)	182 (6%)	71 (13%)	1,627 (29%)	0 (0%)	107 (8%)	697 (17%)
Psychostimulants adhd	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	39 (1%)	0 (0%)	0 (0%)	<5

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 91. Medications recorded at the time of the diagnosis of lung cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	486	27,757	332	20,343	5,288	20,068	2,581	11,844	16,828
Agents acting on the renin angiotensin system	84 (17%)	9,335 (34%)	73 (22%)	4,471 (22%)	1,423 (27%)	8,129 (41%)	<5	3,201 (27%)	1,358 (8%)
Antibacterials for systemic use	54 (11%)	2,689 (10%)	64 (19%)	886 (4%)	460 (9%)	3,067 (15%)	<5	721 (6%)	3,455 (21%)
Antidepressants	49 (10%)	3,335 (12%)	15 (5%)	1,121 (6%)	427 (8%)	3,597 (18%)	<5	2,591 (22%)	779 (5%)
Antiepileptics	10 (2%)	1,403 (5%)	10 (3%)	220 (1%)	83 (2%)	2,131 (11%)	0 (0%)	996 (8%)	636 (4%)
Antiinflammatory and antirheumatic products	37 (8%)	2,299 (8%)	23 (7%)	1,266 (6%)	309 (6%)	2,957 (15%)	0 (0%)	569 (5%)	2,060 (12%)
Antineoplastic agents	6 (1%)	443 (2%)	<5	117 (1%)	81 (2%)	190 (1%)	0 (0%)	114 (1%)	355 (2%)
Antipsoriatics	0 (0%)	15 (0%)	0 (0%)	5 (0%)	5 (0%)	52 (0%)	0 (0%)	15 (0%)	13 (0%)
Antithrombotic agents	104 (21%)	8,865 (32%)	23 (7%)	3,265 (16%)	1,689 (32%)	3,426 (17%)	0 (0%)	1,919 (16%)	2,288 (14%)
Beta blocking agents	85 (17%)	3,341 (12%)	52 (16%)	3,490 (17%)	1,186 (22%)	3,701 (18%)	<5	2,155 (18%)	1,461 (9%)
Calcium channel blockers	39 (8%)	6,094 (22%)	35 (11%)	1,681 (8%)	738 (14%)	3,054 (15%)	0 (0%)	2,450 (21%)	802 (5%)
Diuretics	34 (7%)	5,843 (21%)	23 (7%)	2,418 (12%)	769 (15%)	3,612 (18%)	<5	2,036 (17%)	1,172 (7%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Drugs for acid related disorders	120 (25%)	6,635 (24%)	56 (17%)	3,569 (18%)	1,718 (32%)	9,603 (48%)	<5	4,312 (36%)	2,321 (14%)
Drugs for obstructive airway diseases	86 (18%)	7,247 (26%)	69 (21%)	2,861 (14%)	1,382 (26%)	7,819 (39%)	0 (0%)	4,178 (35%)	3,693 (22%)
Drugs used in diabetes	33 (7%)	2,564 (9%)	20 (6%)	1,509 (7%)	604 (11%)	4,147 (21%)	<5	1,193 (10%)	808 (5%)
Hormonal contraceptives for systemic use	6 (1%)	186 (1%)	0 (0%)	50 (0%)	17 (0%)	143 (1%)	0 (0%)	61 (1%)	17 (0%)
Immunosuppressants	6 (1%)	358 (1%)	5 (2%)	129 (1%)	92 (2%)	348 (2%)	0 (0%)	135 (1%)	94 (1%)
Lipid modifying agents	102 (21%)	9,591 (35%)	31 (9%)	2,897 (14%)	1,687 (32%)	7,782 (39%)	<5	4,715 (40%)	1,030 (6%)
Opioids	131 (27%)	3,449 (12%)	30 (9%)	1,922 (9%)	588 (11%)	4,620 (23%)	<5	3,004 (25%)	3,575 (21%)
Psycholeptics	108 (22%)	3,307 (12%)	42 (13%)	1,207 (6%)	729 (14%)	6,492 (32%)	0 (0%)	1,378 (12%)	2,784 (17%)
Psychostimulants adhd	<5	70 (0%)	0 (0%)	13 (0%)	7 (0%)	71 (0%)	0 (0%)	<5	<5

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 92. Medications recorded at the time of the diagnosis of leukaemia and lymphoma, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	815	25,172	884	33,640	3,009	28,831	3,029	10,429	20,690
Agents acting on the renin angiotensin system	135 (17%)	7,714 (31%)	155 (18%)	6,516 (19%)	654 (22%)	10,019 (35%)	<5	2,451 (24%)	1,447 (7%)
Antibacterials for systemic use	80 (10%)	1,545 (6%)	87 (10%)	1,291 (4%)	154 (5%)	3,611 (13%)	<5	486 (5%)	2,688 (13%)
Antidepressants	108 (13%)	2,079 (8%)	38 (4%)	1,268 (4%)	153 (5%)	5,641 (20%)	0 (0%)	1,587 (15%)	695 (3%)
Antiepileptics	32 (4%)	778 (3%)	24 (3%)	228 (1%)	34 (1%)	2,381 (8%)	<5	572 (5%)	384 (2%)
Antiinflammatory and antirheumatic products	88 (11%)	1,438 (6%)	62 (7%)	1,579 (5%)	142 (5%)	3,333 (12%)	<5	355 (3%)	2,783 (13%)
Antineoplastic agents	125 (15%)	1,119 (4%)	26 (3%)	256 (1%)	74 (2%)	1,389 (5%)	0 (0%)	153 (1%)	1,062 (5%)
Antipsoriatics	<5	12 (0%)	<5	10 (0%)	0 (0%)	49 (0%)	0 (0%)	11 (0%)	13 (0%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Antithrombotic agents	210 (26%)	7,122 (28%)	59 (7%)	3,856 (11%)	681 (23%)	3,793 (13%)	<5	1,294 (12%)	2,379 (11%)
Beta blocking agents	140 (17%)	2,518 (10%)	109 (12%)	4,581 (14%)	508 (17%)	4,490 (16%)	<5	1,616 (15%)	1,226 (6%)
Calcium channel blockers	32 (4%)	4,751 (19%)	54 (6%)	2,278 (7%)	301 (10%)	3,718 (13%)	<5	1,601 (15%)	758 (4%)
Diuretics	52 (6%)	4,434 (18%)	32 (4%)	2,964 (9%)	352 (12%)	5,179 (18%)	<5	1,456 (14%)	931 (4%)
Drugs for acid related disorders	171 (21%)	4,610 (18%)	99 (11%)	4,023 (12%)	774 (26%)	11,816 (41%)	<5	2,800 (27%)	2,014 (10%)
Drugs for obstructive airway diseases	64 (8%)	2,509 (10%)	47 (5%)	1,203 (4%)	232 (8%)	4,638 (16%)	<5	1,465 (14%)	1,189 (6%)
Drugs used in diabetes	61 (7%)	1,956 (8%)	49 (6%)	2,178 (6%)	284 (9%)	4,762 (17%)	<5	839 (8%)	756 (4%)
Hormonal contraceptives for systemic use	20 (2%)	287 (1%)	7 (1%)	167 (0%)	46 (2%)	239 (1%)	0 (0%)	106 (1%)	75 (0%)
Immunosuppressants	8 (1%)	368 (1%)	8 (1%)	184 (1%)	58 (2%)	536 (2%)	0 (0%)	106 (1%)	121 (1%)
Lipid modifying agents	150 (18%)	6,667 (26%)	80 (9%)	3,575 (11%)	693 (23%)	7,829 (27%)	6 (0%)	2,898 (28%)	1,113 (5%)
Opioids	68 (8%)	1,209 (5%)	40 (5%)	1,048 (3%)	157 (5%)	3,436 (12%)	<5	1,173 (11%)	1,691 (8%)
Psycholeptics	145 (18%)	1,538 (6%)	76 (9%)	961 (3%)	239 (8%)	8,266 (29%)	0 (0%)	652 (6%)	1,849 (9%)
Psychostimulants adhd	7 (1%)	61 (0%)	<5	23 (0%)	11 (0%)	153 (1%)	0 (0%)	6 (0%)	9 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 93. Medications recorded at the time of the diagnosis of melanoma, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	130	17,145	526	28,972	3,096	7,928	1,797	5,235	8,820
Agents acting on the renin angiotensin system	22 (17%)	4,079 (24%)	63 (12%)	2,845 (10%)	570 (18%)	2,634 (33%)	<5	1,199 (23%)	510 (6%)
Antibacterials for systemic use	<5	703 (4%)	17 (3%)	404 (1%)	79 (3%)	754 (10%)	0 (0%)	165 (3%)	923 (10%)
Antidepressants	8 (6%)	989 (6%)	21 (4%)	499 (2%)	172 (6%)	1,225 (15%)	<5	654 (12%)	218 (2%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Antiepileptics	<5	333 (2%)	8 (2%)	81 (0%)	33 (1%)	512 (6%)	0 (0%)	186 (4%)	129 (1%)
Antiinflammatory and antirheumatic products	8 (6%)	602 (4%)	27 (5%)	804 (3%)	78 (3%)	884 (11%)	0 (0%)	144 (3%)	836 (9%)
Antineoplastic agents	<5	119 (1%)	<5	173 (1%)	24 (1%)	85 (1%)	0 (0%)	44 (1%)	57 (1%)
Antipsoriatics	0 (0%)	12 (0%)	0 (0%)	25 (0%)	<5	8 (0%)	0 (0%)	<5	8 (0%)
Antithrombotic agents	16 (12%)	2,638 (15%)	7 (1%)	1,258 (4%)	410 (13%)	701 (9%)	0 (0%)	471 (9%)	452 (5%)
Beta blocking agents	20 (15%)	1,094 (6%)	35 (7%)	1,794 (6%)	378 (12%)	994 (13%)	0 (0%)	662 (13%)	371 (4%)
Calcium channel blockers	9 (7%)	2,392 (14%)	16 (3%)	974 (3%)	243 (8%)	903 (11%)	<5	737 (14%)	261 (3%)
Diuretics	<5	1,846 (11%)	16 (3%)	1,009 (3%)	276 (9%)	994 (13%)	<5	591 (11%)	191 (2%)
Drugs for acid related disorders	15 (12%)	1,588 (9%)	27 (5%)	1,169 (4%)	481 (16%)	2,218 (28%)	<5	1,011 (19%)	373 (4%)
Drugs for obstructive airway diseases	5 (4%)	960 (6%)	10 (2%)	366 (1%)	167 (5%)	875 (11%)	<5	483 (9%)	374 (4%)
Drugs used in diabetes	8 (6%)	916 (5%)	27 (5%)	742 (3%)	176 (6%)	945 (12%)	<5	338 (6%)	243 (3%)
Hormonal contraceptives for systemic use	<5	495 (3%)	7 (1%)	133 (0%)	70 (2%)	51 (1%)	0 (0%)	130 (2%)	41 (0%)
Immunosuppressants	0 (0%)	148 (1%)	<5	131 (0%)	27 (1%)	118 (1%)	0 (0%)	61 (1%)	36 (0%)
Lipid modifying agents	24 (18%)	3,354 (20%)	35 (7%)	1,420 (5%)	567 (18%)	2,012 (25%)	<5	1,319 (25%)	396 (4%)
Opioids	7 (5%)	300 (2%)	6 (1%)	272 (1%)	53 (2%)	601 (8%)	<5	348 (7%)	368 (4%)
Psycholeptics	26 (20%)	576 (3%)	27 (5%)	343 (1%)	157 (5%)	1,863 (23%)	0 (0%)	172 (3%)	553 (6%)
Psychostimulants adhd	0 (0%)	55 (0%)	<5	<5	6 (0%)	24 (0%)	0 (0%)	<5	<5

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 94. Medications recorded at the time of the diagnosis of ovarian cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	54	2,842	217	4,603	473	3,244	572	1,704	3,085
Agents acting on the renin angiotensin system	7 (13%)	703 (25%)	25 (12%)	604 (13%)	82 (17%)	805 (25%)	<5	281 (16%)	202 (7%)
Antibacterials for systemic use	<5	152 (5%)	19 (9%)	122 (3%)	18 (4%)	294 (9%)	0 (0%)	73 (4%)	510 (17%)
Antidepressants	<5	287 (10%)	9 (4%)	207 (4%)	33 (7%)	614 (19%)	0 (0%)	284 (17%)	116 (4%)
Antiepileptics	<5	73 (3%)	7 (3%)	23 (0%)	<5	214 (7%)	0 (0%)	78 (5%)	36 (1%)
Antiinflammatory and antirheumatic products	6 (11%)	243 (9%)	13 (6%)	189 (4%)	23 (5%)	631 (19%)	0 (0%)	88 (5%)	832 (27%)
Antineoplastic agents	<5	26 (1%)	0 (0%)	18 (0%)	6 (1%)	27 (1%)	0 (0%)	12 (1%)	11 (0%)
Antipsoriatics	0 (0%)	<5	0 (0%)	<5	<5	6 (0%)	0 (0%)	<5	0 (0%)
Antithrombotic agents	25 (46%)	448 (16%)	5 (2%)	483 (10%)	76 (16%)	724 (22%)	0 (0%)	143 (8%)	959 (31%)
Beta blocking agents	8 (15%)	224 (8%)	19 (9%)	488 (11%)	64 (14%)	343 (11%)	0 (0%)	166 (10%)	187 (6%)
Calcium channel blockers	<5	427 (15%)	9 (4%)	210 (5%)	42 (9%)	226 (7%)	<5	172 (10%)	91 (3%)
Diuretics	6 (11%)	492 (17%)	10 (5%)	379 (8%)	58 (12%)	516 (16%)	0 (0%)	195 (11%)	196 (6%)
Drugs for acid related disorders	<5	546 (19%)	25 (12%)	523 (11%)	113 (24%)	1,205 (37%)	0 (0%)	456 (27%)	380 (12%)
Drugs for obstructive airway diseases	<5	231 (8%)	6 (3%)	91 (2%)	29 (6%)	302 (9%)	0 (0%)	159 (9%)	148 (5%)
Drugs used in diabetes	7 (13%)	129 (5%)	11 (5%)	159 (3%)	45 (10%)	326 (10%)	0 (0%)	94 (6%)	103 (3%)
Hormonal contraceptives for systemic use	<5	66 (2%)	<5	55 (1%)	7 (1%)	33 (1%)	0 (0%)	25 (1%)	25 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Immunosuppressants	0 (0%)	24 (1%)	<5	17 (0%)	6 (1%)	31 (1%)	0 (0%)	6 (0%)	12 (0%)
Lipid modifying agents	14 (26%)	576 (20%)	18 (8%)	274 (6%)	87 (18%)	622 (19%)	0 (0%)	343 (20%)	124 (4%)
Opioids	10 (19%)	192 (7%)	8 (4%)	176 (4%)	21 (4%)	415 (13%)	0 (0%)	270 (16%)	571 (19%)
Psycholeptics	12 (22%)	284 (10%)	12 (6%)	179 (4%)	56 (12%)	1,031 (32%)	0 (0%)	138 (8%)	436 (14%)
Psychostimulants adhd	0 (0%)	7 (0%)	<5	<5	0 (0%)	11 (0%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 95. Medications recorded at the time of the diagnosis of pancreatic cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	123	6,587	193	6,387	1,252	6,705	907	2,354	8,139
Agents acting on the renin angiotensin system	21 (17%)	2,281 (35%)	37 (19%)	1,776 (28%)	327 (26%)	2,960 (44%)	0 (0%)	666 (28%)	696 (9%)
Antibacterials for systemic use	<5	390 (6%)	17 (9%)	161 (3%)	35 (3%)	703 (10%)	0 (0%)	82 (3%)	1,226 (15%)
Antidepressants	21 (17%)	654 (10%)	<5	380 (6%)	95 (8%)	1,426 (21%)	0 (0%)	363 (15%)	358 (4%)
Antiepileptics	<5	246 (4%)	5 (3%)	47 (1%)	19 (2%)	596 (9%)	0 (0%)	126 (5%)	218 (3%)
Antiinflammatory and antirheumatic products	7 (6%)	505 (8%)	17 (9%)	286 (4%)	62 (5%)	725 (11%)	0 (0%)	67 (3%)	1,092 (13%)
Antineoplastic agents	0 (0%)	46 (1%)	<5	40 (1%)	8 (1%)	54 (1%)	0 (0%)	9 (0%)	65 (1%)
Antipsoriatics	0 (0%)	<5	0 (0%)	<5	0 (0%)	8 (0%)	0 (0%)	<5	<5
Antithrombotic agents	31 (25%)	1,777 (27%)	13 (7%)	1,234 (19%)	330 (26%)	1,258 (19%)	<5	303 (13%)	1,234 (15%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Beta blocking agents	19 (15%)	709 (11%)	34 (18%)	1,324 (21%)	264 (21%)	1,264 (19%)	0 (0%)	393 (17%)	640 (8%)
Calcium channel blockers	12 (10%)	1,340 (20%)	17 (9%)	669 (10%)	169 (13%)	1,047 (16%)	0 (0%)	424 (18%)	371 (5%)
Diuretics	7 (6%)	1,188 (18%)	5 (3%)	887 (14%)	159 (13%)	1,372 (20%)	0 (0%)	330 (14%)	425 (5%)
Drugs for acid related disorders	40 (33%)	2,245 (34%)	41 (21%)	1,826 (29%)	489 (39%)	3,674 (55%)	<5	1,008 (43%)	1,937 (24%)
Drugs for obstructive airway diseases	8 (7%)	646 (10%)	11 (6%)	201 (3%)	100 (8%)	971 (14%)	0 (0%)	273 (12%)	424 (5%)
Drugs used in diabetes	24 (20%)	1,147 (17%)	26 (13%)	968 (15%)	254 (20%)	2,119 (32%)	0 (0%)	455 (19%)	879 (11%)
Hormonal contraceptives for systemic use	0 (0%)	35 (1%)	<5	5 (0%)	7 (1%)	81 (1%)	0 (0%)	19 (1%)	11 (0%)
Immunosuppressants	<5	49 (1%)	<5	27 (0%)	15 (1%)	88 (1%)	0 (0%)	12 (1%)	25 (0%)
Lipid modifying agents	24 (20%)	2,022 (31%)	17 (9%)	993 (16%)	366 (29%)	2,354 (35%)	0 (0%)	796 (34%)	497 (6%)
Opioids	31 (25%)	1,157 (18%)	24 (12%)	650 (10%)	135 (11%)	1,469 (22%)	<5	657 (28%)	2,731 (34%)
Psycholeptics	28 (23%)	790 (12%)	27 (14%)	412 (6%)	139 (11%)	2,356 (35%)	0 (0%)	242 (10%)	1,634 (20%)
Psychostimulants adhd	<5	20 (0%)	0 (0%)	6 (0%)	5 (0%)	31 (0%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 96. Medications recorded at the time of the diagnosis of prostate cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	920	29,476	1,067	51,871	4,527	22,704	7,069	15,485	36,620
Agents acting on the renin angiotensin system	227 (25%)	10,337 (35%)	242 (23%)	7,895 (15%)	1,348 (30%)	10,598 (47%)	<5	4,942 (32%)	1,910 (5%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Antibacterials for systemic use	39 (4%)	1,686 (6%)	458 (43%)	2,432 (5%)	239 (5%)	3,324 (15%)	<5	503 (3%)	3,369 (9%)
Antidepressants	59 (6%)	1,540 (5%)	25 (2%)	849 (2%)	160 (4%)	2,284 (10%)	<5	1,346 (9%)	647 (2%)
Antiepileptics	13 (1%)	568 (2%)	17 (2%)	165 (0%)	43 (1%)	1,292 (6%)	<5	555 (4%)	351 (1%)
Antiinflammatory and antirheumatic products	68 (7%)	1,487 (5%)	70 (7%)	1,586 (3%)	162 (4%)	2,043 (9%)	0 (0%)	496 (3%)	2,184 (6%)
Antineoplastic agents	<5	151 (1%)	6 (1%)	118 (0%)	31 (1%)	136 (1%)	0 (0%)	91 (1%)	84 (0%)
Antipsoriatics	0 (0%)	11 (0%)	<5	15 (0%)	<5	49 (0%)	0 (0%)	22 (0%)	16 (0%)
Antithrombotic agents	261 (28%)	7,739 (26%)	66 (6%)	4,623 (9%)	1,159 (26%)	3,506 (15%)	0 (0%)	1,828 (12%)	1,911 (5%)
Beta blocking agents	171 (19%)	2,694 (9%)	151 (14%)	4,562 (9%)	792 (17%)	3,850 (17%)	<5	2,586 (17%)	1,420 (4%)
Calcium channel blockers	85 (9%)	6,255 (21%)	87 (8%)	2,674 (5%)	603 (13%)	3,635 (16%)	<5	3,434 (22%)	959 (3%)
Diuretics	61 (7%)	3,756 (13%)	25 (2%)	2,563 (5%)	515 (11%)	3,246 (14%)	<5	1,861 (12%)	780 (2%)
Drugs for acid related disorders	152 (17%)	3,752 (13%)	70 (7%)	3,162 (6%)	1,044 (23%)	7,962 (35%)	<5	3,772 (24%)	1,332 (4%)
Drugs for obstructive airway diseases	68 (7%)	2,404 (8%)	55 (5%)	905 (2%)	304 (7%)	3,580 (16%)	<5	1,826 (12%)	1,090 (3%)
Drugs used in diabetes	107 (12%)	2,402 (8%)	61 (6%)	2,208 (4%)	431 (10%)	4,213 (19%)	<5	1,399 (9%)	1,034 (3%)
Hormonal contraceptives for systemic use	<5	111 (0%)	0 (0%)	<5	0 (0%)	41 (0%)	0 (0%)	0 (0%)	0 (0%)
Immunosuppressants	<5	174 (1%)	<5	132 (0%)	37 (1%)	237 (1%)	0 (0%)	122 (1%)	92 (0%)
Lipid modifying agents	265 (29%)	8,915 (30%)	128 (12%)	4,652 (9%)	1,333 (29%)	8,595 (38%)	<5	5,859 (38%)	1,564 (4%)
Opioids	55 (6%)	930 (3%)	19 (2%)	904 (2%)	138 (3%)	1,742 (8%)	<5	1,195 (8%)	1,730 (5%)
Psycholeptics	134 (15%)	1,028 (3%)	49 (5%)	751 (1%)	222 (5%)	4,804 (21%)	<5	507 (3%)	1,938 (5%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Psychostimulants adhd	<5	49 (0%)	0 (0%)	22 (0%)	5 (0%)	73 (0%)	0 (0%)	0 (0%)	<5

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 97. Medications recorded at the time of the diagnosis of stomach cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	42	4,137	191	4,737	678	5,059	488	1,055	3,300
Agents acting on the renin angiotensin system	9 (21%)	1,366 (33%)	32 (17%)	1,015 (21%)	195 (29%)	2,096 (41%)	0 (0%)	290 (27%)	241 (7%)
Antibacterials for systemic use	0 (0%)	197 (5%)	17 (9%)	119 (3%)	17 (3%)	396 (8%)	<5	42 (4%)	368 (11%)
Antidepressants	<5	337 (8%)	6 (3%)	199 (4%)	39 (6%)	915 (18%)	0 (0%)	138 (13%)	104 (3%)
Antiepileptics	<5	101 (2%)	<5	41 (1%)	11 (2%)	410 (8%)	0 (0%)	50 (5%)	48 (1%)
Antiinflammatory and antirheumatic products	<5	148 (4%)	12 (6%)	134 (3%)	18 (3%)	315 (6%)	0 (0%)	13 (1%)	230 (7%)
Antineoplastic agents	<5	32 (1%)	<5	15 (0%)	6 (1%)	45 (1%)	0 (0%)	<5	150 (5%)
Antipsoriatics	0 (0%)	<5	0 (0%)	<5	0 (0%)	11 (0%)	0 (0%)	<5	0 (0%)
Antithrombotic agents	10 (24%)	1,069 (26%)	5 (3%)	680 (14%)	190 (28%)	910 (18%)	0 (0%)	171 (16%)	413 (13%)
Beta blocking agents	13 (31%)	424 (10%)	20 (10%)	742 (16%)	146 (22%)	913 (18%)	0 (0%)	209 (20%)	237 (7%)
Calcium channel blockers	<5	845 (20%)	8 (4%)	375 (8%)	104 (15%)	716 (14%)	0 (0%)	192 (18%)	106 (3%)
Diuretics	<5	706 (17%)	0 (0%)	509 (11%)	101 (15%)	1,023 (20%)	0 (0%)	162 (15%)	193 (6%)
Drugs for acid related disorders	21 (50%)	2,226 (54%)	78 (41%)	1,322 (28%)	329 (49%)	3,189 (63%)	<5	581 (55%)	1,349 (41%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Drugs for obstructive airway diseases	<5	435 (11%)	12 (6%)	127 (3%)	71 (10%)	781 (15%)	0 (0%)	149 (14%)	151 (5%)
Drugs used in diabetes	11 (26%)	424 (10%)	12 (6%)	345 (7%)	89 (13%)	1,090 (22%)	0 (0%)	120 (11%)	155 (5%)
Hormonal contraceptives for systemic use	0 (0%)	26 (1%)	0 (0%)	11 (0%)	8 (1%)	45 (1%)	0 (0%)	6 (1%)	<5
Immunosuppressants	0 (0%)	40 (1%)	<5	13 (0%)	9 (1%)	73 (1%)	0 (0%)	<5	16 (0%)
Lipid modifying agents	10 (24%)	1,284 (31%)	16 (8%)	601 (13%)	190 (28%)	1,670 (33%)	0 (0%)	368 (35%)	168 (5%)
Opioids	11 (26%)	290 (7%)	6 (3%)	243 (5%)	45 (7%)	670 (13%)	0 (0%)	143 (14%)	498 (15%)
Psycholeptics	5 (12%)	308 (7%)	14 (7%)	219 (5%)	62 (9%)	1,523 (30%)	0 (0%)	83 (8%)	368 (11%)
Psychostimulants adhd	0 (0%)	6 (0%)	0 (0%)	<5	<5	16 (0%)	0 (0%)	<5	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 98. Medications recorded 0 to 90 days after the diagnosis of bone cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	18	322	31	965	0	1,071	37	290	594
Agents acting on the renin angiotensin system	<5	77 (24%)	7 (23%)	145 (15%)	0	305 (28%)	0 (0%)	70 (24%)	92 (15%)
Antibacterials for systemic use	<5	106 (33%)	8 (26%)	77 (8%)	0	342 (32%)	<5	84 (29%)	235 (40%)
Antidepressants	<5	44 (14%)	<5	58 (6%)	0	207 (19%)	<5	69 (24%)	90 (15%)
Antiepileptics	<5	53 (16%)	<5	7 (1%)	0	176 (16%)	0 (0%)	56 (19%)	159 (27%)
Antiinflammatory and antirheumatic products	<5	95 (30%)	8 (26%)	179 (19%)	0	461 (43%)	0 (0%)	56 (19%)	279 (47%)
Antineoplastic agents	<5	41 (13%)	<5	10 (1%)	0	17 (2%)	0 (0%)	<5	48 (8%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Antipsoriatics	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	<5	0 (0%)	<5	0 (0%)
Antithrombotic agents	5 (28%)	80 (25%)	<5	127 (13%)	0	269 (25%)	0 (0%)	47 (16%)	248 (42%)
Beta blocking agents	<5	42 (13%)	5 (16%)	111 (12%)	0	139 (13%)	0 (0%)	43 (15%)	89 (15%)
Calcium channel blockers	<5	54 (17%)	<5	59 (6%)	0	104 (10%)	0 (0%)	51 (18%)	53 (9%)
Diuretics	<5	57 (18%)	<5	66 (7%)	0	153 (14%)	0 (0%)	47 (16%)	67 (11%)
Drugs for acid related disorders	<5	103 (32%)	5 (16%)	156 (16%)	0	611 (57%)	<5	132 (46%)	263 (44%)
Drugs for obstructive airway diseases	<5	43 (13%)	<5	35 (4%)	0	158 (15%)	<5	44 (15%)	76 (13%)
Drugs used in diabetes	<5	26 (8%)	<5	56 (6%)	0	117 (11%)	0 (0%)	33 (11%)	59 (10%)
Hormonal contraceptives for systemic use	<5	14 (4%)	<5	<5	0	11 (1%)	0 (0%)	5 (2%)	8 (1%)
Immunosuppressants	0 (0%)	8 (2%)	<5	8 (1%)	0	13 (1%)	0 (0%)	<5	13 (2%)
Lipid modifying agents	5 (28%)	74 (23%)	<5	83 (9%)	0	245 (23%)	0 (0%)	82 (28%)	60 (10%)
Opioids	5 (28%)	182 (57%)	6 (19%)	100 (10%)	0	405 (38%)	0 (0%)	158 (54%)	341 (57%)
Psycholeptics	5 (28%)	52 (16%)	6 (19%)	47 (5%)	0	399 (37%)	<5	56 (19%)	209 (35%)
Psychostimulants adhd	0 (0%)	<5	0 (0%)	0 (0%)	0	7 (1%)	0 (0%)	<5	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 99. Medications recorded 0 to 90 days after the diagnosis of brain cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	128	3,510	132	3,240	297	3,955	507	932	3,318
Agents acting on the renin angiotensin system	16 (12%)	1,057 (30%)	37 (28%)	708 (22%)	77 (26%)	1,408 (36%)	<5	225 (24%)	731 (22%)
Antibacterials for systemic use	14 (11%)	748 (21%)	32 (24%)	259 (8%)	72 (24%)	1,036 (26%)	<5	208 (22%)	1,783 (54%)
Antidepressants	25 (20%)	617 (18%)	19 (14%)	311 (10%)	20 (7%)	1,070 (27%)	0 (0%)	220 (24%)	484 (15%)
Antiepileptics	38 (30%)	1,370 (39%)	44 (33%)	570 (18%)	84 (28%)	2,214 (56%)	6 (1%)	420 (45%)	1,614 (49%)
Antiinflammatory and antirheumatic products	13 (10%)	350 (10%)	17 (13%)	345 (11%)	52 (18%)	1,090 (28%)	0 (0%)	57 (6%)	954 (29%)
Antineoplastic agents	<5	1,523 (43%)	34 (26%)	52 (2%)	54 (18%)	35 (1%)	0 (0%)	<5	1,247 (38%)
Antipsoriatics	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	9 (0%)	0 (0%)	<5	<5
Antithrombotic agents	22 (17%)	881 (25%)	9 (7%)	476 (15%)	88 (30%)	694 (18%)	<5	132 (14%)	1,052 (32%)
Beta blocking agents	22 (17%)	458 (13%)	18 (14%)	462 (14%)	43 (14%)	537 (14%)	<5	146 (16%)	611 (18%)
Calcium channel blockers	6 (5%)	676 (19%)	19 (14%)	280 (9%)	31 (10%)	487 (12%)	<5	187 (20%)	454 (14%)
Diuretics	9 (7%)	667 (19%)	9 (7%)	284 (9%)	22 (7%)	655 (17%)	<5	120 (13%)	422 (13%)
Drugs for acid related disorders	42 (33%)	2,494 (71%)	59 (45%)	854 (26%)	149 (50%)	2,892 (73%)	8 (2%)	654 (70%)	2,422 (73%)
Drugs for obstructive airway diseases	13 (10%)	367 (10%)	13 (10%)	115 (4%)	14 (5%)	594 (15%)	<5	137 (15%)	477 (14%)
Drugs used in diabetes	14 (11%)	402 (11%)	8 (6%)	243 (8%)	43 (14%)	695 (18%)	<5	98 (11%)	671 (20%)
Hormonal contraceptives for systemic use	<5	75 (2%)	<5	17 (1%)	5 (2%)	25 (1%)	0 (0%)	19 (2%)	37 (1%)
Immunosuppressants	<5	73 (2%)	<5	15 (0%)	<5	50 (1%)	0 (0%)	6 (1%)	36 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Lipid modifying agents	19 (15%)	899 (26%)	14 (11%)	360 (11%)	73 (25%)	1,083 (27%)	<5	270 (29%)	477 (14%)
Opioids	20 (16%)	1,066 (30%)	15 (11%)	257 (8%)	49 (16%)	672 (17%)	<5	308 (33%)	1,114 (34%)
Psycholeptics	32 (25%)	1,683 (48%)	43 (33%)	393 (12%)	135 (45%)	1,929 (49%)	5 (1%)	364 (39%)	1,937 (58%)
Psychostimulants adhd	<5	21 (1%)	<5	10 (0%)	<5	23 (1%)	0 (0%)	0 (0%)	<5

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 100. Medications recorded 0 to 90 days after the diagnosis of breast cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	1,853	31,873	1,243	56,337	6,553	31,931	5,180	18,134	38,047
Agents acting on the renin angiotensin system	405 (22%)	8,300 (26%)	330 (27%)	7,560 (13%)	1,285 (20%)	8,632 (27%)	34 (1%)	3,893 (21%)	5,830 (15%)
Antibacterials for systemic use	244 (13%)	8,927 (28%)	312 (25%)	2,963 (5%)	887 (14%)	8,191 (26%)	47 (1%)	4,347 (24%)	13,584 (36%)
Antidepressants	372 (20%)	3,996 (13%)	127 (10%)	2,628 (5%)	621 (9%)	6,987 (22%)	29 (1%)	4,550 (25%)	4,726 (12%)
Antiepileptics	39 (2%)	1,801 (6%)	47 (4%)	273 (0%)	72 (1%)	2,419 (8%)	8 (0%)	1,236 (7%)	1,893 (5%)
Antiinflammatory and antirheumatic products	309 (17%)	5,263 (17%)	206 (17%)	3,969 (7%)	929 (14%)	9,474 (30%)	18 (0%)	1,573 (9%)	21,303 (56%)
Antineoplastic agents	17 (1%)	13,407 (42%)	23 (2%)	404 (1%)	203 (3%)	272 (1%)	<5	187 (1%)	1,964 (5%)
Antipsoriatics	<5	21 (0%)	0 (0%)	24 (0%)	<5	36 (0%)	<5	43 (0%)	40 (0%)
Antithrombotic agents	348 (19%)	5,529 (17%)	59 (5%)	4,146 (7%)	926 (14%)	5,019 (16%)	13 (0%)	1,548 (9%)	7,587 (20%)
Beta blocking agents	456 (25%)	3,978 (12%)	223 (18%)	5,775 (10%)	1,006 (15%)	3,416 (11%)	21 (0%)	2,409 (13%)	5,150 (14%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Calcium channel blockers	140 (8%)	4,723 (15%)	127 (10%)	2,737 (5%)	673 (10%)	2,557 (8%)	35 (1%)	2,652 (15%)	2,960 (8%)
Diuretics	169 (9%)	5,539 (17%)	48 (4%)	3,211 (6%)	776 (12%)	4,427 (14%)	26 (1%)	2,541 (14%)	2,881 (8%)
Drugs for acid related disorders	468 (25%)	6,539 (21%)	193 (16%)	5,081 (9%)	2,084 (32%)	15,275 (48%)	70 (1%)	5,738 (32%)	15,446 (41%)
Drugs for obstructive airway diseases	152 (8%)	3,705 (12%)	91 (7%)	1,949 (3%)	594 (9%)	4,056 (13%)	18 (0%)	2,949 (16%)	4,633 (12%)
Drugs used in diabetes	178 (10%)	2,281 (7%)	63 (5%)	2,176 (4%)	456 (7%)	3,145 (10%)	11 (0%)	1,285 (7%)	2,329 (6%)
Hormonal contraceptives for systemic use	34 (2%)	1,422 (4%)	22 (2%)	1,082 (2%)	310 (5%)	294 (1%)	<5	811 (4%)	512 (1%)
Immunosuppressants	7 (0%)	386 (1%)	10 (1%)	245 (0%)	60 (1%)	289 (1%)	<5	195 (1%)	341 (1%)
Lipid modifying agents	440 (24%)	6,781 (21%)	133 (11%)	3,441 (6%)	1,146 (17%)	6,399 (20%)	52 (1%)	4,210 (23%)	3,936 (10%)
Opioids	215 (12%)	3,860 (12%)	82 (7%)	2,124 (4%)	743 (11%)	4,294 (13%)	30 (1%)	4,240 (23%)	8,979 (24%)
Psycholeptics	458 (25%)	5,886 (18%)	368 (30%)	2,552 (5%)	1,533 (23%)	12,320 (39%)	32 (1%)	3,099 (17%)	10,598 (28%)
Psychostimulants adhd	16 (1%)	172 (1%)	<5	45 (0%)	21 (0%)	140 (0%)	0 (0%)	10 (0%)	26 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 101. Medications recorded 0 to 90 days after the diagnosis of colorectal cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	382	29,279	762	24,061	5,400	29,755	3,848	11,798	23,146
Agents acting on the renin angiotensin system	80 (21%)	10,414 (36%)	297 (39%)	6,074 (25%)	1,579 (29%)	12,880 (43%)	48 (1%)	3,491 (30%)	4,528 (20%)
Antibacterials for systemic use	48 (13%)	6,598 (23%)	208 (27%)	1,583 (7%)	683 (13%)	7,442 (25%)	36 (1%)	2,764 (23%)	8,449 (37%)
Antidepressants	50 (13%)	3,140 (11%)	53 (7%)	1,296 (5%)	381 (7%)	5,489 (18%)	18 (0%)	2,143 (18%)	2,017 (9%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Antiepileptics	12 (3%)	1,718 (6%)	42 (6%)	200 (1%)	68 (1%)	2,321 (8%)	11 (0%)	768 (7%)	1,718 (7%)
Antiinflammatory and antirheumatic products	35 (9%)	2,872 (10%)	110 (14%)	1,632 (7%)	394 (7%)	5,514 (19%)	10 (0%)	610 (5%)	6,758 (29%)
Antineoplastic agents	8 (2%)	9,811 (34%)	125 (16%)	163 (1%)	351 (6%)	209 (1%)	0 (0%)	108 (1%)	7,524 (33%)
Antipsoriatics	0 (0%)	26 (0%)	0 (0%)	11 (0%)	6 (0%)	62 (0%)	0 (0%)	21 (0%)	22 (0%)
Antithrombotic agents	95 (25%)	9,234 (32%)	123 (16%)	5,248 (22%)	1,694 (31%)	14,201 (48%)	17 (0%)	2,359 (20%)	14,617 (63%)
Beta blocking agents	82 (21%)	5,437 (19%)	216 (28%)	4,610 (19%)	1,239 (23%)	5,499 (18%)	29 (1%)	2,348 (20%)	4,417 (19%)
Calcium channel blockers	29 (8%)	6,361 (22%)	104 (14%)	2,367 (10%)	783 (14%)	4,469 (15%)	30 (1%)	2,426 (21%)	2,552 (11%)
Diuretics	35 (9%)	6,882 (24%)	89 (12%)	3,315 (14%)	893 (17%)	6,351 (21%)	19 (0%)	2,183 (19%)	3,429 (15%)
Drugs for acid related disorders	93 (24%)	9,559 (33%)	217 (28%)	5,190 (22%)	1,922 (36%)	17,522 (59%)	60 (2%)	4,706 (40%)	8,851 (38%)
Drugs for obstructive airway diseases	27 (7%)	3,859 (13%)	53 (7%)	1,081 (4%)	537 (10%)	5,134 (17%)	16 (0%)	2,015 (17%)	2,870 (12%)
Drugs used in diabetes	44 (12%)	3,554 (12%)	103 (14%)	2,263 (9%)	722 (13%)	6,352 (21%)	13 (0%)	1,475 (13%)	2,509 (11%)
Hormonal contraceptives for systemic use	9 (2%)	279 (1%)	<5	69 (0%)	45 (1%)	349 (1%)	0 (0%)	86 (1%)	104 (0%)
Immunosuppressants	<5	372 (1%)	12 (2%)	145 (1%)	49 (1%)	317 (1%)	<5	140 (1%)	246 (1%)
Lipid modifying agents	82 (21%)	9,297 (32%)	148 (19%)	3,478 (14%)	1,686 (31%)	10,289 (35%)	54 (1%)	4,339 (37%)	3,507 (15%)
Opioids	79 (21%)	7,499 (26%)	150 (20%)	1,645 (7%)	849 (16%)	4,923 (17%)	27 (1%)	3,574 (30%)	9,289 (40%)
Psycholeptics	89 (23%)	5,237 (18%)	208 (27%)	1,579 (7%)	1,156 (21%)	10,607 (36%)	20 (1%)	2,266 (19%)	6,351 (27%)
Psychostimulants adhd	<5	102 (0%)	<5	18 (0%)	13 (0%)	172 (1%)	0 (0%)	<5	<5

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 102. Medications recorded 0 to 90 days after the diagnosis of corpus uteri cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	60	4,910	260	5,113	622	4,858	899	2,453	6,121

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Agents acting on the renin angiotensin system	15 (25%)	1,944 (40%)	101 (39%)	1,083 (21%)	174 (28%)	1,887 (39%)	12 (1%)	812 (33%)	1,138 (19%)
Antibacterials for systemic use	12 (20%)	1,351 (28%)	104 (40%)	351 (7%)	113 (18%)	1,254 (26%)	13 (1%)	734 (30%)	2,373 (39%)
Antidepressants	7 (12%)	609 (12%)	33 (13%)	295 (6%)	51 (8%)	1,210 (25%)	7 (1%)	567 (23%)	631 (10%)
Antiepileptics	<5	258 (5%)	16 (6%)	35 (1%)	<5	462 (10%)	<5	153 (6%)	230 (4%)
Antiinflammatory and antirheumatic products	10 (17%)	1,127 (23%)	90 (35%)	429 (8%)	113 (18%)	1,549 (32%)	<5	244 (10%)	3,321 (54%)
Antineoplastic agents	0 (0%)	899 (18%)	<5	24 (0%)	11 (2%)	40 (1%)	<5	33 (1%)	67 (1%)
Antipsoriatrics	0 (0%)	<5	0 (0%)	0 (0%)	0 (0%)	<5	0 (0%)	<5	<5
Antithrombotic agents	13 (22%)	1,217 (25%)	53 (20%)	806 (16%)	158 (25%)	2,598 (53%)	5 (1%)	450 (18%)	4,910 (80%)
Beta blocking agents	11 (18%)	888 (18%)	72 (28%)	813 (16%)	128 (21%)	752 (15%)	6 (1%)	487 (20%)	947 (15%)
Calcium channel blockers	<5	980 (20%)	37 (14%)	394 (8%)	89 (14%)	571 (12%)	<5	516 (21%)	587 (10%)
Diuretics	8 (13%)	1,299 (26%)	19 (7%)	533 (10%)	139 (22%)	954 (20%)	11 (1%)	574 (23%)	667 (11%)
Drugs for acid related disorders	11 (18%)	1,225 (25%)	51 (20%)	675 (13%)	236 (38%)	2,397 (49%)	17 (2%)	803 (33%)	1,589 (26%)
Drugs for obstructive airway diseases	6 (10%)	490 (10%)	19 (7%)	184 (4%)	55 (9%)	581 (12%)	6 (1%)	317 (13%)	688 (11%)
Drugs used in diabetes	11 (18%)	728 (15%)	36 (14%)	406 (8%)	92 (15%)	873 (18%)	5 (1%)	368 (15%)	633 (10%)
Hormonal contraceptives for systemic use	0 (0%)	70 (1%)	0 (0%)	84 (2%)	20 (3%)	123 (3%)	0 (0%)	40 (2%)	197 (3%)
Immunosuppressants	<5	69 (1%)	<5	24 (0%)	5 (1%)	56 (1%)	<5	35 (1%)	51 (1%)
Lipid modifying agents	13 (22%)	1,430 (29%)	40 (15%)	444 (9%)	160 (26%)	1,344 (28%)	14 (2%)	792 (32%)	732 (12%)
Opioids	12 (20%)	782 (16%)	33 (13%)	282 (6%)	69 (11%)	905 (19%)	15 (2%)	675 (28%)	1,841 (30%)
Psycholeptics	15 (25%)	815 (17%)	64 (25%)	260 (5%)	136 (22%)	1,856 (38%)	7 (1%)	410 (17%)	1,469 (24%)
Psychostimulants adhd	0 (0%)	10 (0%)	0 (0%)	6 (0%)	<5	26 (1%)	0 (0%)	<5	<5

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 103. Medications recorded 0 to 90 days after the diagnosis of oesophageal cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	53	3,168	35	3,121	837	1,860	763	3,223	2,487
Agents acting on the renin angiotensin system	10 (19%)	1,163 (37%)	17 (49%)	769 (25%)	251 (30%)	711 (38%)	9 (1%)	1,055 (33%)	456 (18%)
Antibacterials for systemic use	5 (9%)	622 (20%)	9 (26%)	205 (7%)	94 (11%)	443 (24%)	5 (1%)	640 (20%)	912 (37%)
Antidepressants	13 (25%)	440 (14%)	<5	212 (7%)	60 (7%)	328 (18%)	<5	668 (21%)	260 (10%)
Antiepileptics	<5	252 (8%)	<5	41 (1%)	13 (2%)	158 (8%)	0 (0%)	267 (8%)	183 (7%)
Antiinflammatory and antirheumatic products	5 (9%)	287 (9%)	10 (29%)	240 (8%)	64 (8%)	360 (19%)	0 (0%)	122 (4%)	459 (18%)
Antineoplastic agents	0 (0%)	1,618 (51%)	<5	18 (1%)	48 (6%)	10 (1%)	0 (0%)	35 (1%)	576 (23%)
Antipsoriatics	0 (0%)	7 (0%)	0 (0%)	<5	0 (0%)	6 (0%)	0 (0%)	7 (0%)	6 (0%)
Antithrombotic agents	16 (30%)	1,129 (36%)	6 (17%)	593 (19%)	279 (33%)	417 (22%)	<5	657 (20%)	769 (31%)
Beta blocking agents	14 (26%)	649 (20%)	11 (31%)	585 (19%)	197 (24%)	356 (19%)	<5	704 (22%)	503 (20%)
Calcium channel blockers	11 (21%)	723 (23%)	<5	270 (9%)	149 (18%)	256 (14%)	<5	732 (23%)	259 (10%)
Diuretics	9 (17%)	745 (24%)	<5	399 (13%)	145 (17%)	332 (18%)	5 (1%)	617 (19%)	324 (13%)
Drugs for acid related disorders	28 (53%)	2,215 (70%)	26 (74%)	1,246 (40%)	559 (67%)	1,452 (78%)	24 (3%)	2,537 (79%)	1,947 (78%)
Drugs for obstructive airway diseases	7 (13%)	535 (17%)	<5	205 (7%)	112 (13%)	434 (23%)	<5	632 (20%)	412 (17%)
Drugs used in diabetes	<5	367 (12%)	<5	263 (8%)	102 (12%)	385 (21%)	<5	435 (13%)	278 (11%)
Hormonal contraceptives for systemic use	0 (0%)	7 (0%)	0 (0%)	6 (0%)	<5	40 (2%)	0 (0%)	10 (0%)	8 (0%)
Immunosuppressants	0 (0%)	34 (1%)	<5	19 (1%)	7 (1%)	23 (1%)	0 (0%)	53 (2%)	30 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Lipid modifying agents	9 (17%)	1,076 (34%)	6 (17%)	444 (14%)	274 (33%)	595 (32%)	10 (1%)	1,282 (40%)	318 (13%)
Opioids	21 (40%)	1,528 (48%)	20 (57%)	356 (11%)	224 (27%)	559 (30%)	7 (1%)	1,453 (45%)	1,505 (61%)
Psycholeptics	14 (26%)	946 (30%)	10 (29%)	298 (10%)	259 (31%)	760 (41%)	<5	1,053 (33%)	991 (40%)
Psychostimulants adhd	0 (0%)	26 (1%)	<5	<5	<5	13 (1%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 104. Medications recorded 0 to 90 days after the diagnosis of kidney cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	33	6,498	289	9,149	1,068	7,404	950	1,096	6,394
Agents acting on the renin angiotensin system	5 (15%)	3,024 (47%)	149 (52%)	2,234 (24%)	409 (38%)	3,625 (49%)	15 (2%)	414 (38%)	1,496 (23%)
Antibacterials for systemic use	<5	2,051 (32%)	112 (39%)	667 (7%)	209 (20%)	2,277 (31%)	13 (1%)	323 (29%)	2,287 (36%)
Antidepressants	5 (15%)	730 (11%)	19 (7%)	408 (4%)	94 (9%)	1,485 (20%)	5 (1%)	235 (21%)	599 (9%)
Antiepileptics	0 (0%)	539 (8%)	22 (8%)	64 (1%)	18 (2%)	711 (10%)	0 (0%)	92 (8%)	451 (7%)
Antiinflammatory and antirheumatic products	<5	1,292 (20%)	76 (26%)	547 (6%)	133 (12%)	1,287 (17%)	0 (0%)	94 (9%)	1,305 (20%)
Antineoplastic agents	0 (0%)	871 (13%)	17 (6%)	68 (1%)	32 (3%)	65 (1%)	0 (0%)	18 (2%)	779 (12%)
Antipsoriatics	0 (0%)	7 (0%)	0 (0%)	<5	<5	22 (0%)	0 (0%)	<5	8 (0%)
Antithrombotic agents	11 (33%)	2,249 (35%)	84 (29%)	1,566 (17%)	380 (36%)	1,945 (26%)	7 (1%)	251 (23%)	2,955 (46%)
Beta blocking agents	11 (33%)	1,512 (23%)	99 (34%)	1,538 (17%)	296 (28%)	1,538 (21%)	8 (1%)	259 (24%)	1,289 (20%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Calcium channel blockers	<5	1,994 (31%)	68 (24%)	988 (11%)	232 (22%)	1,620 (22%)	13 (1%)	328 (30%)	1,081 (17%)
Diuretics	<5	1,714 (26%)	38 (13%)	1,091 (12%)	221 (21%)	1,679 (23%)	5 (1%)	228 (21%)	927 (14%)
Drugs for acid related disorders	11 (33%)	2,289 (35%)	86 (30%)	1,380 (15%)	427 (40%)	3,701 (50%)	17 (2%)	467 (43%)	1,591 (25%)
Drugs for obstructive airway diseases	<5	918 (14%)	27 (9%)	404 (4%)	134 (13%)	1,298 (18%)	6 (1%)	220 (20%)	900 (14%)
Drugs used in diabetes	5 (15%)	1,043 (16%)	48 (17%)	807 (9%)	176 (16%)	1,531 (21%)	5 (1%)	165 (15%)	828 (13%)
Hormonal contraceptives for systemic use	0 (0%)	32 (0%)	0 (0%)	18 (0%)	6 (1%)	84 (1%)	0 (0%)	5 (0%)	19 (0%)
Immunosuppressants	0 (0%)	106 (2%)	<5	47 (1%)	22 (2%)	173 (2%)	0 (0%)	24 (2%)	92 (1%)
Lipid modifying agents	10 (30%)	2,364 (36%)	65 (22%)	1,187 (13%)	382 (36%)	2,668 (36%)	15 (2%)	466 (43%)	976 (15%)
Opioids	12 (36%)	1,877 (29%)	73 (25%)	645 (7%)	244 (23%)	1,516 (20%)	13 (1%)	412 (38%)	2,726 (43%)
Psycholeptics	<5	1,139 (18%)	67 (23%)	499 (5%)	224 (21%)	2,677 (36%)	<5	223 (20%)	1,582 (25%)
Psychostimulants adhd	0 (0%)	52 (1%)	0 (0%)	6 (0%)	6 (1%)	32 (0%)	0 (0%)	0 (0%)	<5

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 105. Medications recorded 0 to 90 days after the diagnosis of liver cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	35	3,338	75	3,214	557	5,618	456	1,297	4,177
Agents acting on the renin angiotensin system	11 (31%)	1,304 (39%)	34 (45%)	1,031 (32%)	164 (29%)	2,456 (44%)	<5	475 (37%)	878 (21%)
Antibacterials for systemic use	6 (17%)	832 (25%)	30 (40%)	307 (10%)	94 (17%)	1,560 (28%)	5 (1%)	349 (27%)	1,661 (40%)
Antidepressants	5 (14%)	440 (13%)	7 (9%)	199 (6%)	53 (10%)	1,122 (20%)	<5	289 (22%)	480 (11%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Antiepileptics	<5	308 (9%)	<5	41 (1%)	10 (2%)	577 (10%)	<5	120 (9%)	291 (7%)
Antiinflammatory and antirheumatic products	<5	348 (10%)	16 (21%)	217 (7%)	70 (13%)	649 (12%)	0 (0%)	68 (5%)	1,031 (25%)
Antineoplastic agents	<5	757 (23%)	11 (15%)	26 (1%)	17 (3%)	39 (1%)	<5	8 (1%)	534 (13%)
Antipsoriatics	0 (0%)	<5	0 (0%)	<5	<5	18 (0%)	0 (0%)	<5	<5
Antithrombotic agents	15 (43%)	1,285 (38%)	14 (19%)	832 (26%)	209 (38%)	1,497 (27%)	<5	252 (19%)	1,506 (36%)
Beta blocking agents	7 (20%)	890 (27%)	26 (35%)	902 (28%)	173 (31%)	1,852 (33%)	<5	476 (37%)	1,087 (26%)
Calcium channel blockers	<5	805 (24%)	15 (20%)	418 (13%)	73 (13%)	1,025 (18%)	<5	290 (22%)	545 (13%)
Diuretics	8 (23%)	1,612 (48%)	19 (25%)	906 (28%)	162 (29%)	2,366 (42%)	<5	505 (39%)	1,338 (32%)
Drugs for acid related disorders	12 (34%)	1,697 (51%)	29 (39%)	1,083 (34%)	288 (52%)	3,588 (64%)	6 (1%)	784 (60%)	1,846 (44%)
Drugs for obstructive airway diseases	<5	496 (15%)	10 (13%)	187 (6%)	89 (16%)	1,163 (21%)	<5	256 (20%)	757 (18%)
Drugs used in diabetes	11 (31%)	877 (26%)	17 (23%)	644 (20%)	122 (22%)	1,830 (33%)	<5	439 (34%)	931 (22%)
Hormonal contraceptives for systemic use	<5	14 (0%)	<5	5 (0%)	<5	138 (2%)	0 (0%)	8 (1%)	7 (0%)
Immunosuppressants	<5	75 (2%)	<5	31 (1%)	7 (1%)	140 (2%)	0 (0%)	26 (2%)	54 (1%)
Lipid modifying agents	9 (26%)	1,088 (33%)	12 (16%)	566 (18%)	189 (34%)	1,510 (27%)	<5	516 (40%)	573 (14%)
Opioids	13 (37%)	1,568 (47%)	27 (36%)	454 (14%)	195 (35%)	1,515 (27%)	<5	630 (49%)	2,616 (63%)
Psycholeptics	10 (29%)	1,144 (34%)	20 (27%)	381 (12%)	201 (36%)	2,215 (39%)	<5	417 (32%)	1,868 (45%)
Psychostimulants adhd	0 (0%)	14 (0%)	0 (0%)	0 (0%)	<5	55 (1%)	0 (0%)	0 (0%)	<5

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 106. Medications recorded 0 to 90 days after the diagnosis of lung cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	486	27,757	332	20,343	5,288	20,068	2,581	11,844	16,828
Agents acting on the renin angiotensin system	95 (20%)	10,283 (37%)	127 (38%)	5,327 (26%)	1,638 (31%)	8,481 (42%)	21 (1%)	3,676 (31%)	3,344 (20%)
Antibacterials for systemic use	102 (21%)	9,888 (36%)	150 (45%)	2,328 (11%)	1,443 (27%)	7,262 (36%)	18 (1%)	3,987 (34%)	7,862 (47%)
Antidepressants	63 (13%)	5,027 (18%)	31 (9%)	1,705 (8%)	617 (12%)	4,532 (23%)	17 (1%)	3,575 (30%)	2,254 (13%)
Antiepileptics	14 (3%)	3,638 (13%)	36 (11%)	346 (2%)	140 (3%)	3,229 (16%)	10 (0%)	1,891 (16%)	2,227 (13%)
Antiinflammatory and antirheumatic products	67 (14%)	5,937 (21%)	68 (20%)	2,346 (12%)	786 (15%)	5,999 (30%)	14 (1%)	1,202 (10%)	4,545 (27%)
Antineoplastic agents	7 (1%)	12,005 (43%)	39 (12%)	186 (1%)	244 (5%)	247 (1%)	<5	188 (2%)	2,602 (15%)
Antipsoriatics	0 (0%)	30 (0%)	0 (0%)	9 (0%)	6 (0%)	56 (0%)	0 (0%)	27 (0%)	29 (0%)
Antithrombotic agents	131 (27%)	11,573 (42%)	51 (15%)	4,626 (23%)	2,187 (41%)	5,382 (27%)	13 (1%)	2,896 (24%)	6,397 (38%)
Beta blocking agents	102 (21%)	6,095 (22%)	107 (32%)	4,457 (22%)	1,458 (28%)	4,101 (20%)	15 (1%)	2,740 (23%)	3,919 (23%)
Calcium channel blockers	44 (9%)	6,796 (24%)	52 (16%)	2,149 (11%)	893 (17%)	3,341 (17%)	14 (1%)	2,862 (24%)	2,039 (12%)
Diuretics	49 (10%)	8,498 (31%)	53 (16%)	3,424 (17%)	1,039 (20%)	4,654 (23%)	13 (1%)	2,768 (23%)	3,319 (20%)
Drugs for acid related disorders	171 (35%)	13,958 (50%)	133 (40%)	5,550 (27%)	2,713 (51%)	14,061 (70%)	47 (2%)	6,772 (57%)	7,733 (46%)
Drugs for obstructive airway diseases	116 (24%)	9,879 (36%)	108 (33%)	4,472 (22%)	1,896 (36%)	9,841 (49%)	26 (1%)	5,434 (46%)	7,028 (42%)
Drugs used in diabetes	40 (8%)	3,589 (13%)	31 (9%)	1,922 (9%)	720 (14%)	4,484 (22%)	10 (0%)	1,559 (13%)	2,109 (13%)
Hormonal contraceptives for systemic use	11 (2%)	221 (1%)	<5	54 (0%)	21 (0%)	521 (3%)	0 (0%)	82 (1%)	47 (0%)
Immunosuppressants	6 (1%)	585 (2%)	9 (3%)	163 (1%)	114 (2%)	364 (2%)	<5	180 (2%)	203 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Lipid modifying agents	121 (25%)	10,730 (39%)	69 (21%)	3,533 (17%)	1,931 (37%)	8,024 (40%)	37 (1%)	5,465 (46%)	2,616 (16%)
Opioids	170 (35%)	14,317 (52%)	149 (45%)	3,888 (19%)	1,899 (36%)	9,339 (47%)	37 (1%)	6,971 (59%)	9,691 (58%)
Psycholeptics	153 (31%)	9,593 (35%)	114 (34%)	2,485 (12%)	1,904 (36%)	9,363 (47%)	19 (1%)	4,334 (37%)	7,424 (44%)
Psychostimulants adhd	<5	197 (1%)	0 (0%)	21 (0%)	25 (0%)	111 (1%)	0 (0%)	<5	<5

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 107. Medications recorded 0 to 90 days after the diagnosis of leukaemia and lymphoma, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	815	25,172	884	33,640	3,009	28,831	3,029	10,429	20,690
Agents acting on the renin angiotensin system	160 (20%)	8,624 (34%)	276 (31%)	7,804 (23%)	749 (25%)	10,473 (36%)	36 (1%)	2,850 (27%)	3,677 (18%)
Antibacterials for systemic use	152 (19%)	6,625 (26%)	290 (33%)	3,479 (10%)	623 (21%)	8,898 (31%)	20 (1%)	2,247 (22%)	7,929 (38%)
Antidepressants	140 (17%)	2,941 (12%)	87 (10%)	1,794 (5%)	217 (7%)	6,318 (22%)	16 (1%)	2,142 (21%)	1,891 (9%)
Antiepileptics	39 (5%)	1,627 (6%)	52 (6%)	320 (1%)	41 (1%)	2,962 (10%)	<5	806 (8%)	1,051 (5%)
Antiinflammatory and antirheumatic products	131 (16%)	2,737 (11%)	140 (16%)	3,002 (9%)	295 (10%)	5,971 (21%)	11 (0%)	646 (6%)	5,127 (25%)
Antineoplastic agents	132 (16%)	9,144 (36%)	118 (13%)	439 (1%)	232 (8%)	2,236 (8%)	<5	407 (4%)	3,004 (15%)
Antipsoriatics	<5	29 (0%)	<5	22 (0%)	<5	56 (0%)	0 (0%)	24 (0%)	46 (0%)
Antithrombotic agents	240 (29%)	9,695 (39%)	114 (13%)	5,071 (15%)	861 (29%)	5,098 (18%)	14 (0%)	1,811 (17%)	5,330 (26%)
Beta blocking agents	165 (20%)	4,617 (18%)	215 (24%)	5,763 (17%)	609 (20%)	4,936 (17%)	21 (1%)	1,973 (19%)	3,338 (16%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Calcium channel blockers	40 (5%)	5,441 (22%)	104 (12%)	2,894 (9%)	375 (12%)	4,085 (14%)	25 (1%)	1,934 (19%)	2,032 (10%)
Diuretics	69 (8%)	6,197 (25%)	85 (10%)	3,854 (11%)	465 (15%)	6,274 (22%)	18 (1%)	1,890 (18%)	2,802 (14%)
Drugs for acid related disorders	219 (27%)	7,614 (30%)	306 (35%)	5,853 (17%)	1,152 (38%)	15,783 (55%)	56 (2%)	4,127 (40%)	6,566 (32%)
Drugs for obstructive airway diseases	83 (10%)	3,720 (15%)	89 (10%)	1,953 (6%)	325 (11%)	5,696 (20%)	20 (1%)	2,010 (19%)	2,878 (14%)
Drugs used in diabetes	68 (8%)	2,677 (11%)	89 (10%)	2,796 (8%)	344 (11%)	5,103 (18%)	20 (1%)	1,098 (11%)	1,929 (9%)
Hormonal contraceptives for systemic use	23 (3%)	371 (1%)	21 (2%)	209 (1%)	66 (2%)	423 (1%)	0 (0%)	132 (1%)	239 (1%)
Immunosuppressants	11 (1%)	1,954 (8%)	15 (2%)	250 (1%)	79 (3%)	646 (2%)	<5	163 (2%)	348 (2%)
Lipid modifying agents	178 (22%)	7,743 (31%)	137 (15%)	4,490 (13%)	789 (26%)	8,211 (28%)	55 (2%)	3,466 (33%)	2,728 (13%)
Opioids	109 (13%)	4,242 (17%)	113 (13%)	1,882 (6%)	461 (15%)	5,112 (18%)	24 (1%)	2,395 (23%)	4,429 (21%)
Psycholeptics	180 (22%)	4,217 (17%)	167 (19%)	1,759 (5%)	586 (19%)	10,323 (36%)	8 (0%)	1,440 (14%)	5,136 (25%)
Psychostimulants adhd	10 (1%)	116 (0%)	<5	36 (0%)	16 (1%)	246 (1%)	0 (0%)	8 (0%)	31 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 108. Medications recorded 0 to 90 days after the diagnosis of melanoma, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	130	17,145	526	28,972	3,096	7,928	1,797	5,235	8,820
Agents acting on the renin angiotensin system	26 (20%)	4,609 (27%)	128 (24%)	3,351 (12%)	643 (21%)	2,715 (34%)	30 (2%)	1,345 (26%)	1,401 (16%)
Antibacterials for systemic use	19 (15%)	4,942 (29%)	95 (18%)	1,285 (4%)	355 (11%)	1,905 (24%)	25 (1%)	1,204 (23%)	2,936 (33%)
Antidepressants	11 (8%)	1,332 (8%)	38 (7%)	689 (2%)	203 (7%)	1,348 (17%)	12 (1%)	872 (17%)	619 (7%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Antiepileptics	6 (5%)	705 (4%)	18 (3%)	104 (0%)	39 (1%)	620 (8%)	5 (0%)	262 (5%)	358 (4%)
Antiinflammatory and antirheumatic products	20 (15%)	1,937 (11%)	76 (14%)	1,595 (6%)	291 (9%)	1,801 (23%)	<5	370 (7%)	3,203 (36%)
Antineoplastic agents	<5	1,121 (7%)	14 (3%)	234 (1%)	42 (1%)	108 (1%)	0 (0%)	64 (1%)	250 (3%)
Antipsoriatics	0 (0%)	27 (0%)	<5	32 (0%)	<5	10 (0%)	0 (0%)	19 (0%)	16 (0%)
Antithrombotic agents	22 (17%)	3,352 (20%)	25 (5%)	1,624 (6%)	496 (16%)	975 (12%)	7 (0%)	577 (11%)	1,490 (17%)
Beta blocking agents	26 (20%)	2,041 (12%)	74 (14%)	2,190 (8%)	447 (14%)	1,032 (13%)	10 (1%)	759 (14%)	1,035 (12%)
Calcium channel blockers	11 (8%)	2,775 (16%)	31 (6%)	1,185 (4%)	301 (10%)	956 (12%)	16 (1%)	847 (16%)	719 (8%)
Diuretics	8 (6%)	2,404 (14%)	23 (4%)	1,263 (4%)	322 (10%)	1,095 (14%)	14 (1%)	681 (13%)	564 (6%)
Drugs for acid related disorders	20 (15%)	2,513 (15%)	63 (12%)	1,667 (6%)	660 (21%)	2,806 (35%)	21 (1%)	1,364 (26%)	1,063 (12%)
Drugs for obstructive airway diseases	8 (6%)	1,546 (9%)	31 (6%)	584 (2%)	225 (7%)	1,066 (13%)	11 (1%)	706 (13%)	883 (10%)
Drugs used in diabetes	9 (7%)	1,182 (7%)	33 (6%)	917 (3%)	193 (6%)	993 (13%)	8 (0%)	409 (8%)	611 (7%)
Hormonal contraceptives for systemic use	<5	584 (3%)	11 (2%)	159 (1%)	90 (3%)	67 (1%)	0 (0%)	160 (3%)	117 (1%)
Immunosuppressants	<5	317 (2%)	<5	152 (1%)	40 (1%)	125 (2%)	<5	80 (2%)	107 (1%)
Lipid modifying agents	33 (25%)	3,889 (23%)	61 (12%)	1,757 (6%)	637 (21%)	2,080 (26%)	33 (2%)	1,520 (29%)	1,046 (12%)
Opioids	11 (8%)	1,357 (8%)	26 (5%)	481 (2%)	176 (6%)	938 (12%)	6 (0%)	862 (16%)	1,219 (14%)
Psycholeptics	31 (24%)	1,463 (9%)	77 (15%)	588 (2%)	330 (11%)	2,153 (27%)	<5	448 (9%)	1,341 (15%)
Psychostimulants adhd	<5	85 (0%)	<5	<5	13 (0%)	30 (0%)	0 (0%)	<5	<5

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 109. Medications recorded 0 to 90 days after the diagnosis of ovarian cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	54	2,842	217	4,603	473	3,244	572	1,704	3,085
Agents acting on the renin angiotensin system	11 (20%)	787 (28%)	52 (24%)	768 (17%)	108 (23%)	848 (26%)	<5	346 (20%)	489 (16%)
Antibacterials for systemic use	12 (22%)	942 (33%)	68 (31%)	382 (8%)	83 (18%)	901 (28%)	5 (1%)	465 (27%)	1,414 (46%)
Antidepressants	6 (11%)	400 (14%)	25 (12%)	320 (7%)	50 (11%)	712 (22%)	<5	393 (23%)	370 (12%)
Antiepileptics	<5	145 (5%)	14 (6%)	32 (1%)	<5	264 (8%)	<5	120 (7%)	155 (5%)
Antiinflammatory and antirheumatic products	9 (17%)	667 (23%)	87 (40%)	382 (8%)	88 (19%)	1,233 (38%)	<5	182 (11%)	1,694 (55%)
Antineoplastic agents	<5	1,997 (70%)	<5	36 (1%)	18 (4%)	31 (1%)	<5	17 (1%)	85 (3%)
Antipsoriatics	0 (0%)	<5	0 (0%)	<5	<5	6 (0%)	0 (0%)	<5	<5
Antithrombotic agents	27 (50%)	628 (22%)	37 (17%)	818 (18%)	122 (26%)	1,665 (51%)	<5	305 (18%)	2,281 (74%)
Beta blocking agents	10 (19%)	386 (14%)	36 (17%)	652 (14%)	81 (17%)	377 (12%)	<5	228 (13%)	522 (17%)
Calcium channel blockers	5 (9%)	493 (17%)	20 (9%)	281 (6%)	52 (11%)	249 (8%)	<5	233 (14%)	268 (9%)
Diuretics	10 (19%)	670 (24%)	27 (12%)	536 (12%)	76 (16%)	667 (21%)	<5	284 (17%)	469 (15%)
Drugs for acid related disorders	8 (15%)	1,178 (41%)	68 (31%)	812 (18%)	212 (45%)	1,926 (59%)	8 (1%)	729 (43%)	1,554 (50%)
Drugs for obstructive airway diseases	<5	327 (12%)	12 (6%)	153 (3%)	47 (10%)	369 (11%)	<5	234 (14%)	383 (12%)
Drugs used in diabetes	9 (17%)	197 (7%)	17 (8%)	208 (5%)	52 (11%)	338 (10%)	<5	130 (8%)	201 (7%)
Hormonal contraceptives for systemic use	<5	87 (3%)	6 (3%)	64 (1%)	9 (2%)	59 (2%)	0 (0%)	28 (2%)	55 (2%)
Immunosuppressants	0 (0%)	36 (1%)	<5	21 (0%)	7 (1%)	32 (1%)	<5	11 (1%)	28 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Lipid modifying agents	16 (30%)	658 (23%)	33 (15%)	356 (8%)	99 (21%)	645 (20%)	6 (1%)	408 (24%)	313 (10%)
Opioids	13 (24%)	1,011 (36%)	37 (17%)	350 (8%)	111 (23%)	722 (22%)	5 (1%)	650 (38%)	1,641 (53%)
Psycholeptics	16 (30%)	781 (27%)	57 (26%)	348 (8%)	140 (30%)	1,416 (44%)	<5	419 (25%)	1,060 (34%)
Psychostimulants adhd	0 (0%)	19 (1%)	<5	<5	0 (0%)	16 (0%)	0 (0%)	<5	<5

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 110. Medications recorded 0 to 90 days after the diagnosis of pancreatic cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	123	6,587	193	6,387	1,252	6,705	907	2,354	8,139
Agents acting on the renin angiotensin system	26 (21%)	2,433 (37%)	69 (36%)	2,098 (33%)	372 (30%)	3,071 (46%)	5 (1%)	746 (32%)	1,736 (21%)
Antibacterials for systemic use	12 (10%)	1,951 (30%)	69 (36%)	514 (8%)	201 (16%)	1,954 (29%)	7 (1%)	535 (23%)	3,654 (45%)
Antidepressants	31 (25%)	1,048 (16%)	16 (8%)	622 (10%)	147 (12%)	1,760 (26%)	<5	547 (23%)	1,046 (13%)
Antiepileptics	<5	778 (12%)	17 (9%)	63 (1%)	26 (2%)	863 (13%)	<5	312 (13%)	713 (9%)
Antiinflammatory and antirheumatic products	15 (12%)	895 (14%)	42 (22%)	537 (8%)	190 (15%)	1,416 (21%)	<5	138 (6%)	2,306 (28%)
Antineoplastic agents	0 (0%)	2,997 (45%)	<5	60 (1%)	37 (3%)	61 (1%)	<5	11 (0%)	575 (7%)
Antipsoriatics	0 (0%)	<5	0 (0%)	<5	0 (0%)	9 (0%)	0 (0%)	<5	7 (0%)
Antithrombotic agents	40 (33%)	2,391 (36%)	42 (22%)	1,821 (29%)	446 (36%)	2,324 (35%)	6 (1%)	530 (23%)	3,562 (44%)
Beta blocking agents	26 (21%)	1,151 (17%)	60 (31%)	1,624 (25%)	297 (24%)	1,355 (20%)	<5	463 (20%)	1,734 (21%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Calcium channel blockers	15 (12%)	1,461 (22%)	34 (18%)	829 (13%)	192 (15%)	1,109 (17%)	<5	498 (21%)	941 (12%)
Diuretics	10 (8%)	1,963 (30%)	31 (16%)	1,267 (20%)	221 (18%)	1,839 (27%)	<5	461 (20%)	1,535 (19%)
Drugs for acid related disorders	52 (42%)	4,208 (64%)	97 (50%)	2,574 (40%)	735 (59%)	4,989 (74%)	12 (1%)	1,624 (69%)	4,728 (58%)
Drugs for obstructive airway diseases	13 (11%)	906 (14%)	19 (10%)	340 (5%)	139 (11%)	1,134 (17%)	<5	363 (15%)	1,359 (17%)
Drugs used in diabetes	27 (22%)	1,806 (27%)	40 (21%)	1,288 (20%)	333 (27%)	2,455 (37%)	5 (1%)	657 (28%)	1,995 (25%)
Hormonal contraceptives for systemic use	0 (0%)	43 (1%)	<5	6 (0%)	8 (1%)	248 (4%)	0 (0%)	23 (1%)	32 (0%)
Immunosuppressants	<5	136 (2%)	<5	35 (1%)	21 (2%)	90 (1%)	<5	18 (1%)	69 (1%)
Lipid modifying agents	31 (25%)	2,253 (34%)	38 (20%)	1,200 (19%)	417 (33%)	2,501 (37%)	9 (1%)	921 (39%)	1,206 (15%)
Opioids	44 (36%)	4,049 (61%)	89 (46%)	1,337 (21%)	615 (49%)	2,884 (43%)	13 (1%)	1,584 (67%)	6,002 (74%)
Psycholeptics	45 (37%)	2,653 (40%)	76 (39%)	919 (14%)	558 (45%)	3,380 (50%)	10 (1%)	1,067 (45%)	4,186 (51%)
Psychostimulants adhd	<5	83 (1%)	<5	9 (0%)	18 (1%)	48 (1%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 111. Medications recorded 0 to 90 days after the diagnosis of prostate cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	920	29,476	1,067	51,871	4,527	22,704	7,069	15,485	36,620
Agents acting on the renin angiotensin system	291 (32%)	11,501 (39%)	459 (43%)	9,382 (18%)	1,541 (34%)	10,928 (48%)	86 (1%)	5,632 (36%)	5,908 (16%)
Antibacterials for systemic use	119 (13%)	8,730 (30%)	714 (67%)	5,593 (11%)	1,323 (29%)	8,118 (36%)	45 (1%)	2,852 (18%)	13,495 (37%)
Antidepressants	84 (9%)	2,176 (7%)	52 (5%)	1,233 (2%)	216 (5%)	2,653 (12%)	24 (0%)	1,872 (12%)	2,037 (6%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Antiepileptics	20 (2%)	1,281 (4%)	33 (3%)	214 (0%)	53 (1%)	1,538 (7%)	13 (0%)	784 (5%)	1,073 (3%)
Antiinflammatory and antirheumatic products	130 (14%)	3,821 (13%)	181 (17%)	3,153 (6%)	443 (10%)	4,125 (18%)	25 (0%)	1,141 (7%)	7,496 (20%)
Antineoplastic agents	10 (1%)	2,238 (8%)	13 (1%)	201 (0%)	65 (1%)	181 (1%)	<5	142 (1%)	353 (1%)
Antipsoriatics	0 (0%)	30 (0%)	<5	19 (0%)	5 (0%)	56 (0%)	0 (0%)	34 (0%)	44 (0%)
Antithrombotic agents	321 (35%)	9,928 (34%)	172 (16%)	6,725 (13%)	1,479 (33%)	5,276 (23%)	31 (0%)	2,530 (16%)	7,986 (22%)
Beta blocking agents	230 (25%)	5,011 (17%)	300 (28%)	5,713 (11%)	935 (21%)	4,078 (18%)	45 (1%)	2,997 (19%)	4,500 (12%)
Calcium channel blockers	111 (12%)	7,025 (24%)	176 (16%)	3,325 (6%)	728 (16%)	3,870 (17%)	64 (1%)	4,060 (26%)	3,018 (8%)
Diuretics	89 (10%)	5,075 (17%)	49 (5%)	3,377 (7%)	642 (14%)	3,727 (16%)	36 (1%)	2,317 (15%)	2,424 (7%)
Drugs for acid related disorders	213 (23%)	5,980 (20%)	150 (14%)	4,447 (9%)	1,403 (31%)	9,618 (42%)	80 (1%)	5,163 (33%)	4,850 (13%)
Drugs for obstructive airway diseases	97 (11%)	3,591 (12%)	93 (9%)	1,503 (3%)	407 (9%)	4,157 (18%)	34 (0%)	2,563 (17%)	3,329 (9%)
Drugs used in diabetes	128 (14%)	3,268 (11%)	116 (11%)	2,846 (5%)	496 (11%)	4,393 (19%)	22 (0%)	1,690 (11%)	2,955 (8%)
Hormonal contraceptives for systemic use	<5	164 (1%)	0 (0%)	<5	0 (0%)	84 (0%)	0 (0%)	<5	0 (0%)
Immunosuppressants	7 (1%)	342 (1%)	10 (1%)	164 (0%)	44 (1%)	248 (1%)	<5	165 (1%)	297 (1%)
Lipid modifying agents	334 (36%)	10,324 (35%)	224 (21%)	5,753 (11%)	1,550 (34%)	8,918 (39%)	133 (2%)	6,866 (44%)	4,991 (14%)
Opioids	90 (10%)	3,415 (12%)	56 (5%)	1,688 (3%)	358 (8%)	2,674 (12%)	35 (0%)	2,728 (18%)	6,779 (19%)
Psycholeptics	171 (19%)	2,800 (9%)	140 (13%)	1,361 (3%)	595 (13%)	5,973 (26%)	12 (0%)	1,229 (8%)	5,105 (14%)
Psychostimulants adhd	<5	95 (0%)	<5	32 (0%)	10 (0%)	81 (0%)	0 (0%)	0 (0%)	6 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 112. Medications recorded 0 to 90 days after the diagnosis of stomach cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	42	4,137	191	4,737	678	5,059	488	1,055	3,300
Agents acting on the renin angiotensin system	11 (26%)	1,492 (36%)	64 (34%)	1,189 (25%)	214 (32%)	2,148 (42%)	<5	332 (31%)	601 (18%)
Antibacterials for systemic use	<5	852 (21%)	56 (29%)	350 (7%)	81 (12%)	1,186 (23%)	<5	231 (22%)	1,209 (37%)
Antidepressants	<5	536 (13%)	16 (8%)	308 (7%)	50 (7%)	1,066 (21%)	<5	208 (20%)	327 (10%)
Antiepileptics	<5	247 (6%)	8 (4%)	59 (1%)	13 (2%)	507 (10%)	0 (0%)	83 (8%)	211 (6%)
Antiinflammatory and antirheumatic products	<5	292 (7%)	23 (12%)	258 (5%)	42 (6%)	674 (13%)	<5	26 (2%)	620 (19%)
Antineoplastic agents	<5	2,084 (50%)	6 (3%)	24 (1%)	41 (6%)	73 (1%)	0 (0%)	8 (1%)	1,069 (32%)
Antipsoriatics	0 (0%)	<5	0 (0%)	<5	0 (0%)	13 (0%)	0 (0%)	<5	<5
Antithrombotic agents	14 (33%)	1,398 (34%)	32 (17%)	998 (21%)	229 (34%)	1,699 (34%)	0 (0%)	250 (24%)	1,392 (42%)
Beta blocking agents	13 (31%)	769 (19%)	40 (21%)	928 (20%)	170 (25%)	982 (19%)	<5	253 (24%)	662 (20%)
Calcium channel blockers	<5	945 (23%)	19 (10%)	475 (10%)	113 (17%)	768 (15%)	<5	221 (21%)	305 (9%)
Diuretics	<5	998 (24%)	9 (5%)	684 (14%)	132 (19%)	1,250 (25%)	<5	225 (21%)	587 (18%)
Drugs for acid related disorders	25 (60%)	3,232 (78%)	138 (72%)	1,751 (37%)	482 (71%)	4,093 (81%)	10 (2%)	825 (78%)	2,455 (74%)
Drugs for obstructive airway diseases	<5	590 (14%)	21 (11%)	208 (4%)	84 (12%)	893 (18%)	<5	197 (19%)	466 (14%)
Drugs used in diabetes	12 (29%)	557 (13%)	19 (10%)	453 (10%)	104 (15%)	1,138 (22%)	<5	152 (14%)	380 (12%)
Hormonal contraceptives for systemic use	0 (0%)	34 (1%)	<5	12 (0%)	10 (1%)	131 (3%)	0 (0%)	10 (1%)	10 (0%)
Immunosuppressants	0 (0%)	67 (2%)	<5	21 (0%)	9 (1%)	73 (1%)	0 (0%)	6 (1%)	37 (1%)

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Lipid modifying agents	14 (33%)	1,416 (34%)	28 (15%)	701 (15%)	214 (32%)	1,716 (34%)	<5	429 (41%)	470 (14%)
Opioids	15 (36%)	1,583 (38%)	46 (24%)	497 (10%)	190 (28%)	1,348 (27%)	6 (1%)	455 (43%)	1,775 (54%)
Psycholeptics	9 (21%)	1,175 (28%)	62 (32%)	466 (10%)	195 (29%)	2,179 (43%)	6 (1%)	344 (33%)	1,238 (38%)
Psychostimulants adhd	0 (0%)	24 (1%)	0 (0%)	<5	5 (1%)	27 (1%)	0 (0%)	<5	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 113. Procedures recorded 0 to 90 days after the diagnosis of bone cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	18	322	31	965	0	1,071	37	290	594
Bone marrow transplantation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Radiotherapy	0 (0%)	34 (11%)	5 (16%)	7 (1%)	0	0 (0%)	<5	8 (3%)	133 (22%)
Surgical procedure	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0	0 (0%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 114. Procedures recorded 0 to 90 days after the diagnosis of brain cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	128	3,510	132	3,240	297	3,955	507	932	3,318
Bone marrow transplantation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Radiotherapy	0 (0%)	2,029 (58%)	58 (44%)	49 (2%)	0 (0%)	0 (0%)	30 (6%)	56 (6%)	1,862 (56%)
Surgical procedure	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 115. Procedures recorded 0 to 90 days after the diagnosis of breast cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	1,853	31,873	1,243	56,337	6,553	31,931	5,180	18,134	38,047
Bone marrow transplantation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Radiotherapy	8 (0%)	9,461 (30%)	184 (15%)	882 (2%)	0 (0%)	0 (0%)	102 (2%)	446 (2%)	11,285 (30%)
Surgical procedure	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 116. Procedures recorded 0 to 90 days after the diagnosis of colorectal cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	382	29,279	762	24,061	5,400	29,755	3,848	11,798	23,146
Bone marrow transplantation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5
Radiotherapy	<5	3,120 (11%)	113 (15%)	120 (0%)	0 (0%)	0 (0%)	48 (1%)	214 (2%)	3,663 (16%)
Surgical procedure	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	<5

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 117. Procedures recorded 0 to 90 days after the diagnosis of corpus uteri cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	60	4,910	260	5,113	622	4,858	899	2,453	6,121
Bone marrow transplantation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Radiotherapy	<5	117 (2%)	39 (15%)	44 (1%)	0 (0%)	0 (0%)	42 (5%)	54 (2%)	1,420 (23%)
Surgical procedure	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 118. Procedures recorded 0 to 90 days after the diagnosis of oesophageal cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	53	3,168	35	3,121	837	1,860	763	3,223	2,487
Bone marrow transplantation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Radiotherapy	<5	1,100 (35%)	14 (40%)	22 (1%)	0 (0%)	0 (0%)	38 (5%)	75 (2%)	814 (33%)
Surgical procedure	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 119. Procedures recorded 0 to 90 days after the diagnosis of kidney cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	33	6,498	289	9,149	1,068	7,404	950	1,096	6,394
Bone marrow transplantation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Radiotherapy	0 (0%)	275 (4%)	5 (2%)	10 (0%)	0 (0%)	0 (0%)	8 (1%)	11 (1%)	358 (6%)
Surgical procedure	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 120. Procedures recorded 0 to 90 days after the diagnosis of liver cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	35	3,338	75	3,214	557	5,618	456	1,297	4,177
Bone marrow transplantation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Radiotherapy	0 (0%)	100 (3%)	<5	6 (0%)	0 (0%)	0 (0%)	5 (1%)	<5	152 (4%)
Surgical procedure	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 121. Procedures recorded 0 to 90 days after the diagnosis of lung cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	486	27,757	332	20,343	5,288	20,068	2,581	11,844	16,828
Bone marrow transplantation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Radiotherapy	<5	8,721 (31%)	46 (14%)	148 (1%)	0 (0%)	0 (0%)	103 (4%)	511 (4%)	4,491 (27%)
Surgical procedure	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 122. Procedures recorded 0 to 90 days after the diagnosis of leukaemia and lymphoma, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	815	25,172	884	33,640	3,009	28,831	3,029	10,429	20,690
Bone marrow transplantation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	10 (0%)	26 (0%)
Radiotherapy	0 (0%)	767 (3%)	5 (1%)	47 (0%)	0 (0%)	0 (0%)	17 (1%)	37 (0%)	772 (4%)
Surgical procedure	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	10 (0%)	26 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 123. Procedures recorded 0 to 90 days after the diagnosis of melanoma, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	130	17,145	526	28,972	3,096	7,928	1,797	5,235	8,820
Bone marrow transplantation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Radiotherapy	0 (0%)	135 (1%)	<5	29 (0%)	0 (0%)	0 (0%)	<5	10 (0%)	187 (2%)
Surgical procedure	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 124. Procedures recorded 0 to 90 days after the diagnosis of ovarian cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	54	2,842	217	4,603	473	3,244	572	1,704	3,085
Bone marrow transplantation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Radiotherapy	0 (0%)	13 (0%)	<5	<5	0 (0%)	0 (0%)	<5	<5	24 (1%)
Surgical procedure	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 125. Procedures recorded 0 to 90 days after the diagnosis of pancreatic cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	123	6,587	193	6,387	1,252	6,705	907	2,354	8,139
Bone marrow transplantation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Radiotherapy	0 (0%)	93 (1%)	0 (0%)	<5	0 (0%)	0 (0%)	<5	5 (0%)	159 (2%)
Surgical procedure	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 126. Procedures recorded 0 to 90 days after the diagnosis of prostate cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	920	29,476	1,067	51,871	4,527	22,704	7,069	15,485	36,620
Bone marrow transplantation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Radiotherapy	<5	2,859 (10%)	91 (9%)	323 (1%)	0 (0%)	0 (0%)	153 (2%)	184 (1%)	4,090 (11%)
Surgical procedure	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank

Table 127. Procedures recorded 0 to 90 days after the diagnosis of stomach cancer, by database (2016–2022).

	IQVIA LPD	DK-DHR	EBB	IQVIA DA	IPCI	SIDIAP	UKBB	CPRD_GOLD	FinOMOP-THL
Number of patients	42	4,137	191	4,737	678	5,059	488	1,055	3,300
Bone marrow transplantation	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
Radiotherapy	0 (0%)	398 (10%)	<5	9 (0%)	0 (0%)	0 (0%)	5 (1%)	15 (1%)	124 (4%)
Surgical procedure	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

IQVIA LPD=IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium); DK-DHR=Danish Data Health Registries; EBB=Estonian Biobank; FinOMOP-THL=Finnish Care Register for Health Care; IQVIA DA=IQVIA Disease Analyzer Germany (IQVIA DA Germany); IPCI=Integrated Primary Care Information; SIDIAP=The Information System for the Development of Research in Primary Care; CPRD GOLD=Clinical Practice Research Datalink GOLD; UKBB=UK BioBank